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FOREWORD
This toxicological profile is prepared in accordance with guidelines developed by the Agency for 
Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews 
the key literature that describes a substance's toxicologic properties. Other pertinent literature is also 
presented, but is described in less detail than the key studies. The profile is not intended to be an 
exhaustive document; more comprehensive sources of specialty information are referenced.
The focus of the profiles is on health and toxicologic information. Each toxicological profile begins 
with a public health statement that describes, in nontechnical language, a substance's relevant toxicological 
properties. Following the public health statement is information concerning levels of significant human 
exposure and, where known, significant health effects. The adequacy of information to determine a 
substance's health effects is described in a health effects summary. Data needs that are of significance to 
protection of public health are identified by ATSDR and EPA.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects o f each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of 
exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, 
and local levels; interested private sector organizations and groups; and members of the public. We plan to 
revise these documents in response to public comments and as additional data become available.
Therefore, we encourage comments that will make the toxicological profile series of the greatest use.
Comments should be sent to:
Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Environmental Medicine 
1600 Clifton Road, N.E.
Mail Stop F-62 
Atlanta, Georgia 30333
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 
104(i)(l) directs the Administrator of ATSDR to . .effectuate and implement the health related 
authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances 
most commonly found at facilities on the CERCLA National Priorities List and that pose the most 
significant potential threat to human health, as determined by ATSDR and the EPA. Section 1 Q4(i)(3) of 
CERCLA, as amended, directs the Administrator o f ATSDR to prepare a toxicological profile for each 
substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances 
not found at sites on the National Priorities List, in an effort to . .establish and maintain inventory of 
literature, research, and studies on the health effects of toxic substances” under CERCLA Section 
104{i)( 1XB), to respond to requests for consultation under section 104(iX4), and as otherwise necessaiy to 
support the site-specific response actions conducted by ATSDR.
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that 
has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and oilier Federal 
scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a 
nongovernmental panel and is being made available for public review. Final responsibility for the contents 
and views expressed in this toxicological profile resides with ATSDR.
Howard Frumkin, M.D., Dr. P.H. 
Director, National Center for Environmental 
Health/Agency for Toxic Substances and Disease 
Registry
Thomas R. Frieden, M.D., M.P.H. 
Administrator, Agency for Toxic Substances and 
Disease Registry
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Q UICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance. Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions.
Primary Chapters/Sections o f Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance. It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure.
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health.
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are 
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure.
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health
issues: 
Section 1.6 
Section 1.7 
Section 3.7 
Section 6.6
How Can (Chemical X) Affect Children?
How Can Families Reduce the Risk of Exposure to (Chemical X)? 
Children’s Susceptibility 
Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: I-8OO-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided. Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE viii
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials. Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH.
The National Institute o f Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association o f Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues. Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.
The American College o f Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.
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PEER REVIEW
A peer review panel was assembled for acrylamide. The panel consisted of the following members:
1. Herman Bolt, M.D., Ph.D., Professor Emeritus, Leibniz Research Centre for Working 
Environment and Human Factors, Dortmund, Germany
2. Timothy Fennell, Ph.D., Senior Research Chemist, RTI International, Drug Metabolism and 
Pharmacokinetics Department, Research Triangle Park, NC
3. James Klaunig, Ph.D., Professor of Public Health, Director, Center for Environmental Health, 
Indiana University School of Medicine, Indianapolis, IN
These experts collectively have knowledge of acrylamide‘s physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile. A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR.
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1. PUBLIC HEALTH STATEMENT
This public health statement tells you about acrylamide and the effects of exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities. Acrylamide has been found in at least 3 of the 1,699 current or former NPL 
sites. Although the total number of NPL sites evaluated for this substance is not known, the possibility 
exists that the number of sites at which acrylamide is found may increase in the future as more sites are 
evaluated. This information is important because these sites may be sources of exposure and exposure to 
this substance may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment. Such a release does not always lead to exposure. You 
can be exposed to a substance only when you come in contact with it. You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact.
If you are exposed to acrylamide, many factors will determine whether you will be harmed. These factors 
include the dose (how much), the duration (how long), and how you come in contact with it. You must 
also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and 
state of health.
1.1 WHAT IS ACRYLAMIDE?
White or colorless, 
odorless crystalline 
solid
Acrylamide can violently react when melting. When heated, acrid 
fumes may be released.
Used in industry Acrylamide is used to make polyacrylamide, which is mainly used in 
treating effluent from water treatment plants and industrial processes.
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1.2 WHAT HAPPENS TO ACRYLAMIDE WHEN IT ENTERS THE ENVIRONMENT?
ACRYLAMIDE 2
Most commonly found 
in water
Acrylamide may enter drinking water if polyacrylamide is used in the 
treatment process. It can be found in soils, but is rarely found in air.
Rapidly broken down 
in soil and water
If acrylamide enters soil or water, it will be broken down quickly by 
bacteria.
1.3 HOW MIGHT I BE EXPOSED TO ACRYLAMIDE?
Water and soil Drinking water can sometimes contain acrylamide. It can enter drinking 
water from the treatment process of municipal supplies as well as from 
substances used to construct dams and wells. Acrylamide breaks 
down quickly in water and soil, but there is still a chance of exposure if 
you live near a plastics or dye plants.
Inhalation and dermal 
contact
If you smoke, or breathe second-hand tobacco smoke, you might be 
exposed to acrylamide. Tobacco smoke is a major source of 
acrylamide exposure within the general population. People involved in 
the production or use of acrylamide and acrylamide-containing products 
are exposed if they breathe in air that contains acrylamide. They may 
also be exposed by coming into skin contact with acrylamide.
Food Acrylamide is formed in foods that are rich in carbohydrates (particularly 
potatoes) when they are fried, grilled, or baked at normal cooking 
temperatures. Levels of acrylamide in these foods increase with higher 
temperatures and longer cooking times. Protein-based foods (such as 
meats) probably contain low amounts of acrylamide. Ingestion of foods 
that contain acrylamide is a primary source of exposure.
1.4 HOW CAN ACRYLAMIDE ENTER AND LEAVE MY BODY?
May enter your body 
through food, drinking 
water, breathing, and 
skin contact
Acrylamide can enter your body when you eat foods containing 
acrylamide. Drinking water that contains acrylamide will have a similar 
effect. Breathing tobacco smoke may cause some level of acrylamide 
to enter your lungs. Acrylamide can also enter your body if it comes in 
contact with your skin. Dermal contact with acrylamide can occur if you 
work in the manufacture of acrylamide or polyacrylamide gels.
Leaves through bodily 
fluids
Once in your body, acrylamide enters your body fluids. Acrylamide and 
its breakdown products leave your body mostly through urine; small 
amounts may leave through feces, exhaled air, and breast milk.
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1.5 HOW CAN ACRYLAMIDE AFFECT MY HEALTH?
This section looks at studies concerning potential health effects in animal and human studies.
ACRYLAMIDE 3
Nervous system 
effects
Nervous system effects such as muscle weakness, numbness in hands 
and feet, sweating, unsteadiness, and clumsiness were reported in 
some acrylamide workers. However, most people are not exposed to 
acrylamide levels high enough to cause these effects.
Reproductive effects Acrylamide reduces the ability of male animals to produce offspring and 
could cause similar effects in humans, but not likely at exposure levels 
experienced by most people.
Cancer Acrylamide has caused several types of cancer in animals. We do not 
know whether acrylamide causes cancer in humans.
1.6 HOW CAN ACRYLAMIDE AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age.
Effects in children Acrylamide is expected to affect children in the same manner as adults. 
It is not known whether children are more susceptible than adults to the 
effects of acrylamide.
Developmental effects Effects such as decreased body weight, decreased startle responses, 
and decreased levels of some chemicals involved in transmission of 
brain signals were seen in some animals exposed to acrylamide before 
or shortly following birth. There are no reports of acrylamide causing 
developmental effects in humans.
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO ACRYLAMIDE?
Limit exposure to 
tobacco and second­
hand smoke
Tobacco smoke contains acrylamide. Avoid smoking or breathing in 
second-hand smoke.
Reduce consumption 
of foods that contain 
acrylamide
Avoid eating a lot of carbohydrate-rich foods that are cooked at high 
temperatures (e.g., French fries). Foods with higher protein content 
appear to have lower amounts of acrylamide. Avoid overcooking foods.
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1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 
ACRYLAMIDE?
ACRYLAMIDE 4
Can be measured in 
blood and urine
Acrylamide and its breakdown products can be measured in blood and 
urine. These measurements may be useful in estimating how much 
acrylamide has entered the body.
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health. Regulations 
can be enforced by law. The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances. Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels. These are levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value. This critical value is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans. Sometimes 
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available. 
For the most current information, check with the federal agency or organization that provides it.
Some regulations and recommendations for acrylamide include the following:
Levels in drinking 
water set by EPA
The EPA has determined that exposure to acrylamide in drinking water 
at concentrations of 1.5 mg/L for one day or 0.3 mg/L for 10 days is not 
expected to cause any adverse effects in a child.
Levels in workplace 
air set by OSHA
OSHA set a legal limit of 0.3 mg/m3 for acrylamide in air averaged over 
an 8-hour work day.
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1.10 WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location of occupational and environmental health clinics. These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You may 
request a copy of the ATSDR ToxProfiles™ CD-ROM by calling the toll-free information and technical 
assistance number at I-8OO-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
1600 Clifton Road NE
Mailstop F-62
Atlanta, GA 30333
Fax: 1-770-488-4178
Organizations for-profit may request copies of final Toxicological Profiles from the following:
National Technical Information Service (NTIS) 
5285 Port Royal Road 
Springfield, VA 22161 
Phone: 1-800-553-6847 or 1-703-605-6000 
Web site: http://www.ntis.gov/
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2. RELEVANCE TO PUBLIC HEALTH
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO ACRYLAMIDE IN THE 
UNITED STATES
Acrylamide is an industrial chemical used mainly in the production of polyacrylamides, which are used 
primarily as flocculants for clarifying drinking and treating municipal and industrial effluents. In the oil 
industry, acrylamide is used as a flow control agent to enhance oil production from wells. Acrylamide 
and polyacrylamides are also used in the production of dyes and organic chemicals, contact lenses, 
cosmetics and toiletries, permanent-press fabrics, textiles, pulp and paper products; also in ore processing, 
sugar refining, and as a chemical grouting agent and soil stabilizer for the construction of tunnels, sewers, 
wells, and reservoirs. In 2008, approximately 141,000 metric tons of acrylamide were produced in the 
United States.
Acrylamide may be released to the environment during production and use of polyacrylamides, which are 
used as clarifiers in water treatment. Residual monomer in the polyacrylamide is the main source of 
drinking water contamination by acrylamide. It can be released to soil and land from plastics and dye 
industries and from acrylamide-containing grouting agents used in reservoirs and wells. Acrylamide is 
rarely found in the atmosphere.
Acrylamide is not considered highly persistent in the environment. It is expected to be highly mobile in 
soil and water and is highly susceptible to biodegradation in both media. It can be removed from soils by 
hydrolysis, though it is typically not present in soil or the atmosphere. Acrylamide is not expected to 
significantly bioconcentrate.
Acrylamide is sometimes present in drinking water due to leaching of monomer during treatment 
processes. Acrylamide was identified in food samples cooked at high temperatures. Concentrations of 
acrylamide in food vary with the type of food, cooking method, temperature, water content, food 
thickness, and length of heating. Carbohydrate-rich foods typically contain the highest levels of 
acrylamide.
Exposure to acrylamide occurs mainly through ingestion, dermal contact, and inhalation. Ingestion of 
foods containing acrylamide appears to be one of the most common methods of exposure for the general 
public. Average estimated intake of acrylamide from food sources ranged from 0.3 to 0.8 ^g/kg bw/day. 
Children may be susceptible to food-borne exposure 2-3 times that of adults on a body weight basis.
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Ingestion of contaminated drinking water can result in exposure to acrylamide. Inhalation of tobacco 
smoke, including second-hand smoke, can result in inhalation exposure for both adults and children. In 
the body, acrylamide can cross the placenta and result in exposure to unborn children. Breast milk has 
been shown to contain acrylamide in mothers with diets high in acrylamide-containing foods.
Occupational exposure to acrylamide is primarily due to dermal contact when handling bags and drums of 
the chemical, followed by inhalation of dust or aerosols.
2.2 SUMMARY OF HEALTH EFFECTS
Neurological Effects. Ataxia and skeletal muscle weakness are hallmark symptoms of acrylamide- 
induced central-peripheral neuropathy. Available information in humans includes case reports and cross­
sectional studies in which reported symptoms of neuropathy were primarily associated with occupational 
exposure potential via both inhalation and dermal contact. Numerous animal studies confirm the 
neurological effects of acrylamide exposure. Available information in animals primarily involves oral 
exposure. Clinical signs can be elicited following single oral dosing in the range of 100-200 mg/kg; 
lower dose levels require repeated dosing to elicit clinical signs. Histopathological evidence of 
acrylamide-induced peripheral neuropathy has been observed in rats receiving oral doses as low as 
1 mg/kg/day for 3 months; the observed degenerative effects in peripheral nerve fibers at such dose levels 
have been shown to be completely reversible within a few months following the cessation of exposure 
(Burek et al. 1980).
Reproductive Effects. Pre- and postimplantation losses and decreased numbers of live fetuses have 
been observed in rats and mice receiving repeated oral doses of acrylamide in the range of 3­
60 mg/kg/day. Results of dominant lethality testing and crossover trials indicate that acrylamide-induced 
reproductive effects are male mediated. Other reported effects in acrylamide-treated laboratory animals 
include decreased sperm mobility, degenerative effects in spermatids, and testicular atrophy.
Cancer. Available cohort mortality studies of occupationally-exposed workers have not found 
associations between acrylamide and mortality from cancer. Available human data on cancer risk from 
acrylamide in food include case-control studies and reports from ongoing prospective studies. These 
studies provide little evidence for acrylamide-induced cancer in humans exposed to acrylamide in the 
diet.
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Results of two similarly-designed lifetime studies in orally-exposed rats provide clear evidence of 
acrylamide-induced carcinogenicity. Reported effects common to both studies include significantly 
increased incidences of thyroid (follicular cell) tumors, mesotheliomas of the tunica vaginalis testis, and 
mammary gland tumors. Findings of significantly increased incidences of adrenal pheochromocytomas in 
male rats and tumors of the oral cavity, central nervous system (glial origin), pituitary, and clitoris or 
uterus in female rats in the earlier bioassay were not replicated in the second bioassay.
Acrylamide was reported to initiate skin tumors in female mice administered repeated oral doses of 
acrylamide followed by dermal applications of 12-O-tetradecanoylphorbol-13-acetate (TPA, a tumor 
promoter) to the shaved back.
EPA assigned the descriptor B2 (probable human carcinogen) to acrylamide based on “inadequate human 
data and sufficient evidence of carcinogenicity in animals; significantly increased incidences of benign 
and/or malignant tumors at multiple sites in both sexes of rats, and carcinogenic effects in a series of one- 
year limited bioassays in mice by several routes of exposures.” EPA noted that positive genotoxicity 
data, adduct formation activity, and structure-activity relationships to vinyl carbamate and acrylonitrile 
provide support to the classification. The International Agency for Research on Cancer assigned 
acrylamide to Group 2A (probably carcinogenic to humans) based on similar assessment. The National 
Toxicology Program has determined that acrylamide is reasonably anticipated to be a human carcinogen.
Body Weight Effects. Depressed body weight, including actual body weight loss, and depressed body 
weight gain were consistently reported in laboratory animals following oral exposure to acrylamide. 
Significantly depressed mean body weight was observed in male prepubertal and adult ddy mice (range of
6-13% less than control mean body weight) was noted during 3-5 days following single oral dosing at 
150 mg/kg (Sakamoto et al. 1988). Very slight to slight initial weight loss was reported following single 
oral administration of acrylamide at 126 mg/kg in rats and guinea pigs and 63 mg/kg in rabbits. 
Repeated-dose oral exposure of rats to doses as low as 15 mg/kg/day for 5 consecutive days resulted in 
significantly depressed body weight gain (approximately 40% less than controls); higher doses (30­
60 mg/kg/day) caused actual weight loss. An 8-week dosing period to dogs at 7 mg/kg/day resulted in 
weight loss. Weight loss was reported in cats receiving acrylamide orally for 16 weeks at 15 mg/kg/day.
A daily dose as low as 7.5 mg/kg/day during gestation days 6-20 resulted in approximately 12% 
depressed maternal weight gain in rats.
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2.3 MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for acrylamide. An 
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects. MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate 
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised.
Inhalation MRLs
No inhalation MRLs were derived due to the lack of appropriate data on the effects of inhalation exposure 
to acrylamide.
Numerous accounts of associations between exposure to acrylamide and neurological impairment are 
available (Auld and Bedwell 1967; Bachmann et al. 1992; Calleman et al. 1994; Davenport et al. 1976; 
Donovan and Pearson 1987; Dumitru 1989; Fullerton 1969; Garland and Patterson 1967; Gjerl0ff et al. 
2001; Hagmar et al. 2001; He et al. 1989; Igisu and Matsuoka 2002; Igisu et al. 1975; Kesson et al. 1977; 
Mapp et al. 1977; Mulloy 1996; Myers and Macun 1991; Takahashi et al. 1971). Most associations were 
made from occupational exposure scenarios that likely included inhalation and dermal (and possibly oral) 
exposure. Acrylamide levels in the workplace air were measured in some instances; however, reliable 
exposure-response data are not available.
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Acrylamide-induced health effects in laboratory animals following inhalation exposure to acrylamide 
were assessed in two studies that did not include multiple exposure levels. Mortalities and central 
nervous system effects were observed in dogs exposed to acrylamide dust at a concentration of
15.6 mg/m3 for 6 hours/day for up to 16 days (American Cyanamid Company 1953a). There were no 
signs of adverse effects in similarly-exposed guinea pigs. No adverse effects were seen in cats exposed to 
what was described as a “saturated” vapor for 6 hours/day, 5 days/week for 3 months at a mean analytical 
concentration of 1.65 ppm (4.8 mg/m3) (Dow Chemical Company 1957).
Oral MRLs
An MRL of 0.02 mg/kg/day has been derived for acute-duration oral exposure (14 days or less) to 
acrylamide.
Available human data are limited to case reports that include findings of persistent peripheral neuropathy 
in a subject who intentionally ingested 18 g of acrylamide crystals (Donovan and Pearson 1987) and signs 
of central and peripheral neurological deficits in family members exposed (likely via oral and dermal 
routes) to acrylamide in well water at a concentration of 400 ppm (Igisu and Matsuoka 2002; Igisu et al. 
1975). Epidemiologic studies designed to evaluate noncancer health effects in groups of orally-exposed 
subjects have not been conducted.
Single oral doses elicit clinical signs of acrylamide-induced neurological effects in laboratory animals at 
lethal or near-lethal doses (American Cyanamid Company 1953c; Fullerton and Barnes 1966; McCollister 
et al. 1964; Tilson and Cabe 1979). Repeated oral dosing elicits clinical signs at lower daily dose levels. 
For example, convulsions and ataxia were noted as early as day 14 in rats administered acrylamide by 
daily gavage at 25 mg/kg/day for 21 days (Dixit et al. 1981). Daily exposure of male mice to acrylamide 
in the drinking water for 12 days at an estimated dose of 25.8 mg/kg/day caused decreased rotarod 
performance and increased hindlimb splay as early as days 6 and 8, respectively (Gilbert and Maurissen 
1982).
Histopathological evaluations of nervous tissues following acute-duration oral exposure to acrylamide are 
limited to electron microscope results from peripheral nerve preparations in subgroups of control and 
high-dose (20 mg/kg/day) male rats administered acrylamide in the drinking water for up to 93 days 
(Burek et al. 1980). No signs of acrylamide-induced degenerative effects were observed after 7 days of 
treatment, but degeneration in axons and myelin sheath were noted after 33 days of treatment. These
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interim assessments were not performed at lower dose levels and the effect of treatment following 14 days 
(maximum acute-duration exposure period as defined by ATSDR) was not assessed.
Acrylamide-induced effects on body weight have been reported in rats following acute-duration oral 
exposure to acrylamide. In one study, repeated-dose oral exposure of rats to doses as low as 
15 mg/kg/day for 5 consecutive days resulted in significantly depressed body weight gain (approximately 
40% less than controls); higher doses (30-60 mg/kg/day) caused actual weight loss, whereas no effect on 
body weight was seen at a dose level of 5 mg/kg/day (Tyl et al. 2000b). Another study reported 
significantly lower mean body weight (magnitude 8%) as early as treatment day 13 in male rats 
administered acrylamide in the drinking water at a concentration resulting in an estimated dose level of 
20 mg/kg/day, but no effect on body weight at an estimated dose level of 5 mg/kg/day (Burek et al. 1980).
Daily oral administration of acrylamide to male rats at 15 mg/kg/day for as little as 5 days followed by 
mating with unexposed female rats resulted in reduced mating, decreased fertility, and male-mediated 
increased pre- and postimplantation losses; these effects were not seen at 5 mg/kg/day (Sublet et al. 1989; 
Tyl et al. 2000b). A similarly-designed study (Tyl et al. 2000b) confirmed the findings of acrylamide- 
induced increased implantation loss, although, based on pairwise comparisons with controls, statistical 
significance was achieved only at the highest dose level (60 mg/kg/day). Tyl et al. (2000b) also noted 
significantly decreased body weight gain during the 5 days of dosing at 15 mg/kg/day and actual weight 
loss at higher doses, findings not included in the study report of Sublet et al. (1989). Based on the 
reproducible results for male-mediated implantation loss in the studies of Sublet et al. (1989) and Tyl et 
al. (2000b) and the lack of supporting information regarding the body weight effects, the male-mediated 
implantation loss was selected as the critical effect for deriving an acute-duration oral MRL for 
acrylamide. As discussed in detail in Appendix A, benchmark dose (BMD) analysis was applied to 
provide a point of departure (BMCL10) of 1.78 mg/kg/day; an uncertainty factor of 100 (10 for 
extrapolation from animals to humans and 10 for human variability) was applied, resulting in an acute- 
duration oral MRL of 0.02 mg/kg/day for acrylamide.
An MRL of 0.002 mg/kg/day has been derived for intermediate-duration oral exposure (15-364 days) 
to acrylamide.
No human data are available regarding health effects associated with intermediate-duration oral exposure 
to acrylamide.
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Results of available animal studies demonstrate that neurological effects in males and females and 
reproductive effects in males are the most sensitive noncancer effects associated with intermediate- 
duration oral exposure to acrylamide (Burek et al. 1980; Chapin et al. 1995; Johnson et al. 1984, 1985, 
1986; Sakamoto and Hashimoto 1986; Smith et al. 1986; Tyl et al. 2000a, 2000b; Zenick et al. 1986).
The lowest dose level reported to induce male-mediated implantation losses was 2.8 mg/kg/day in male 
Long-Evans rats receiving acrylamide from the drinking water for 80 days; this study identified a no­
observed-adverse effect level (NOAEL) of 1 mg/kg/day (Smith et al. 1986). Ultrastructural degenerative 
peripheral nerve changes were observed at a dose level as low as 1 mg/kg/day in male F344 rats receiving 
acrylamide from the drinking water for up to 93 days; this study identified a NOAEL of 0.2 mg/kg/day 
(Burek et al. 1980). Available data suggest that neurological effects represent a more sensitive point of 
departure than reproductive effects for deriving intermediate- and chronic-duration oral MRLs for 
acrylamide. Therefore, degenerative nerve change was selected as the critical effect for deriving an 
intermediate-duration oral MRL for acrylamide. The study of Burek et al. (1980) was selected as the 
principal study because it identified the lowest lowest-observed-adverse-effect-level (LOAEL) for the 
critical effect. A NOAEL/LOAEL approach was selected because results of the ultrastructural 
evaluations included only 3 of 10 rats/group and were reported only as the total numbers of fields (per 
group) with ultrastructural changes as axolemma invaginations or Schwann cells without axons and/or 
with degenerating myelin. The lack of adequate quantitative data precludes the utilization of BMD 
analysis to derive an intermediate-duration oral MRL for acrylamide. The NOAEL of 0.2 mg/kg/day was 
selected as the point of departure and was divided by an uncertainty factor of 100 (10 for extrapolation 
from animals to humans and 10 for human variability) to yield an intermediate-duration oral MRL of 
0.002 mg/kg/day for acrylamide.
No chronic-duration oral MRL was derived for acrylamide.
No human data are available to evaluate neurological effects following chronic-duration oral exposure to 
acrylamide. Two chronic toxicity and carcinogenicity bioassays are available for male and female F344 
rats receiving acrylamide from the drinking water for up to 2 years (Friedman et al. 1995; Johnson et al. 
1984, 1985, 1986). One study included dose levels of 0, 0.01, 0.1, 0.5, and 2.0 mg/kg/day (Johnson et al. 
1984, 1985, 1986); the other study included dose levels of 0, 0.1, 0.5, or 2 mg/kg/day in males and 0, 1.0, 
or 3.0 mg/kg/day in females (Friedman et al. 1995). Both studies identified a NOAEL of 0.5 mg/kg/day 
and a LOAEL of 2 mg/kg/day for histopathological evidence of degenerative nerve changes. These 
values are slightly higher than the NOAEL of 0.2 mg/kg/day and the LOAEL of 1 mg/kg/day for 
degenerative nerve changes in the intermediate-duration oral study used to derive an intermediate-
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duration oral MRL for acrylamide. These differences may be solely the result of differences in dose 
spacing. Because the NOAEL of 0.5 mg/kg/day used as a potential point of departure for deriving a 
chronic-duration oral MRL for acrylamide is slightly higher than the NOAEL of 0.2 mg/kg/day that 
serves as the point of departure for the intermediate-duration oral MRL of 0.002 mg/kg/day, the 
intermediate-duration oral MRL of 0.002 mg/kg/day is expected to be protective of chronic-duration oral 
exposure to acrylamide.
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3. HEALTH EFFECTS
3.1 INTRODUCTION
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of acrylamide. It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15-364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest- 
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction. However, the 
Agency has established guidelines and policies that are used to classify these end points. ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not
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the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective. Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of acrylamide are 
indicated in Table 3-4 and Figure 3-2. Because cancer effects could occur at lower exposure levels, 
Figure 3-2 also shows a range for the upper bound of estimated excess risks, ranging from a risk of 1 in 
10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA.
A User's Guide has been provided at the end of this profile (see Appendix B). This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure
3.2.1.1 Death
Human data are available from two cohort mortality studies of occupational exposure to acrylamide, one 
by Collins et al. (1989) with most recent follow up by Marsh et al. (2007) and one by Sobel et al. (1986) 
with follow up by Swaen et al. (2007). In these studies, no significant associations were found between 
occupational exposure to acrylamide and incidences of death from all causes. See Section 3.1.2.7 
(Cancer) for more detailed information regarding these cohorts and assessments of death due to cancers.
Reliable information regarding death in animals following inhalation exposure to acrylamide is limited. 
In a study performed for the American Cyanamid Company (1953a), two dogs, seven rats, and seven 
guinea pigs (sex and strain unspecified) were exposed to acrylamide dust at 15.6 mg/m3 for 6 hours/day, 
5 days/week for up to 12 exposures in a 16-day period. Four of the seven rats died overnight following 
the first exposure period and two of the remaining rats died a few days later. One of the dogs died on
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study day 15; there were no deaths among the guinea pigs. The study authors stated that >90% of the 
particles were in the respirable range (0.3-1.2 ^m).
Reliable inhalation mortality data for each species are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.1.2 Systemic Effects
No human or animal data were located regarding cardiovascular, gastrointestinal, musculoskeletal, 
hepatic, renal, endocrine, or dermal effects following inhalation exposure to acrylamide.
Respiratory Effects. Available information regarding acrylamide-associated respiratory effects is 
restricted to complaints of nose and throat irritation in a group of tunnel workers who had been 
occupationally exposed to acrylamide and N-methylolacrylamide in a chemical grouting agent for 
2 months (Hagmar et al. 2001). Increasing incidences of complaints were associated with increasing 
levels of hemoglobin adducts of acrylamide.
Hematological Effects. No data were located regarding hematological effects in humans following 
inhalation of acrylamide. Available information in animals is limited to a study in which four rats were 
exposed to acrylamide as a “saturated” vapor for 6 hours/day, 5 days/week for 3 months at a mean 
analytical concentration of 1.65 ppm (4.8 mg/m3); the exposures did not affect hematology results 
(American Cyanamid Company 1954).
Ocular Effects. Available information regarding acrylamide-associated ocular effects is restricted to 
complaints of eye irritation in a group of tunnel workers who had been occupationally exposed to 
acrylamide and N-methylolacrylamide in a chemical grouting agent for 2 months (Hagmar et al. 2001). 
Increasing incidences of complaints were associated with increasing levels of hemoglobin adducts of 
acrylamide.
Body Weight Effects. No data were located regarding body weight effects in humans following 
inhalation of acrylamide. Available information in animals is limited to a study in which four rats were 
exposed to acrylamide as a “saturated” vapor for 6 hours/day, 5 days/week for 3 months at a mean
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Table 3-1 Levels of Significant Exposure to Acrylamide - Inhalation
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
LOAEL
System
NOAEL
(m g/m 3)
Less Serious 
(m g/m 3)
Serious
(mg/m3)
Reference 
C hem ical Form C om m ents
ACUTE EXPOSURE
Death
1 Rat 
(NS)
4 d 
a hr/d 15.6 (death of 4/7 rats in 1 day American Cyanamid Company 
and 2 others before day 1953a 
8)
N euro log ica l
2 Rat 
(NS)
4 d 
a hr/d
INTERMEDIATE EXPOSURE
Death
Z Dog
(NS)
1a d
5 d/wk 
a hr/d
15.6 (loss of coordination and 
equilibrium on exposure 
day 4)
American Cyanamid Company 
1953a
15.6 (death of 1/2 dogs on day American Cyanamid Company 
15) 1953a
System ic
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5 d/wk 
a hr/d
Hemato 4.8
N euro log ica l
5 Gn Pig 
(NS)
1a d
5 d/wk 
a hr/d
Bd Wt 4.8
15.a
American Cyanamid Company 
1954
Acrylamide
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Table 3-1 Levels of Significant Exposure to Acrylamide - Inhalation (continued)
E xposure/ LOAEL
D uration /
Key  to  Spec ies Frequency NOAEL Less S erious Serious Reference
F igure (S train) (Route) System  (mg/m3) (mg/m3) (mg/m3) C hem ical Form  C om m ents
Cat 3 mo
5 d/wk
6 hr/d
4.8 American Cyanamid Company 
1954
Acrylamide
7
a The number corresponds to entries in Figure 3-1.
Bd W t = body weight; d = day(s); Hemato = hematological; hr = hour(s); LOAEL = lowest-observed-adverse-effect level; mo = month(s); NOAEL = no-observed-adverse-effect level; 
NS = not specified; week(s)
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Figure 3-1 Levels of Significant Exposure to Acrylamide - Inhalation
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analytical concentration of 1.65 ppm (4.8 mg/m3); the exposures did not affect body weights (American 
Cyanamid Company 1954).
3.2.1.3 Immunological and Lymphoreticular Effects
No data were located regarding immunological or lymphoreticular effects in humans or animals following 
inhalation exposure to acrylamide.
3.2.1.4 Neurological Effects
Information in humans is available from numerous case reports in which acrylamide exposure has been 
associated with signs of impaired neurological performance in central and peripheral nervous systems that 
include impaired motor function and muscle weakness (Auld and Bedwell 1967; Davenport et al. 1976; 
Dumitru 1989; Fullerton 1969; Garland and Patterson 1967; Gjerl0ff et al. 2001; Igisu et al. 1975; Kesson 
et al. 1977; Mapp et al. 1977; Mulloy 1996; Takahashi et al. 1971). Human data are also available from 
cross-sectional studies that included self-reported symptoms and neurological evaluations of acrylamide­
exposed workers with potential for inhalation and dermal (and possibly oral) exposure (Bachmann et al. 
1992; Calleman et al. 1994; Hagmar et al. 2001; He et al. 1989; Myers and Macun 1991). Although the 
case reports and cross-sectional studies provide supportive evidence of acrylamide-induced neurotoxicity, 
they lack information regarding relative contributions of natural exposure routes (inhalation, oral, 
dermal), exposure-response relationships, and other confounding exposures. They are therefore 
unsuitable for meaningful quantitative risk analysis.
He et al. (1989) evaluated health end points in workers employed for 1-18 months at a factory in China 
that began producing acrylamide and polyacrylamide in 1984. A referent group consisted of unexposed 
workers from the same town. Concentrations of acrylamide in the workplace air (determined by gas 
chromatography) reached 5.56-9.02 mg/m3 between March and June 1985 during polymerization when 
there was an exceptional increase in production, and decreased to an average of 0.0324 mg/m3 (range not 
specified) after July 1985. The workers were evaluated in October 1985. The study authors reported that 
heavy skin contamination by aqueous acrylamide monomer was common among the workers. An 
acrylamide level of 410 mg/L was measured in the water in which three of the workers washed their 
hands. Personal interviews were conducted to obtain information on demographic factors, occupational 
history, symptoms, past illnesses, and family history. Physical and neurological examinations, visual 
acuity and visual field testing, skin temperature measurements, electrocardiography, and
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electroencephalography were performed. Sixty-nine of the exposed workers and 48 of the referent 
workers were subjected to electroneuromyographic examinations.
As shown in Table 3-2, significantly greater percentages of the acrylamide-exposed group reported skin 
peeling from the hands, anorexia, numbness and coldness in hands and feet, lassitude, sleepiness, muscle 
weakness, clumsiness of the hands, unsteady gait, difficulty in grasping, and stumbling and falling. The 
authors stated that initial symptoms of skin peeling were the result of dermal exposure to aqueous 
acrylamide and that other symptoms appeared following 3-10 months of occupational exposure. Greater 
percentages of acrylamide-exposed workers exhibited erythema of the hands, sensory impairments 
(vibration, pain, and touch sensation), diminished reflexes, and intention tremor (Table 3-2). Electrical 
activity, monitored in both the abductor pollicis brevis and abductor digiti minimi muscles of the hand, 
revealed electromyographic abnormalities in the acrylamide-exposed workers that included denervation 
potentials (3/69 exposed workers), prolonged duration of motor units (40/69), increased polyphasic 
potentials (29/69), and discrete pattern of recruitment (9/69). These abnormalities were not seen in 
referent workers, with the exception of prolonged duration of motor units (4/48 referents). Significantly 
increased mean duration and mean amplitude of motor unit potentials and significantly decreased mean 
amplitude of sensory unit potentials were seen in the acrylamide-exposed group compared to the referent 
group. Assessment of visual acuity and visual field, nerve conduction velocity, electrocardiography, and 
electroencephalography revealed no significant exposure-related effects.
Calleman et al. (1994) performed a cross-sectional analysis of hemoglobin adduct formation and 
neurological effects in a group of 41 factory workers who were exposed to acrylamide (and acrylonitrile, 
from which acrylamide is formed) for 1 month to 11.5 years (mean 3 years) during the production of 
acrylamide and polyacrylamide at a factory in China. As determined by station sampling and gas 
chromatography, mean acrylamide air concentrations were 1.07 and 3.27 mg/m3 in the synthesis and 
polymerization rooms, respectively, during the summer of 1991. Mean exposure concentrations during 
the time of collection of biomarker data (September 1991) were lower, averaging 0.61 and 0.58 mg/m3 in 
synthesis and polymerization rooms, respectively. Information regarding demographic factors, smoking 
and drinking habits, height and weight, occupational history, past illnesses, current symptoms, and 
reproductive history were collected by questionnaire. Neurological examinations were performed 
approximately 1 hour after a work shift. Vibration sensitivity thresholds were measured in fingers and
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Table 3-2. Self-Reported Neurological Symptoms and Observed Clinical Signs 
Among Acrylamide Workers and Nonexposed Workers
Acry lam ide  group (n=71) Reference group (n=51)
Sym ptom N um ber Percent N um ber Percent
Skin peeling from the hands 38 53.5a 2 3.9
Numbness in the hands and feet 15 21.1b 2 3.9
Lassitude 14 19.7b 1 1.9
Sleepiness 12 16.9b 0 0
Muscle weakness 11 15.4b 0 0
Clumsiness of the hands 8 11.2a 0 0
Anorexia 8 11.2a 1 1.9
Unsteady gait 6 oo 4 Q
)
0 0
Coldness of the hands and feet 6 8.4a 0 0
Difficulty in grasping 5 7.0a 0 0
Stumbling and falling 5 7.0a 0 0
Sweating 27 38.0 14 27.4
Dizziness 7 9.8 2 3.9
Cramping pain 6 8.4 5 9.8
Sign
Erythema of hands 16 22.5b 0 0
Skin peeling from the hands 16 22.5b 1 1.9
Sensory impairments
16.9bVibration sensation 12 0 0
Pain sensation 7 9.8a 0 0
Touch sensation 6 8.4a 0 0
Position sensation 1 1.4 0 0
Muscle atrophy in hands 4 5.6 0 0
Diminished reflexes
Biceps 12 16.9b 0 0
Triceps 10 14.0 4 7.8
Knee 11 15.4a 1 1.9
Ankle 8 11.2a 1 1.9
Loss of reflexes
Biceps 3 4.2 0 0
Triceps 5 7.0 1 1.9
Knee 5 7.0a 0 0
Ankle 17 23.9b 0 0
Intention tremor 13 18.3a 2 3.9
Positive Romberg’s sign 15 21.1 3 5.8
ap <0.05
bp <0.01 (x2 test)
Source: He et al. 1989
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toes. Physical and neurological examinations and electroneuromyographic (ENMG) testing were 
performed. For each test, a nonexposed referent group was included. Quantitative assessment of 
contributions of dermal and inhalation exposure were not made, although in the synthesis area of the 
factory where neurological symptoms were most severe, dermal contact was considered to have been the 
major exposure route.
As shown in Table 3-3, a variety of symptoms and signs of adverse health effects were noted in 
acrylamide-exposed workers (Calleman et al. 1994). Other significant (p<0.01) effects in the exposed 
workers included increased (magnitude >60%) vibration threshold, decreased (10- 20%) conduction 
velocity in the peroneal and sural nerves, and increased (25-36%) latency in median, ulnar, and peroneal 
nerves. Neurotoxicity index scores, a quantitative expression of the severity of peripheral neuropathy, 
decreased with physical distance from the synthesis room where the monomer itself was handled. This 
relationship was not reflected by results of hand or foot vibration sensitivity measurements.
Hagmar et al. (2001) performed a health examination on a group of 210 tunnel construction workers who 
had been occupationally exposed for 2 months to a chemical grouting agent containing acrylamide and 
N-methylolacrylamide. Workers were expected to have experienced dermal exposure as well as 
inhalation exposure. Venous blood samples were drawn and questionnaires and physical examinations 
were administered 1-5 weeks after exposure was stopped. Quantitative exposure data were limited to two 
personal air samples showing concentrations of 0.27 and 0.34 mg/m3 for the sum of acrylamide and 
N-methylolacrylamide; further analysis suggested that the air contained a 50:50 mixture of these 
compounds. The health examination included an extensive questionnaire and a physical examination that 
included unspecified tests of peripheral nerve function. Blood samples for the analysis of adducts of 
acrylamide with N-terminal valines in hemoglobin were drawn within a month after construction work 
was completed. A group of 50 subjects who claimed recently developed or deteriorated peripheral 
nervous function at the initial physical examination was subjected to more detailed neurophysiologic 
examinations and 6-month follow-up clinical (n=29) and neurophysiological (n=26) examinations. Those 
with remaining symptoms were examined for up to 18 months postexposure.
Hemoglobin adduct levels for 18 nonsmoking unexposed referents varied between 0.02 and 0.07 nmol/g 
globin. Adduct levels in 47 of the 210 tunnel workers did not exceed the highest level of the referents. 
The remaining workers were divided into three categories according to adduct levels as follows: 89 with
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Table 3-3. Prevalence of Symptoms and Signs of Adverse Health Effects in 
Acrylamide-Exposed Workers and Controls
Sym ptom  or sign Exposed (percent) C ontro ls (n=10)
Numbness of extremities 29/41 (71)a 0
Fatigue 29/41 (71)a 0
Sweating of hands and feet 28/41 (71)a 0
Skin peeling 24/41 (59)a 0
Menstruation disorders 4/7 (57) NA
Loss of pain sensation 22/41 (54)a 0
Loss of touch sensation 19/41 (46)b 0
Dizziness 18/41 (44)b 0
Anorexia 17/41 (41)b 0
Loss of vibration sensation 17/41 (41)b 0
Nausea 16/41 (39)b 0
Loss of ankle reflexes 12/41 (29) 0
Headache 11/41 (27) 0
Unsteady gait 9/41 (22) 0
Loss of knee jerk 8/41 (20) 0
Unsteady Romberg sign 8/41 (20) 0
Loss of triceps reflexes 4/41 (10) 0
Loss of biceps reflexes 4/41 (10) 0
ap <0.01 (x2 test) 
bp <0.05
Source: Calleman et al. 1994
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0.08-0.29 nmol/g globin, 36 with 0.3-1.0 nmol/g globin, and 38 with 1.0-17.7 nmol/g globin. The study 
authors noted a significant (p<0.05) association between self-reported exposure categories and adduct 
levels. Significant positive correlations (p<0.05) between prevalence of self-reported peripheral nervous 
symptoms, irritant symptoms, and symptoms of general discomfort with adduct levels were found. For 
example, in the groups with adduct levels <0.08 nmol/g globin, 0.08-0.29 nmol/g globin, 0.3-1.0 nmol/g 
globin, and > 1.0 nmol/g globin, incidences of reported numbness or tingling in the feet or legs were 
2/47 (4%), 10/89 (11%), 9/36 (25%), and 14/38 (37%), respectively. Irritant symptoms and symptoms of 
general discomfort typically disappeared following the end of a workday, whereas peripheral nervous 
symptoms persisted. Follow-up examinations revealed that 58% of the subjects with early signs of 
impaired peripheral nervous function improved, while only 4% showed signs of deterioration.
Myers and Macun (1991) investigated peripheral neuropathy in a cohort of 66 workers in a South African 
factory that produced polyacrylamide. The investigation followed clinical diagnosis of peripheral 
neuropathy in five workers at the factory. The workforce was divided into a number of exposure 
categories, based on environmental sampling and discussions with workers. Exposure levels for the 
various tasks ranged from 0.07 to 2.5 times the National Institute of Occupational Safety and Health 
(NIOSH) recommended exposure limit (REL) of 0.3 mg/m3. Workers were then classified as being 
exposed to airborne acrylamide when exposure levels exceeded the REL (n=22), and unexposed when 
exposure levels were below the REL (n=41). Workers completed a questionnaire that was designed to 
capture social, medical, and occupational history. A standard blind neurological examination was also 
performed.
The exposed group showed higher prevalences of abnormalities for all symptoms (weakness, sensation, 
balance, fatigue, visual, loss of weight, urogenital, and fingertip skin), most signs (fingertip effects, light 
touch, tactile discrimination, pain), and reflexes, coordination, motor weakness, gait, and Rombergism. 
Statistically significant differences between exposed and unexposed groups for individual effects were 
seen only for abnormal sensation symptoms and signs in fingertip skin (including color, peeling, and 
sweating). The overall prevalence of acrylamide-related abnormalities among the exposed was 66.7%, 
which was statistically significantly higher (p<0.05) than that of the unexposed group (prevalence of 
14.3%). The authors stated that most workers observed to have abnormalities (number not reported) were 
employed in areas where exposures were highest (1.6-2.5 times the REL).
Bachmann et al. (1992) performed a follow-up investigation in July 1990 at the same South African 
factory that had been examined in 1986 by Myers and Macun (1991). The study design was similar to
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that of Myers and Macun (1991), but included measurements of vibration sensation threshold. Among 
82 workers employed at follow-up, increased prevalences of symptoms of tingling and numbness in hands 
and feet, weakness and pain in arms and legs, peeling hand skin, and sweating hands were reported by 
exposed workers, compared with those classified as being unexposed. The symptoms of numbness, limb 
pain, and peeling and sweating of hands were statistically significantly increased in exposed workers. 
Results of clinical examinations provided supporting evidence for the reported increased symptoms of 
peeling and sweating of the hands. No gross neurological abnormalities were found. Mean vibration 
sensation thresholds were similar among unexposed and exposed groups, even when adjusting for age, 
and no association was found between vibration thresholds and any symptoms.
Information regarding neurological effects in animals exposed to acrylamide by the inhalation route is 
limited to a single study report in which seven rats, seven guinea pigs, and two dogs were exposed to dust 
of acrylamide at an analytical concentration of 15.6 mg/m3 for 6 hours/day, 5 days/week for up to 
12 exposures in a 16-day period (American Cyanamid Company 1953a). Reported signs of neurological 
effects in the three rats that survived to exposure termination on day 4 included loss of equilibrium and 
coordination. There was no mention of neurological signs in the exposed dogs, although one of the dogs 
lost weight and died on day 15. No toxic signs were seen in the guinea pigs.
3.2.1.5 Reproductive Effects
No data were located regarding reproductive effects in humans or animals following inhalation exposure 
to acrylamide.
3.2.1.6 Developmental Effects
No data were located regarding developmental effects in humans or animals following inhalation 
exposure to acrylamide.
3.2.1.7 Cancer
Human data are available from two cohort mortality studies of occupational exposure to acrylamide, one 
by Collins et al. (1989) with most recent follow up by Marsh et al. (2007) and one by Sobel et al. (1986) 
with follow up by Swaen et al. (2007). Exposure to acrylamide was considered to have occurred 
primarily via inhalation and dermal exposure.
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Collins et al. (1989) conducted a cohort mortality study of all male workers (8,854, of which 2,293 were 
exposed to acrylamide) who had been hired between January 1, 1925 and January 31, 1973 at four 
American Cyanamid factories, three in the United States (Fortier, Louisiana [1295 workers]; Warners, 
New Jersey [7,153 workers]; and Kalamazoo, Michigan [60 workers]) and one in the Netherlands (Botlek 
[346 workers]). Estimations of acrylamide exposure were based on available monitoring data and worker 
knowledge of past jobs and processes. Mortality rates among the factory workers were compared with 
the expected number of deaths among men of the United States from 1925 to 1980 or the Netherlands 
from 1950 to 1982 to derive standardized mortality ratios (SMRs) as a measure of relative risk for each 
cohort. No statistically significantly elevated all cause or cause-specific SMRs were found among 
acrylamide-exposed workers (including cancer of the digestive or respiratory systems, bone, skin, 
reproductive organs, bladder, kidney, eye, central nervous system, thyroid, or lymphatic system). Trend 
tests showed no increased risk of mortality due to cancer at several sites (digestive tract, respiratory 
system, prostate, central nervous system, or lymphopoietic system) with increasing level of exposure to 
acrylamide.
The most recent update report of the cohort of Collins et al. (1989) includes study periods of 1925-2002 
for the 8,508 workers in the three facilities in the United States and 1965-2004 for the 344 workers at the 
Botlek plant in the Netherlands (the original cohort of 346 people included 2 females who were excluded 
in the follow up) (Marsh et al. 2007). Among the workers at the three facilities in the United States 
(during which 4,650 deaths occurred among the 8,508 workers in the period of 1925-2002), excess and 
deficit overall mortality risks were observed for cancer sites implicated in oral studies in experimental 
animals: brain and other central nervous system (SMR 0.67, 95% confidence interval [CI] 0.40-1.05), 
thyroid gland (SMR 1.38, 95% CI 0.28-4.02), and testis and other male genital organs (SMR 0.64, 95% 
CI 0.08-2.30); and for sites selected in the original report (Collins et al. 1989) of this cohort: respiratory 
system cancer (SMR 1.17, 95% CI 1.06-1.27), esophagus (SMR 1.20, 95% CI 0.86-1.63), rectum (SMR 
1.25, 95% CI 0.84-1.78), pancreas (SMR 0.94, 95% CI 0.70-1.22), and kidney (SMR 1.01, 95% CI 0.66­
1.46). None of the mortality excesses were statistically significant, except for respiratory system cancer, 
which Collins et al. (1989) attributed to muriatic acid (hydrochloric acid) exposure. No significantly 
elevated SMRs were found for rectal, pancreatic, or kidney cancers in exploratory exposure-response 
analyses conducted according to the following exposure parameters and categories: duration of 
employment (<1, 1-, and 15+ years), time since first employment (<20, 20-, and 30+ years), duration of 
exposure (unexposed, 0.001-, 5-, and 20+ years), cumulative exposure (<0.001, 0.001-, 0.03-, and 0.30+ 
mg/m3-years), and estimated mean exposure concentrations (unexposed, 0.001-, 0.02-, and 0.3+ mg/m3).
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Sobel et al. (1986) conducted a mortality study on a cohort of 371 workers assigned to acrylamide and 
polymerization operations at a Dow Chemical facility in the United States between 1955 and 1979. 
Analysis and review of air monitoring data and job classifications resulted in estimates of personal 8-hour 
time-weighted average acrylamide concentrations of 0.1-1.0 mg/m3 before 1957, 0.1-0.6 mg/m3 from 
1957 to 1970, and 0.1 mg/m3 thereafter. SMRs, calculated for categories in which at least two deaths 
were observed, were based on mortality of white males in the United States. No significantly increased 
incidences of cancer-related deaths were observed within the cohort.
Followup to the Sobel et al. (1986) study cohort was expanded to include employees hired through 2001 
(Swaen et al. 2007). Exposure to acrylamide was retrospectively assessed based on personal samples 
from the 1970s onwards and area samples from the entire study period. Fewer acrylamide workers died 
(n=141) than expected (n=172.1). No cause-specific SMR for any of the investigated types of cancer was 
exposure related. The authors reported more total pancreatic cancer deaths (n=5) than expected (n=2.3) 
(SMR 222.2, 95% CI 72.1-518.5); however, three of the five were in the low-dose group, with no 
apparent dose-response relationship with acrylamide exposure.
No data were located regarding cancer in animals following inhalation exposure to acrylamide. EPA 
(IRIS 2009) calculated an inhalation unit risk of 1.3x10-3 (mg/m3)-1 for acrylamide based on results of a 
2-year cancer bioassay in orally-exposed male and female F344 rats (Johnson et al. 1986) and route-to- 
route extrapolation (see Section 3.2.2.7 for details of the oral study). The air concentrations associated 
with risk of 1x 10-4, 1x 10-5, and 1x 10-6 are 0.08, 0.008, and 0.0008 mg/m3, respectively.
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3.2.2 Oral Exposure
3.2.2.1 Death
There are no reports of human deaths associated with oral exposure to acrylamide.
Acrylamide has been demonstrated to be lethal to laboratory animals following a single oral dose. 
Reported oral LD5 0  values in rats range from 150 to 413 mg/kg (American Cyanamid Company 1973, 
1977; Dow Chemical Company 1957; Fullerton and Barnes 1966; McCollister et al. 1964; Tilson and 
Cabe 1979; Union Carbide Corporation 1947). Reported LD5 0  values in mice, guinea pigs, and rabbits 
range from 107 to 195 mg/kg (American Cyanamid Company 1951; Dow Chemical Company 1957; 
Hashimoto et al. 1981; McCollister et al. 1964).
Repeated oral exposure to acrylamide has also been associated with death in laboratory animals. In one 
rat study, a single 100 mg/kg dose was not lethal, but two 100 mg/kg doses administered 24 hours apart 
resulted in mortalities (Fullerton and Barnes 1966). Sublet et al. (1989) reported death in a group of male 
Long-Evans hooded rats administered acrylamide by daily gavage for 5 days at a dose of 75 mg/kg/day. 
Longer repeated-dose exposure periods to lower daily doses are lethal as well. For example, a dose level 
of 50 mg/kg was lethal to rats receiving 12 daily gavage doses of 50 mg/kg in a 15-day period; the deaths 
occurred within a few days following the cessation of dosing (Fullerton and Barnes 1966). An 
acrylamide gavage dose of 30 mg/kg/day resulted in the death of 4/10 male and 2/10 female rats during 
the third week of daily dosing (Schulze and Boysen 1991). During the last 4 months of a 2-year study in 
which male and female rats received acrylamide from the drinking water at an estimated dose level of 
2 mg/kg/day, decreased survival of both sexes was noted; the increased mortality was statistically 
significant by study termination (Johnson et al. 1984, 1986).
Reliable acute oral LD5 0  values for death and other mortality data for each species are recorded in 
Table 3-4 and plotted in Figure 3-2.
3.2.2.2 Systemic Effects
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each 
species and duration category are recorded in Table 3-4 and plotted in Figure 3-2.
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral
Key to Species
Figure (Strain)
Exposure/
D ura tion /
F requency
(Route)
LOAEL
NOAEL Less Serious 
System  (m g/kg/day) (m g/kg/day)
Serious
(m g/kg/day)
Reference 
C hem ical Form
ACUTE EXPOSURE
Death
1 Rat
(Wistar)
Once
(GW)
294 M (LD5G) American Cyanamid Company 
1973
Rat Once 413 M (LD50) American Cyanamid Company
(Sprague- (GW) 1977
Dawley)
2
Rat Once 18G (LD5G) Dow Chemical Company 1957;
(NS) (GW) McCollister et al. 1964
3
Rat
(albino)
Once
(GW)
Rat
(albino)
2 d 
1 x/d 
(GW)
2G3 F (LD5G) Fullerton and Barnes 1966 
Acrylamide
100 (most rats died within 3 Fullerton and Barnes 1966
days following 2 days of Acrylamide 
dosing)
4
5
Rat Once M ,LD50) Tilson and Cabe 1979
(Fischer- 344) (GW) ( ) ^ b m i *
Rat Once 316 m (LD50) Union Carbide Corporation
(albino) (GW) 1947
6
7
Mouse Once 195 m (LD5G) American Cyanamid Company
(albino) (G) 1951
8
C om m ents
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to  Spec ies Freque" cy  NOAEL Less S erious Serious Reference
F igure (S train) (Route) System  (m g/kg/day) (m g/kg/day) (m g/kg/day) C hem ical Form  C om m ents
9 Mouse Once
(NS)
1G7 M (LD5G) Hashimoto et al. 1981 
Acrylamide
1O Gn Pig 
(NS)
Once
(GW)
18G (LD5G) Dow Chemical Company 1957; 
McCollister et al. 1964
11 Rabbit
(NS)
Once
(GW)
15G (LD5G) Dow Chemical Company 1957; 
McCollister et al. 1964
System ic
12 Rat 13 d
(Fischer- 344) (W)
Bd Wt 5 M 2G M (8% decreased mean
body weight)
Burek et al. 198G 
Acrylamide
13 Rat 1 d Bd Wt 5 M 15 M (significantly depressed Tyl et al. 2000b
(Long- Evans) body weight gain duhng Acrylamide
(GW) 5 days o f acrylamide
administration)
14 Rat Gd 6-17
(Fischer- 344) (GW)
Bd Wt 2G F Walden et al. 1981 
Acrylamide
Maternal body weight
15 Mouse Once 
ddY (NS)
Bd Wt 100 M 150 M (significantly depressed
body weight)
Sakamoto et al. 1988 
Acrylamide
16 Gn Pig Once
(NS) (GW)
Bd Wt 126 (very slight initial body 
weight loss)
Dow Chemical Company 1957; 
McCollister et al. 1964
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference
Figure  (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents
17 Rabbit
(NS)
Once
(GW)
Bd Wt 63 (slight initial weight loss) Dow Chemical Company 1957; 
McCollister et al. 1964
N euro log ica l
18 Rat 7 d
(Fischer- 344) (W)
2G M Burek et al. 198G 
Acrylamide
1S Rat Up to 21 d
(Wistar) 1 x/d 
(G)
25 M (convulsions and ataxia Dixit et a|. 1981 
as early as treatment day Acrylamide 
14)
20 Rat
(albino)
Once
(GW)
203 F (fine tremors) Fullerton and Barnes 1966 
Acrylamide
21 Rat
(albino)
Once
(GW)
100 (fine tremors) Fullerton and Barnes 1966 
Acrylamide
22 Rat
(albino)
2 d 
1 x/d 
(GW)
1GG (generalized weakness) Fu||er t°n and Barnes 1966
Acrylamide
23 Rat
(NS)
Once
(GW)
126 F (lethargy) McCollister et al. 1964 
Acrylamide
24 Rat Once
(Fischer- 344) (GW)
1GG M 200 M (decreases in hindlimb T ils°n  and Cabe 1979
grip strength and Acrylamide
locomotory performance)
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference
F igure (S train) (Route) System  (m g/kg/day) (m g/kg/day) (m g/kg/day) C hem ical Form
25 Rat 5 d
(Long- Evans) 1 x/d 
(GW)
3G M 45 M (clinical signs of 
neurotoxicity)
Tyl et al. 2GGGb 
Acrylamide
26 Rat Gd 6-17
(Fischer- 344) (GW)
2G F Walden et al. 1981 
Acrylamide
27 Mouse
(BALB/c)
12 d
(W)
25.8 F (decreased rotarod
performance, increased 
hindlimb splay as early 
as days 6-8)
Gilbert and Maurissen 1982 
Acrylamide
28 Dog Once 100 (severe neurological American Cyanamid Company
(M °ngre|) (C) impairment of the limbs) 1953c
2S Rabbit
(NS)
Once
(GW)
R eproductive
30 Rat 5 d
(Long- Evans) 1 x/d 
(GW)
b
5 M
126 (tremors)
15 M (depressed fertility, 
increased
preimplantation loss)
McCollister et al. 1964 
Acrylamide
Sublet et al. 1989 
Acrylamide
C om m ents
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference
F igure (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents
31 Rat 5 d
(Long- Evans) 1 x/d 
(GW)
3G M 45 M (significantly increased 
postimplantation losses)
Tyl et al. 2GGGb 
Acrylamide
A significant trend for 
increased
postimplantation loss 
was observed at doses 
from 15 to 60 
mg/kg/day
32 Rat 5 d
(Fischer- 344) 1 x/d 
(GW)
30 M (significantly elevated 
pre- and
post-implantation losses)
Working et al. 1987 
Acrylamide
33 Mouse
ddY
Once
(NS)
100 M (histologic abnormalities 
in spermatids)
Sakamoto et al. 1988 
Acrylamide
INTERMEDIATE EXPOSURE
Death
34 Rat 21 d
(albino) (F)
47 M (4/1G deaths during 21 
days of exposure)
American Cyanamid Company 
1953b
35 Rat 28 d
(Fischer- 344) (W)
25 M (death of 8/10 male rats 
during exposure week 4)
American Cyanamid Company 
1991
24 F (death of 5/10 female 
rats during exposure 
week 4)
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
LOAEL
System
NOAEL Less Serious 
(m g/kg/day) (m g/kg/day)
Serious
(m g/kg/day)
Reference 
C hem ical Form C om m ents
36 Rat
(albino)
12 doses in 
15 d 
(GW)
50 (death within a few days 
posttreatment)
Fullerton and Barnes 1966 
Acrylamide
37 Rat
(Sprague-
Dawley)
5 wk 
7 d/wk 
1 x/d 
(GW)
30 (death of 4/10 males and Schulze and Boysen 1991 
2/10 females during Acrylamide 
treatment week 3)
System ic
38 Rat
(albino)
21 d 
(F)
Bd Wt 47 M (severely depressed 
body weight gain)
American Cyanamid Company Magnitude not 
1953b specified
39 Rat
(Sprague-
Dawley)
2 wk premating 
and
Gd G-19 
(F)
Bd Wt 3.82 F American Cyanamid Company 
1979
Acrylamide
40 Rat 28 d
(Fischer- 344) (W)
Endocr 12 M 19 M (decreased serum
testosterone, 73% less 
than controls)
American Cyanamid Company 
1991
Bd Wt 12 M 
9 F
19 (emaciation)
41 Rat up to 93 d
(Fischer- 344) (W)
Hemato 1 F 5 F (decreases in packed cell
volume, erythrocytes, 
hemoglobin)
Burek et al. 198G 
Acrylamide
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference
Figure  (S tra in ) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents
42 Rat
(Sprague-
Dawley)
Gd 6-20 
1 x/d 
(GW)
Bd Wt 2.5 F 7.5 F (12% decreased
maternal weight gain)
Field et al. 1990 
Acrylamide
W eight gain minus 
gravid uterine weight
43 Rat
(Wistar)
21 d lactation 
period 
1 x/d
(G)
Bd Wt 25 F (net maternal weight loss Friedman et a l. 1999 
during 21-day lactation Acrylamide 
treatment period)
44 Rat
(Sprague-
Dawley)
5 wk 
7 d/wk 
1x/d 
(GW)
Bd Wt 30 (decreased mean body 
weight, 27% lower than 
controls)
Schulze and Boysen 1991 
Acrylamide
45 Rat
(Wistar)
90 d
(W)
Bd Wt 23.7 M Tanii and Hashimoto 1983 
Acrylamide
46 Rat
(Sprague-
Dawley)
Gd 6- Ld 10 
1 x/d 
(GW)
Bd Wt 5 F 10 F (approximately 33% Wise et al. 1995 
depressed maternal body A ciy lam ide 
weight gain during 10 
days of postpartum 
exposure)
47 Mouse
(CD-1)
Gd 6-20 
1 x/d 
(GW)
Bd Wt 45 F Field et al. 1990 
Acrylamide
48 Mouse
(ICR)
Up to 38 d
(W)
Bd Wt 90.8 M (body weight loss) Ko et al. 1999 
Acrylamide
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
Exposure/
D uration /
Key to  Species
F igure (Strain) (Route)
LOAEL
NOAEL Less Serious 
System  (m g/kg/day) (m g/kg/day)
Serious
(m g/kg/day)
Reference 
C hem ical Form C om m ents
49 Dog 8 wk 
(F)
Bd Wt 7 (up to 12% weight loss) Satchell and McLeod 1981
Acrylamide
50 Cat Up to 16 wk 
(F)
Bd Wt 15 (body weight loss,
magnitude unspecified)
Post and McLeod 1977a 
Acrylamide
N euro log ica l
51 Monkey 44-61 d 
5 d/wk 
1 x/d
10 F (c linical s igns of  Dow Chemical Company 1981; Histopathological
peripheral neuropathy) Maurissen et al. 1983 evaluation ° f  nerve
tissue not performed
Acrylamide
52 Monkey 6-1G wk 
5 d/wk 
1 x/d
10 (degenerative changes in Eskin et a l. 1985 
visual nerve fibers) Acrylamide
53 Monkey NS 
1 x/d 3G (peripheral neuropathy) Leswing and Ribe|in 1969
Acrylamide
54 Monkey
(NS)
up to 363 d 
5 d/wk 
(F)
3 F 10 F (clinical signs o f McCollister et al. 1964
peripheral neuropathy) Acrylamide
Only 1 animal per dose 
group; no clear signs of 
toxicity at 3 mg/kg/day
55 Monkey 33-47 d 
5 d/wk 
1 x/d
1G F (ataxia, adverse visual Merigan et a|. 1985
effects) Acrylamide
56 Rat 21 d
(albino) (F)
47 M (paralysis of hind limbs) American Cyanamid Company
1953b
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
LOAEL
NOAEL Less Serious 
System  (m g/kg/day) (m g/kg/day)
Serious
(m g/kg/day)
Reference 
C hem ical Form C om m ents
57 Rat
(albino)
NS
5 d/wk 
(G)
25 M (clinical signs o f American Cyanamid Company
peripheral neuropathy) 1959
58 Rat
(Sprague-
Dawley)
2 wk premating 
and
Gd G-19 
(F)
3.82 F American Cyanamid Company 
1979
Acrylamide
59 Rat 28 d
(Fischer- 344) (W)
12 M 
9 F
19 (clinical signs of
peripheral neuropathy)
American Cyanamid Company Histopathol° gical 
1991 evaluation of nerve
tissue not performed
60 Rat up to 93 d
(Fischer- 344) (W)
G.2 M 1 M (reversible ultrastructural 
degeneration in sciatic 
nerve fibers)
20 (progressive signs of 
peripheral neuropathy)
Burek et al. 198G 
Acrylamide
61 Rat
(Wistar)
Up to 21 d 
1 x/d
(G)
25 M (complete hindlimb 
paralysis by treatment 
day 21)
Dixit et al. 1981 
Acrylamide
62 Rat
(Wistar)
21 d lactation 
period 
1 x/d
(G)
25 F (progressive clinical 
signs o f neuropathy 
beginning as early as 
treatment day 4)
Friedman et al. 1999 
Acrylamide
electron microscopic 
examinations were not 
performed on sciatic 
nerve
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
NOAEL Less Serious 
System  (m g/kg/day) (m g/kg/day)
LOAEL
Serious
(m g/kg/day)
Reference 
C hem ical Form C om m ents
63 Rat
(albino)
12 doses in 
15 d 
(GW)
50 (severe weakness) Fullerton and Barnes 1966 
Acrylamide
64 Rat
(albino)
variable
(F)
6 (slight leg weakness after Fullerton and Barnes 1966 
40 weeks of exposure) Acrylamide
65 Rat
(albino)
38 d 
(F)
25 (severe leg weakness) Fullerton and Barnes 1966
Acrylamide
66 Rat
(albino)
Variable 
5 d/wk 
1 x/d 
(GW)
25 (severe leg weakness by Fullerton and Barnes 1966 
28 days of treatment) Acrylamide
67 Rat
(albino)
55 doses 
5 d/wk 
1 x/d 
(GW)
1G F Fullerton and Barnes 1966 Histopathological
evaluation of nerve
Acrylamide tissue not performed
68 Rat
(albino)
Variable 
1 d/wk 
1 x/d 
(GW)
100 (signs o f severe
neuropathy by the third 
dose)
Fullerton and Barnes 1966 
Acrylamide
Younger rats appeared 
to be less severely 
affected.
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
LOAEL
NOAEL Less Serious 
System  (m g/kg/day) (m g/kg/day)
Serious
(m g/kg/day)
Reference 
C hem ical Form C om m ents
69 Rat 21 d
(Fischer- 344) (W)
3 M 
1G F
10 M (clinical and Gorzinski et al. 1979
histopathologic evidence 
o f peripheral neuropathy)
30 F (clinical and
histopathologic evidence 
o f peripheral neuropathy)
70 Rat 3 mo
(Fischer- 344) 6 mo 
(W)
0.5 M 2 M (electron microscopic
degenerative effects in 
sciatic nerve fibers)
Johnson et al. 1984, 1986 
Acrylamide
71 Rat
(Sprague-
Dawley)
5 wk 
7 d/wk 
1x/d 
(GW)
10 (degenerative effects in Schulze and Boysen 1991 
nerve fibers) Acrylamide
72 Rat
(Sprague-
Dawley)
GD6-PD21
(W)
3.72 F 7.89 F (abnormal gait) Takahashi et al. 2GG9 
Acrylamide
73 Rat
(Wistar)
9G d
(W)
M 14.5 M (decreased rotarod 
performance)
Tanii and Hashimoto 1983 
Acrylamide
Electron microscopic 
evaluations o f nerve 
tissues not performed
74 Rat 4 wk
(Fischer- 344) 5 d/wk 
(GW)
1G M (hindlimb dysfunction) Ti|son and Cabe 1979
Acrylamide
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Freq uency NOAEL Less S erious Serious Reference
Figure  (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents
75 Rat 16 wk
(Fischer- 344) (W)
5 F 5 M (slight axonal 
fragmentation in 
peripheral nerves o f 6/6 
males assessed)
Tyl et al. 2000a 
Acrylamide
Assessment included 
clinical signs, 
histopathological 
evaluations of 
peripheral nerves
76 Rat
(Sprague-
Dawley)
Gd 6- Ld 10 
1 x/d 
(GW)
10 F 15 F (hindlimb splay in 100% 
o f dams during the first 
few days of postpartum 
exposure)
Wise et al. 1995 
Acrylamide
Histopathology of 
peripheral nerve tissue 
was not performed
77 Rat 10 wk
(Long- Evans) (W)
7.9 M (increased incidences of Zenick et a l. 1986 
hindlimb splay) Acrylamide
14.6 F (increased incidences of 
foot splay)
NOAEL for neurological 
effects not established 
due to lack of 
histopathologic 
assessment of 
peripheral nerve tissue
78 Mouse
(CD-1)
Gd 6-20 
1 x/d 
(GW)
15 F 45 F (up to 48% incidence of Field et a l. 1990 
hindlimb splay) Acrylamide
79 Mouse 8 wk 
2 x/wk 
(NS)
36 M (clinical signs of
peripheral neuropathy, Acrylamide 
testicular atrophy)
Hashimoto et al. 1981
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference
F igure (S train) (Route) System  (m g/kg/day) (m g/kg/day) (m g/kg/day) C hem ical Form  C om m ents
80 Mouse
(ICR)
Up to 38 d
(W)
90.8 M (clinically and
histopathologically 
confirmed peripheral 
neuropathy)
Ko et al. 1999 
Acrylamide
81 Mouse
(ICR)
NS
(W)
82 Dog
(Mongrel)
19 wk 
6 d/wk 
1 x/day 
(C)
83 Dog
(Mongrel)
29 d 
7 d/wk 
1 x/day 
(C)
84 Dog 6-7 wk 
(C)
85 Dog 8 wk 
(F)
91.8 M (clinical signs of
peripheral neuropathy; 
ultrastructural 
degeneration in 
cutaneous nerve 
terminals)
Ko et al. 2000; Ko et al. 2002 
Acrylamide
(loss of coordination in 
the rear extremities)
American Cyanamid Company 
1953c
10 F (incoordination and 
weakness o f the hind 
legs)
American Cyanamid Company 
1953c
5.7 (clinical evidence of 
neuropathy)
Hersch et al. 1989a 
Acrylamide
7 (clinical signs of
peripheral neuropathy)
Satchell and McLeod 1981 
Acrylamide
8
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
NOAEL Less Serious 
System  (m g/kg/day) (m g/kg/day)
LOAEL
Serious
(m g/kg/day)
Reference 
C hem ical Form C om m ents
86 Cat NS 
1 x/d 20 (peripheral neuropathy)
Leswing and Ribelin 1969 
Acrylamide
87 Cat
(NS)
up to 367 d 
5 d/wk 
(F)
(twitching motion in 
hindquarters at 26 days, 
slightly unsteady gait at 
47 days, definite 
weakness in the 
hindquarters at 68 days)
McCollister et al. 1964 
Acrylamide
Histopathological 
evaluation of nerve 
tissue not performed
3
88 Cat Up to 16 wk 
(F)
15 (initial weakness of 
hindlimbs and 
subsequent paralysis of 
fore- and hind-limbs)
Post and McLeod 1977a 
Acrylamide
89 Baboon up to 137 d 
1 x/d 
(F)
R eproductive
90 Rat 28 d
(Fischer- 344) (W)
12 M
10 (peripheral neuropathy)
19 M (atrophy o f the testes 
and/or seminal vesicles)
Hopkins 1970 
Acrylamide
American Cyanamid Company 
1991
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Freq uency NOAEL Less S erious Serious Reference
Figure  (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form ____________________ C om m ents
91 Rat 80 d 1.5 M 2.8 M (male-mediated Smith et al. 1986
(L °ng- Evans) (W) increased Acrylamide
postimplantation loss)
92 Rat 16 wk
(Fischer- 344) (W)
5 M (dominant lethal mutation Tyl et a l. 2000a 
effects) Acrylamide
(decreases in 
implantations and 
number o f live pups)
2
5
5.1 F 7.9 F (decreased pup body 8.8 M (male-mediated Zenick et a l. 1986
(Long- Evans) (W) weight) reproductive effects Acrylam ide
including decreased 
percentage impregnation 
o f nonexposed females 
and increased 
postimplantation loss)
94 Mouse
(CD-1)
16-22 wk 
(W)
3.1 M 7.5 M (increased early 
resorptions, total 
postimplantation loss, 
decreased numbers of 
live fetuses, decreased 
numbers of live pups; 
apparently male 
mediated)
Chapin et al. 1995 
Acrylamide
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference
F igure (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents
95 Mouse
ddY
D evelopm enta l
96 Rat
(Sprague-
Dawley)
4 wk
(W)
2 wk premating 
and
Gd G-19 
(F)
9 M 
18.7 F
3.82
13.3 M (decreased number of 
fetuses/dam)
Sakamoto and Hashimoto 
1986
Acrylamide
American Cyanamid Company 
1979
Acrylamide
Assessment included 
mating and pregnancy 
indices, litter data, and 
offspring growth and 
survival
97 Rat
(Sprague-
Dawley)
Gd 6-2G 
1 x/d 
(GW)
15 Field et al. 199G 
Acrylamide
Assessment included 
external, visceral, and 
skeletal examinations 
of offspring
98 Rat 15 wk
(Fischer- 344) Gd 1-21 
Ppd 1-84
(GW)
1.3 6 (effects on measures of 
cognitive motivation)
Garey and Paule 2007 
Acrylamide
99 Rat
(Wistar)
Throughout 
lactation via 
mothers or 
5 d 
1 x/d 
(G)
25 M (neurochemical changes Husain et a l. 1987 
in brain regions) Acrylamide
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
LOAEL
NOAEL Less Serious 
System  (m g/kg/day) (m g/kg/day)
Serious
(m g/kg/day)
Reference 
C hem ical Form C om m ents
>o
Y
1GG Rat
(Sprague-
Dawley)
GD6-PD21
(W)
7.89 14.56 (>40% decreased mean Takahashi et a l. 2OO9
pup body weight) Acrylamide
1G1
o
73
A
0 
P c
CD1
C
Co
1G2
Rat
(Sprague-
Dawley)
Mouse
(CD-1)
Gd 6- Ld 1G 
1 x/d 
(GW)
Gd 6-2G 
1 x/d 
(GW)
15
5 F (significantly decreased 
pup body weight during 
the preweaning period, 
as much as 9% lower 
than controls)
15 (increased overall 
horizontal activity and 
decreased auditory 
startle response)
45 (decreased mean fetal 
body weight; 15% lower 
than controls)
Wise et al. 1995 
Acrylamide
Field et al. 199G 
Acrylamide
Assessment included 
external, visceral, and 
skeletal examinations 
of offspring
.
H
m
A
o—I C/)
CHRONIC EXPOSURE
Death
1G3 Rat 2 yr
(Fischer- 344) (W)
2 (significantly decreased 
survival after 24 months 
o f treatment)
Johnson et al. 1984, 1986 
Acrylamide
^ 1
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference
F igure (S train) (Route) System  (m g/kg/day) (m g/kg/day) (m g/kg/day) C hem ical Form
S ystem ic
1G4 Rat 2 yr
(Fischer- 344) (W)
Resp 2 M 
d
3 F
Friedman et al. 1995 
Acrylamide
Cardio 2 M 
d
3 F
Gastro 2 M 
d
3 F
Hemato 2 M 
d
3 F
Musc/skel 2 M 
d
3 F
Hepatic 2 M 
d
3 F
Renal 2 M 
d
3 F
Endocr 2 M 
d
3 F
C om m ents
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to  Spec ies Freq uency NOAEL Less S erious Serious Reference
Figure  (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents
1Q5 Rat 2 yr
(Fischer- 344) (W)
N euro log ica l
106 Rat 2 yr
(Fischer- 344) (W)
Resp
Cardio 2
Gastro 2
Hemato 2
Musc/skel 2
Hepatic 2
Renal 2
Endocr 2
G.5 M
Johnson et al. 1984, 1986 
Acrylamide
2 M (light microscopic 
evidence o f peripheral 
nerve degeneration)
Friedman et al. 1995 
Acrylamide
electron microscopy 
not conducted
2
1Q7 Rat 2 yr
(Fischer- 344) (W)
G.5 (light microscopic 
evidence of moderate to 
severe degeneration in 
sciatic nerve fibers)
Johnson et al. 1984, 1986 
Acrylamide
2
108 Cat
(NS)
up to 367 d 
5 d/wk 
(F)
(clinical signs of 
peripheral neuropathy)
McCollister et al. 1964 
Acrylamide
3
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Freq uency NOAEL Less S erious Serious Reference
Figure  (S train) (______)__________System  (m g/kg/day) (m g/kg/day)____________________ (m g/kg/day)_________________ C hem ical Form____________________ C om m ents
R eproductive
109 Rat 2 yr
(Fischer- 344) (W)
Friedman et al. 1995 
Acrylamide
Gross and 
histopathological 
evaluations of 
reproductive organs 
and tissues
2
110 Rat 2 yr
(Fischer- 344) (W)
Johnson et al. 1984, 1986 
Acrylamide
Gross and 
histopathological 
evaluations of 
reproductive organs 
and tissues
2
Cancer
111 Rat 2 yr 1 F (CEL: mammary gland Friedman et al. 1995 Tunica vag ina|is
(Fischer- 344) (W) fibroadenomas and Acrylamide mesotheliomas and
adenomas or carcinomas thyroid gland tumors
combined) observed at high dose
(2 and 3 mg/kg/day in
males and females,
respectively)
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Table 3-4 Levels of Significant Exposure to Acrylamide - Oral (continued)
E xposure/ LOAEL
D uration /
Key  to' Spec ies Frequency NOAEL Less S erious Serious Reference
F igure (S train) (Route) System  (m g/kg/day) (m g/kg/day) (m g/kg/day) C hem ical Form  C om m ents
112 Rat 2 yr 0 5 M (CEL: testicular sac Johnson et al. 1984, 1986 At 2 mg/kg/day,
(Fischer- 344) (W) mesotheliomas) Acrylamide increased incidences of
'  Acrylamide tumors at other sites in
both males and 
females
a The number corresponds to entries in Figure 3-2.
b Study results used to derive an acute-duration oral minimal risk level (MRL) o f 0.02 mg/kg/day for acrylamide, as described in detail in Appendix A. Benchmark dose (BMD) 
analysis was performed on male-mediated implantation loss data to identify a point o f departure (BMDL10 of 1.78 mg/kg/day) which was divided by an uncertainty factor o f 1O0 (10 
for extrapolation from animals to humans and 10 for human variability).
c Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.002 mg/kg/day for acrylamide. The NOAEL of 0.2 mg/kg/day was divided by an uncertainty factor of 100 
(10 for extrapolation from animals to humans and 10 for human variability).
d Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 3-2. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented.
Bd W t = body weight; (C) = capsule; Cardio = cardiovascular; CEL = cancer effect level; d = day(s);; Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = 
gastrointestinal; Gd = gestation day; Gn Pig = guinea pig; (GW) = gavage in water; Hemato = hematological; Ld = lactation day; LD50 = lethal dose, 50% kill; LOAEL = 
lowest-observed-adverse-effect level; M = male; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; ppd = post-parturition 
day; Resp = respiratory; (W) = drinking water; wk = week(s); x = time(s); yr = year(s)
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Figure 3-2 Levels of Significant Exposure to Acrylamide - Oral
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Figure 3-2 Levels of Significant Exposure to Acrylamide - Oral (Continued)
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Figure 3-2 Levels of Significant Exposure to Acrylamide - Oral (Continued)
Intermediate (15-364 days)
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Figure 3-2 Levels of Significant Exposure to Acrylamide - Oral (Continued)
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Respiratory Effects. No data were located regarding respiratory effects in humans following oral 
exposure to acrylamide.
No clinical signs or gross or histopathological evidence of respiratory effects were observed in male or 
female F344 rats administered acrylamide in the drinking water for up to 93 days at concentrations 
resulting in doses up to 20 mg/kg/day (Burek et al. 1980) or for up to 2 years at concentrations resulting 
in doses up to 2 or 3 mg/kg/day (Friedman et al. 1995; Johnson et al. 1984, 1986).
Cardiovascular Effects. No data were located regarding cardiovascular effects in humans following 
oral exposure to acrylamide.
No clinical signs or gross or histopathological evidence of cardiovascular effects were observed in male 
or female F344 rats administered acrylamide in the drinking water for up to 93 days at concentrations 
resulting in doses up to 20 mg/kg/day (Burek et al. 1980) or up to 2 years at concentrations resulting in 
doses up to 2 or 3 mg/kg/day (Friedman et al. 1995; Johnson et al. 1984, 1986).
Gastrointestinal Effects. No data were located regarding gastrointestinal effects in humans following 
oral exposure to acrylamide.
No clinical signs or gross or histopathological evidence of gastrointestinal effects were observed in male 
or female F344 rats administered acrylamide in the drinking water for up to 93 days at concentrations 
resulting in doses up to 20 mg/kg/day (Burek et al. 1980) or up to 2 years at concentrations resulting in 
doses up to 2 or 3 mg/kg/day (Friedman et al. 1995; Johnson et al. 1984, 1986).
Hematological Effects. No data were located regarding hematological effects in humans following 
oral exposure to acrylamide.
Burek et al. (1980) reported significant decreases in packed cell volume (PCV), erythrocyte counts, and 
hemoglobin in male and female F344 rats at day 76 during administration of acrylamide in their drinking 
water at a dose level of 20 mg/kg/day. These effects were also noted in females (but not males) dosed at 
5 mg/kg/day for 93 days. Hematological evaluations at 3, 6, 12, 18, and 24 months on male and female 
F344 rats receiving acrylamide doses as high as 2 mg/kg/day from the drinking water for up to 2 years 
revealed no evidence of treatment-related effects (Johnson et al. 1984, 1986).
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE
3. HEALTH EFFECTS
57
Musculoskeletal Effects. No data were located regarding musculoskeletal effects in humans 
following oral exposure to acrylamide.
Atrophy of skeletal muscles in the posterior area was noted in F344 rats receiving acrylamide at a dose 
level of 20 mg/kg/day from the drinking water for up to 93 days; however, this effect was considered the 
likely result of acrylamide-induced peripheral neuropathy (Burek et al. 1980).
Renal Effects. No data were located regarding renal effects in humans following oral exposure to 
acrylamide.
Urinalysis and gross and histopathological evaluations revealed no evidence of renal effects in male or 
female F344 rats administered acrylamide in the drinking water for up to 93 days at concentrations 
resulting in doses up to 20 mg/kg/day (Burek et al. 1980) or up to 2 years at concentrations resulting in 
doses up to 2 or 3 mg/kg/day (Friedman et al. 1995; Johnson et al. 1984, 1986). Although distended 
bladders were occasionally observed in laboratory animals following repeated-dose oral exposure, this 
effect may be the result of acrylamide-induced effects on nerve fibers that innervate the bladder (Fullerton 
and Barnes 1966).
Endocrine Effects. No data were located regarding endocrine effects in humans following oral 
exposure to acrylamide.
Significantly decreased mean serum testosterone levels (27 and 9% of the control mean) were noted in 
adult male F344 rats administered acrylamide in the drinking water for 28 days at concentrations resulting 
in estimated acrylamide doses of 19 and 25 mg/kg/day, respectively; there were no statistically significant 
effects on serum testosterone levels at 14-day interim assessment (American Cyanamid Company 1991). 
In the same study, serum levels of the thyroid hormones thyroxin (T4 ) and triiodothyronine (T3 ) and 
serum prolactin were assessed in both male and female F344 rats receiving acrylamide from the drinking 
water at estimated doses up to 24-25 mg/kg/day. High-dose males exhibited significantly increased mean 
T4  concentration compared to controls at 14-day interim assessment and significantly decreased mean T3  
and T4  concentrations at study termination. Terminal (28-day) mean T3  level was significantly decreased 
in 19 mg/kg/day males as well. Mean T3  and T4  levels in treated female rats were not significantly 
different from controls at either time point. Serum prolactin levels were significantly decreased in 19 and 
25 mg/kg/day males at the 14-day interim assessment, but not at terminal assessment. No significant
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effects on serum prolactin levels were seen in treated female rats. At terminal sacrifice, no significant 
treatment-related effects on thyroid weights were seen in males or females at any dose level.
Gross and histopathological assessments revealed no evidence of endocrine effects in male or female 
F344 rats administered acrylamide in the drinking water for up to 93 days at concentrations resulting in 
doses up to 20 mg/kg/day (Burek et al. 1980) or up to 2 years at concentrations resulting in doses up to 2 
or 3 mg/kg/day (Friedman et al. 1995; Johnson et al. 1984, 1986).
Dermal Effects. No data were located regarding dermal effects in humans or animals following oral 
exposure to acrylamide.
Ocular Effects. No data were located regarding ocular effects in humans following oral exposure to 
acrylamide.
Ophthalmological evaluations revealed no evidence of ocular effects in male or female F344 rats 
administered acrylamide in the drinking water for up to 93 days at concentrations resulting in doses up to 
20 mg/kg/day (Burek et al. 1980) or up to 2 years at concentrations resulting in doses up to 2 or 
3 mg/kg/day (Friedman et al. 1995; Johnson et al. 1984, 1986).
Acrylamide-induced neurological effects on the visual system of orally-exposed primates are discussed in 
Section 3.2.2.4 (Neurological Effects).
Body Weight Effects. No data were located regarding body weight effects in humans following oral 
exposure to acrylamide.
Depressed body weight, including actual body weight loss, was consistently reported in laboratory 
animals following single or repeated oral exposure to acrylamide.
Slight initial weight loss (magnitude not specified) was reported following a single oral dose of 126 mg
acrylamide/kg in rats and guinea pigs and 63 mg/kg in rabbits (Dow Chemical Company 1957). 
Significantly depressed body weight was observed for several days in mice dosed once at 150 mg/kg
(lethal dose), but not at 100 mg/kg (sublethal dose) (Sakamoto et al. 1988).
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Depressed body weight or actual body weight loss was observed in repeat-dosing studies as well. Weight 
loss was noted in 3- and 6-week-old mice receiving a high daily dose (90.8 mg/kg) of acrylamide for 20 
and 38 days, respectively (Ko et al. 1999). Most repeated-dose oral studies, however, identified much 
lower body weight effect levels. At treatment day 13 of a 3-month study, significantly decreased mean 
body weights (8% lower than controls) were observed in male and female rats receiving acrylamide at 
20 mg/kg/day from the drinking water (Burek et al. 1980). Significantly depressed body weight gain 
(approximately 40% less than controls) was noted in male Long-Evans rats receiving 15 mg/kg/day of 
acrylamide for 5 consecutive days; there were no apparent acrylamide-induced effects at 5 mg/kg/day 
(Tyl et al. 2000b). Severely depressed body weight gain (approximately 50% that of controls) was 
observed during 21 days of exposure of male albino rats to acrylamide in the food at a concentration 
resulting in an estimated daily acrylamide dose of 47 mg/kg/day (American Cyanamid Company 1953b). 
This dose level resulted in the death of 3/10 of the rats by the end of the treatment period; three surviving 
rats exhibited somewhat greater weight gain than controls during a 10-week recovery period. Severely 
depressed body weight and emaciation were reported in studies of rats administered acrylamide for 
periods of 3-5 weeks at doses in the range of 19-30 mg/kg/day (American Cyanamid Company 1953b, 
1991; Schulze and Boysen 1991). Tanii and Hashimoto (1983), however, reported no significant effects 
on body weight in male Wistar rats administered acrylamide in the drinking water for 90 days at 
concentrations resulting in estimated doses as high as 23.7 mg/kg/day. Dogs and cats are also susceptible 
to the body weight effects of orally-administered acrylamide. An 8-week dosing period to dogs at 
7 mg/kg/day resulted in weight loss (Satchell and McLeod 1981). Cats dosed for 12-16 weeks at 
15 mg/kg/day exhibited weight loss of unspecified magnitude (Post and McLeod 1977a).
Several groups of investigators assessed effects of maternal body weight on rat or mouse dams receiving 
oral acrylamide during gestation and/or lactation. A daily dose as low as 7.5 mg/kg/day during gestation 
days 6-20 resulted in approximately 12% depressed maternal weight gain in rats, but a NOAEL of 
45 mg/kg/day was identified in similarly-treated mouse dams (Field et al. 1990). Net maternal weight 
loss was observed in rat dams administered acrylamide at 25 mg/kg/day during 21 days of lactation 
(Friedman et al. 1999). Wise et al. (1995) treated rat dams with 5 or 15 mg/kg/day from gestation day 6 
through lactation day 10; no body weight effects were seen at the 5 mg/kg/day dose level, but 
approximately 33% depressed maternal weight gain was noted during the 10-day lactation period in the 
15 mg/kg/day group.
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3.2.2.3 Immunological and Lymphoreticular Effects
No data were located regarding immunological or lymphoreticular effects in humans or animals following 
oral exposure to acrylamide.
3.2.2.4 Neurological Effects
Neurological deficits are a hallmark of acrylamide toxicity. Most evidence in humans derives from 
occupational exposures that predominantly involved inhalation and dermal routes (see Section 3.2.1.4). 
Available information regarding the neurological effects of oral exposure in humans is limited to a case 
report of persistent peripheral neuropathy in a subject who intentionally ingested 18 g of acrylamide 
crystals (Donovan and Pearson 1987) and signs of central and peripheral neurological deficits in family 
members exposed (likely via oral and dermal routes) to acrylamide in well water at a concentration of 
400 ppm (Igisu and Matsuoka 2002; Igisu et al. 1975). Epidemiologic studies designed to evaluate 
noncancer health effects in groups of orally-exposed subjects have not been conducted.
Neurological effects associated with oral exposure to acrylamide have been well characterized in 
laboratory animals and include clinical signs such as twitching, loss of balance, tremors, lethargy, and 
general weakness and more subtle indicators of functional deficits such as decreased rotarod performance 
and increased limb or foot splay. Evidence of degenerative lesions in peripheral nerve fibers, as observed 
by light and electron microscopy, have been detected at oral doses lower than those eliciting clinical signs 
and other overt indications of functional deficit.
Clinical signs have been elicited following single oral exposure of rats, rabbits, and dogs to doses in the 
range of 100-200 mg/kg (American Cyanamid Company 1953c; Fullerton and Barnes 1966; McCollister 
et al. 1964; Tilson and Cabe 1979). Five daily doses to rats at 45 mg/kg (Tyl et al. 2000b) or 75 mg/kg 
(Sublet et al. 1989) elicited typical clinical signs of peripheral neuropathy. Ko et al. (1999) noted the 
onset of altered gait as early as treatment day 5 in 3- and 8-week-old mice receiving acrylamide from the 
drinking water at approximately 90 mg/kg/day. Friedman et al. (1999) and Dixit et al. (1981) observed 
clinical signs of neurological effects as early as treatment days 4 and 14, respectively, in rats receiving 
acrylamide at 25 mg/kg/day. Gilbert and Maurissen (1982) reported decreased rotarod performance and 
increased hindlimb splay as early as days 6-8 of a 12-day exposure of mice receiving acrylamide from the 
drinking water at an estimated dose of 25.8 mg/kg/day.
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Clinical signs and other indicators of acrylamide-induced functional neurological deficit, such as 
increased hindlimb splay and decreased rotarod performance, during intermediate-duration (15-364 days) 
exposure have been observed in several animal species. In rats and cats, dose levels in the range of 8­
25 mg/kg/day elicited overt signs of neurological deficit as early as 3-8 weeks following the initiation of 
treatment (American Cyanamid Company 1991; Burek et al. 1980; Fullerton and Barnes 1966; Gorzinski 
et al. 1979; Leswing and Ribelin 1969; McCollister et al. 1964; Post and McLeod 1977a; Takahashi et al. 
2009; Tanii and Hashimoto 1983; Tilson and Cabe 1979; Wise et al. 1995; Zenick et al. 1986). Slight leg 
weakness was reported after 40 weeks of oral dosing at 6 mg/kg/day in one rat study (Fullerton and 
Barnes 1966). In dogs, dose levels of 5.7-10 mg/kg/day elicited clinical signs within 3-4 weeks 
(American Cyanamid Company 1953c; Hersch et al. 1989a; Satchell and McLeod 1981). Hashimoto et 
al. (1981) noted typical signs of peripheral neuropathy and diminished rotarod performance in male mice 
treated at 36 mg/kg/day, 2 days/week for 8 weeks. In primates (monkeys, baboons), clinical signs were 
elicited by doses of 10-30 mg/kg/day for periods of 42-61 days (Eskin et al. 1985; Hopkins 1970; 
Leswing and Ribelin 1969; Maurissen et al. 1983; Merigan et al. 1985). Higher levels of oral dosing 
typically result in earlier onset of clinical signs and more severe effects with continued dosing.
Histopathological assessment of acrylamide-induced neurological effects includes studies in which light 
and electron microscope evaluations were performed on peripheral nerve fibers of rats administered 
acrylamide in the drinking water (Burek et al. 1980; Johnson et al. 1984, 1985, 1986). In the study of 
Burek et al. (1980), the rats received estimated doses of 0.05-20 mg/kg/day for up to 93 days. This study 
identified a NOAEL of 0.2 mg/kg/day and a LOAEL of 1 mg/kg/day for increased incidences of 
ultrastructural degeneration (axolemma invaginations with cell organelles and/or dense bodies) in the 
sciatic nerve; higher doses elicited more pronounced degenerative effects that could also be detected by 
light microscopy. Clinical signs of peripheral neuropathy were elicited at the 20 mg/kg/day dose level. 
The study of Johnson et al. (1984, 1985, 1986) employed estimated dose levels of 0.01, 0.1, 0.5, and
2.0 mg/kg/day for up to 2 years. Interim evaluations of peripheral nerve fibers were performed at 3, 6, 12, 
and 18 months; however electron microscope evaluations at interims >12 months were inconclusive due 
to high incidences of degenerative results attributed in part to aging. The studies of Johnson et al. (1984, 
1985, 1986) identified a NOAEL of 0.5 mg/kg/day and a LOAEL of 2 mg/kg/day for increased incidences 
of ultrastructural degeneration (axolemma invaginations) in the sciatic nerve at 3, 6, and 12 months and 
for light microscopy evidence of degenerative effects in peripheral nerve fibers at 12-24 months; there 
were no clinical signs of neurological effects at any dose level . Friedman et al. (1995) duplicated the 
study design of Johnson et al. (1986), but excluded electron microscopy in histopathological evaluations 
of peripheral nerve fibers. The study of Friedman et al. (1995) also identified a NOAEL of 0.5 mg/kg/day
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and a LOAEL of 2 mg/kg/day for peripheral nerve degeneration as revealed by light microscopy in the 
absence of clinical signs of neurological effects. Histopathological evidence (light microscope) of 
degenerative effects was also noted in fibers from cervical and lumbar spinal cord, gasserian and dorsal 
root ganglia, and sciatic, tibial, and sural nerves of male and female Sprague-Dawley rats that had 
received acrylamide by gavage for 5 weeks at doses of 10 and 30 mg/kg/day (Schulze and Boysen 1991). 
The most severe changes were observed in the large fibers of the tibial and sural nerves of high-dose rats. 
In a 2-generation study of F-344 rats, Tyl et al. (2000a) reported degenerative effects in peripheral nerve 
fibers of F0 (but not female or Fj male or female) rats that had received acrylamide from the drinking 
water at 5 mg/kg/day for 16 weeks.
Information regarding the neurodevelopmental toxicity of acrylamide is discussed in Section 3.2.2.6.
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in 
each species and duration category are recorded in Table 3-4 and plotted in Figure 3-2.
3.2.2.5 Reproductive Effects
No studies were located regarding acrylamide-induced reproductive effects in humans.
Animal studies designed to assess the reproductive toxicity of orally-administered acrylamide revealed 
pre- and postimplantation losses and decreased numbers of live fetuses in rats and mice at repeated doses 
in the range of 3-60 mg/kg/day (Chapin et al. 1995; Sakamoto and Hashimoto 1986; Smith et al. 1986; 
Sublet et al. 1989; Tyl et al. 2000a, 2000b; Working et al. 1987; Zenick et al. 1986).
Results of dominant lethality testing (Chapin et al. 1995; Smith et al. 1986; Tyl et al. 2000a, 2000b) and 
crossover trials (Chapin et al. 1995; Sakamoto and Hashimoto 1986; Zenick et al. 1986) indicate that 
acrylamide induces male-mediated reproductive effects at repeated oral doses in the range of 2.8­
19 mg/kg/day. Sublet et al. (1989) reported statistically significant moderately decreased sperm mobility 
in Long-Evans rats administered acrylamide at a gavage dose of 45 mg/kg/day for 5 days, but suggested 
that this effect was not solely responsible for poorer reproductive performance. In apparent contrast, Tyl 
et al. (2000b) found no significant effects on sperm parameters in Long-Evans hooded rats following 
repeated oral dosing at levels as high as 60 mg/kg/day and suggested that indicators of acrylamide- 
induced reproductive toxicity such as pre-and post-implantation loss and decreased numbers of live 
fetuses may be at least partly the result of impaired mating performance due to acrylamide neurotoxicity.
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Histologic indicators of degenerative effects were reported in spermatids of ddY mice administered 
acrylamide by daily gavage for 5 days at dose levels of 100 or 150 mg/kg/day (Sakamoto et al. 1988). 
Other investigators reported evidence of acrylamide-induced testicular atrophy in F344 rats receiving 
acrylamide in the drinking water for 28 or 90 days at concentrations resulting in estimated acrylamide 
doses of 19 or 5 mg/kg/day, respectively (American Cyanamid Company 1991; Burek et al. 1980). Gross 
and histopathologic examinations of reproductive organs and tissues from male rats receiving acrylamide 
from the drinking water for up to 2 years at estimated doses as high as 2 mg/kg/day revealed no signs of 
acrylamide-induced effects (Friedman et al. 1995; Johnson et al. 1984, 1986).
Prebreeding exposure of female mice to acrylamide at 18.7 mg/kg/day (Sakamoto and Hashimoto 1986) 
or female Long-Evans rats to doses up to 14.6 mg/kg/day (Zenick et al. 1986) did not adversely affect 
reproductive performance variables such as fertility or implantation when the animals were bred with 
nonexposed males. Gross and histopathologic examinations of reproductive organs and tissues from 
female rats receiving acrylamide from the drinking water for up to 2 years at estimated doses as high as 
2-3 mg/kg/day revealed no signs of acrylamide-induced effects (Friedman et al. 1995; Johnson et al.
1984, 1986).
Atrophy of the testes and/or seminal vesicles was reported in F-344 rats receiving acrylamide at 19 or 
25 mg/kg/day from the drinking water for 28 days; this effect was not seen at 12 mg/kg/day (American 
Cyanamid Company 1991).
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in 
each species and duration category are recorded in Table 3-4 and plotted in Figure 3-2.
3.2.2.6 Developmental Effects
No studies were located regarding acrylamide-induced developmental effects in humans.
Several reports are available in which developmental toxicity was assessed in the offspring of rat or 
mouse dams administered acrylamide via daily gavage during gestation and/or lactation (American 
Cyanamid Company 1979; Field et al. 1990; Friedman et al. 1999; Garey and Paule 2007; Husain et al. 
1987; Takahashi et al. 2009; Walden et al. 1981; Wise et al. 1995).
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Body weight decreases and decreased auditory startle response were noted in offspring of female 
Sprague-Dawley rats exposed to 5 and 15 mg/kg-day, respectively, on gestation days 6-10 (Wise et al. 
1995). No exposure-related fetal malformations or variations (gross, visceral, or skeletal) were found in 
offspring of Sprague-Dawley rats administered acrylamide at doses of 2.5, 7.5, or 15 mg/kg/day on 
gestation days 6-20 or in CD-1 mice at doses of 3, 15, or 45 mg/kg/day on gestation days 6-17 (Field et 
al. 1990). The highest dose in each species was maternally toxic, as evidenced by depressed maternal 
weight gain in the rats and mice and increased hindlimb splay in the mice. There were no indications of 
treatment-related developmental effects in the offspring of Sprague-Dawley rat dams administered 
acrylamide at doses up to nearly 4 mg/kg/day for 2 weeks premating and throughout gestation (American 
Cyanamid Company 1979). Decreased mean fetal body weight (approximately 15% lower than controls) 
was noted in the offspring of CD-1 mouse dams administered acrylamide by gavage at 45 mg/kg/day 
during gestation days 6-20; a NOAEL for this effect was 15 mg/kg/day (Field et al. 1990). Significantly 
depressed mean body weights were reported in offspring of Sprague-Dawley rat dams administered 
acrylamide in the drinking water at 100 ppm (mean acrylamide intake 14.56 mg/kg/day) from gestation 
day 6 through postnatal day 21; the male and female pups exhibited approximately 42 and 46% lower 
mean body weights, respectively, than unexposed control pups (Takahashi et al. 2009). At lower mean 
maternal exposure levels doses (25 and 50 ppm; mean doses of 3.72 and 7.89 mg/kg/day, respectively), 
pup body weights did not differ significantly from those of controls. There were no signs of acrylamide- 
induced neurotoxicity or testicular toxicity in pups of any exposure group. The 100 ppm dams exhibited 
increasing severity of gait abnormalities from postnatal day 2 onward; abnormal gait was observed in 
50 ppm dams from postnatal day 18 onward.
Periodic significantly decreased brain levels of selected catecholamines (noradrenaline, dopamine, 
5-hydroxytryptamine) were noted in pups of rat dams administered acrylamide at 25 mg/kg/day during 
lactation only (Husain et al. 1987). Similar effects on brain catecholamines were observed in rat pups 12­
21 days of age at the beginning of a 5-day period in which they were administered acrylamide by gavage 
at 25 mg/kg/day; these effects were not seen in rat pups that were 60 days of age at the initiation of dosing 
(Husain et al. 1987). Decreased performance in an operant test of cognitive motivation was reported in 
adolescent F344 rats exposed during gestation and lactation and extending through 12 weeks of age at an 
average dose of 6 mg/kg/day, but not at 1.3 mg/kg/day (Garey and Paule 2007). Significant decreases in 
whole brain levels of noradrenaline, dopamine, and 5-hydroxytryptamine were observed in pups of rat 
dams administered acrylamide at 25 mg/kg/day during lactation. Walden et al. (1981) found significant 
alterations in intestine enzyme levels in young Sprague-Dawley rat pups whose mothers had received 
acrylamide via gavage on gestation days 6-17 at 20 mg/kg/day; the toxicological significance of these
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findings is uncertain. Friedman et al. (1999) reported increased mortality and reduced body weights in 
pups of rat dams dosed at 25 mg/kg/day during lactation; however, serious maternal toxicity was noted as 
well.
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in 
each species and duration category are recorded in Table 3-4 and plotted in Figure 3-2.
3.2.2.7 Cancer
Available epidemiology studies on increased risk of cancer from acrylamide in food include case-control 
studies (Michels et al. 2006; Mucci et al. 2003, 2004, 2005; Pelucchi et al. 2006, 2007; Wilson et al. 
2009a) and reports from ongoing prospective studies (Hogervorst et al. 2007, 2008a, 2008b; Larsson et al. 
2009a, 2009b, 2009c, 2009d; Mucci et al. 2006; Wilson et al. 2009b). These studies provide little 
evidence for acrylamide-induced cancer in humans exposed to acrylamide in the diet. See Section 3.2.1.7 
(Cancer) for information regarding cancer among acrylamide workers primarily exposed via inhalation 
and dermal routes.
Case-control Studies. No statistically significant associations were found between self-reported 
consumption of foods with high (300-1,200 ^g/kg) or moderate (30-299 ^g/kg) acrylamide 
concentrations and increased risk of large bowel, kidney, or bladder cancer in a population-based case- 
control study (692 controls and 875, 391, and 186 large bowel, kidney, and bladder cancer cases, 
respectively) (Augustsson et al. 1999; Mucci et al. 2003). Information on intake of various foods and 
nutrients was assessed by questionnaire. Cancer cases were born in Sweden between 1918 and 1942 and 
resided in Stockholm for at least 1 month between November 1992 and December 1994. Controls were 
selected from a Swedish national population registry and matched to cases by age and gender.
Mucci et al. (2005) assessed acrylamide intake of >43,000 women, including 667 breast cancer cases, 
who were enrolled in the Swedish Women’s Lifestyle and Health Cohort. The estimated average daily 
acrylamide intake among the participants was 25.9 ^g/day and was based on results of food frequency 
questionnaires (FFQs) and the Swedish National Food Administration database of information on 
acrylamide content of selected food items. After ranking the women into quintiles of estimated 
acrylamide intake (means of 12, 20, 25, 31, and 44 ^g/day), there was no significant increased risk of 
breast cancer in the higher quintiles compared to the lowest quintile.
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Within an integrated network of Italian and Swiss hospital-based case-control studies to investigate the 
relation between dietary acrylamide intake and cancers at several sites, no significant associations were 
found between estimated dietary acrylamide intake and cancers of the oral cavity and pharynx, esophagus, 
large bowel, larynx, breast, ovary, or prostate (Pelucchi et al. 2006). Dietary acrylamide intake was 
estimated based on results of FFQs and average content of acrylamide in foods from resources of the 
World Health Organization and Swiss Federal Office of Public Health. In another case-control study that 
included four areas of Italy, no significant association was found between total dietary acrylamide intake 
and renal cell cancer (Pelucchi et al. 2007). In this study, statistically significantly elevated odds ratios 
(ORs: 1.49, 95% CI 1.18-1.87; 1.70, 95% CI 1.25-2.30) were noted for weekly white bread portions of 
7-<21 and >21, respectively; however, the study authors indicated that the relationship between white 
bread consumption and renal cell cancer might be explained by a high glycemic content and consequent 
effect on levels of insulin-like growth factors.
Wilson et al. (2009a) conducted a case-control study to assess possible associations between acrylamide 
and prostate cancer risk using two measures of acrylamide exposure: intake from FFQs and acrylamide- 
hemoglobin adduct levels in blood samples. Dietary data were available for 1,499 prostate cancer cases 
and 1,118 controls from a Cancer of the Prostate in Sweden (CAPS) population-based case-control study. 
Acrylamide-hemoglobin adduct levels were measured in blood samples from a subset of 170 prostate 
cancer cases and 161 controls. Controls were randomly selected from the Swedish Population Registry 
and were frequency matched to cases by 5-year age groups and region of residence. No significant 
association was found between acrylamide exposure (as measured by FFQ or acrylamide-hemoglobin 
adduct levels) and risk of prostate cancer.
Michels et al. (2006) conducted a case-control study to evaluate whether diet during preschool age 
affected a woman’s risk of breast cancer later in life. Cases and controls were selected from participants 
in two prospective cohort studies, the Nurses’ Health Study and the Nurses’ Health Study II. Information 
concerning childhood diet of the nurses at ages 3-5 years was obtained from FFQs filled out by the 
mothers of the participants. The median year of birth of the mothers was 1914 for case mothers and 1913 
for control mothers. The results indicated an increased risk of breast cancer among woman who had 
frequently consumed French fries at preschool age. For one additional serving of French fries per week, 
the OR for breast cancer adjusted for adult life breast cancer risk factors was 1.27 (95% CI= 1.12-1.44). 
Consumption of whole milk was associated with a slightly decreased risk of breast cancer (covariate- 
adjusted OR for every additional glass of milk per day=0.90; 95% CI=0.82-0.99). Intake of none of the 
nutrients calculated was related to the breast cancer risk in this study. The authors noted that they did not
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observe a similar association of breast cancer with frequent consumption of hot dogs or ground beef, 
suggesting that French fry consumption was not a marker of “fast food” habits. The study results suggest 
a possible association between diet before puberty and the subsequent risk of breast cancer, but the 
conclusions and the study are of limited use. No information is available on cooking methods or 
acrylamide content in the foods being evaluated, and the ability of mothers to accurately recall preschool 
diets of their daughters is questionable.
No significant associations were found between acrylamide-hemoglobin or glycidamide-hemoglobin 
adduct levels and total breast cancer in a Danish nested case-control study that examined breast cancer 
and acrylamide exposure using acrylamide-hemoglobin and glycidamide-hemoglobin adduct levels in red 
blood cells as presumed biomarkers for oral exposure to acrylamide (Olesen et al. 2008). After adjusting 
for confounding factors including smoking behavior, the study authors noted that a 10-fold increase in 
acrylamide-hemoglobin adduct levels was associated with a 1.9 (95% CI 0.9-4.0) times higher risk of 
breast cancer and a 5-fold increase (which corresponds to the range in acrylamide-hemoglobin adduct 
levels among nonsmokers) was associated with a 1.6 (95% CI 0.9-2.6) times higher risk. A significant 
positive association was observed between acrylamide-hemoglobin adduct level and ER+ breast cancer; a 
10-fold increase in adduct level was associated with a 4.9 (95% CI 1.2-20) times increased risk in 
smokers and 2.7 (95% CI 1.1-6.6) times increased risk after adjustment for smoking. However, this 
study is limited by the relatively small number of subjects (374 cases and 374 controls) and uncertainty 
regarding extrapolation of acrylamide exposure as assessed by a few months of acrylamide-hemoglobin 
adduct measurements to a lifetime of exposure.
Mucci et al. (2004) analyzed data from a large population-based Swedish case-control study of renal cell 
cancer. FFQs were used to collect information on intake of 11 food items with elevated acrylamide levels 
as ascertained through extensive food databases in Sweden and the United States and quartiles of daily 
food and acrylamide intake were created. This study found no evidence that food items with elevated 
acrylamide were associated with a higher risk of renal cell cancer risk.
Prospective Studies. Recent and ongoing prospective studies designed to evaluate possible associations 
between acrylamide in food and risk of cancers at various sites include cohorts from Sweden (Larsen et 
al. 2009a, 2009b, 2009c, 2009d; Mucci et al. 2006), the United States (Wilson et al. 2009b), and the 
Netherlands (Hogervorst et al. 2007, 2008a, 2008b). Most studies found no statistically significant 
associations between acrylamide in food and risks of cancers of the esophagus, stomach, or pancreas 
(Hogervorst et al. 2008b); colon or rectum (Hogervorst et al. 2008b; Larsen et al. 2009c; Mucci et al.
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2006); bladder or prostate (Hogervorst et al. 2008a); breast (Hogervorst et al. 2007; Larsson et al. 2009d; 
Wilson et al. 2009b); endometrium (Hogervorst et al. 2007; Larsson et al. 2009a), or ovarian epithelium 
(Larsson et al. 2009b). Exceptions include increased risks of postmenopausal endometrial and ovarian 
cancer (Hogervorst et al. 2007) and renal cell cancer (Hogervorst et al. 2008a) with increasing dietary 
acrylamide in prospective studies of a Dutch population, but in these studies, estimations of dietary 
acrylamide levels in foods on the market at baseline in 1986 were based on food samples analyzed since 
2001 and questionnaires did not include details regarding specifics of food preparation. Some of the 
tumor sites observed in animal studies (thyroid, testis, central nervous system) have not been evaluated in 
humans, and there are limitations in some of the study methods and cohort sizes in the prospective 
studies.
Information regarding the carcinogenicity of acrylamide in orally-exposed animals is available from two 
similarly-designed 2-year bioassays (Friedman et al. 1995; Johnson et al. 1984, 1985, 1986) in which 
groups of male and female F344 rats were administered acrylamide in the drinking water at 
concentrations calculated to provide doses up to 2 mg/kg/day (3 mg/kg/day for high-dose female rats of 
the Friedman et al. 1995 study). Selected tumor types with significantly increased incidences in 
acrylamide-treated rats from both studies are summarized in Table 3-5. Significantly increased 
incidences of mesotheliomas of the tunica vaginalis testis were observed by Johnson et al. (1984, 1986) in 
male rats at the two highest dose levels (0.5 and 2 mg/kg/day). Additional findings included significantly 
increased incidences of thyroid (follicular cell) adenomas (no carcinomas), mesotheliomas of the tunica 
vaginalis testis, and benign adrenal pheochromocytoma in high-dose males and mammary gland benign 
tumors (adenoma, fibroadenomas, or fibroma), central nervous system tumors of glial origin, thyroid 
(follicular cell) adenomas or adenocarcinomas, squamous papillomas of the oral cavity, uterine 
adenocarcinomas, benign clitoral gland adenomas, and pituitary gland adenomas in high-dose females. 
The study of Friedman et al. (1995) noted increased incidences of tunica vaginalis mesothelioma and 
thyroid gland (follicular cell) adenoma (and adenoma or carcinoma) in high-dose males and thyroid gland 
follicular cell neoplasms (adenomas and carcinomas combined) in high-dose females and mammary gland 
tumors (fibroadenomas or combined fibroadenomas and carcinomas) in low- and high-dose (1 and 
3 mg/kg/day) females. The findings of statistically significant increased incidences of adrenal 
pheochromocytomas in male rats, oral cavity tumors in female rats, central nervous system tumors of glial 
origin, and clitoral or uterine tumors in female rats in the earlier bioassay (Johnson et al. 1986) were not 
replicated in the second bioassay (Friedman et al. 1995); however, Rice (2005) reported that the study of 
Friedman et al. (1995) did not include examination of all the brains or spinal cords in the treatment groups
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Table 3-5. Incidence of Tumors with Statistically Significant Increases in 2-Year 
Bioassays with F344 Rats Exposed to Acrylamide in Drinking Water
Dose (m g/kg/day)
R eference/tum or type 0 0 0.01 0.1 0.5 1.0 2.0 3.0
Johnson et al. 1986; males
Follicular cell adenoma 1/60 - 0/58 2/59 1/59 - 7/59a -
Tunica vaginalis mesothelioma 3/60 - 0/60 7/60 11/60a - 10/60a -
Adrenal pheochromocytoma 3/60 - 7/59 7/60 5/60 - 10/60a -
Johnson et al. 1986; females
Follicular cell adenoma/ 1/58 - 0/59 1/59 1/58 - 5/60b -
carcinoma
Mammary adenocarcinoma 2/60 - 1/60 1/60 2/58 - 6/61 -
Mammary benign 10/60 - 11/60 9/60 19/58 - 23/61a -
Mammary benign + malignantc 12/60 - 12/60 10/60 21/58 - 29/61a -
Central nervous system 1/60 - 2/59 1/60 1/60 - 9/61a -
tumors of glial origin
Oral cavity malignant + benign 0/60 - 3/60 2/60 3/60 - 8/60a -
Uterus adenocarcinoma 1/60 - 2/60 1/60 0/59 - 5/60b -
Clitoral adenoma, benign 0/2 - 1/3 3/4 2/4 - b/55/ -
Pituitary gland adenoma 25/59 - 30/60 32/60 27/60 - 32/60b -
Friedman et al. 1995; malesd
Follicular cell 2/102 f - 12/203 5/101 - 17/75a -
adenoma/carcinoma
Tunica vaginalis mesothelioma8 4/102 4/102 - 9/204 8/102 - 13/75a -
Friedman et al. 1995; femalesd
Follicular cell adenoma/ 1/50 1/50 - - - 10/100 - 23/100a
carcinoma 7/46 4/50 - - - 21/94a - 30/95a
Mammary benign + malignant
S ta tistica lly significantly (p<0.05) different from control, Fisher's Exact test.
bStatistically significantly (p<0.05) different from control, after Mantel-Haenszel mortality adjustment. 
inc idences of benign and adenocarcinoma were added herein, based on an assumption that rats assessed with 
adenocarcinoma were not also assessed with benign mammary gland tumors.
dTwo control groups were included in the study design to assess variability in background tumor responses. 
inc idences reported herein are those originally reported by Friedman et al. (1995) and not those reported in the 
reevaluation study by latropoulos et al. (1998).
fThe data reported in Table 4 in Friedman et al. (1995) noted one follicular cell adenoma in the second control group; 
however, the raw data obtained in the Tegeris Laboratories (1989) report (and used in the time-to-tumor analysis) 
listed no follicular cell adenomas in this group. The corrected number for adenomas (0) and the total number (2) of 
combined adenomas and carcinomas in the second control group are used in the tables of this assessment.
Sources: Friedman et al. 1995; Johnson et al. 1986
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and that seven reported cases of a morphologically distinctive category of primary brain tumor described 
as “malignant reticulosis” were excluded from the analysis.
The cancer effect levels (CELs) from the rat cancer bioassays of Johnson et al. (1984, 1986) and 
Friedman et al. (1995) are recorded in Table 3-4 and plotted in Figure 3-2.
The potential for acrylamide to initiate skin tumors was examined in two studies of female mice 
administered acrylamide at oral dose levels of 0, 12.5, 25, or 50 mg/kg/day, 6 times during a 2-week 
period, followed 2 weeks later by dermal applications of 12-O-tetradecanoylphorbol-13-acetate (TPA, a 
tumor promoter) to the shaved back 3 times/week for 20 weeks (Bull et al. 1984a, 1984b). Incidences of 
skin papillomas and skin carcinomas were significantly elevated in the mice receiving acrylamide at oral 
dose levels of 25 and/or 50 mg/kg/day, indicating that acrylamide initiated skin tumors under the 
conditions of the studies.
EPA, IARC, and the Department of Health and Human Services have concluded that acrylamide is likely 
to be carcinogenic to humans. This conclusion is based on lack of adequate human data and sufficient 
evidence of carcinogenicity in the animal studies summarized above. The Department of Health and 
Human Services (NTP 2005) assigned the cancer descriptor “reasonably anticipated to be a human 
carcinogen”. IARC (1994) assigned acrylamide to Group 2A (probably carcinogenic to humans). EPA 
(IRIS 2009) assigned the classification of B2; probable human carcinogen. Based on the results of 
Johnson et al. (1986), EPA derived an oral slope factor of 4.5 (mg/kg/day)-1 for acrylamide. For cancer 
risks of 1x10"4-1x10"6, the corresponding dose levels range from 2.2x10-5 to 2.2x10-7 mg/kg/day. These 
risk levels are presented in Figure 3-2.
3.2.3 Dermal Exposure
3.2.3.1 Death
There are no reports of human deaths associated with dermal exposure to acrylamide.
Acrylamide has been demonstrated to be lethal to laboratory animals following a single dermal dose. 
Reported dermal LD50 values are 252 mg/kg in rats (American Cyanamid Company 1973) and 941 mg/kg 
in rabbits (American Cyanamid Company 1977). Dow Chemical Company (1957) reported that one of 
two rabbits administered a single 24-hour dermal dose of 1,000 mg/kg died 2 days following dosing.
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Reliable acute dermal LD50 values for death and other mortality data for each species are recorded in 
Table 3-6.
3.2.3.2 Systemic Effects
No human or animal data were located regarding respiratory, cardiovascular, gastrointestinal, 
hematological, musculoskeletal, hepatic, renal, or endocrine effects following dermal exposure to 
acrylamide.
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each 
species and duration category are recorded in Table 3-6.
Dermal Effects. Peeling of the skin was a common complaint among workers in factories with 
measurable acrylamide levels in the air and probable dermal exposure as well (Bachmann et al. 1992; 
Calleman et al. 1994; He et al. 1989; Myers and Macun 1991). Available information in animals is 
limited. Slight dermal irritation was reported in rats and rabbits following single dermal application of 
acrylamide in the range of 200-1,120 mg/kg (American Cyanamid Company 1951, 1973, 1977; Dow 
Chemical Company 1957). There was no evidence of dermal irritation in male mice receiving dermal 
applications of acrylamide for 5 days at doses ranging from 25 to 125 mg/kg/day (Gutierrez-Espeleta et 
al. 1992).
Ocular Effects. No data were located regarding ocular effects in humans following dermal exposure to 
acrylamide. Mild to moderate irritation was noted in the eyes of rabbits following ocular instillation of 
acrylamide (in water); irritation resolved during the ensuing 24 hours (American Cyanamid Company 
1951; Dow Chemical Company 1957).
Body Weight Effects. No data were located regarding body weight effects in humans following 
dermal exposure to acrylamide. Available information in animals is restricted to a report of very slight 
initial weight loss (magnitude not specified) among a group of two rabbits administered a single 
500 mg/kg dermal dose of acrylamide (Dow Chemical Company 1957) and another report of weight loss 
Table 3-6 in rabbits administered acrylamide dermally at 50 mg/kg/day for 5 weeks (Rohm and Haas 
Company 1975).
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Table 3-6 Levels of Significant Exposure to Acrylamide - Dermal
Species
(Strain)
E xposure/
D uration /
Frequency
(Route) System NOAEL Less Serious
LOAEL
Serious
Reference 
C hem ical Form Com m ents
ACUTE EXPOSURE
Death
Rat Once
(albino) 252 M (LD5G) 
mg/kg
American Cyanamid Company 
1973
Mouse 5 d 
1 x/d
™  , Gutierrez-Espeleta et al. 1992 
200 M (4/8 died during 30 days
mg/kg/day following cessation of Acrylamide
dosing)
Rabbit
(New
Zealand)
Once
941 M (LD5G) 
mg/kg
American Cyanamid Company 
1977
Rabbit
(NS)
Once  ___ , ,  „  , ,  Dow Chemical Company 1957;
(death of 1/2 rabbits) McCollister et al. 1964
mg/kg
System ic
Mouse 5 d 
1 x/d
Dermal 125 M 
mg/kg/day
Gutierrez-Espeleta et al. 1992 Histopathological
Acrylamide evaluations of 
peripheral nerve fibers 
not performed
Rabbit Once n ermal __American Cyanamid Company
(albino) 18 h Dermal 1120 M (slight dermal irritation 1951 y H y
( ) mg/kg in 1/3 rabbits)
AC
R
YLAM
ID
E 
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Table 3-6 Levels of Significant Exposure to Acrylamide - Dermal (continued)
Species
(Strain)
Exposure/
D uration /
F requency
(Route)
LOAEL
System NOAEL Less Serious Serious
Reference 
C hem ical Form C om m ents
N euro log ica l
Rat
(albino)
Once
R eproductive
Mouse 5 d
1 x/d 25 M 
mg/kg
2GG M (unspecified CNS 
mg/kg symptoms)
American Cyanamid Company 
1973
5G M 
mg/kg
(significantly increased 
number o f dead 
implants)
Gutierrez-Espeleta et al. 1992 
Acrylamide
INTERMEDIATE EXPOSURE
N euro log ica l
Rabbit 5 wk
(New 3 x/d
Zealand)
5G (clinical signs of 
mg/kg/day peripheral neuropathy)
Rohm and Haas Company 1975 
Acrylamide
d = day(s); hr = hour(s); LD5G = lethal dose, 5G% kill; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect level; wk = week(s); x = time(s)
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E 
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3.2.3.3 Immunological and Lymphoreticular Effects
No human or animal data were located regarding immunological or lymphoreticular effects following 
dermal exposure to acrylamide.
3.2.3.4 Neurological Effects
Available human data consist of occupational exposure scenarios with suspected inhalation and dermal 
exposure. See Section 3.2.1.4 for information regarding neurological effects in occupationally-exposed 
workers. Unspecified clinical signs of central nervous system effects were reported in rats that died 
following single dermal application of acrylamide at doses in the range of 200-800 mg/kg (American 
Cyanamid Company 1973). Clinical signs that included shaking and loss of coordination were reported 
in rabbits following single dermal application at doses in the range of 784-1,568 mg/kg (American 
Cyanamid Company 1977). Clinical signs of hindlimb neuropathy became apparent during treatment 
week 4 in a study of rabbits administered acrylamide dermally for 5 weeks at 50 mg/kg/day (Rohm and 
Haas Company 1975).
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in 
each species and duration category are recorded in Table 3-6.
3.2.3.5 Reproductive Effects
No data were located regarding reproductive effects in humans following dermal exposure to acrylamide. 
Dermal applications of acrylamide to male mice for 5 days at doses ranging from 25 to 125 mg/kg/day 
followed by matings to unexposed female mice resulted in significantly increased numbers of dead 
implants (Gutierrez-Espeleta et al. 1992). At doses >50 mg/kg/day, significantly decreased numbers of 
living embryos were noted as well; this effect is indicative of dominant lethality.
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in 
each species and duration category are recorded in Table 3-6.
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3.2.3.6 Developmental Effects
No data were located regarding developmental effects in humans or animals following dermal exposure to 
acrylamide.
3.2.3.7 Cancer
No data were located regarding cancer associated with dermal exposure to acrylamide in humans.
The potential for acrylamide to initiate skin tumors was examined in a study of female mice administered 
acrylamide at dermal dose levels of 0, 12.5, 25, or 50 mg/kg/day, 6 times during a 2-week period, 
followed 2 weeks later by dermal applications of 12-O-tetradecanoylphorbol-13-acetate (TPA, a tumor 
promoter) to the shaved back 3 times/week for 20 weeks (Bull et al. 1984a). Incidences of skin 
papillomas and skin carcinomas were not significantly elevated at any acrylamide dose level. It was 
concluded that acrylamide did not act as a skin tumor initiator under the conditions of the study.
3.3 GENOTOXICITY
The genotoxicity of acrylamide has been studied both in vivo and in vitro. Studies are limited almost 
exclusively to laboratory rodents and nonmammalian species with the exception of a few in vitro assays 
of human cells. Results indicate that acrylamide is genotoxic and most potent in its ability to induce 
clastogenic effects (including heritable translocations in offspring of acrylamide-exposed male rodents 
mated with untreated females), deoxyribonucleic acid (DNA) damage, and gene mutations (including 
male-germ-cell-mediated dominant lethal mutations and heritable specific-locus mutations).
Table 3-7 summarizes the results of in vivo assays for acrylamide. Numerous assays have been 
performed in rodents. Dominant lethal mutations were induced consistently following administration of 
acrylamide via oral, dermal, or intraperitoneal injection in rodents (Adler et al. 2000; Chapin et al. 1995; 
Gutierrez-Espeleta et al. 1992; Sakamoto and Hashimoto 1986; Shelby et al. 1987; Smith et al. 1986; 
Sublet et al. 1989; Tyl et al. 2000a, 2000b; Working et al. 1987; Zenick et al. 1986). Exposure via 
intraperitoneal injection was also associated with specific locus mutations in offspring of male mice 
exposed to 50-125 mg/kg acrylamide before mating to untreated females (Ehling and Neuhäuser-Klaus
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Species (test system )
Mammalian gene mutation 
Mouse Dominant lethal +
mutation
Mouse Dominant lethal +
mutation
Mouse Dominant lethal +
mutation
Mouse Dominant lethal +
mutation
Rat Dominant lethal +
mutation
Rat Dominant lethal +
mutation
Rat Dominant lethal +
mutation
Rat Dominant lethal +
mutation
Rat Dominant lethal +
mutation
Mouse Dominant lethal +
mutation
Mouse (spleen Gene mutation
lymphocytes, tk and 
HPRT loci)
Reference
1x125 mg/kg, intraperitoneal Adler et al. 2000 
injection of males before 
mating with untreated 
females
5x40 or 50 mg/kg, Shelby et al. 1987
intraperitoneal injection of 
males before mating with 
untreated females
6 weeks; 0.81, 3.19, or Chapin et al. 1995
7.22 mg/kg/day, drinking 
water of males before mating 
with untreated females
4 weeks; 3.3-16.3 mg/kg/day Sakamoto and 
estimated drinking water Hashimoto 1986 
doses of males before
mating with untreated 
females
64 days; 0.5,5.0 mg/kg/day Tyl et al. 2000a,
drinking water of males 2000b
before mating with untreated 
females
5 days; 5, 15, 30, 45, or Sublet et al. 1989 
60 mg/kg drinking water of
males before mating with 
untreated females
5 days; 30 mg/kg gavage of Working et al. 1987 
males before mating with 
untreated females
80 days; 1.5, 2.8, or Smith et al. 1986
5.8 mg/kg/day, drinking 
water of males before mating 
with untreated females
10 weeks; 4.65, 7.86, or Zenick et al. 1986
11.53 mg/kg/day estimated
drinking water doses of
males before mating with
untreated females
5 days 25-125 mg/kg/day, Gutierrez-Espeleta
dermal exposure of males et al. 1992
before mating with untreated 
females
0, 0.14, or 0.70 mmol/kg, Von Tungeln et al.
intraperitoneal injection on 2009
postnatal days 1, 8, or 15
3. HEALTH EFFECTS
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Table 3-7. Genotoxicity of Acrylamide In Vivo
Species (test system ) End point R esult Test conditions R eference
Mouse (spleen 
lymphocytes, tk and 
HPRT loci)
Gene mutation + 0, 0.14, or 0.70 mmol/kg, 
intraperitoneal injection on 
postnatal days 1-8
Von Tungeln et al. 
2009
Mouse (liver cells, 
lymphocyte HPRT 
locus)
Gene mutation + 3-4  weeks; 100 or 500 mg/L 
drinking water
Manjanatha et al. 
2006
Muta® Mouse (lac z 
loci)
Gene mutation + 5x50 mg/kg intraperitoneal 
injection
Hoorn et al. 1993
Muta® Mouse (lac z 
loci)
Gene mutation — 1x50-100 mg/kg, 
intraperitoneal injection
Krebs and Favor 
1997
Mouse (offspring coat 
color loci)
Gene mutation + 1x50 or 75 mg/kg, 
intraperitoneal injection of 
pregnant females
Neuhäuser-Klaus 
and Schmahl 1989
Mouse (offspring coat 
color loci)
Gene mutation + 3x50 or 75 mg/kg, 
intraperitoneal injection of 
pregnant females
Neuhäuser-Klaus 
and Schmahl 1989
Mouse (offspring coat 
color loci)
Gene mutation + 5x50 mg/kg, intraperitoneal 
injection of males before 
mating with untreated 
females
Russell et al. 1991
Mouse (offspring coat Gene mutation 
color loci)
Chromosomal alterations in mammalian cells
+ 1x100-125 mg/kg, 
intraperitoneal injection of 
males before mating with 
untreated females
Ehling and
Neuhäuser-Klaus
1992
Mouse (bone 
marrow)
Chromosomal
aberration
+ 1x50-150 mg/kg, 
intraperitoneal injection
Adler et al. 1988
Mouse (bone Chromosomal + 1x100 mg/kg, intraperitoneal Cihak and
marrow) aberration injection Vontorkova 1988
Mouse (bone 
marrow)
Chromosomal
aberration
— 1x100-200 mg/kg, 
intraperitoneal injection
Shiraishi 1978
Mouse (bone 
marrow)
Chromosomal
aberration
— 7-21 days 78 mg/kg-day diet Shiraishi 1978
Rat (bone marrow) Chromosomal
aberration
— 1x100 mg/kg, intraperitoneal 
injection
Krishna and Theiss 
1995
Mouse (spleen 
lymphocyte)
Chromosomal
aberration
— 1x50-125 mg/kg, 
intraperitoneal injection
Backer et al. 1989
Mouse (splenocyte) Chromosomal
aberration
— 1x100 mg/kg, intraperitoneal 
injection
Kligerman et al. 
1991
Mouse
(spermatogonia)
Chromosomal
aberration
— 1x50-150 mg/kg, 
intraperitoneal injection
Adler et al. 1988
Mouse
(spermatogonia)
Chromosomal
aberration
— 1x50-125 mg/kg, 
intraperitoneal injection
Backer et al. 1989
Mouse
(spermatogonia)
Chromosomal
aberration
— 5x50 mg/kg/day, 
intraperitoneal injection
Adler 1990
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Species (test system) End point Result Test conditions Reference
Mouse
(spermatocyte)
Chromosomal
aberration
+ 1x100 mg/kg, intraperitoneal 
injection
Adler 1990
Mouse (first cleavage Chromosomal + 1x75 or 125 mg/kg or Pacchierotti et al.
one-cell zygote) aberration 5x50 mg/kg/day, 
intraperitoneal injection of 
males before mating with 
untreated females
1994
Mouse (first cleavage Chromosomal 
zygote) aberration
+ 5x50 mg/kg/day, 
intraperitoneal injection of 
males before mating with 
untreated females
Marchetti et al. 1997
Mouse (offspring 
spermatocyte)
Heritable
translocation
+ 5x40-50 mg/kg/day, 
intraperitoneal injection of 
males before mating with 
untreated females
Shelby et al. 1987
Mouse (offspring 
spermatid)
Heritable
translocation
+ 1x50-100 mg/kg, 
intraperitoneal injection of 
males before mating with 
untreated females
Adler et al. 1994
Mouse (offspring 
spermatocyte)
Heritable
translocation
+ 5x50 mg/kg/day, dermal 
exposure of males before 
mating with untreated 
females
Adler et al. 2004
Mouse (offspring 
spermatocyte)
Heritable
translocation
+ 5x50 mg/kg/day, 
intraperitoneal injection
Adler 1990
Mouse (bone 
marrow)
Polyploidy or 
aneuploid
+ 1x100-200 mg/kg, 
intraperitoneal injection
Shiraishi 1978
Mouse (bone 
marrow)
Polyploidy or 
aneuploid
+ 7-21 days 78 mg/kg/day, 
diet
Shiraishi 1978
Mouse (bone 
marrow)
Spindle disturbance - 1x120 mg/kg, intraperitoneal 
injection
Adler et al. 1993
Mouse (bone 
marrow)
Micronucleus + 1x50-125 mg/kg, 
intraperitoneal injection
Adler et al. 1988
Mouse (bone 
marrow)
Micronucleus + 1x100 mg/kg, intraperitoneal 
injection
Cihak and 
Vontorkova 1988
Mouse (bone 
marrow)
Micronucleus + 2 days 25-100 mg/kg/day, 
intraperitoneal injection
Cihak and 
Vontorkova 1988
Mouse (bone 
marrow)
Micronucleus + 1x136 mg/kg, intraperitoneal 
injection
Knaap et al. 1988
Mouse (bone 
marrow)
Micronucleus + 1, 2, or 3 days 42.5­
100 mg/kg/day, 
intraperitoneal injection
Cihak and 
Vontorkova 1990
Sprague-Dawley Rat 
(bone marrow)
Micronucleus - 1x100 mg/kg, intraperitoneal 
injection
Paulsson et al. 2002
Rat (bone marrow) Micronucleus - 1x100 mg/kg, intraperitoneal 
injection
Krishna and Theiss 
1995
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Mouse (reticulocyte) Micronucleus + 1x50-100 mg/kg, 
intraperitoneal injection
Russo et al. 1994
Mouse (reticulocyte) Micronucleus + 1x25-100 mg/kg, 
intraperitoneal injection
Paulsson et al. 2002
Mouse (reticulocyte 
and nonchromatic 
erythrocyte)
Micronucleus 0, 0.14, 0.70 mmol/kg, 
postnatal day 1, 8, 15, 
intraperitoneal injection
Von Tungeln et al. 
2009
Mouse (reticulocyte 
and nonchromatic 
erythrocyte)
Micronucleus 0, 0.14, 0.70 mmol/kg, 
postnatal day 1-8, 
intraperitoneal injection
Von Tungeln et al. 
2009
Mouse (reticulocyte) Micronucleus + 28 days 0-24 mg/kg/day, 
gavage
Zeiger et al. 2009
Mouse
(normochromatic
erythrocyte)
Micronucleus + 28 days 0-24 mg/kg/day, 
gavage
Zeiger et al. 2009
Mouse (erythrocyte) Micronucleus + 5 days 0, 25, 50 mg/kg/day, 
intraperitoneal injection
Ghanayem et al. 
2005b
Mouse (spleen 
lymphocyte)
Micronucleus + 1x50-125 mg/kg, 
intraperitoneal injection
Backer et al. 1989
Mouse (splenocyte) Micronucleus + 1x100 mg/kg, intraperitoneal 
injection
Kligerman et al. 
1991
Mouse (spermatid) Micronucleus + 1x10-100 mg/kg, 
intraperitoneal injection
Collins et al. 1992
Mouse (spermatid) Micronucleus + 1x50-100 mg/kg or 
4x50 mg/kg/day, 
intraperitoneal injection
Russo et al. 1994
Lewis Rat (spermatid) Micronucleus + 1x50-100 mg/kg or 
4x50 mg/kg/day, 
intraperitoneal injection
Xiao and Tates 
1994
Sprague-Dawley rat 
(spermatid)
Micronucleus + 1x50-100 mg/kg or 
4x50 mg/kg/day, 
intraperitoneal injection
Lähdetie et al. 1994
Mouse (germ cell) Synaptonemal 
complex aberration
— 1x50-150 mg/kg 
intraperitoneal injection
Backer et al. 1989
Mouse (germ cell) Synaptonemal
complex asynapsis
ister chromatid exchange
+ 1x50-150 mg/kg, 
intraperitoneal injection 
Asynapsis in meiotic 
prophase
Backer et al. 1989
Mouse (spleen 
lymphocytes)
Chromatid
exchange
+ 1x50-125 mg/kg, 
intraperitoneal injection
Backer et al. 1989
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Species (test system) End point Result Test conditions Reference
Mouse (splenocytes) Chromatid
exchange
DNA damage 
Mouse DNA breakage
(spermatocytes and 
early spermatids)
Mouse (bone marrow, DNA breakage 
spleen, liver, kidney, 
lungs, testes)
Mouse (leukocytes, DNA breakage 
liver, lung)
Rat (hepatocyte)
Rat (spermatocyte)
Mouse (germ cell)
Mouse (testis)
Mouse (liver)
Sprague-Dawley rat 
(liver, lung, kidney, 
brain, testis)
Mouse (liver, kidney, 
brain)
Neonatal mouse 
(whole body)
Unscheduled DNA 
synthesis
Unscheduled DNA 
synthesis
Unscheduled DNA 
synthesis
DNA adduct 
(Alkylation)
DNA adduct 
(Alkylation)
DNA adduct (N7- 
GA-Gua)
DNA adduct (N7- 
GA-Gua)
DNA adduct (N7- 
GA-Gua, N3-GA- 
Ade)
1x100 mg/kg, intraperitoneal Kligerman et al. 
injection 1991
+ 1x0-125 mg/kg,
intraperitoneal injection
+ 1x0-125 mg/kg,
intraperitoneal injection
+ 5 day 0, 25, 50 mg/kg/day,
intraperitoneal injection (wild 
type mice)
-  1x100 mg/kg or
5x30 mg/kg/day, gavage
+ 1x100 mg/kg or
5x30 mg/kg/day, gavage
+ 1x7.8-125 mg/kg,
intraperitoneal injection
+ 1x46 mg/kg, intraperitoneal
injection
+ 1x46 mg/kg, intraperitoneal
injection
+ 1x46 mg/kg, intraperitoneal
injection
+ 1x53 mg/kg, intraperitoneal
injection
+ 1x50 mg/kg, intraperitoneal
injection
Sega and Generoso 
1990
Dobrzynska 2007
Ghanayem et al. 
2005b
Butterworth et al. 
1992
Butterworth et al. 
1992
Sega et al. 1990
Sega et al. 1990
Sega et al. 1990
Segerbäck et al. 
1995
Segerbäck et al. 
1995
Gamboa da Costa 
et al. 2003
Mouse (liver, lung, 
kidney)
DNA adduct (N7- 
GA-Gua, N3-GA- 
Ade)
1x50 mg/kg, intraperitoneal 
injection
Gamboa da Costa 
et al. 2003
Mouse (liver, lung) DNA adduct (N7- 
GA-Gua, N3-GA- 
Ade)
Mouse (lung, liver, DNA adduct (N7- 
splee^  bone marrow) GA-Gua, N3-GA- 
Ade)
1x1-10 mg/kg, 
intraperitoneal injection
0, 0.14, 0.70 mmol/kg 
intraperitoneal injection, 
postnatal day 1, 8, 15
Gamboa da Costa 
et al. 2003
Von Tungeln et al. 
2009
+
+
+
+
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Species (test system ) End point R esult Test conditions R eference
Mouse (lung, liver, 
spleen)
DNA adduct (N7- 
GA-Gua, N3-GA- 
Ade)
+ 0, 0.14, 0.70 mmol/kg 
postnatal day 1-8, 
intraperitoneal injection
Von Tungeln et al. 
2009
Mouse (liver) DNA adduct (GA- 
Gua)
+ 28 days 0-24 mg/kg/day, 
gavage
Zeiger et al. 2009
Mouse (liver, lung, 
kidney, leukocyte, 
testis)
DNA adduct (N7- 
GA-Gua, N3-GA- 
Ade)
+ 1x50 mg/kg, intraperitoneal 
injection
Doerge et al. 2005a
Mouse (liver) DNA adduct (N7- 
GA-Gua, N3-GA- 
Ade)
+ 14 days 1 mg/kg/day, 
drinking water
Doerge et al. 2005a
Rat (liver, brain, 
thyroid, leukocyte, 
mammary gland, 
testis)
DNA adduct (N7- 
GA-Gua, N3-GA- 
Ade)
+ 1x50 mg/kg, intraperitoneal 
injection
Doerge et al. 2005a
Rat (liver) DNA adduct (N7- 
GA-Gua) 
Nonmammalian gene mutation
+ 14 days 1 mg/kg/day, 
drinking water
Doerge et al. 2005a
Drosophila
melanogaster
Sex-linked recessive 
lethal
— 1x40-50 mM, abdominal 
injection
Knaap et al. 1988
D. melanogaster Sex-linked recessive 
lethal
+ 48 hour 0.25-5 mM, larvae 
feeding
Tripathy et al. 1991
D. melanogaster Somatic mutation 
and recombination
+ 1-1.5 mM, larvae feeding 
until pupation
Knaap et al. 1988
D. melanogaster Somatic mutation 
and recombination
+ 10-30 mM, larvae feeding 
until pupation
Batiste-Alentorn et 
al. 1991
D. melanogaster Somatic mutation 
and recombination
+ 48 hour 0.25-5 mM, larvae 
feeding
Tripathy et al. 1991
-  = negative result; + = positive result; DNA = deoxyribonucleic acid
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1992; Russell et al. 1991) and in offspring of pregnant female mice exposed to 50 or 75 mg/kg 
(Neuhäuser-Klaus and Schmahl 1989). Heritable or reciprocal translocations were noted in offspring of 
male mice exposed to 50-100 mg/kg acrylamide via intraperitoneal injection or dermal application before 
mating to untreated females (Adler 1990; Adler et al. 1994, 2004; Shelby et al. 1987). Intraperitoneal 
exposure to acrylamide also increased mutations at the tk and HPRT loci in lymphocytes of mice 
(Majanatha et al. 2006; von Tungeln et al. 2009) and at lac z loci in transgenic mice (Hoorn et al. 1993; 
Krebs and Favor 1997).
Prominent clastogenic effects consistently associated with in vivo exposure include sister chromatid 
exchanges (Backer et al. 1989; Kligerman et al. 1991), micronucleus formation (Backer et al. 1989; Cihàk 
and Vontorkovà 1988, 1990; Collins et al. 1992; Ghanayem et al. 2005b; Kligerman et al. 1991; Knaap et 
al. 1988; Lähdetie et al. 1994; Paulsson et al. 2002; Russo et al. 1994; Xiao and Tates 1994; Zeiger et al. 
2009), and aneuploidy or polyploidy (Shiraishi 1978). Acrylamide induced DNA damage in various 
rodent tissues (including testes and male germ cells), evidenced as DNA breakage (Dobrzynska 2007; 
Ghanayem et al. 2005b; Sega and Generoso 1990), unscheduled DNA synthesis (Butterworth et al. 1992; 
Sega et al. 1990), and DNA adduct formation (Doerge et al. 2005a; Gamboa da Costa et al. 2003; Sega et 
al. 1990; Segerbäck et al. 1995; Von Tungeln et al. 2009; Zeiger et al. 2009). Increases in chromosomal 
aberrations were observed in the first cleavage zygote of acrylamide-treated male mice mated with 
untreated females (Marchetti et al. 1997; Pacchierotti et al. 1994).
Assays for acrylamide-induced chromosomal aberrations in bone marrow, spleen, or spermatogonia of 
acrylamide-treated rodents produced both positive (Adler 1990; Adler et al. 1988; Cihàk and Vontorkovà 
1988) and negative (Adler 1990; Adler et al. 1988; Backer et al. 1989; Kligerman et al. 1991; Krishna and 
Theiss 1995; Shiraishi 1978) results. Acrylamide did not induce micronuclei in a small number of rat and 
mouse assays (Krishna and Theiss 1995; Paulsson et al. 2002; Von Tungeln et al. 2009). Results for 
synaptonemal complex aberrations in male mouse germ cells were negative or only weakly positive 
(Backer et al. 1989). Acrylamide did not induce spindle disturbances in the bone marrow of 
intraperitoneally-injected mice (Adler et al. 1993).
Somatic mutations and recombination (Batiste-Alentorn et al. 1991; Knaap et al. 1988; Tripathy et al. 
1991) and sex-linked recessive lethal mutations (Tripathy et al. 1991) were induced in drosophila larval 
feeding assays. Negative results were obtained for sex-linked recessive lethal mutations in another assay 
that employed abdominal injection (Knaap et al. 1988).
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Table 3-8 summarizes the results of in vitro assays. Acrylamide induced mutations at the tk and HPRT 
loci in several assays with mammalian cells including mouse lymphoma L5178Y cells (Barfknecht et al. 
1988; Knaap et al. 1988; Mei et al. 2008b; Moore et al. 1987) and human promyelocytic leukemia HL-60 
and NB4 cells (Ao et al. 2008). In Chinese hamster V79H3 cells (which do not express genes for CYP 
enzymes), acrylamide did not induce mutations at the HPRT locus (Tsuda et al. 1993). Acrylamide did 
not induce reverse mutations in multiple strains of Salmonella typhimurium or in Escherichia coli WP2 
uvrA- with or without metabolic activation (Hashimoto and Tanii 1985; Jung et al. 1992; Knaap et al.
1988; Lijinsky and Andrews 1980; Müller et al. 1993; Tsuda et al. 1993; Zeiger et al. 1987). One 
exception was a weakly positive result in a few trials of TA98 and TA100, but only with S9 activation 
(Zeiger et al. 1987).
Clastogenic effects associated with in vitro exposure to acrylamide include: chromosomal aberrations in 
mammalian cells (Knaap et al. 1988; Moore et al. 1987; Tsuda et al. 1993); polyploidy, sister chromatid 
exchanges, and spindle disturbances in Chinese hamster cells (Adler et al. 1993; Knaap et al. 1988; 
Martins et al. 2007; Tsuda et al. 1993; Warr et al. 1990); and micronuclei in human hepatoma G2 cells 
(Jiang et al. 2007). Although acrylamide did not induce micronuclei in one in vitro assay using 
seminiferous tubule segments from rats (Lähdetie et al. 1994), micronuclei were induced in spermatids of 
rodents exposed to acrylamide in vivo (Collins et al. 1992; Lähdetie et al. 1994; Russo et al. 1994; Xiao 
and Tates 1994).
DNA damage associated with in vitro exposure to acrylamide includes DNA damage in Bacillus subtilis 
(Tsuda et al. 1993); DNA breakage and oxidative DNA damage in human hepatoma G2 cells (Jiang et al. 
2007); unscheduled DNA synthesis in human mammary epithelial cells (Butterworth et al. 1992); and 
glycidamide-DNA adducts in Chinese hamster V79 cells (Martins et al. 2007), mouse embryonic 
fibroblasts (Besaratinia and Pfeifer 2004), and human bronchial epithelial cells (Besaratinia and Pfeifer 
2004). DNA adducts were not detected when mouse lymphoma cells were incubated with up to 20 mM 
acrylamide, but glycidamide concentrations in the range of 0.5-4 mM induced DNA adducts in these cells 
(Mei et al. 2008b). Acrylamide in vitro exposure also caused cell morphological transformations in 
several mouse cell lines and Syrian hamster embryo cells (Abernethy and Boreiko 1987; Banerjee and 
Segal 1986; Park et al. 2002; Tsuda et al. 1993).
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Result
Activa tion
W ith-
Species (test system ) End point W ith out T est conditions Reference
Prokaryotic
Bacterial gene mutation
Salmonella. Reverse - - 10-10,000 pg/plate Zeiger et al. 1987
typhimurium TA98, mutation +/- S9 activation
TA100, TA1535, Weakly positive in TA98
TA1537 and TA100 in only a few
trials with activation; all
other strains negative
S. typhimurium TA97, Reverse - - 100-10,000 pg/plate Zeiger et al. 1987
TA98, TA100, mutation +/- S9 activation
TA1535
S. typhimurium TA98, Reverse - - 1-100 mg/plate Knaap et al. 1988
TA100, TA102, mutation +/- S9 activation
TA1535, TA1537
S. typhimurium TA98, Reverse — - 0.5-50 mg/plate Tsuda et al. 1993
TA100, TA1535, mutation +/- S9 activation
TA1537
S. typhimurium Reverse - - Up to 5 mg/plate Müller et al. 1993 ;
TA1535 mutation +/- S9 activation Jung et al. 1992
S. typhimurium TA98, Reverse - - Up to 1 mg/plate Lijinsky and Andrews
TA100, TA1535, mutation +/- S9 activation 1980
TA1537, TA1538
S. typhimurium TA98, Reverse - - 0.5-5,000 pg/plate Hashimoto and Tanii
TA100, TA 1535, mutation +/- S9 activation 1985
TA1537, TA1538
Escherichia coli WP2 Reverse - - 0.5-50 mg/plate Tsuda et al. 1993
uvrA mutation +/- S9 activation
Klebsiella. Fluctuation No - 2-10 mg/L Knaap et al. 1988
pneumoniae ur" pro" data
DNA damage and repair and DNA adduct formation
Bacillus subtilis DNA damage + + 1-50 mg/ disk Tsuda et al. 1993
+/- S9 activation
Mammalian gene mutation assays
Mouse lymphoma Gene + + 10 mM Barfknecht et al. 1988
L5178Y TK+/", tk locus mutation
Mouse lymphoma Gene No + 0-0.85 mg/mL Moore et al. 1987
L5178Y TK+/-, tk locus mutation data No activation
Clastogenic response
Mouse lymphoma Gene No + 0-18 mM Mei et al. 1988
L5178Y TK+/-, tk locus mutation data No activation
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Result
Activa tion
W ith -
pecies (test system ) End point W ith out T est conditions Reference
Mouse lymphoma 
L5178Y TK+/-, tk and 
HPRT loci
Gene
mutation
0.5-7.5 mg/mL 
+/- S9 activation 
Mutation only at cytotoxic 
concentrations
Knaap et al. 1988
Mouse lymphoma 
L5178Y TK+/-, HPRT 
locus
Gene
mutation
+ + 0.1-0.5 mg/mL 
Cocultivated activation
Knaap et al. 1988
Chinese hamster 
V79H3, HPRT locus
Gene
mutation
No
data
- 1-7 mM 
No activation
Tsuda et al. 1993
Human promyelocytic Gene 
leukemia HL-60 and mutation 
NB4, HPRT locus
No
data
+ 0-700 mg/L Ao et al. 2008
hromosomal alteration in mammalian cells
Chinese hamster 
V79H3
Chromoso­
mal
aberration
No
data
+ 0.5-5 mM 
No activation
Tsuda et al. 1993
Chinese hamster V79 Chromoso­
mal
aberration
+ + 0.1-3 mg/mL 
+/- S9 activation
Knaap et al. 1988
Chinese hamster V79 Chromoso­
mal
aberration
No
data
0-2,000 pM 
No activation
Martins et al. 2007
Mouse lymphoma 
L5178Y TK+/"
Chromoso­
mal
aberration
No
data
+ 0.65-0.85 mg/mL 
No activation
Moore et al. 1987
Chinese hamster 
V79H3
Polyploidy No
data
+ 0.5-5 mM Tsuda et al. 1993
Chinese hamster 
LUC2 p5
Polyploidy No
data
+ 0.0125-0.5 mg/mL Warr et al. 1990
Chinese hamster V79 Spindle
disturbance
No
data
+ 0.01-1 mg/mL Adler et al. 1993
Chinese hamster 
DON:Wg3h
Spindle
disturbance
No
data
+ 0.2-2 mg/mL Warr et al. 1990
Chinese hamster 
LUC2 p5
Spindle
disturbance
No
data
+ 0.01-1 mg/mL Warr et al. 1990
Rat seminiferous 
tubular segments
Micronucleus No
data
- 5-50 pg/mL Lähdetie et al. 
1994
Human hepatoma G2 Micronucleus No
data
+ 0-2.5 mM Jiang et al. 2007
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Result 
Activa tion  
W ith -
Species (test system ) End point W ith out T est conditions Reference
Sister chromatid exchange
Chinese hamster V79 Chromatid
exchange
+ + 0.1-1 mg/mL Knaap et al. 1988
Chinese hamster V79 Chromatid
exchange
No
data
+ 0.5-2.5 mg/mL Tsuda et al. 1993
Chinese hamster V79 Chromatid
exchange
No
data
+ 0-2,000 |jM Martins et al. 2007
DNA damage and repair and DNA adduct formation
Human hepatoma G2 DNA
breakage
No
data
+ 0-20 mM Jiang et al. 2007
Human hepatoma G2 Oxidative 
DNA damage
No
data
+ 0-20 mM Jiang et al. 2007
F344 Rat primary Unscheduled No — 0.01-1 mM Butterworth et al.
hepatocytes DNA
synthesis
data 1992
Human mammary Unscheduled No + 1-10 mM Butterworth et al.
epithelial DNA
synthesis
data 1992
Chinese hamster V79 DNA adducts 
(N7-GA-Gua, 
N3-GA-Ade)
No
data
+ 0-2,000 j M Martins et al. 2007
Mouse lymphoma DNA adducts No — 0-20 mM Mei et al. 2008b
L5178Y TK+/- (N7-GA-Gua,
N3-GA-Ade)
data
Big Blue mouse DNA adducts No + 0, 0.0032, 0.320. and Besaratinia and
embryonic fibroblasts (N7-GA-Gua,
Nl-GA-Ade,
N3-GA-Ade)
data 16 mM Pfeifer 2004
Human bronchial DNA adducts No + 0, 0.320 and 3.2 mM Besaratinia and
epithelial (N7-GA-Gua,
Nl-GA-Ade,
N3-GA-Ade)
data Pfeifer 2004
Cell transformation
Mouse C3H/10T1/2 Morphologi­
cal
transforma­
tion
No
data
+ 25-200 jg /m L Banerjee and Segal 
1986
Mouse NIH/3T3 Morphologi­
cal
transforma­
tion
No
data
+ 2-200 jg /m L Banerjee and Segal 
1986
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Species (test system ) End point
Result 
Activa tion  
W ith- 
W ith  out T est conditions Reference
Mouse C3H/10T1/2 Morphologi­
cal
transforma­
tion
No -  
data
10-300 ^g/mL Abernethy and 
Boreiko 1987
Mouse BALB/c 3T3 Morphologi­
cal
transforma­
tion
No + 
data
0.5-2 mM Tsuda et al. 1993
Syrian hamster 
embryo
Morphologi­
cal
transforma­
tion
No + 
data
0.1-0.7 mM Park et al. 2002
Syrian hamster 
embryo
Morphologi­
cal
transforma­
tion
No -  
data
0.001-10 mM Kaster et al. 1998
-  = negative result; + = positive result; DNA = deoxyribonucleic acid
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3.4 TOXICOKINETICS
Acrylamide and its principal and toxicologically significant (epoxide) metabolite, glycidamide, react with 
various biologically significant targets. The chemical basis for these interactions is strongly associated 
with the degree of electrophilicity (electron deficiency) with nucleophilic centers (i.e., unshared 
electrons). Electrophiles and nucleophiles are generally characterized as being either “hard” or “soft” 
corresponding to a spectral range of high or low charge densities or electronegativity for reactivity 
(Pearson and Songstad 1967). Due to its a,P-unsaturated structure and ready capacity to undergo 
Michael-type additions, acrylamide may be classified as a “soft” electrophile. Soft electrophiles like 
acrylamide react readily with soft nucleophiles such as the thiol groups of proteins or glutathione. 
Glycidamide, on the other hand, has a relatively high positive charge density, and acts as a hard 
electrophile, more capable of reacting with centers of high electronegativity (i.e., hard nucleophiles) such 
as the purine and pyrimidine bases in DNA (Dearfield et al. 1995; Lopachin and DeCaprio 2005;). 
Hemoglobin adducts have been used as biomarkers of exposure to acrylamide and are based on the 
assumption that a measured adduct level represents a steady-state level from a continuous exposure to 
acrylamide over the previous 120 days, which is the average life span of a red blood cell. Hemoglobin 
adduct levels provide a direct measure of the total amount of acrylamide and its reactive metabolite, 
glycidamide, in the blood over a given time period, which is quantified as the area under the curve (AUC 
in amount-unit time/volume). AUC is the integral of “concentration” (e.g., mg or mmol/L) x “time” (e.g., 
minutes or hours). Under the reasonable assumption that the amount of parent or reactive toxicant in 
blood indicates the amount available to bind to tissue macromolecules or DNA, hemoglobin adducts 
provide a relevant internal metric for use in estimating the risk of acrylamide toxicity.
3.4.1 Absorption
Detection of hemoglobin adducts of acrylamide in exposed workers and volunteers provides qualitative 
evidence of absorption. Controlled human studies of the formation of hemoglobin adducts of acrylamide 
following oral and dermal exposure provide some information regarding the extent of absorption via these 
exposure routes. Available animal data indicate that acrylamide is readily and rapidly absorbed following 
inhalation and oral exposure, and somewhat less readily absorbed following dermal exposure.
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Hagmar et al. (2001) measured hemoglobin adducts of acrylamide in a group of 210 tunnel construction 
workers who were occupationally exposed for 2 months to a chemical grouting agent containing 
acrylamide and N-methylolacrylamide. Within 1 month after construction work was completed, blood 
samples were drawn for the analysis of adducts of acrylamide with N-terminal valines (acrylamideVal) in 
hemoglobin. Workers were expected to have experienced both inhalation and dermal exposure. 
Quantitative exposure data were limited to two personal air samples showing concentrations of 0.27 and 
0.34 mg/m3 for the sum of acrylamide and N-methylolacrylamide; further analysis suggested that the air 
contained a 50:50 mixture of these compounds. Hemoglobin adduct levels for 18 nonsmoking unexposed 
reference subjects varied between 0.02 and 0.07 nmol/g globin. The frequency distribution of adduct 
levels in the 210 tunnel workers was as follows: 47 with <0.08 nmol/g globin; 89 with 0.08-0.29 nmol/g; 
36 with 0.3-1.0 nmol/g; and 38 with 1.0-17.7 nmol/g. Adduct levels were determined in blood samples 
collected at intervals up to 5 months after cessation of exposure from five workers with initial levels 
ranging from about 2.2 to 4.4 nmol/g. Adduct levels decreased to background levels within 120 days, 
consistent with the approximate 120-day life of red blood cells.
Hemoglobin adduct levels were measured in 41 Chinese workers who were exposed to acrylamide for 
0.1-8 years (Bergmark et al. 1993). AcrylamideVal hemoglobin levels were measured. Workers were 
involved in the production of acrylamide (via the hydration of acrylonitrile) and polyacrylamide. The 
adduct levels in exposed workers ranged from 0.3 to 34 nmol acrylamide/g hemoglobin. AcrylamideVal 
levels were not detected in blood samples of 10 control workers from the same city who had not been 
occupationally exposed to acrylamide (or acrylonitrile). Blood samples from 5 of the 41 exposed workers 
were also analyzed for hemoglobin adducts of glycidamide (glycidamideVal), a principal metabolite of 
acrylamide in animals (see also Section 3.4.3, Metabolism). A statistically significant linear relationship 
was observed between levels of acrylamideVal and glycidamideVal in these five workers; the ratio 
between acrylamideVal and glycidamideVal was approximately 3:10. Average levels of acrylamide in air 
samples were 1.52 and 0.73 mg/m3 for workplaces involved with polymerization and synthesis processes, 
respectively. Workers involved in these processes showed average acrylamideVal levels of 7.3±3.4 
(n=12, polymerization) and 14.7±10.6 nmol/g hemoglobin (n=14, synthesis).
Bergmark et al. (1993) made the following assumptions based on a central assumption that these workers 
may have experienced only inhalation exposure: (1) adducts are stable during the life of erythrocytes;
(2) the lifespan of human erythrocytes is about 120 days (17 weeks); (3) the second-order reaction rate
3.4.1.1 Inhalation Exposure
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constant for the reaction of acrylamideVal in human hemoglobin is 4.4x10-6 [L (g Hb)-1hour -1] (based on 
in vitro experiments); (4) the human ventilation rate is 0.2 L minute-1 kg bw-1; and (5) inhaled acrylamide 
is 100% absorbed. Using these assumptions, the predicted levels of acrylamideVal were only 0.93 and 
0.44 nmol/g hemoglobin, respectively. The large disparity between the observed and predicted adduct 
levels resulted in the conclusion that dermal contact may have been the predominant source of absorption 
in these workers.
Animal studies indicate that inhaled acrylamide is readily absorbed (Sumner et al. 2003). Male F344 rats 
and B6C3F1 mice were exposed to approximately 3 ppm of a mixture of [13C]-labeled acrylamide and 
[14C]-labeled acrylamide vapor via nose-only inhalation for 6 hours. Selected rats and mice were 
sacrificed immediately following the exposure period for determination of [14C] content in tissues, an 
indicator of the extent of absorption of inhaled acrylamide. The remaining rats and mice were monitored 
for 24-hour elimination of acrylamide and metabolites via urine, feces, and expired air. Immediately 
following the 6-hour exposure period, approximately 18 and 8 ^mol of [14C]-equivalents were recovered 
from tissues and carcasses of the rats and mice, respectively. At the end of the 24-hour postexposure 
period, 42% of the total recovered radioactivity was in urine, feces, and nose-tube and cage washes of 
rats; <3% was in exhaled air; and 56% remained in the body. In mice, 51% was recovered in urine, feces, 
and nose-tube and cage washes; <3% was in exhaled air, and 46% remained in the body. Fractional 
absorption could not be determined from the presented data because ventilation rates were apparently not 
measured.
3.4.1.2 Oral Exposure
Fennell and coworkers evaluated metabolism and hemoglobin adduct formation (Fennell et al. 2005b) and 
kinetics of elimination of urinary metabolites of acrylamide (Fennell et al. 2006) following oral 
administration of [1,2,3-13C3]-acrylamide to 24 adult male volunteers exposed under controlled 
conditions. All volunteers were aspermic (i.e., clinically sterile because of the potential for adverse 
effects of acrylamide on sperm), and had not used tobacco products for the prior 6 months. The health of 
the volunteers was continually monitored. Acrylamide was administered in an aqueous solution (single 
dose of 0.5, 1, or 3 mg/kg) to the volunteers. For the 3 mg/kg dose group, approximately 40% of the 
administered dose was recovered as urinary metabolites in the 24-hour urine. Approximately 86% of the 
urinary metabolites were derived from GSH conjugation and excreted as N-acetyl-S-(3-amino-3- 
oxopropyl)cysteine and its S-oxide; the remainder included glycidamide, glyceramide, and low levels of 
N-acetyl-S-(3-amino-2-hydroxy-3-oxopropyl)cysteine. Mean levels of hemoglobin adducts of acrylamide
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(13C3-acrylamideVal) and glycidamide (13C3-glycidamideVal) in the 3 mg/kg group at 24 hours 
postadministration were 2,479 and 1,076 fmol/mg globin, respectively. These findings demonstrate that 
orally-administered acrylamide is rapidly and readily absorbed by the gastrointestinal tract.
Fuhr et al. (2006) evaluated the toxicokinetics of acrylamide in six young healthy volunteers after the 
consumption of a meal containing 0.94 mg of acrylamide. Urine was collected up to 72 hours thereafter. 
Unchanged acrylamide; its mercapturic acid metabolite, N-acetyl-S-(2-carbamoylethyl)cysteine (AAMA), 
its epoxy derivative, glycidamide; and the respective metabolite of glycidamide, N-acetyl-S-(2-hydroxy-
2-carbamoylethyl)cysteine (GAMA), were quantified in the urine by liquid chromatography-mass 
spectrometry. Toxicokinetic variables were obtained by noncompartmental methods. Overall, 
approximately 60% of the dose was recovered in the urine. Although no glycidamide was found, 
unchanged acrylamide, AAMA, and GAMA accounted for urinary excretion of approximately 4.5, 50, 
and 6% of the dose, respectively. These results indicate that most of the acrylamide ingested with food is 
absorbed in humans.
Boettcher et al. (2006a) investigated the human metabolism of acrylamide to AAMA and GAMA in a 
healthy male volunteer who received a single dose of about 1 mg deuterium-labeled (d(3)) acrylamide, 
representing 13 ^g/kg body weight, in drinking water. Urine samples before dosing and within 46 hours 
after the dose were analyzed for d(3)-AAMA and d(3)-GAMA. Total recovery of AAMA and GAMA in 
the 24-hour urine was about 51% of the administered dose, which provides additional demonstration of 
the rapid and extensive absorption of ingested acrylamide.
Boettcher et al. (2006b) reported the influence of an acrylamide-free diet on the excretion of urinary 
mercapturic acid metabolites derived from acrylamide in three healthy volunteers who fasted for 
48 hours. Urinary acrylamide mercapturic acid metabolites were considerably reduced after 48 hours of 
fasting, with levels even well below the median level in nonsmokers. These results indicate that the 
acrylamide in the diet is the main source of environmental acrylamide exposure in humans, apart from 
smoking.
Bjellaas et al. (2007a) reported urinary mercapturic acid derivatives of acrylamide in a clinical study 
comprised of 53 subjects. Median intakes (range) of acrylamide were estimated based on 24-hour dietary 
recall as 21 (13-178) ^g for nonsmokers and 26 (12-67) ^g for smokers. The median dietary exposure to 
acrylamide was estimated to be 0.47 (range 0.17-1.16) ^g/kg body weight per day. The median (range) 
total excretion of acrylamide in urine during 24 hours was 16 (7-47) ^g for nonsmokers and 74 (38-106)
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^g for smokers. In a multiple linear regression analysis, a statistically significant correlation was found 
between the urinary excretion of acrylamide metabolites and intake of aspartic acid, protein, starch, and 
coffee.
Studies in rats indicate that orally administered acrylamide is rapidly and extensively absorbed by the 
gastrointestinal tract (Dixit et al. 1982; Doerge et al. 2005b; Fennell et al. 2005a; Kadry et al. 1999; Miller 
et al. 1982; Ramsey et al. 1984). The time course of urinary elimination of radioactivity from male F344 
rats during a 7-day period following single oral doses of 10 mg/kg [2,3-14C]-acrylamide was essentially 
the same as that observed with male F344 rats following single intravenous dosing at 10 mg/kg 
[2,3-14C]-acrylamide (Miller et al. 1982). This observation suggests that 100% of the oral dose was 
absorbed. The time courses of urinary elimination of radioactivity were similar for groups of rats given 
single 1, 10, or 100 mg/kg oral doses of radiolabeled acrylamide, suggesting that the extent of absorption 
was not affected by dose level in the tested range. The rapidity of absorption was demonstrated by 
observations that peak plasma levels of radioactivity were attained by 1 hour after administration and that 
53-67% of administered radioactivity was detected in the urine collected within 24 hours of 
administration (Miller et al. 1982). Similar results indicating rapid and extensive oral absorption were 
reported for studies in which male Sprague-Dawley rats were given single 50 mg/kg oral doses of 
[1-14C]-acrylamide (Kadry et al. 1999). Radioactivity was detected in blood 5 minutes after 
administration, and peak plasma levels of radioactivity occurred at 38 minutes after administration. 
Approximately 51% of administered radioactivity was detected in urine collected within 24 hours of 
administration (Kadry et al. 1999). Fennell et al. (2005a) administered 3 mg/kg of 
[1,2,3-13C3]-acrylamide by gavage to male F344 rats. The total amount of acrylamide metabolites 
recovered in urine by 24 hours after dosing was 50%, which is similar to that reported by Miller et al. 
(1982) and Kadry et al. (1999).
Doerge et al. (2005c) compared the toxicokinetics of acrylamide and glycidamide in serum and tissues of 
male and female B6C3F1 mice following a single 0.1 mg/kg acrylamide dose by intravenous injection or 
gavage or a comparable dose of acrylamide from a feeding exposure for 30 minutes. Study groups also 
received an equimolar amount of glycidamide from either intravenous injection or gavage dosing. 
Following oral dosing, acrylamide was rapidly absorbed, widely distributed to tissues, and efficiently 
converted to glycidamide. Liver levels of glycidamide-DNA adducts were increased at 8 hours 
postdosing when acrylamide had been eliminated from the serum. Oral glycidamide dosing also resulted 
in rapid absorption, wide distribution to tissues, and liver DNA adduct levels that were approximately 
40% higher than those from an equimolar dose of orally-administered acrylamide. Based on the kinetics
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE
3. HEALTH EFFECTS
93
of acrylamide following intravenous injection, oral administration from the diet attenuated acrylamide 
bioavailability to 23% of the intravenous dose, and aqueous gavage attenuated acrylamide bioavailability 
to 32-52%. In contrast, oral exposure resulted in higher relative internal glycidamide levels compared 
with levels following an intravenous injection, likely due to a first-pass effect but possibly the result of 
some other kinetic change.
3.4.1.3 Dermal Exposure
Fennell and coworkers evaluated metabolism and hemoglobin adduct formation (Fennell et al. 2005b) and 
kinetics of elimination of urinary metabolites of acrylamide (Fennell et al. 2006) following dermal 
administration of [1,2,3-13C3]-acrylamide to 24 adult male volunteers exposed under controlled 
conditions. All volunteers were aspermic (i.e., clinically sterile because of the potential for adverse 
effects of acrylamide on sperm) and had not used tobacco products for the prior 6 months. The health of 
the volunteers was continually monitored. Acrylamide was administered as three daily 24-hour occluded 
dermal doses of 3 mg/kg. Mean levels of hemoglobin adducts of acrylamide (13C3-acrylamideVal) and 
glycidamide (13C3-glycidamideVal) increased from 116 and 55 fmol/mg globin, respectively, following 
the first exposure period to 464 and 316 fmol/mg globin, respectively, following the last exposure period. 
Based on total amount administered, formation of acrylamideVal after dermal exposure was much lower 
than after oral administration (4.9 vs. 74.7 nmol/g globin/mmol acrylamide/kg). Approximately 4.5% of 
the administered dose was recovered as urinary metabolites through day 4. Dermal exposure also resulted 
in much lower formation of glycidamideVal (9.7% of that formed following oral exposure).
Animal studies confirm that acrylamide is readily absorbed following dermal exposure (Ramsey et al. 
1984; Sumner et al. 2003). In male F344 rats, an average of 22% of an occluded dermal dose of 
162 mg/kg [2,3-14C]-labeled acrylamide was absorbed during a 24-hour exposure period (Sumner et al. 
2003). Following dermal administration of [1,3-14C]-labeled acrylamide to other F344 rats, peak plasma 
concentrations of acrylamide occurred at approximately 2 and 5 hours postadministration, respectively 
(Ramsey et al. 1984). The peak concentration at the high dose was about 20-fold higher than that of the 
low dose.
Results of an in vitro study describe dermal absorption of acrylamide. Marty and Vincent (1998) applied 
[14C]-labeled acrylamide (in an aqueous gel of 2% polyacrylamide) to biopsied human abdominal skin for 
24 hours at acrylamide concentrations of 1.28 or 2 ppm. Approximately 28 and 21% of the applied doses, 
respectively, was recovered in the receptor fluid. Between 1.6 and 3.4% of applied doses was recovered
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in dermis and epidermis. The authors estimated total absorption of acrylamide to be 33.2 and 26.7% at 
low and high concentration, respectively, based on radioactivity recovered from the receptor phase, 
epidermis, and dermis.
3.4.2 Distribution
Results from several animal studies indicate that, following absorption, radioactivity from radiolabeled 
acrylamide is widely distributed with no specific accumulation in any tissues other than red blood cells 
(Barber et al. 2001a; Crofton et al. 1996; Edwards 1975; Hashimoto and Aldridge 1970; Ikeda et al. 1985; 
Kadry et al. 1999; Marlowe et al. 1986; Miller et al. 1982; Ramsey et al. 1984) and late-staged spermatids 
(Sega et al. 1989). Results of intravenous injection studies in pregnant animals indicate that acrylamide 
and/or its metabolites readily cross the placenta and are distributed within the developing fetus in a 
manner similar to that of the pregnant mother (Ikeda et al. 1983, 1985; Marlowe et al. 1986). In a recent 
study designed to assess hemoglobin adduct levels of acrylamide in blood samples of pregnant mothers 
and umbilical cord blood of neonates, the concentration in umbilical cord blood was approximately 50% 
of that found in the blood of the mother, indicating that acrylamide readily passes from mother to 
developing fetus (Schettgen et al. 2004a).
3.4.2.1 Inhalation Exposure
Immediately following a 6-hour inhalation exposure of male F344 rats to 3 ppm of [14C]/[13C]-acrylamide 
vapor, the rank of acrylamide equivalent concentrations was: blood cells (~7 ^g/g) > testes, skin, liver, 
and kidneys (~6 ^g/g) > brain, spleen, lung, and epididymis (~4 ^g/g) (Sumner et al. 2003). Acrylamide 
equivalent concentrations in similarly-treated male B6C3F1 mice were: testes (~14 ^g/g) > skin and liver 
(~11 ^g/g) > epididymis (~8 ^g/g) > brain (~7 ^g/g) > lung and blood (~6 ^g/g) > fat (~5 ^g/g) (Sumner 
et al. 2003).
3.4.2.2 Oral Exposure
Following 13 daily oral doses of [1,3-14C]-labeled acrylamide at 0.05 or 30 mg/kg/day, tissue 
concentrations of acrylamide in male F344 rats were similar among tissues with the exception of red 
blood cells, which showed higher concentrations, presumably due to the formation of acrylamideVal 
and/or glycidamideVal hemoglobin adducts (Ramsey et al. 1984). Mean concentrations (^g equivalents 
[14C]-acrylamide per gram of tissue) at the high dose were 383.7 ^g/g in red blood cells, 87.74 ^g/g in 
liver, 70.43 ^g/g in kidneys, 70.60 ^g/g in epididymis, 67.14 ^g/g in testis, 54.00 ^g/g in sciatic nerve,
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53.52 ^g/g in brain, 47.56 ^g/g in carcass, 39.11 ^g/g in skin, and 16.45 ^g/g in plasma. At the low dose, 
the mean concentration in red blood cells was 1.26 ^g/g (approximately 61% of the total recovered dose) 
compared with a range of 0.07-0.13 ^g/g in other tissues.
In Sprague-Dawley rats given single 50 mg/kg oral doses of [1-14C]-labeled acrylamide, tissue 
concentrations of radioactivity at 28 and 144 hours postadministration were indicative of wide 
distribution of acrylamide metabolites among tissues with no evidence for accumulation in toxicity targets 
(Kadry et al. 1999). These results suggest the binding of acrylamide in the absence of its accumulation in 
erythrocytes or neural tissue. At 28 hours, brain, thyroid, testes, adrenal, pancreas, thymus, liver, kidney, 
heart, and spleen showed a narrow range of mean concentrations, approximately 0.05-0.10% of the initial 
dose/g. Higher concentrations were noted in the skin, bone marrow, stomach, and lung (0.15-0.18% of 
the initial dose/g); only the gastric contents showed a markedly higher concentration (1.37% of the initial 
dose/g. At 144 hours after administration, tissue concentrations were uniformly low for tissues including 
the gastric contents, ranging from 0.01 to 0.05% of the initial dose/g, with the exception of skin, bone 
marrow, and lung, which exhibited mean concentrations of 0.06, 0.08, and 0.19% of the initial dose/g, 
respectively.
3.4.2.3 Dermal Exposure
Following 24-hour dermal exposure of male F344 rats to 162 mg/kg [14C]-labeled acrylamide, the highest 
concentration of acrylamide equivalents (excluding skin at the application site) was found in blood cells 
(71 ^g/g), followed by skin at nondosing sites (~28 ^g/g); liver, spleen, testes, and kidneys (~21 ^g/g); 
lungs, thymus, brain, and epididymis (~14 ^g/g); and fat (<4 ^g/g) (Sumner et al. 2003).
3.4.3 Metabolism
Results from rat and mouse studies indicate that acrylamide is rapidly metabolized and excreted 
predominantly in the urine as metabolites (Dixit et al. 1982; Edwards 1975; Miller et al. 1982; Ramsey et 
al. 1984; Sumner et al. 1992, 1999, 2003; Twaddle et al. 2004). Figure 3-3 depicts a metabolic scheme 
for acrylamide adapted from reports of Calleman (1996), IARC (1994), and Sumner et al. (1992, 1999). 
According to the metabolic scheme, acrylamide reacts readily with glutathione to form a glutathione 
conjugate, which is further metabolized to N-acetyl-S-(3-amino-3-oxopropyl)cysteine or S-(3-amino-
3-oxopropyl)cysteine. Another initial step, catalyzed by CYP2E1, involves oxidation of acrylamide to the 
epoxide derivative, glycidamide. Glycidamide can react with glutathione to form conjugates that are
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further metabolized to N-acetyl-S-(3-amino-2-hydroxy-3-oxopropyl)cysteine or N-acetyl-S-(1- 
carbamoyl-2-hydroxyethyl)cysteine. Glycidamide may also undergo hydrolysis, perhaps catalyzed by 
epoxide hydrolases, leading to the formation of 2,3-dihydroxypropionamide and 2,3-dihydroxypropionic 
acid.
Both acrylamide and glycidamide react with nucleophilic sites in macromolecules (including hemoglobin 
and DNA) in Michael-type additions (Bergmark et al. 1991, 1993; Segerbäck et al. 1995; Solomon et al. 
1985). In rats, the binding index of acrylamide to cysteine in hemoglobin was extremely high 
(6,400 pmol/g Hb/^mol acrylamide/kg); the binding index of glycidamide to cysteine was 1,820 pmol/g 
Hb/^mol glycidamide/kg. The lower binding index for glycidamide may be the result of lower reactivity 
toward hemoglobin-cysteine and shorter half-life in blood. Rate constants of 0.0054 and 0.021 M"1s"1 for 
reactions of acrylamide with human serum albumin and glutathione, respectively, were reported by Tong 
et al. (2004), suggesting that these reactions account for most of the elimination of absorbed acrylamide. 
Doerge et al. (2005a) measured DNA adducts following a single intraperitoneal administration of 
acrylamide to adult B6C3F1 mice and F344 rats at 50 mg/kg. Glycidamide-derived DNA adducts of 
adenine and guanine formed in all tissues examined, including target tissues identified in rodent 
carcinogenicity bioassays and nontarget tissues. Dosing rats and mice with an equimolar amount of 
glycidamide (61 mg/kg) typically produced higher levels of DNA adducts than those observed from the 
acrylamide dose. Gamboa da Costa et al. (2003) measured DNA adduct formation in selected tissues of 
adult and whole body DNA of 3-day-old neonatal mice treated with acrylamide and glycidamide. In adult 
mice, DNA adduct formation was observed in liver, lung, and kidney; glycidamide treatment produced 
modestly higher adduct levels than acrylamide treatment. However, glycidamide-treated neonates 
exhibited 5-7-fold higher whole-body DNA adduct levels than the acrylamide-treated neonates.
Results from studies o f CYP2E1 null and wild-type mice demonstrate the importance of 
CYP2E1 in catalyzing the oxidative formation o f glycidamide from acrylamide. Following oral
13administration o f single 50 mg/kg doses o f [1,2,3- C]-acrylamide to wild-type mice, 
considerable amounts o f metabolites derived from glycidamide were found in the 24-hour urine 
(Sumner et al. 1999). Approximately 22% of the excreted metabolites were derived from 
glutathione conjugation with glycidamide (N-acetyl-S-[3-amino-2-hydroxy-3-oxopropyl]cysteine 
and N-acetyl-S-[1-carbamoyl-2-hydroxyethyl]cysteine) and 28% were derived from glycidamide 
and its hydrolysis products (2,3-dihydroxypropionamide and 2,3-dihydroxypropionic acid). In
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Figure 3-3. Metabolic Scheme for Acrylamide and Its Metabolite Glycidamide*
a c r y l a m i d e  H b  a d d u c t s  g l y c i d a m i d e  H b  a d d u c t s
H 2 C = C — C  — n h 2
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*Processes involving several steps are represented with broken arrows.
GSH = reduced glutathione; Hb = hemoglobin; N-AcCys = N-acetylcysteine 
Sources: Calleman 1996; Fennell et al. 2006; IARC 1994a; Sumner et al. 1992, 1999
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contrast, no evidence was found for the formation of these metabolites in the 24-hour urine of CYP2E1 
null mice or wild-type mice treated with the CYP2E1 inhibitor, aminobenzotriazole. The wild-type and 
CYP2E1-null mice excreted a similar percentage of the administered dose in the urine within 24 hours 
(about 30%), suggesting that the CYP2E1-null mice compensated for the CYP2E1 deficiency by 
metabolizing more of the administered acrylamide via direct conjugation with glutathione.
Ghanayem et al. (2005c) investigated the formation of hemoglobin adducts of acrylamide and 
glycidamide and DNA adducts of glycidamide in wild-type and CYP2E1-null mice following the 
administration of a single 50 mg/kg dose of acrylamide via intraperitoneal injection. At 6 hours 
posttreatment, mean plasma levels of acrylamide and glycidamide were 0.84 and 33.0 ^M, respectively, 
in the wild-type mice and 115 and 1.7 ^M, respectively, in the CYP2E1-null mice. Levels of hemoglobin 
adducts of acrylamide were approximately 2-fold higher in the CYP2E1-null mice compared to the wild­
type mice. Although only traces of DNA adducts of glycidamide were seen in the CYP2E1-null mice, 
levels were 52-66 times higher in the wild type mice. These results demonstrate the importance of 
CYP2E1 in the epoxidation of acrylamide to glycidamde and the formation of hemoglobin adducts and 
glycidamide-DNA adducts.
N-Acetyl-S-(3-amino-3-oxopropyl)cysteine has been identified as the major urinary metabolite of 
acrylamide in male F344 rats exposed to oral doses of 1-100 mg/kg [2,3-14C]-labeled acrylamide (Miller 
et al. 1982) and in male F344 rats and B6C3F1 mice exposed to oral doses of 50 mg/kg 
[1,2,3-13C]-acrylamide (Sumner et al. 1992).
Following oral administration of [1,2,3-13C]-acrylamide (50 mg/kg) to rats and mice, glycidamide and 
glycidamide-derived metabolites accounted for about 33% (rats) and 59% (mice) of the total metabolites 
excreted in the urine within 24 hours, indicating that acrylamide is transformed to glycidamide to a 
greater extent in mice than in rats (Sumner et al. 1992). Similar results were reported in a study of 
metabolites in urine collected for 24 hours after 6-hour inhalation exposure (nose only) of rats and mice to 
3 ppm [14C]/[13C]-acrylamide where glycidamide and glycidamide-derived metabolites accounted for 36% 
(rats) and 73% (mice) of total metabolites excreted in the urine within 24 hours (Sumner et al. 2003). 
Following dermal application of 138 mg/kg [1,2,3-13C]-acrylamide, male F344 rats excreted 
approximately 2% of the applied dose in the 24-hour urine as GSH-acrylamide derived metabolites 
(~50% of the urinary metabolites), glycidamide (~17%), and GSH-glycidamide derived metabolites 
(~31%) (Sumner et al. 2003).
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Figure 3-3 does not include a possible minor pathway in which CO2  may be released from the hydrolysis 
products of glycidamide, because of conflicting results from several studies. Following intravenous 
administration of 100 mg/kg [1-1 4 C]-labeled acrylamide to male albino Porton rats, about 6% of the 
injected dose of radioactivity was exhaled as CO2  in 8 hours (Hashimoto and Aldridge 1970), but 
following administration of [2,3-1 4 C]-labeled acrylamide to male Fischer 344 rats, no radioactivity was 
detected in exhaled breath (Miller et al. 1982). Sumner et al. (1992) hypothesized that these results may 
be consistent with the existence of a minor pathway involving metabolism of 2,3-dihydroxypropionamide 
to glycerate and hydroxypyruvate with the subsequent release of CO2  and production of glycoaldehyde, 
but they did not detect two-carbon metabolites in urine of mice exposed to [1,2,3-1 3 C]-acrylamide. In 
other experiments, no exhaled 1 4 CO2  was detected following 50 mg/kg oral dosing of [1-1 4 C]-labeled 
acrylamide to male Sprague-Dawley rats (Kadry et al. 1999), whereas 3-4% of intravenously injected 
[1,3-1 4 C]-acrylamide (2 or 100 mg/kg) was detected as 1 4 CO2  in exhaled breath of male Fischer 344 rats 
(Ramsey et al. 1984).
Species differences in acrylamide metabolism are apparent. Twaddle et al. (2004) administered 
acrylamide at approximately 50 mg/kg via gavage to adult male and female B6C3F1 mice. Serum 
concentrations of acrylamide and glycidamide were taken at 0.5, 1, 2, 4, and 8 hours postdosing. Livers 
were removed from control and acrylamide-treated mice and analyzed for glycidamide-derived DNA 
adducts. The results indicated no systematic sex differences in acrylamide or glycidamide serum levels at 
each time point. Twaddle et al. (2004) estimated an acrylamide half-life of elimination from plasma at 
0.73 hours. This value in mice can be compared to an estimate of 2 hours in F344 rats following a 
subchronic oral administration of 2.8 mM acrylamide in drinking water for 34 days or subacute 
intraperitoneal doses at 50 mg/kg/day for 11 days (Barber et al. 2001). Miller et al. (1982) estimated a 
1.7-hour half-life for acrylamide in rat blood following a 10 mg/kg intravenous dose. Twaddle et al. 
(2004) reported an elimination half-life of 1.9 hours for the acrylamide-treated mice, which is identical to 
that measured by Barber et al. (2001) in rats. Barber et al. (2001) also reported a 
glycidamide/acrylamide-areas under the curve (AUC) ratio of 0.18 for Sprague-Dawley rats treated with 
20 mg/kg acrylamide by gavage. This contrasts to the observation of equal AUCs for glycidamide and 
acrylamide in B6C3F1 mice (Twaddle et al. 2004). Since rats and mice had a comparable glycidamide 
elimination half-life, this approximately 5-fold difference in internal exposure to glycidamide for mice 
compared with rats is considered to be the result of an increased rate of glycidamide formation in the 
mouse.
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The metabolism of acrylamide has also been investigated in controlled human studies (Boettcher et al. 
2006a; Fennell et al. 2005b, 2006; Fuhr et al. 2006).
Fennell and coworkers evaluated metabolism and hemoglobin adduct formation (Fennell et al. 2005b) and 
kinetics of elimination of urinary metabolites (Fennell et al. 2006) following oral and dermal 
administration of [1,2,3-13C3)-acrylamide and/or [2,3-14C]-acrylamide to 24 adult male volunteers. 
Metabolism of the administered acrylamide was investigated by 13C nuclear magnetic resonance (NMR) 
spectroscopy (Fennell et al. 2005b) and by liquid chromatography-tandem mass spectroscopy (Fennell et 
al. 2006). Urinary metabolites accounted for approximately 40% of a 3 mg/kg oral dose of acrylamide 
and 4.5% of a 3 mg/kg/day repeated (3 consecutive days) dermal dose (Fennell et al. 2006). 
Approximately 86% of the recovered urinary metabolites were derived from glutathione conjugation and 
excreted as N-acetyl-S-(3-amino-3-oxopropyl)cysteine and its S-oxide. Glycidamide, glyceramide 
(2,3-dihydroxypropionamide), and low levels of N-acetyl-S-(3-amino-2-hydroxy-3-oxopropyl)cysteine 
were also detected in urine (Fennell et al. 2005b). On oral administration, a linear dose response was 
observed for acrylamideVal and glycidamideVal in hemoglobin. The main pathway of metabolism in 
humans was via direct glutathione conjugation, forming N-acetyl-S-(3-amino-3-oxopropyl)cysteine and 
its S-oxide, which has not been reported previously (Fennell et al. 2006). Epoxidation to glycidamide 
was the other important pathway, with glyceramide formed as a major metabolite in humans.
Glycidamide was detected in low amounts. The glutathione conjugation of glycidamide, which is a major 
pathway in rodents, appeared to occur at very low levels in humans. Metabolism via glycidamide in 
humans was approximately 12% of the total urinary metabolites. This is considerably lower than the 
amount of glycidamide-derived metabolites reported for oral administration of acrylamide in rats (28% at 
50 mg/kg, [Sumner et al. 2003]) and in mice (59% at 50 mg/kg [Sumner et al. 1992]). It should be noted 
that glyceramide has only been quantitated in human urine by NMR spectroscopy in combination with 
administration of [1,2,3-13C3]-acrylamide.
The Fennell et al. (2005b) study also provided data on the amount of hemoglobin adducts derived from 
acrylamide and glycidamide following administration of a defined dose of acrylamide to adult male 
volunteers. Both acrylamideVal and glycidamideVal increased linearly with increasing dose of 
acrylamide administered orally, suggesting that saturation of the conversion of acrylamide to glycidamide 
is not reached in the dosing range of 0.5-3.0 mg/kg. The ratio of glycidamideVal: acrylamideVal 
produced by administration of acrylamide was similar to the ratio of the background adducts prior to 
exposure. Compared with the equivalent oral administration in rats (3 mg/kg), the ratio of 
glycidamideVal:acrylamideVal was lower in humans (0.44 compared to 0.84 for the rat), and the absolute
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amounts of acrylamideVal and glycidamideVal formed were approximately 2.7- and 1.4-fold higher, 
respectively, in humans compared to rats.
Fennell et al. (2005b) calculated the expected amount of adduct that would accumulate in men from 
continuous exposure based on the amount of adduct formed/day of exposure, and from the lifespan of the 
erythrocyte. Oral intake of 1 ^g/kg acrylamide/day (1.05 fmol acrylamideVal/mg globin/day) for the 
lifespan of the erythrocyte (120 days) was estimated to result in the accumulation of adducts to 
63 fmol/mg globin. Daily dermal exposure to 1 ^g/kg acrylamide (0.18 fmol acrylamideVal/mg 
globin/day) for the lifespan of the erythrocyte (120 days) would result in the accumulation of adducts to 
10.8 fmol acrylamideVal/mg globin. With workplace exposure of 5 days/week, this would decrease to 
approximately 7.8 fmol acrylamideVal/mg globin.
Boettcher et al. (2006a) investigated the human metabolism of acrylamide to AAMA and GAMA in a 
healthy male volunteer who received a single dose of about 1 mg deuterium-labeled (d(3)) acrylamide, 
representing 13 ^g/kg body weight, in drinking water. Urine samples before dosing and within 46 hours 
after the dose were analyzed for d(3)-AAMA and d(3)-GAMA using liquid chromatography-mass 
spectrometry (LC-MS). Total recovery in urine after 24 hours was about 51% as the sum of AAMA and 
GAMA and was similar to recoveries in rats (53-66%) given a gavage dose of 0.1 mg/kg (Doerge et al.
2007). After 2 days, AAMA accounted for 52% of the total acrylamide dose, and was the major 
metabolite of acrylamide in humans. GAMA accounted for 5%, and appeared as a minor metabolite of 
acrylamide. A urinary ratio of 0.1 was observed for GAMA/AAMA compared to previously reported 
values of 0.2 for rats and 0.5 for mice (Doerge et al. 2005b, 2005c). The authors concluded that the 
metabolic fate of acrylamide in humans was more similar to that in rats than in mice as previously 
demonstrated in terms of hemoglobin adducts.
Fuhr et al. (2006) evaluated the urinary levels of acrylamide, AAMA, glycidamide, and GAMA (using 
LC-MS) in six young healthy volunteers after the consumption of a meal containing 0.94 mg of 
acrylamide. Urine was collected up to 72 hours thereafter. No glycidamide was found. Unchanged 
acrylamide, AAMA, and GAMA accounted for urinary excretion of approximately 4.5, 50, and 6% of the 
dose, respectively. Conjugation with glutathione exceeded the formation of the reactive metabolite 
glycidamide. The data suggest 2- and 4-fold lower relative internal exposures for glycidamide from 
dietary acrylamide in humans compared with rats and mice, respectively.
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Hemoglobin adducts of acrylamide and glycidamide and urinary metabolites have been used as 
biomarkers of exposure to acrylamide (Bergmark 1997; Bergmark et al. 1993; Boettcher et al. 2005; 
Calleman et al. 1994). Refer to Section 3.8. for detailed information regarding biomarkers of exposure to 
acrylamide.
3.4.4 Elimination and Excretion
Available human and animal data indicate that urinary excretion of acrylamide metabolites is the primary 
route of elimination of absorbed acrylamide (Barber et al. 2001a; Boettcher et al. 2006a; Doerge et al. 
2007; Fennell et al. 2005b, 2006; Fuhr et al. 2006; Hashimoto and Aldridge 1970; Kadry et al. 1999; 
Miller et al. 1982; Ramsey et al. 1984; Sumner et al. 1992, 1999, 2003).
3.4.4.1 Inhalation Exposure
No human data were located regarding excretion and elimination following inhalation exposure to 
acrylamide. Sumner et al. (2003) exposed male F344 rats and B6C3F1 mice nose-only to a mixture of 
[1,2,3-13C]-acrylamide (90%) and [2,3-14C]-acrylamide (10%) vapors at an average analytical 
concentration of 1.17 ppm for 6 hours. During a 24-hour postexposure period, the distribution of the 
inhaled dose in the rats was: 31% in the urine, 56% retained in the body, 3% in the feces, and 2% as 
exhaled organic volatiles and 14CO2. The distribution of the inhaled dose in the mice was: 27% in the 
urine, 46% in tissues, 5% in feces, 2% as organic volatiles, and 1% as14CO2.
3.4.4.2 Oral Exposure
Approximately 34% of an orally-administered 3 mg/kg dose of acrylamide to adult male volunteers was 
recovered in the total urinary metabolites within 24 hours of administration (Fennell et al. 2005b). In a 
male volunteer who received a single dose of about 1 mg deuterium-labeled acrylamide (representing 
13 ^g/kg body weight) in drinking water, elimination via urinary AAMA and GAMA followed a 
two-phase pattern (Boettcher et al. 2006a). Elimination half-lives of both AAMA and GAMA were 
estimated to be approximately 3.5 hours for the first phase and >10 hours up to few days for the second 
phase. After 2 days, urinary AAMA and GAMA accounted for 52 and 5%, respectively, of the total 
acrylamide dose. The ratio GAMA/AAMA was approximately 0.2.
Fuhr et al. (2006) measured acrylamide and metabolite levels in a 72-hour urine collection from six young 
healthy volunteers after the consumption of a meal containing 0.94 mg of acrylamide. Unchanged
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acrylamide, AAMA, and GAMA accounted for urinary excretion of approximately 4, 50, and 10%, 
respectively, of the administered dose; glycidamide was not detected. Estimated elimination half-lives for 
the unchanged acrylamide, AAMA, and GAMA were 2.4, 17.4, and 25.1 hours, respectively.
Heudorf et al. (2009) reported median levels of 36 ^g AAMA/L and 13 ^g GAMA/L in the urine of 
110 children (63 boys and 47 girls; 5-6 years of age). Children who reported higher regular consumption 
of French fries had significantly higher urinary levels of acrylamide metabolites. Based on the urinary 
levels of AAMA and GAMA, mean estimated acrylamide dietary intakes were 1.13 ^g/kg/day (creatinine 
excretion based model) and 0.81 ^g/kg/day (volume based model). The ratio GAMA/AAMA was 
approximately 0.4, which is 2-fold higher than that observed by Boettcher et al. (2006a) in adults. Based 
on this finding, Heudorf et al. (2009) suggest that acrylamide may undergo oxidative metabolism to a 
greater extent in children than adults.
In male Fischer 344 rats given oral (1, 10, or 100 mg/kg) doses of [2,3-14C]-acrylamide, about 60 and 
70% of the administered radioactivity was excreted in urine collected within 24 hours and 7 days, 
respectively (Miller et al. 1982). Less than 2% of radioactivity in the urine was accounted for by 
acrylamide. Elimination of radioactivity from tissues was biphasic with half-lives of about 5 and 8 hours, 
respectively. The elimination time course of parent compound from tissues exhibited single phase 
exponential elimination with a half-life of about 2 hours. Fecal excretion accounted for 4.8 and 6% of 
administered radioactivity at 24 hours and 7 days, respectively. Bile-duct cannulated rats given single 
intravenous 10 mg/kg doses of [2,3-14C]-acrylamide excreted about 15% of the administered radioactivity 
as metabolites within about 6 hours; <1% of radioactivity in the bile was in the form of acrylamide 
(Miller at al. 1982). These results are consistent with the existence of enterohepatic circulation of 
metabolites.
Doerge et al. (2007) administered acrylamide to male and female rats and mice at 0.1 mg/kg by oral 
gavage or via the diet and measured the percentages of parent compound and metabolites in the 24-hour 
urine. For rats and mice combined, the percentage of total dose excreted as the sum of acrylamide and its 
metabolites (glycidamide, AAMA, and GAMA) averaged 49%. Excretion of glycidamide and 
glycidamide-derived species was typically greater in mice than rats.
No radiolabeled CO2 was captured from rats given [2,3-14C]-acrylamide orally (Kadry et al. 1999; Miller 
et al. 1982). However, intravenous injection of rats with a 100 mg/kg dose of [1-14C]-labeled acrylamide 
(Hashimoto and Aldridge 1970) or a 2 mg/kg dose of [1,3-14C]-labeled acrylamide (Ramsey et al. 1984)
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resulted in the capture of about 6 and 4%, respectively, of the radioactivity as CO2 in the expired air 
during the subsequent 6-8 hours.
3.4.4.3 Dermal Exposure
Fennell et al. (2006) exposed 24 adult male volunteers to dermal applications of [1,2,3-13C3]-acrylamide 
under controlled conditions. Acrylamide was administered as three daily 24-hour occluded dermal doses 
of 3 mg/kg. Approximately 4.5% of the administered dose (12.35% of the absorbed dose) was recovered 
as urinary metabolites through day 4. Urinary recovery included 13C3-acrylamide (~4% of total urinary 
recovery) and metabolites 13C3-cysteine-S-propionamide (13C3-CP; ~0.8%), 13C3-N-acetyl cysteine-S- 
propionamide (13C3-NACP; ~70%), 13C3-NACP sulfoxide (~22.5%), 13C3-GAMA3 (~2.6%), and 
13C3-GAMA2 (~0.4%). Glycidamide was not detected in the majority of the urine samples. 
13C3-Acrylamide and 13C3-CP were detected in 2-4 hour urine samples collected on the first day. 13C3- 
NACP and its sulfoxide were first detectable in the urine between 4 and 8 hours posttreatment. The 
mercapturic acids of glycidamide (13C3-GAMA2 and 13C3-GAMA2) were first detectable in the urine 
between 8 and 16 hours posttreatment. The metabolite, glycidamide, was not detectable in the majority of 
the urine samples collected over the 4-day period.
Sumner et al. (2003) exposed male F344 rats to [2,3-14C]-labeled acrylamide under occluded dermal 
conditions for 24 hours. During a 24-hour postexposure period, approximately 8% of the applied dose 
(36% of the absorbed dose) was excreted in the urine, 3% as volatiles and 14CO2 in exhaled air, <1% in 
feces, and53% remained in tissues.
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry 
models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE
3. HEALTH EFFECTS
105
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species. The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance- 
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these 
solutions.
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species. 
Figure 3-4 shows a conceptualized representation of a PBPK model.
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Figure 3-4. Conceptual Representation of a Physiologically Based 
Pharmacokinetic (PBPK) Model for a 
Hypothetical Chemical Substance
Inhaled c h e m ica l  ^ |------► Exhaled chem ical
C hem ica ls  
contacting skin
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source: adapted from Krishnan and Andersen 1994
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If PBPK models for acrylamide exist, the overall results and individual models are discussed in this 
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations.
Physiologically based pharmacokinetic (PBPK) models for acrylamide are available (Calleman et al. 
1992, 1993; Kirman et al. 2003; Walker et al. 2007; Young et al. 2007).
Calleman et al. (1992, 1993) Model
Calleman et al. (1992, 1993) developed a nonlinear dosimetric model to simultaneously determine 
hemoglobin adduct formation by acrylamide and its genotoxic metabolite, glycidamide, in rats. The 
model is not useful for human health risk assessment.
Kirman et al. (2003) Model
Kirman et al. (2003) developed a PBPK model (Figure 3-5) to predict the behavior of acrylamide and its 
epoxide metabolite, glycidamide, in the rat for intravenously-, intraperitoneally-, or orally-administered 
acrylamide. The model includes components for both acrylamide and glycidamide, each consisting of 
five compartments (arterial blood, venous blood, liver, lung, and all other tissues). The acrylamide 
component is linked to the glycidamide portion of the model via metabolism in the liver. Model 
parameters are listed in Table 3-9. Rat physiological parameters were selected from measured data 
(Brown et al. 1997; Kedderis et al. 1996). Partition coefficients for acrylamide were estimated based on 
an algorithm derived by Poulin and Krishnan (1995, 1996a, 1996b) using specific chemical properties. 
Partition coefficients for glycidamide were derived by application of a proportionality constant of 3.2 to 
the values calculated for acrylamide (Kedderis et al. 1996). Metabolism of acrylamide and glycidamide 
are represented only in the liver. Estimated values for metabolism and tissue binding were based on 
fitting of the model to metabolism and urinary elimination data from Miller et al. (1982), Ramsey et al. 
(1984), Raymer et al. (1993), and Sumner at al. (1992). Depletion and resynthesis of glutathione were 
included in the model structure (D’Souza et al. 1988).
The PBPK model of Kirman et al. (2003) was developed to predict the behavior of acrylamide and 
glycidamide in the rat. The model has only been partially validated in rats and is not useful for human 
risk assessment.
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Figure 3-5. Schematic of the Kirman et al. (2003) Physiologically Based 
Pharmacokinetic (PBPK) Model for Acrylamide
Acrylamide Glycidamide
EH = epoxide hydrolase; GST = glutathione ^-transferase; i.p. = intraperitoneal injection; i.v. = intravenous 
injection;
Source: Kirman et al. 2003
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Table 3-9. Original Model Parameter Values for Rats in the Kirman et al. (2003)
Physiologically Based Toxicokinetic (PBTK) Model
Param eter
group Param eter Sym bol (units) Value R eference/source
Rat physiology
Absorption
Body weight BW (kg) Study specific Study specific
Cardiac output QCC (L/hour- 
kg)
14 Kedderis et al. 1996
Alveolar ventilation QPC (L/hour- 
kg)
14 Kedderis et al. 1996
Liver blood flow QLC (fraction 
QCC)
0.25 Kedderis et al. 1996
Fraction arterial FABC (fraction 
VB)
0.S5 Kedderis et al. 1996
Fraction venous FVBC (fraction 
VB)
0.65 Kedderis et al. 1996
Liver volume VLC (fraction 
BW)
0.04 Brown et al. 1997
Tissue volume VTC (fraction 
BW)
0.87 Calculated (0.91-VLC)
Tissue blood flow QTC (fraction 
QCC)
0.75 Calculated (1-QLC)
Volume blood VBC (fraction 
BW)
0.06 Brown et al. 1997
Hemoglobin
concentration
HGB (g/L) 1.5 Kedderis et al. 1996
Fraction blood cells FBC (fraction 
VB)
0.44 Kedderis et al. 1996
Fraction blood serum FBS (fraction 
VB)
0.56 Kedderis et al. 1996
Absorption rate from 
gastrointestinal tract 
(oral dose) or 
intraperitoneal cavity 
(intraperitoneal dose)
KA (/hour) 5 Model simulations fit to 
Miller et al. 1982; 
Ramsey et al. 1984; 
Raymer et al. 199S
Infusion time 
(intravenous dose)
TINF (hour) 0.00S Model simulations fit to 
Miller et al. 1982;
Ramsey et al. 1984; 
Raymer et al. 199S
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Table 3-9. Original Model Parameter Values for Rats in the Kirman et al. (2003)
Physiologically Based Toxicokinetic (PBTK) Model
Param eter
group Param eter Sym bol (units) Value R eference/source
Partition
coefficients
Metabolism
Blood:air, AA
Liver:blood, AA
Tissue:blood, AA
Blood:air, GA
Liver:blood, GA
Tissue:blood, GA
Cytochrome P-450 
oxidation rate, AA
Cytochrome P-450, 
Michaelis-Menten 
constant, AA
Epoxide hydrolase 
hydrolysis rate, GA
Epoxide hydrolase, 
Michaelis-Menten 
constant, GA
Reaction with 
glutathione, AA
Reaction with 
glutathione, GA
PB1 (unitless) 31,000,000 Estimated 
PL1 (unitless) 0.83
PL1 0.95
PB2 (unitless)
PL2 (unitless)
PT2 (unitless)
VMAXC1
(mg/hour-kg)
KMC1 (mg/L)
VMAXC2
(mg/hour-kg)
KMC2 (mg/L)
KGSTC1 
(L/mmol GSH- 
hr)
KGSTC2 
(L/mmol GSH- 
hour)
98,000,000
2.7
3.0
1.6
10
1.9
100
0.55
0.8
Poulin and Krishnan 
1995 ,1996a, 1996b
Poulin and Krishnan 
1995 ,1996a, 1996b
Poulin and Krishnan 
1995 ,1996a, 1996b 
Poulin and Krishnan 
1995 ,1996a, 1996b 
Poulin and Krishnan 
1995 ,1996a, 1996b 
Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993; Sumner et al. 
1992
Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993; Sumner et al. 
1992
Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993; Sumner et al. 
1992
Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993; Sumner et al. 
1992
Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993; Sumner et al. 
1992
Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993; Sumner et al. 
1992
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Table 3-9. Original Model Parameter Values for Rats in the Kirman et al. (2003)
Physiologically Based Toxicokinetic (PBTK) Model
Param eter
group Param eter Sym bol (units) Value R eference/source
Tissue binding Binding to hemoglobin, 
AA
KHGB1
(L/gHGB)
0.5 Model simulations fit to 
Miller et al. 1982, Raymer 
et al. 1993
Binding to hemoglobin, 
GA
KHGB2
(L/gHGB-hour)
0.25 Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993
Binding to liver
macromolecules,
acrylamide
KFEEL1 (/hour) 0.2 Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993
Binding to liver 
macromolecules, GA
KFEEL2 (/hour) 0.1 Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993
Binding to tissue 
macromolecules, AA
KFEET1 (/hour) 0.08 Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993
Binding to tissue 
macromolecules, GA
KFEET1 (/hour) 0.04 Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993
Binding to blood 
macromolecules, AA
KFEEB1 (/hour) 0.01 Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993
Binding to blood 
macromolecules, GA
KFEEB2 (/hour) 0.005 Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993
Protein turnover KPT (/hour) 0.008 Model simulations fit to 
Miller et al. 1982; Raymer 
et al. 1993
Glutathione GSH production rate KGSHP
(mmol/hour)
0.025 D’Souza et al. 1988
GSH loss rate KGSHL (/hour) 0.35 D’Souza et al. 1988
Initial GSH 
concentration in liver
GSHL0
(mmol/L)
7.0 D’Souza et al. 1988
AA = acrylamide; GA = glycidamide; GSH = glutathione 
Source: Kirman et al. 2003
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Young et al. (2007) Model
Young et al. (2007) produced a PBPK/toxicodynamic (TD) model to predict the behavior of acrylamide, 
glycidamide, and their respective glutathione conjugates in rats, mice, and humans (Figure 3-6). The 
model was developed using PostNatal, a windows-based program from the U.S. FDA’s National Center 
for Toxicological Research (NCTR). The program controls up to four PBPK model units (depicted as 
PBPK 1-4 in Figure 3-6) under one shell with multiple input and output options. Each PBPK unit is 
comprised of 28 organ/tissue/fluid components maintained independently or connected through metabolic 
pathways. Pharmacodynamic components for liver glycidamide-DNA adducts and hemoglobin adducts 
with acrylamide and glycidamide are included in the model as well. Dose administration can be either 
acrylamide or glycidamide. All metabolism and urinary elimination are considered first order.
Physiological parameters were assigned values from within the PostNatal program based on animal 
species, gender, and total body weight. Serum acrylamide and glycidamide concentrations and urinary 
elimination levels for male and female rats and mice were simulated from intravenous and oral 
administration of 0.1 or 0.12 mg/kg glycidamide. Adduct formation and decay rates were determined 
from a 6-week exposure to 1 mg/kg acrylamide in the drinking water followed by 6 weeks of 
nontreatment.
The data used to calibrate the Young et al. (2007) model for rats and mice include acrylamide serum 
levels in rats following intraperitoneal administration (Raymer et al. 1993); plasma acrylamide and 
glycidamide levels, and acrylamide and glycidamide hemoglobin adduct levels following relatively high 
(50 mg/kg bw) repeat intraperitoneal dosing in rats for 11 days or 2.8 mM of acrylamide in drinking 
water for 47 days (Barber et al. 2001); urinary excretion profile and acrylamide and glycidamide 
hemoglobin adduct levels following dosing via intraperitoneal injection (50 mg/kg), gavage (50 mg/kg), 
dermal application (150 mg/kg), or inhalation (3 ppm for 6 hours) (Sumner et al. 2003); and serum and 
tissue levels of acrylamide and glycidamide, and liver glycidamide-DNA adduct data in rats and mice 
following relatively low-dose administration via intravenous injection (acrylamide and glycidamide at 
0.1-0.12 mg/kg), gavage (acrylamide and glycidamide at 0.12 and 50 mg/kg), diet (~0.1 mg/kg over 
30 minutes), and drinking water (~1 mg/kg acrylamide over 42 days) (Doerge et al. 2005a, 2005b,
2005c). The single and multiple oral data from Barber et al. (2001) were combined with the urinary 
elimination data of Sumner et al. (1992, 2003) and simulated with the model. The Raymer et al. (1993)
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Figure 3-6. Schematic of the Young et al. (2007) Physiologically Based 
Pharmacokinetic/Toxicodynamic (PBPK/TD) Model For 
Acrylamide and Glycidamide*
Input Input
urine urine
*Block diagram for the metabolism of AA to GA and further metabolism of both to their glutathione 
conjugates. All pharmacokinetic and pharmacodynamic (PD) processes are first order.
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data were also combined with the urinary elimination data of Sumner et al. (1992, 2003) and simulated in 
a similar manner. The NCTR tissue data (Doerge et al. 2005a, 2005b, 2005c) were used to develop 
partition coefficients. Only those tissues specifically analyzed for acrylamide or glycidamide were 
partitioned differently from the blood compartment. Values for the human parameters were calibrated 
against urinary excretion data (Fennell et al. 2005b; Fuhr et al. 2006) and hemoglobin adduct data from a 
dietary exposure (Boettcher et al. 2005).
Values for the metabolism and elimination of acrylamide or glycidamide, for acrylamide or glycidamide 
binding to hemoglobin, and for glycidamide-DNA adduct formation were derived by optimizing the fit of 
the simulation results to individual animal data. All rate constants for the metabolic and elimination 
processes, the binding and decay of acrylamide or glycidamide to hemoglobin, and the binding of 
glycidamide to liver macromolecule are represented as first order. Although Young et al. (2007) 
calibrated their model parameter values in a logical sequence against the data identified in the paper, a 
number of sensitive parameters were allowed to vary when fitting the individual animal data so as to 
optimize the model fit to each set of data. The authors evaluated the resulting differences among the 
model parameter values relative to gender and study conditions for insights into the toxicokinetics of 
acrylamide and glycidamide, and to assess the uncertainty in the model parameter values. Although there 
are statistically significant differences in some cases in the fitted model parameter values for basic 
physiological functions such as excretion of acrylamide-GSH conjugates in urine (which varies as much 
as 4-6 for model fits to different studies), the authors argued that the ranges of values are not exceedingly 
wide considering that different routes of administration for different chemicals are all being compared, 
and that there is very little difference for each metabolic rate constant when comparing across gender, 
dose, and route.
For the purpose of quantitative risk assessment, a PBPK model is generally developed to produce a single 
set of parameter values that fits at least the most relevant data for a particular application. Evaluating the 
importance of uncertainty in parameter values also depends upon the choice of the dose metric and its 
sensitivity to parameters of interest. For useful application of the PBPK model of Young et al. (2007) to 
human health risk, additional studies are needed to identify a single set of parameters, and to evaluate the 
sensitivity of various dose metrics to the parameters that are the most uncertain.
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Walker et al. (2007) Model
Walker et al. (2007) described an adaptation of the PBPK model of Kirman et al. (2003) to account for:
(1) hemoglobin adduct data for rats (Fennell et al. 2003) and (2) extrapolation to adult humans using 
human adduct data (Fennell et al. 2004, 2005b). The Walker et al. (2007) model incorporates available 
information regarding children’s changing physiology and metabolic capacity for selected processes 
involved in acrylamide disposition (i.e., CYP2E1, glutathione conjugation, epoxide hydrolase). However, 
this model has not been calibrated or validated with respect to acrylamide dosimetry in children.
3.5 MECHANISMS OF ACTION
3.5.1 Pharmacokinetic Mechanisms
Acrylamide is readily absorbed via all natural routes of exposure (inhalation, oral, dermal) and is 
distributed throughout the body via the blood. No studies were located regarding mechanisms for 
acrylamide absorption across lung, gut, or skin; processes may include passive and/or facilitative 
mechanisms. Acrylamide and its reactive metabolite, glycidamide, readily bind to hemoglobin, but do not 
accumulate appreciably in any tissues. Acrylamide metabolism is relatively rapid; both parent compound 
and the epoxide, glycidamide, appear to be involved in acrylamide toxicity. Animal data demonstrate the 
importance of CYP2E1 in acrylamide metabolism. Metabolism is assumed to take place primarily in the 
liver. Urinary excretion of conjugated acrylamide derivatives represents the major excretory pathway for 
acrylamide.
3.5.2 Mechanisms of Toxicity
Neurotoxic Effects. The neurotoxicity of acrylamide has been assessed since the 1950s in numerous 
animal studies; notable signs and symptoms include hindfoot splay, decreased grip strength, and 
increasingly impaired mobility with continued exposure (see Sections 3.2.1.4, 3.2.2.4, and 3.2.3.4 for 
detailed information regarding neurological effects in animals administered acrylamide by inhalation, 
oral, and dermal exposure routes, respectively). Observations of neurological effects in acrylamide­
exposed humans include muscle weakness and other signs of functional impairments (Calleman et al. 
1994; Hagmar et al. 2001; He et al. 1989). Early histopathologic investigations performed on acrylamide- 
intoxicated animals revealed degenerative effects in distal portions of large peripheral nerve fibers and 
associated myelin sheath (Spencer and Schaumberg 1974, 1977). The degeneration was observed to 
progress proximally in a process termed “dying back”. Early hypotheses to explain this “dying back”
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effect involved damage to axonal neurofilaments, impairment of cellular metabolism, effects on axonal 
transport mechanisms, and disruption of axon cytoskeleton (Cavanaugh 1964; Harris et al. 1994; Harry 
1992; Lapadula et al. 1989; LoPachin and Lehning 1994; Padilla et al. 1993; Pleasure et al. 1969; Sickles 
1991; Spencer et al. 1979).
Specific mechanisms of acrylamide neurotoxicity have not been clearly elucidated. However, results of 
numerous studies designed to assess mechanisms of acrylamide-induced neurological effects have led to 
two major hypotheses: (1) acrylamide-induced disruption of fast axonal transport (Sickles et al. 2002a) 
and (2) acrylamide-induced disruption of nitric oxide signaling at nerve terminals (LoPachin and Barber 
2006; LoPachin et al. 2008). In addition, recent work by Zhu et al. (2008) provides some support to a 
hypothetical mode of action whereby acrylamide exposure results in increases in reactive oxygen species, 
damage to cellular macromolecules, and subsequent degeneration of neural tissues.
Disruption o f Fast Axonal Transport. The hypothesis that acrylamide induces peripheral neuropathy via 
disruption of fast axonal transport proposes the binding of acrylamide to kinesin, which leads to 
impairment of the fast axonal transport system responsible for the distal delivery of macromolecules.
This would result in deficiencies in proteins responsible for maintaining axonal structure and function. 
The particular vulnerability of distal axons and nerve terminals is based on the large axonal volume and 
transport distance from cell body to distal regions. Kinesin, which plays an integral role in intracellular 
transport along microtubules, is inhibited by neurotoxic doses of acrylamide. Evidence was provided 
from results of a microtubule motility assay in which preincubation of purified kinesin with acrylamide 
produced a dose-dependent loss of numbers of microtubules moving over a bed of kinesin and less-steady 
locomotory activity (Sickles et al. 1996). These effects were proposed to result from covalent adduction 
through sulfhydryl alkylation by acrylamide. Comparable effects were produced by glycidamide.
Disruption o f Nitric Oxide Signaling at Nerve Terminals. The hypothesis that acrylamide induces 
peripheral neuropathy via disruption of nitric oxide signaling at nerve terminals was proposed by 
LoPachin and coworkers (LoPachin and Barber 2006; LoPachin et al. 2008) based on critical review of 
available data for conjugated a,P-unsaturated carbonyl derivatives, a group of type-2 alkenes that includes 
acrylamide. The hypothesis is based on evidence that: (1) acrylamide inhibits neurotransmission in 
peripheral and central synapses and (2) soft electrophiles such as acrylamide form Michael-type adducts 
with soft nucleophilic sulfhydryl groups on protein cysteine residues.
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According to the review of LoPachin and Barber (2006), the functional status of many synaptic processes 
is determined by proteins whose activity is regulated by the redox state of highly nucleophilic sulfhydryl 
groups within corresponding catalytic triads. Acrylamide (a soft electrophile) forms adducts with soft 
nucleophilic sulfhydryl groups on cysteine residues (reviewed in LoPachin and DeCaprio 2005). Results 
of early electrophysiological studies demonstrated acrylamide-induced neurotransmitter inhibition at 
peripheral and central synapses (reviewed in LoPachin et al. 2002, 2003). Results of subsequent 
mechanistic studies indicate that acrylamide causes decreases in neurotransmitter release, uptake, and 
storage (Barber and LoPachin 2004; LoPachin et al. 2004, 2006) and that these effects may be mediated 
by acrylamide-sulfhydryl adduction of specific cysteine residues on functionally critical proteins (Barber 
and LoPachin 2004). Because the cysteine-acrylamide adduction sites are also sites of nitric oxide 
nitrosylation (Jaffrey et al. 2001; Stamler et al. 2001), it has been suggested that acrylamide inhibits 
synaptic activity by disrupting nitric oxide signaling (LoPachin and Barber 2006). LoPachin and 
coworkers suggest that acrylamide itself, and not its major electrophilic metabolite glycidamide, is 
responsible for the neurotoxicity because glycidamide is a hard electrophile that forms adducts with hard 
nucleophiles (nitrogen, carbon, oxygen) consistent with glycidamide adducts on adenine and guanine 
bases.
Reactive Oxygen Species Hypothesis. Results of Zhu et al. (2008) provide some indication that 
acrylamide-induced neurotoxicity may involve enhancement of lipid peroxidation and decreased 
antioxidative capacity, depletion of neural glutathione levels and antioxidant enzyme activities, leading to 
increased levels of reactive oxygen species, damage to cellular macromolecules, and subsequent 
degeneration of neural tissues. Time-dependent decreased glutathione levels and anti-reactive oxygen 
species activities and increased malondialdehyde levels in sciatic nerve preparations were highly 
correlated with changes in electrophysiological indices of acrylamide-induced neurotoxicity in rats 
receiving repeated intraperitoneally-injected doses of 40 mg/kg acrylamide.
Reproductive Effects. Mechanisms of acrylamide-induced reproductive toxicity are poorly 
understood. There is some indication that mutagenic effects on male germ cells may play a significant 
role (see Section 3.3 Genotoxic Effects). Available data provide suggestions that acrylamide-induced 
male dominant lethal mutations may involve clastogenic events from binding of acrylamide and/or 
glycidamide to spermatid protamines or spindle fiber proteins and/or direct alkylation of DNA by 
glycidamide (Adler et al. 2000; Perrault 2003; Sega et al. 1989; Tyl and Friedman 2003; Tyl et al. 2000b). 
Tyl and Friedman (2003) also suggested that adverse effects on mounting, sperm motility, and 
intromission could be related to distal axonopathy resulting from binding of acrylamide to motor proteins.
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Results of one study using male CYP2E1-null and wild-type mice demonstrate the importance of 
metabolism in acrylamide-induced germ cell mutations (Ghanayem et al. 2005a). The male mice were 
administered acrylamide via intraperitoneal injection for 5 consecutive days at dose levels of 0, 12.5, 24, 
or 50 mg/kg/day and subsequently mated with untreated B6C3F1 female mice. Dose-related increased 
incidences of dominant lethal mutations and decreases in numbers of pregnant females and proportion of 
living fetuses were observed in females mated to wild-type male mice. No significant changes in any 
fertility parameters were seen in females mated to CYP2E1-null male mice. These results demonstrate 
the importance of CYP2E1-mediated epoxidation to acrylamide-induced germ cell mutations in male 
mice.
Genotoxic/Carcinogenic Effects. Specific mechanisms whereby acrylamide induces tumors in 
laboratory animals are not understood at present. However, the weight of evidence supports a mutagenic 
mode of action (Besaratinia and Pfeiffer 2005, 2007; Dearfield et al. 1995; Moore et al. 1987; Segerback 
et al. 1995). Evidence for a mutagenic mode of action includes findings that: (1) acrylamide is 
metabolized by CYP2E1 to DNA-reactive glycidamide; (2) acrylamide and glycidamide induce mutations 
in lymphocyte HPRT and liver cll cells; (3) DNA adducts of glycidamide have been detected in tissues of 
all relevant tumor targets of acrylamide-and glycidamide-exposed male and female rats and mice;
(4) glycidamide is mutagenic to bacteria and male mouse germ cells and male and female mouse somatic 
cells in vivo; (5) acrylamide induces heritable translocations and specific locus mutations in germ cells of 
exposed male mice; (6) acrylamide induces clastogenic effects in mouse lymphoma assays; and 
(7) dominant lethal effects in rodents occur at subchronic oral exposure levels comparable to those 
associated with carcinogenic effects in chronically-exposed rats. These findings support a proposed mode 
of action whereby acrylamide is metabolized to the relatively long-lived epoxide, glycidamide, which 
reacts with proteins and DNA, causing mutations that persist in viable somatic cells, resulting in tumor 
formation. Ghanayem et al. (2005b) observed significant dose-related increases in micronucleated 
erythrocytes and DNA damage in somatic cells (leukocytes, liver, lung) of acrylamide-treated wild-type 
mice, but not in CYP2E1-null mice, indicating that genetic damage in somatic cells is dependent on 
metabolism of acrylamide by CYP2E1. Allen et al. (2005) investigated dose-response relationships from 
in vivo genotoxicity data (chromosomal damage, gene mutations, and recombinations in somatic and 
germ cells) for acrylamide using three different mathematical models according to end point; the 
investigation included benchmark dose calculations. The results were not consistent with a genotoxic 
mode of action for the thyroid tumors reported in 2-year cancer bioassays in rats (Friedman et al. 1995; 
Johnson et al. 1984, 1986). Based on these results, Allen et al. (2005) suggested that a nongenotoxic 
mode of action may be primarily responsible for acrylamide-induced thyroid tumors in rats.
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Another hypothetical mode of action involves disruption of hormone levels or hormone signaling for 
acrylamide-induced tumors in hormonally-sensitive tissues including mammary gland and thyroid or 
tissues adjacent to hormonally sensitive tissue, such as tunica vaginalis mesothelium (DFG 2009,
Dourson et al. 2008; Environ 2002; Haber et al. 2009; Klaunig 2008; Shipp et al. 2006). In support of 
this hypothetical mode of action, American Cyanamid Company (1991) reported decreases in serum 
testosterone and thyroid hormone (T3 and T4) levels in rats following oral exposure to acrylamide.
The induction of cellular proliferation is yet another proposed mode of action for acrylamide 
carcinogenicity in selected target tissues, although limited supporting data are available. Lafferty et al. 
(2004) demonstrated that tumorigenic doses of acrylamide administered to male rats induced cell 
proliferation in thyroid, tunica vaginalis, and adrenal medulla (tumor target tissues), but not in liver or 
adrenal cortex (nontarget tissues).
3.5.3 Animal-to-Human Extrapolations
Available data from rats and mice indicate that acrylamide is transformed to glycidamide to a greater 
extent in mice than rats. Following oral administration of radiolabeled acrylamide (50 mg/kg), 
glycidamide and glycidamide-derived metabolites accounted for about 33% (rats) and 59% (mice) of the 
total metabolites excreted in the urine within 24 hours (Sumner et al. 1992). Similar results were reported 
in a study of metabolites in urine collected for 24 hours after 6-hour inhalation exposure (nose only) of 
rats and mice to 3 ppm acrylamide where glycidamide and glycidamide-derived metabolites accounted for 
36 % (rats) and 73 % (mice) of total metabolites excreted in the urine within 24 hours (Sumner et al. 
2003).
Available PBPK models for acrylamide (Kirman et al. 2003; Walker et al. 2009; Young et al. 2007) have 
not been adequately calibrated and validated for useful extrapolation from animals to humans.
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial. The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a
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naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment. Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen. Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997). Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans after exposure to acrylamide.
One repeated-dose oral study in rats reported acrylamide-induced decreases in serum testosterone levels, 
thyroid hormone (T3 and T4) levels, and prolactin (American Cyanamid Company 1991).
No in vitro studies were located regarding endocrine disruption of acrylamide.
3.7 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
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effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.
Relevant animal and in vitro models are also discussed.
Children are not small adults. They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the 
extent of their exposure. Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s). Damage 
may not be evident until a later stage of development. There are often differences in pharmacokinetics 
and metabolism between children and adults. For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978). Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification. There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). 
Children and adults may differ in their capacity to repair damage from chemical insults. Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer.
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Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical. For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993).
Specific information regarding acrylamide-induced health effects in children was not located.
Neurotoxic end points have been examined in acrylamide-exposed mature and immature animals; 
however, with respect to possible age-related differences in susceptibility to acrylamide neurotoxicity, 
results are conflicting. Some reports indicate that young animals may be less susceptible than older ones 
(Fullerton and Barnes 1966; Kaplan et al. 1973), whereas other reports present evidence that young 
animals may be more sensitive (Ko et al. 1999; Suzuki and Pfaff 1973). In rats administered acrylamide 
orally at 100 mg/kg/day, Fullerton and Barnes (1966) noted that 26-week-old rats experienced earlier and 
more severe neurotoxic effects than 5-week-old rats. In contrast, Ko et al. (1999) reported that oral 
administration of acrylamide at 91 mg/kg/day resulted in earlier onset and more rapid progression of 
neuropathy in 3-week-old mice compared to 8-week-old mice. Studies that employed intraperitoneal 
injection of acrylamide also yielded conflicting results (Kaplan et al. 1973; Suzuki and Pfaff 1973). In 
rats repeatedly injected with 50 mg/kg acrylamide, earlier and more prominent degenerative 
histopathologic changes were noted in peripheral nerves of 1-day-old pups compared to adults. Kaplan et 
al. (1973) found the opposite in rats repeatedly injected with the same dose; 14-week-old rats experienced 
impaired rotarod performance earlier than 5-week-old rats (although the younger rats recovered more 
slowly).
Cancer is also a possible human health effect based on evidence that carcinogenic responses in rats 
chronically exposed to acrylamide throughout adulthood are likely mediated through a mutagenic mode 
of action that could occur in humans. In the absence of direct evidence that early-life exposure leads to 
increased risk for cancer, EPA (2005b) assumes that increased risk occurs with early-life exposure to 
agents that act through a mutagenic mode of action. For acrylamide, no human or animal studies were 
located that examined whether early-life exposure to acrylamide increased the risk for cancer, compared 
with exposure during adulthood alone; however, there is evidence that acrylamide acts through a 
mutagenic carcinogenic mode of action. CYP2E1, which catalyzes acrylamide to its DNA-reactive 
metabolite glycidamide, is not expressed in the developing fetus, but attains levels of expression during 
early postnatal periods that are similar to levels in adults (Johnsrud et al. 2003).
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There is no information regarding developmental health effects as a result of acrylamide exposure in 
humans. Developmental effects observed in acrylamide-exposed rats include decreased brain levels of 
catecholamines, decreased auditory startle response, decreased performance in an operant test of cognitive 
motivation, and decreased body weight (Field et al. 1990; Garey and Paule 2007; Husain et al. 1987; Wise 
et al. 1995). Decreased brain levels of catecholamine resulted from various lengths of exposure via 
lactation or gavage (Husain et al. 1987). Decreased auditory startle response followed exposure during 
gestation (Wise et al. 1995), and decreased performance in an operant test of cognitive motivation 
followed either exposure during gestation, lactation, or through 12 weeks of age (Garey and Paule 2007). 
Acrylamide has been shown to distribute across the placenta in exposed pregnant animals. Two hours 
following intravenous administration of acrylamide to pregnant beagle dogs, concentrations of 
radioactivity in blood, brain, heart, and lung were similar in both maternal and fetal tissues (Ikeda et al. 
1983, 1985; Marlowe et al. 1986). Humans are unlikely to be exposed by intravenous routes, but these 
results show that acrylamide could cross the placenta if exposure was great enough to achieve comparable 
maternal blood levels.
Sorgel et al. (2002) reported the detection of low levels of acrylamide (3.17-18.8 ng/mL) in breast milk 
samples taken from mothers (n=2) during 8 hours following the ingestion of potato chips (estimated 
acrylamide dose of 0.8-1 mg); predose acrylamide in the breast milk was below the level of 
quantification (5 ng/mL).
In studies of offspring of nursing rat dams receiving acrylamide orally at 25 mg/kg/day throughout 
lactation, the dams exhibited severe toxic effects (some mortalities, body weight loss, and hindlimb splay 
in 90% of the dams) (Friedman et al. 1999). Starting at lactation day 4, offspring showed progressively 
decreased body weight, compared with control offspring (at lactation day 21, mean body weight of 
exposed pups was about 43% of the control pup weight); many of the pups died or became moribund 
during the lactational period without exhibiting signs of peripheral neuropathy (Friedman et al. 1999). In 
surviving acrylamide-exposed male pups, grip strength was decreased at postnatal day (PND) 30, 
compared with controls, but was not significantly different from control values at PNDs 60 and 90 
(Friedman et al. 1999). The absence of milk in the stomachs of exposed pups that died or became 
moribund during lactation suggests that inadequate milk supply caused these effects in the offspring. An 
earlier study by Husain et al. (1987) reported complete hindlimb paralysis in male offspring of 
comparably-exposed rat dams of the same strain, but neither of the studies examined breast milk for the 
presence of acrylamide. Free acrylamide was not detected in the serum of Sprague-Dawley rat dams
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receiving acrylamide from the drinking water from gestation day 6 through postnatal day 21 at 
concentrations resulting in mean daily acrylamide doses as high as 14.56 mg/kg (Takahashi et al. 2009). 
No free acrylamide was detected in stomach contents and serum of the pups at postnatal day 14.
However, dose-related increases in acrylamide-Hb adduct levels of both dams and their pups were noted; 
the levels in the pups were >10-fold lower than those of their respective dams.
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment 
of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta. However, several 
factors can confound the use and interpretation of biomarkers of exposure. The body burden of a 
substance may be the result of exposures from more than one source. The substance being measured may 
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from 
exposure to several different aromatic compounds). Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken. It may be difficult to 
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids 
(e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to 
acrylamide are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity. Note that these markers are not often substance specific. They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused 
by acrylamide are discussed in Section 3.8.2.
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A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Acrylamide
Several biomarkers of exposure to acrylamide have been reported in the literature. Unchanged 
acrylamide, its mercapturic acid metabolite, AAMA, its epoxy derivative, glycidamide, and the respective 
metabolite of glycidamide, GAMA, were quantified in the urine of six volunteers after the consumption 
of a meal containing 0.94 mg of acrylamide (Fuhr et al. 2006). Urinary mercapturic acid derivatives of 
acrylamide and/or glycidamide were quantified in other human studies as well (Bjellaas et al. 2007a; 
Boettcher et al. 2005, 2006a, 2006b). Results of epidemiological studies support the use of hemoglobin 
adducts of acrylamide and/or glycidamide as biomarkers of exposure to acrylamide (Bergmark et al.
1993; Boettcher et al. 2005; Calleman et al. 1994; Fennell et al. 2005b, 2006; Hagmer et al. 2001; Olesen 
et al. 2008). Results of animal studies indicate similar biomarkers of exposure to acrylamide.
Metabolites can be measured for assessment of recent exposure. Hemoglobin adducts provide a 
biomarker of exposure for longer periods. See the introductory paragraph in Section 3.4 (Toxicokinetics) 
for a more detailed discussion of hemoglobin adduct levels as biomarkers of exposure.
It should be noted that hemoglobin adducts of N-methylolacrylamide are indistinguishable from 
hemoglobin adducts of acrylamide.
3.8.2 Biomarkers Used to Characterize Effects Caused by Acrylamide
Glycidamide-derived DNA adduct formation has been quantified in rats and mice exposed to acrylamide 
(Doerge et al. 2005a; Gamboa da Costa et al. 2003). There are no other known biomarkers of effect that 
are considered to be specific to acrylamide exposure.
3.9 INTERACTIONS WITH OTHER CHEMICALS
Nesterova et al. (1999) demonstrated an enhanced effect of acrylamide-induced clastogenicity in male 
mice administered acrylamide in combination with Verapamil (a calcium antagonist). No other
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE
S. HEALTH EFFECTS
126
information was located regarding health effects attributed to interactions between acrylamide and other 
substances.
3.1G POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to acrylamide than will most 
persons exposed to the same level of acrylamide in the environment. Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). 
These parameters result in reduced detoxification or excretion of acrylamide, or compromised function of 
organs affected by acrylamide. Populations who are at greater risk due to their unusually high exposure 
to acrylamide are discussed in Section 6.7, Populations with Potentially High Exposures.
No human data were located regarding populations that would be particularly sensitive to acrylamide 
toxicity.
Available animal data demonstrate increased susceptibility of males to acrylamide-induced reproductive 
effects expressed as male-mediated implantation loss, reduced number of fetuses, and testicular atrophy. 
The dominant lethal effects observed in male, but not female, rodents may be caused by acrylamide- 
induced alkylation of sperm protamine during spermiogenesis (Adler et al. 2000; Generoso et al. 1996; 
Perrault 2003; Sega et al. 1989; Sublet et al. 1989). Key determinants of male reproductive performance 
such as copulatory behavior (Zenick et al. 1986) and sperm motility (Sublet et al. 1989; Tyl et al. 2000b) 
may also be adversely affected by acrylamide.
Available animal data do not suggest gender-related differences in susceptibility to acrylamide 
neurotoxicity. Male and female rats experience similar neurological effects at comparable dose levels 
(Burek et al. 1980; Friedman et al. 1995; Fullerton and Barnes 1996; Johnson et al. 1984, 1986). Results 
of animal cancer bioassays do not indicate any gender-related differences in susceptibility to acrylamide 
carcinogenicity. Chronic exposure of F344 rats to acrylamide in drinking water induced increased 
incidences of thyroid follicular cell tumors in both genders, scrotal sac mesotheliomas in males, and 
mammary gland fibroadenomas in females (Friedman et al. 1995; Johnson et al. 1986).
No human data were located regarding age-related differences in susceptibility to acrylamide toxicity in 
humans. Conflicting reports are available from animal studies. Some reports indicate that young animals 
may be more susceptible than older ones (Ko et al. 1999; Suzuki and Pfaff 1973), whereas other reports
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suggest decreased susceptibility in young animals (Fullerton and Barnes 1966; Kaplan et al. 1973). It 
should be noted that CYP2E1, which catalyzes acrylamide to its DNA-reactive metabolite glycidamide, is 
not expressed in the developing fetus, but attains levels of expression during early postnatal periods that 
are similar to levels in adults (Johnsrud et al. 2003); however, the toxicological significance of this 
finding has not been demonstrated. Refer to Section 3.7 (Children’s Susceptibility) for a detailed 
discussion of children’s susceptibility to acrylamide toxicity.
Genetic polymorphisms in the acrylamide metabolizing P-450 enzyme CYP2E1 have been identified in 
humans (Hanioka et al. 2003). Polymorphisms in CYP2E1 could conceivably confer a differential risk to 
acrylamide toxicity and carcinogenicity. There is currently no quantitative estimate of differences in 
acrylamide or glycidamide tissue or blood levels that might result from CYP2E1 polymorphisms at high 
or low levels of acrylamide exposure. It is also noted that, since both acrylamide and glycidamide can 
exert toxic effects, different catalytic activities of CYP2E1 may result in different spectra of adverse 
effects.
Because the acrylamide metabolite, glycidamide, is DNA reactive, individual differences in DNA repair 
and detoxification mechanisms might influence susceptibility to acrylamide toxicity.
3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to acrylamide. However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to acrylamide. When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice. The following texts provide specific information about treatment following exposures 
to acrylamide:
Currance PL, Clements B, Bronstein AC. 2007. Tri-ortho-cresyl phosphate (TOCP) and related 
compounds. In: Emergency care for hazardous materials exposure. 3rd ed. St. Louis, MO: MosbyJems, 
482-484.
Goldfrank LR, Flomenbaum NE, Lewin NA, et al. 1998. Goldfrank's toxicologic emergencies.
Stamford, CT: Appleton & Lange, 322-324, 475.
Leikin JB, Paloucek FP. 2002. Leikin & Paloucek's poisoning & toxicology handbook. 3rd ed. Hudson, 
OH: Lexi-Comp, Inc., 193-194.
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Palmer RB. 2004. Acrylic acid and derivatives. In: Dart RC, ed. Medical toxicology. 3rd ed. 
Philadelphia, PA: Lippincott Williams & Wilkins, 1358-1368.
The following methods for reducing the toxic effects of acrylamide are applicable to numerous organic 
chemicals; they are not unique to acrylamide.
3.11.1 Reducing Peak Absorption Following Exposure
Rapid absorption of acrylamide can occur following exposure via inhalation, oral, and dermal routes. In 
the case of inhalation exposure, recommendations include removal from the site of exposure, 
establishment of a patent airway in the patient, and accompaniment by suction, ventilation, or 
administration of oxygen by a nonbreathing mask, if necessary (Currance et al. 2007). In the presence of 
airborne acrylamide, an impervious body protector may shield from absorption via dermal exposure 
(Leikin and Paloucek 2002). To reduce percutaneous absorption, immediate decontamination with mild 
liquid soap and large quantities of water has been recommended (Currance et al. 2007; Goldfrank et al. 
1998). To reduce absorption resulting from oral exposure, administration of activated charcoal (Leikin 
and Paloucek 2002; Palmer 2004), particularly within 1 hour of ingestion (Leikin and Paloucek 2002) has 
been recommended. Because of its potential for central nervous system depression and seizures, ipecac- 
induced emesis has been discouraged for treatment of acrylamide ingestion (Currance et al. 2007). Use of 
gastric lavage has not been proven helpful and is not recommended (Palmer 2004).
3.11.2 Reducing Body Burden
No data were located regarding methods for reducing the body burden of absorbed acrylamide.
Animal studies indicate that acrylamide and its metabolites do not accumulate in any tissue other than red 
blood cells (Barber et al. 2001a; Crofton et al. 1996; Edwards 1975; Hashimoto and Aldridge 1970; Ikeda 
et al. 1985; Kadry et al. 1999; Marlowe et al. 1986; Miller et al. 1982; Ramsey et al. 1984) and late staged 
spermatids (Sega et al. 1989) and that elimination of acrylamide and its metabolites is relatively rapid 
(Fuhr et al. 2006; Leikin and Paloucek 2002).
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
The peripheral nervous system is the primary target of acrylamide toxicity in humans and animals. 
Neurotoxic effects have been observed following inhalation, oral, and dermal exposures. Administration
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of pyridoxine has been suggested as a possible treatment to delay the onset of neurotoxic effects (Leikin 
and Paloucek 2002). N-Acetylcysteine has also been utilized, but is of unproven benefit (Leikin and 
Paloucek 2002).
Administration of 2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1#-benzo[D] imidazole to acrylamide­
exposed rodents reduced acrylamide-induced behavioral deficits. This effect is suggestive of a 
therapeutic potential for peripheral neuropathy (Nakagawa-Yagi et al. 2001).
3.12 ADEQUACY OF THE DATABASE
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of acrylamide is available. Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of acrylamide.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Acrylamide
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
acrylamide are summarized in Figure 3-7. The purpose of this figure is to illustrate the existing 
information concerning the health effects of acrylamide. Each dot in the figure indicates that one or more 
studies provide information associated with that particular effect. The dot does not necessarily imply 
anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”. A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public
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health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature.
3.12.2 Identification of Data Needs
Acute-Duration Exposure. Available human information is limited to a single case in which 
intentional ingestion of 18 g of acrylamide resulted in clinical signs of peripheral neuropathy (Donovan 
and Pearson 1987). Limited acute-duration animal data are available for inhalation and dermal exposure 
routes. Clinical signs of neurological effects were observed in laboratory animals exposed to acrylamide 
dust at 15.6 mg/m3, a lethal or near-lethal concentration (American Cyanamid Company 1953a). Acute- 
duration dermal exposure elicited indications of male-mediated decreased fertility in rabbits at 
50 mg/kg/day (Gutierrez-Espeleta et al. 1992), clinical signs of neurological effects in rats at doses 
>200 mg/kg (American Cyanamid Company 1973), and slight initial weight loss and slight dermal 
irritation in rabbits at doses >500 mg/kg (American Cyanamid Company 1951; Dow Chemical Company 
1957).
Numerous reports are available regarding the effects of acute-duration oral exposure in animals. Acute 
oral LD50 values range from 107 to 413 mg/kg (American Cyanamid Company 1951, 1973, 1977; Dow 
Chemical Company 1957; Fullerton and Barnes 1966; Hashimoto et al. 1981; McCollister et al. 1964; 
Tilson and Cabe 1979; Union Carbide Corporation 1947). Symptoms of acrylamide-induced 
neurotoxicity were elicited by single oral doses at lethal or near-lethal levels (100-200 mg/kg) (American 
Cyanamid Company 1953c; Fullerton and Barnes 1966; McCollister et al. 1964; Tilson and Cabe 1979) 
and at lower dose levels (25-45 mg/kg/day) during repeated oral dosing for >14 days (Dixit et al. 1981; 
Gilbert and Maurissen 1982; Tyl et al. 2000b). Single oral dosing at 63-150 mg/kg resulted in depressed 
body weight gain or actual weight loss (Dow Chemical Company 1957; Sakamoto et al. 1988); similar 
effects on body weight were elicited during repeated oral dosing at lower dose levels (15-20 mg/kg/day) 
(Burek et al. 1980; Tyl et al. 2000b). Male-mediated implantation losses were noted following acute- 
duration repeated oral dosing of rats at levels as low as 15-45 mg/kg/day (Sublet et al. 1989; Tyl et al. 
2000b; Working et al. 1987).
Additional acute-duration studies of animals exposed by inhalation could be designed to assess exposure 
concentration-response relationships and provide a basis for an acute-duration inhalation MRL for 
acrylamide, although the general population is not likely to encounter acutely hazardous airborne
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concentrations of acrylamide. Additional dermal studies using multiple dose levels could be designed to 
more extensively characterize the hazards of dermal exposure to acrylamide.
Intermediate-Duration Exposure. Information in humans is available from numerous case reports in 
which acrylamide exposure was associated with signs of impaired neurological performance in central 
and peripheral nervous systems that include impaired motor function and muscle weakness (Auld and 
Bedwell 1967; Davenport et al. 1976; Dumitru 1989; Fullerton 1969; Garland and Patterson 1967; 
Gjerl0ff et al. 2001; Igisu et al. 1975; Kesson et al. 1977; Mapp et al. 1977; Mulloy 1996; Takahashi et al. 
1971). Human data are also available from cross-sectional studies that included self-reported symptoms 
and neurological evaluations of acrylamide-exposed workers with potential for inhalation and dermal (and 
possibly oral) exposure (Bachmann et al. 1992; Calleman et al. 1994; Hagmar et al. 2001; He et al. 1989; 
Myers and Macun 1991). In the cross-sectional studies, workers were exposed for time periods as short 
as 1 month (but predominantly for more than 1 year); typical signs and symptoms of acrylamide-induced 
neuropathy were reported. However, the human studies do not include meaningful exposure-response 
data, and relative contributions of inhalation, dermal, and oral exposure routes could not be determined.
Most available intermediate-duration animal studies employed the oral exposure route. Treatment-related 
deaths were noted at repeated doses in the range of 25-50 mg/kg/day (American Cyanamid Company 
1953b, 1991; Fullerton and Barnes 1966; Schulze and Boysen 1991). Several studies reported 
acrylamide-induced adverse effects on body weight (American Cyanamid Company 1953b, 1979, 1991; 
Field et al. 1990; Friedman et al. 1999; Ko et al. 1999; Post and McLeod 1977a; Satchell and McLeod 
1981; Schulze and Boysen 1991; Tanii and Hashimoto 1983; Wise et al. 1995). One study reported 12% 
decreased maternal weight gain in rats administered acrylamide at a dose as low as 7.5 mg/kg/day during 
gestation days 6-20 (Field et al. 1990). A 28-day drinking water study reported acrylamide-associated 
decreases in serum testosterone and thyroid hormones T3 and T4 in male rats (American Cyanamid 
Company 1991). Male-mediated implantation losses were noted following intermediate-duration 
repeated oral dosing of rats or mice at levels as low as 2.8-13.3 mg/kg/day (Chapin et al. 1995; Sakamoto 
and Hashimoto 1986; Smith et al. 1986; Tyl et al. 2000a; Zenick et al. 1986). The developmental toxicity 
of acrylamide has been assessed to some extent (American Cyanamid Company 1979; Field et al. 1990; 
Garey and Paule 2007; Husain et al. 1987; Sakamoto and Hashimoto 1986; Wise et al. 1995); reported 
effects include neurochemical changes in the neonatal rat brain (Husain et al. 1987), decreased fetal body 
weight (Field et al. 1990), increased activity and decreased startle response (Wise et al. 1995), and subtle 
effects on measures of cognitive motivation (Gary and Paule 2007).
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Numerous studies reported clinical signs and other indicators (e.g., hindlimb splay) of neurological effects 
associated with intermediate-duration oral exposure in laboratory animals at doses in the range of 5.7­
100 mg/kg/day (American Cyanamid Company 1953b, 1953c, 1959, 1991; Burek et al. 1980; Dixit et al. 
1981; Dow Chemical Company 1981; Field et al. 1990; Friedman et al. 1999; Fullerton and Barnes 1966; 
Gorzinski et al. 1979; Hashimoto et al. 1981; Hersch et al. 1989a, 1989b; Hopkins 1970; Ko et al. 1999, 
2000, 2002; Leswing and Ribelin 1969; Maurissen et al. 1983; McCollister et al. 1964; Merigan et al. 
1985; Post and McLeod 1977a; Satchell and McLeod 1981; Tanii and Hashimoto 1983; Tilson and Cabe 
1979; Wise et al. 1995; Zenick et al. 1986). In general, the higher the dose level, the earlier the 
appearance of neurological signs. Some studies included histopathological evaluation of peripheral nerve 
fibers in acrylamide-treated animals (Burek et al. 1980; Eskin et al. 1985; Gorzinski et al. 1979; Johnson 
et al. 1985, 1986; Schulze and Boysen 1991). One study reported ultrastructural evidence of degenerative 
effects in sciatic nerve fibers from male F344 rats that had received acrylamide from the drinking water at 
1 mg/kg/day for up to 93 days and served as the basis for deriving an intermediate-duration oral MRL for 
acrylamide (Burek et al. 1980).
Available intermediate-duration animal data for inhalation and dermal exposure are limited. Death and 
clinical signs of neurotoxicity were reported in dogs repeatedly exposed to acrylamide dust at 
15.6 mg/m3, for up to 16 days (American Cyanamid Company 1953a) and rabbits administered 
acrylamide dermally at 50 mg/kg/day for 5 weeks (Rohm and Haas 1975). No adverse effects were 
observed in cats repeatedly exposed to acrylamide dust at 4.8 mg/m3 for up to 3 months (American 
Cyanamid Company 1954).
Additional intermediate-duration studies of animals exposed by inhalation designed to assess exposure 
concentration-response relationships could serve as the basis for deriving an intermediate-duration 
inhalation MRL for acrylamide. Additional dermal studies using multiple dose levels could be designed 
to better characterize the hazards of intermediate-duration dermal exposure to acrylamide.
Chronic-Duration Exposure and Cancer. Reports of chronic occupational exposure in humans 
describe a spectrum of neurological effects resulting from inhalation (Calleman et al. 1994; Myers and 
Macun 1991) and dermal effects such as peeling of skin as a result of dermal exposure (Bachmann et al. 
1992; Calleman et al. 1994; He et al. 1989; Myers and Macun 1991). Questionnaires, physical 
examinations, neurological examinations, and ENMG tests provide support from a cross-sectional 
analysis on factory workers in China (Calleman et al. 1994). This study also utilized hemoglobin adduct 
levels as a biomarker (Calleman et al. 1994). Neurological effects in rats from chronic oral exposures to
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acrylamide are documented and provide NOAEL and LOAEL for increased incidence of ultrastructural 
degeneration in the sciatic nerve and degenerative effects in peripheral nerve fibers (Johnson et al. 1984, 
1985, 1986).
One case-control human study suggests a possible association between diet before puberty and 
subsequent risk of breast cancer; this particular study, however, is of limited use due to lacking 
documentation of significant factors such as cooking methods and accurate recall (Michels et al. 2006). 
Olesen et al. (2008) discovered a significant positive correlation between acrylamide-hemoglobin adduct 
levels and ER+ breast cancer, but the conclusions are also only of limited use due to the small study size 
and uncertainty regarding extrapolation of exposure. Most prospective studies found no statistically 
significant associations between acrylamide in food and risks of cancers of the esophagus, stomach, or 
pancreas (Hogervorst et al. 2008b); colon or rectum (Hogervorst et al. 2008b; Larsen et al. 2009c; Mucci 
et al. 2006); bladder or prostate (Hogervorst et al. 2008a); breast (Hogervorst et al. 2007; Larsson et al. 
2009d; Wilson et al. 2009b); endometrium (Hogervorst et al. 2007; Larsson et al. 2009a); or ovarian 
epithelium (Larsson et al. 2009b). Exceptions include increased risks of postmenopausal endometrial and 
ovarian cancer (Hogervorst et al. 2007) and renal cell cancer (Hogervorst et al. 2008a) with increasing 
dietary acrylamide. The conclusions of these studies are only somewhat reliable as the estimations of 
dietary acrylamide levels in food on the market at baseline in 1986 are based on food samples analyzed in 
2001 and details regarding the specifics of food preparation are lacking.
Conclusions of a 2-year bioassay of male and female F344 rats include significant increases in thyroid 
(follicular cell) adenomas (no carcinomas), mesotheliomas of the tunica vaginalis testis, mammary gland 
benign tumors (adenoma, fibroadenomas, or fibroma), and pituitary gland adenomas in high dose females 
(Johnson et al. 1984, 1986).
The NCTR (2009) recently performed cancer bioassays on Fischer 344 rats and B6C3F1 mice 
administered acrylamide or glycidamide in the drinking water for 2 years. The carcinogenicity of 
acrylamide and glycidamide has also been assessed in neonatally-exposed B6C3F1 mice. Post-public 
comment drafts of this ATSDR Toxicological Profile for Acrylamide will include available results from 
these carcinogenicity bioassays.
Genotoxicity. The genotoxicity of acrylamide has been studied both in vivo and in vitro. Studies are 
limited almost exclusively to laboratory rodents and nonmammalian species with the exception of a few 
in vitro assays of human cells. Results indicate that acrylamide is genotoxic and most potent in its ability
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to induce clastogenic effects (including heritable translocations in offspring of acrylamide-exposed male 
rodents mated with untreated females), DNA damage, and gene mutations (including male-germ-cell- 
mediated dominant lethal mutations and heritable specific-locus mutations).
Genotoxicity assessments for acrylamide and its metabolite, glycidamide, in rats and mice are currently 
underway at NTCR (2009). Post-public comment drafts of this ATSDR Toxicological Profile for 
Acrylamide will include available results from these assessments.
Reproductive Toxicity. The reproductive toxicity of acrylamide has been studied almost exclusively 
in orally-exposed rats and mice. Pre- and postimplantation losses and decreased numbers of live fetuses 
were noted at repeated doses in the range of 3-60 mg/kg/day (Chapin et al. 1995; Sakamoto and 
Hashimoto 1986; Smith et al. 1986; Sublet et al. 1989; Tyl et al. 2000a, 2000b; Working et al. 1987; 
Zenick et al. 1986).
Results of dominant lethality testing and crossover trials indicate that acrylamide induces male-mediated 
reproductive effects at repeated oral doses in the range of 2.8-19 mg/kg/day (Chapin et al. 1995; 
Sakamoto and Hashimoto 1986; Smith et al. 1986; Tyl et al. 2000a, 2000b; Zenick et al. 1986). Other 
reported effects include decreased sperm mobility in Long-Evans rats receiving acrylamide at 
45 mg/kg/day for 5 days (Sublet et al. 1989), degenerative effects in spermatids of ddY mice dosed at 
100 or 150 mg/kg/day for 5 days (Sakamoto et al. 1988), and testicular atrophy in F344 rats at doses as 
low as 5 mg/kg/day for 90 days (American Cyanamid Company 1991; Burek et al. 1980). In apparent 
contrast, Tyl et al. (2000b) found no significant effects on sperm parameters in Long-Evans hooded rats 
following repeated oral dosing at dose levels as high as 60 mg/kg/day. Gross and histopathologic 
examinations of reproductive organs and tissues from male and female rats receiving acrylamide from the 
drinking water for up to 2 years at estimated doses as high as 2 mg/kg/day revealed no signs of 
acrylamide-induced effects (Friedman et al. 1995; Johnson et al. 1984, 1986). Prebreeding exposure of 
female rats and mice to acrylamide at doses of approximately 14 and 19 mg/kg/day did not adversely 
affect reproductive performance (Sakamoto and Hashimoto 1986; Zenick et al. 1986).
The reproductive toxicity of acrylamide appears to have been adequately characterized in laboratory 
animals. Continued assessment of possible reproductive effects in humans with potential for significant 
exposure to acrylamide is recommended.
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Developmental Toxicity. The developmental toxicity of acrylamide has been assessed only in oral 
studies of rats and mice. Effects include body weight decreases and decreased auditory startle response in 
offspring of female Sprague-Dawley rats exposed to 5 and 15 mg/kg-day, respectively, on gestation days 
6-10 (Wise et al. 1995), decreased mean fetal body weight in offspring of CD-1 mouse dams 
administered acrylamide by gavage at 45 mg/kg/day during gestation days 6-20 (Field et al. 1990), 
decreased mean fetal body weight in offspring of Sprague-Dawley rat dams receiving acrylamide from 
the drinking water (estimated acrylamide intake as high as 14.56 mg/kg/day) from gestation day 6 
throughout lactation (Takahashi et al. 2009), decreased brain levels of selected catecholamines 
(noradrenaline, dopamine, 5-hydroxytryptamine) in pups of rat dams administered acrylamide at 
25 mg/kg/day during lactation only or in young pups receiving the same dose for 5 days (Husain et al. 
1987), and decreased cognitive motivation in adolescent F344 rats exposed during gestation and lactation 
and extending through 12 weeks postpartum (Garey and Paule 2007). No exposure-related fetal 
malformations or variations (gross, visceral, or skeletal) were found in offspring of Sprague-Dawley rats 
administered acrylamide at doses of 2.5, 7.5, or 15 mg/kg/day on gestation days 6-20 or in CD-1 mice at 
doses of 3, 15, or 45 mg/kg/day on gestation days 6-17 (Field et al. 1990).
Section 3.12.3 (Ongoing Studies) lists information regarding an ongoing developmental neurotoxicity 
study in rats. The results of this study should be evaluated prior to assessing a need for additional 
developmental toxicity studies of acrylamide.
Immunotoxicity. No human or animal data were located in which acrylamide was considered to be a 
potential immunological concern. Immunotoxicity studies do not appear necessary at this time.
Neurotoxicity. Information in humans is available from numerous case reports in which acrylamide 
exposure has been associated with signs of impaired neurological performance in central and peripheral 
nervous systems that include impaired motor function and muscle weakness (Auld and Bedwell 1967; 
Davenport et al. 1976; Dumitru 1989; Fullerton 1969; Garland and Patterson 1967; Gjerl0ff et al. 2001; 
Igisu et al. 1975; Kesson et al. 1977; Mapp et al. 1977; Mulloy 1996; Takahashi et al. 1971). Human data 
are also available from cross-sectional studies that included self-reported symptoms and neurological 
evaluations of acrylamide-exposed workers with potential for inhalation and dermal (and possibly oral) 
exposure (Bachmann et al. 1992; Calleman et al. 1994; Hagmar et al. 2001; He et al. 1989; Myers and 
Macun 1991).
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Neurological effects associated with oral exposure to acrylamide have been well characterized in 
laboratory animals and include clinical signs such as twitching, loss of balance, tremors, lethargy, and 
general weakness and more subtle indicators of functional deficits such as decreased rotarod performance 
and increased limb or foot splay. Evidence of degenerative lesions in peripheral nerve fibers, as observed 
by light and electron microscopy, have been detected at oral doses lower than those eliciting clinical signs 
and other overt indications of functional deficit. See Sections 3.2.1.4, 3.2.2.4, and 3.2.3.4 for detailed 
information regarding neurological effects in acrylamide-exposed animals. Available animal data appear 
to adequately characterize acrylamide neurotoxicity; additional neurotoxicity studies do not appear 
necessary at this time.
Refer to Section 3.12.2 (Developmental Effects) for a summary of information regarding acrylamide- 
induced neurodevelopmental effects.
Epidemiological and Human Dosimetry Studies. Early epidemiological studies focused on 
neurological signs and symptoms in workers employed in the manufacture and/or use of acrylamide 
(Bachmann et al. 1992; Calleman et al. 1994; Hagmar et al. 2001; He et al. 1989; Myers and Macun 
1991). Although these studies, as well as available case reports, provide supportive evidence of 
acrylamide-induced neurotoxicity, they lack information regarding relative contributions of natural 
exposure routes (inhalation, oral, dermal), exposure-response relationships, and other confounding 
exposures.
More recent investigations have focused on examining possible associations between acrylamide dietary 
intake and various cancer end points (Hogervorst et al. 2007, 2008a, 2008b; Larsson et al. 2009a, 2009b, 
2009c, 2009d; Michels et al. 2006; Mucci et al. 2003, 2004, 2005, 2006; Pelucchi et al. 2006, 2007; 
Wilson et al. 2009a, 2009b). These studies provide little evidence of acrylamide-induced carcinogenicity 
from estimated intakes through the diet. However, a major deficiency of these studies is the use of 
questionnaires to estimate prior dietary intake of acrylamide.
Continued epidemiological research should focus on improving methods for estimating acrylamide intake. 
Additional information regarding biomarkers of exposure to acrylamide and improved PBPK modeling 
could be beneficial.
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Exposure. Biomarkers of exposure to acrylamide include unchanged acrylamide, its mercapturic acid 
metabolite, AAMA, its epoxy derivative, glycidamide, and the respective metabolite of glycidamide, 
GAMA in urine (Bjellaas et al. 2007a; Boettcher et al. 2005, 2006a, 2006b; Fuhr et al. 2006) and 
hemoglobin adducts of acrylamide and glycidamide (Bergmark et al. 1993; Boettcher et al. 2005; 
Calleman et al. 1994; Fennell et al. 2005b; Hagmer et al. 2001; Olesen et al. 2008). However, 
N-methylolacrylamide forms hemoglobin adducts that are indistinguishable from hemoglobin adducts of 
acrylamide. The development of a method to measure levels of the metabolite, glyceramide, in urine 
could help to determine the relative importance of glycidamide via glutathione conjugation versus 
hydrolysis.
See Section 3.12.3 (Ongoing Studies) for information regarding assessments currently underway to assess 
biomarkers of exposure to acrylamide.
Effect. Glycidamide-DNA adducts may be considered a biomarker of effect from exposure to acrylamide 
(Doerge et al. 2005a; Gamboa da Costa et al. 2003). It is not likely that additional biomarkers of effect 
specific to acrylamide would be identified.
Absorption, Distribution, Metabolism, and Excretion. Available human data indicate that 
acrylamide is readily absorbed following oral or dermal exposure; significant absorption of inhaled 
acrylamide is expected. In animals, acrylamide is readily absorbed following inhalation, oral, or dermal 
exposure. Absorbed acrylamide is widely distributed (accumulates only in red blood cells), rapidly 
metabolized in the liver, and excreted in the urine mainly as acrylamide-derived conjugates. Existing 
PBPK models for acrylamide are not adequate for human health risk assessment. However, as described 
in Section 3.12.3 (Ongoing Studies) a new PBPK model for acrylamide is presently being developed. 
Additional pharmacokinetic studies may be necessary to assist in calibration and validation of PBPK 
models for acrylamide.
Comparative Toxicokinetics. Available data in rats and mice indicate species differences in 
acrylamide metabolism. Additional comparative toxicokinetic studies may be warranted pending the 
outcome of the new PBPK model being developed for acrylamide.
Biomarkers of Exposure and Effect.
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Methods for Reducing Toxic Effects. Suggested methods for reducing absorption of acrylamide 
include removal from exposure source, decontamination of exposed skin with soap and water, and 
administration of activated charcoal within 1 hour following ingestion. There are no known methods for 
reducing the body burden following absorption of acrylamide and no proven methods for interfering with 
the mechanism of action for toxic effects.
Children’s Susceptibility. No specific data were located regarding acrylamide-induced health effects 
in children. The database of information in animals provides conflicting results. Children are not 
expected to be less susceptible than adults to acrylamide toxicity.
Data needs relating to both prenatal and childhood exposures, and developmental effects expressed either 
prenatally or during childhood, are discussed in detail in the Developmental Toxicity subsection above.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs: 
Exposures of Children.
3.12.3 Ongoing Studies
Search of the NCTR website revealed the following (NCTR 2009):
Dr. Frederick Beland (principal investigator), Division of Biochemical Toxicology, is comparing the 
carcinogenicity of acrylamide and its metabolite glycidamide in B6C3F1 mice treated neonatally and in 
B6C3F1 mice and Fischer 344 rats treated for 2 years. The 2-year study is funded by the National 
Toxicology Program (NTP).
Dr. Daniel Doerge (principal investigator), Division of Biochemical Toxicology, in collaboration with the 
Division of Genetic and Reproductive Toxicology and Division of Personalized Nutrition and Medicine 
and funding from the University of Maryland, is working to (1) develop a PBPK/PD model for 
acrylamide and glycidamide and (2) determine mutagenicity of acrylamide and glycidamide in Big Blue® 
rats. Dr. Doerge, in collaboration with the Department of genetic and Reproductive Toxicology and 
funding from NTP, is studying genotoxicity, mutagenicity, and biomarkers of exposure for acrylamide 
and glycidamide in rodents.
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Dr. Merle Paule (principal investigator), Division of Neurotoxicology, in collaboration with the Division 
of Biochemical Toxicology and funding from NTP, is assessing developmental neurotoxicity of 
acrylamide in rats.
Dr. Eden Tareke (principal investigator), Division of Neurotoxicology, is investigating the effects of 
acrylamide on normal human brain cortical neuronal (HCN-1), PC12, and HepG2 cells in vitro.
Search of the Federal Research in Progress database (FEDRIP 2009) revealed the following:
Dr. John Essigmann (principal investigator), Massachusetts Institute of Technology, Cambridge, 
Massachusetts, is investigating the genotoxic effects of several compounds, including acrylamide, with 
the goal of developing new biomarkers. The sponsoring organization is the National Institute of 
Environmental Health Sciences.
Dr. Richard LoPachin (principal investigator), Montefiore Medical Center, Bronx, New York, is 
performing ongoing research to elucidate specific mechanisms responsible for acrylamide toxicity.
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4. CHEM ICAL AND PHYSICAL INFORMATION
4.1 CHEMICAL IDENTITY
Acrylamide is an unsaturated amide that is produced mainly for use as an intermediate in the production 
of polyacrylamide (Abdelmagic 1982; Haberman 2002). Information regarding the chemical identity of 
acrylamide is located in Table 4-1.
4.2 PHYSICAL AND CHEMICAL PROPERTIES
Acrylamide is a white or colorless, odorless crystalline solid. Information regarding the physical and 
chemical properties of acrylamide is located in Table 4-2. Acrylamide is stable at room temperature but 
can violently polymerize at its melting point or under UV light (Lewis 2000, 2007; O’Neil et al. 2006). 
Acrid fumes, as well as NOx , may be released when it is heated to decomposition (Lewis 2000). 
Acrylamide is soluble in water, alcohol, and acetone, and is insoluble in benzene and heptanes (Lewis 
2007).
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Table 4-1. Chemical Identity of Acrylamide
C haracteris tic Inform ation Reference
Chemical name Acrylamide
Synonym(s) AAM; acrylagel; acrylic acid amide; 
acrylic amide; akrylamid (Czech); 
amresco acryl-40; amid kyseliny 
akrylove; ethylenecarboxamide; 
optimum; propenamide; 2-propen- 
amide; propereamide; propenoic 
acid amide; vinyl amide
HSDB 2009; Lewis 2000
Registered trade name(s) No data
Chemical formula C3H5NO HSDB 2009; WHO 2003
Chemical structure
Identification numbers:
CAS registry 79-06-1
NIOSH RTECS NIOSH/AS3325000 NIOSH 2005
EPA hazardous waste U007 HSDB 2009; Lewis 2000
OHM/TADS No data
DOT/UN/NA/IMDG shipping UN 2074; IMO 6.1 HSDB 2009; Lewis 2000
HSDB 191 HSDB 2009
NCI No data
STCC 49 091 83 HSDB 2009
49 131 87 HSDB 2009
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
RTECS = Registry of Toxic Effects of Chemical Substances; STCC = Standard Transport Commodity Code
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Table 4-2. Physical and Chemical Properties of Acrylamide
Property Inform ation Reference
Molecular weight 71.08 Haberman 2002; HSDB 2009
Color White
Colorless
HSDB 2009; Lewis 2000 
Lewis 2007; WHO 2003
Physical state Crystalline solid HSDB 2009; Lewis 2000 
Lewis 2007; WHO 2003
Melting point 84.5 °C Lewis 2007
Boiling point 192.6 °C 
87 °C (2 mm) 
103 °C (5 mm) 
125 °C (25 mm)
Lide 2008
O'Neil et al. 2006
O'Neil et al. 2006
Lewis 2007; O'Neil et al. 2006
Density at 30 °C/4 °C 1.122 HSDB 2009; Lewis 2007
Odor Odorless Lewis 2007
Odor threshold:
Water No data
Air No data
Solubility:
Water at 0 °C No data
at 20 °C 3.711x105 mg/L HSDB 2009
at 30 °C 4.048x105 mg/L HSDB 2009
Organic solvents Soluble in water, alcohol, acetone Lewis 2007
Insoluble in benzene and heptanes Lewis 2007
Partition coefficients:
Log Kow -0.67 HSDB 2009
Log Koc No data
Vapor pressure
at 25 °C 0.9 Pa (7x10-3 mm Hg) Haberman 2002; HSDB 2009
at 40 °C 4.4 Pa (3.3x10-2 mm Hg) Haberman 2002
at 50 °C 9.3 Pa (7.0x10-2 mm Hg) Haberman 2002
Henry's law constant:
at 25 °C 1.7x10-9 atm-m3/mol (estimated) HSDB 2009
Autoignition temperature 424 °C HSDB 2009
Flash point 138 °C (closed cup) HSDB 2009
Flammability limits No data
Conversion factors 
(25 °C, 1 atm)
1 mg/m3=0.34 ppm 
1 ppm=2.95 mg/m3
HSDB 2009
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1 PRODUCTION
No information is available in the TRI database on facilities that manufacture or process acrylamide 
because this chemical is not required to be reported under Section 313 of the Emergency Planning and 
Community Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of 
1986) (EPA 1998).
Acrylamide can be produced from acrylonitrile treated with sulfuric acid or hydrochloric acid, followed 
by base neutralization or use of an ion exclusion column to separate the chemical from its sulfate salt 
(Haberman 2002; HSDB 2009; Lewis 2007; O’Neil et al. 2006). Although historically the primary 
method of acrylamide production, this method results in sulfate byproducts and significant waste streams, 
and thus, commercial acrylamide producers no longer use this process (Haberman 2002). A newer 
process was developed in which a solution of acrylonitrile is passed over a fixed bed copper catalyst at 
85 °C, resulting in an acrylamide solution. This method has been modified by various companies since its 
development. A Raney copper catalyst can also be used in both slurry and fixed-bed reactors (Haberman
2002). American Cyanamid uses a proprietary catalytic direct hydration process to produce acrylamide 
from acrylonitrile, using a reaction of water of solid surfaces of metal, metallic salts, or metallic oxides, 
which avoids the formation of unwanted byproducts (HSDB 2009).
Numerous other methods of acrylamide production have been developed. Acryloyl chloride or acrylic 
anhydride can be reacted with ammonia to yield acrylamide. Microorganisms can also be used to convert 
acrylonitrile to acrylamide via an enzymatic hydration process (Haberman 2002).
Table 5-1 lists the facilities in each state that manufacture, process, or use acrylamide as well as the 
intended use and the range of amounts of acrylamide that are stored on site. There are currently 
216 facilities that produce, process, or use acrylamide in the United States. The data listed in Table 5-1 
are derived from the Toxics Release Inventory (TRI 07 2009). These data should be used with caution, 
however, since only certain types of facilities are required to report. Therefore, this is not an exhaustive 
list. Commercial production of acrylamide in 1983 was reported as 86,233 pounds (HSDB 2009). 
Currently, there are four major producers of acrylamide in the United States, with a combined production 
capacity of approximately 141,000 metric tons (311 million pounds) (SRI 2008). These producers and 
their respective plant locations are provided in Table 5-2.
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Table 5-1. Facilities that Produce, Process, or Use Acrylamide
M inim um  M axim um
N um ber o f am ount on site am ount on site
S ta tea fac ilities in poundsb in poundsb Activ ities  and usesc
AL 4 10,000 9,999,999 6, 14
AR 5 0 99,999 6, y, 12
CA 15 0 9,999,999 1, 2, 3, 4, 6, y, 8, 9, 10
CO 2 0 99,999 6
CT 6 10,000 9,999,999 2, 3, 4, 6
DE 1 0 0 0
FL 3 100,000 999,999 2, 3, 6
GA 8 0 9,999,999 1, 4, 6, y
IL 14 0 9,999,999 2, 3, 6, y, 12
IN 1 10,000 99,999 12
KY 4 10,000 999,999 6, 12
LA 13 0 9,999,999 1, 2, 3, 4, 6, 9, 10, 12, 13
MA 4 1,000 99,999 6, y
MD 4 0 999,999 6, y
MI 21 0 49,999,999 1, 2, 3, 4, 6, y, 8, 10, 11, 12
MO 5 100 99,999 1, 2 , 3, 6, y, 8
NC y 100 999,999 6, y
NE 4 0 99,999 3, y, 8, 11, 12
NJ 8 0 999,999 1, 6, 10, 12, 13
NY 11 100 99,999 6, y, 9, 10, 12
OH 10 0 999,999 1, 6, y, 12, 13
OR 1 1,000 9,999 6
PA 6 0 499,999,999 6
SC 12 0 999,999 6, y, 12
TN 8 0 9,999,999 6, 12
TX 18 0 9,999,999 1, 5, 6, y, 12, 13
UT 1 1,000 9,999 12
VA y 100,000 49,999,999 1, 2, 3, 4, 6
WA 2 100,000 999,999 6, 12
WI 5 0 99,999 2, 3, 6, y
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Table 5-1. Facilities that Produce, Process, or Use Acrylamide
M inim um M axim um
N um ber of am ount on site am ount on site
S ta tea facilities in poundsb in poundsb Activ ities  and usesc
WV 5 0 499,999,999 1, 5, 6, 12
WY 1 1,000,000 9,999,999 9
aPost office state abbreviations used
bAmounts on site reported by facilities in each state
cActivities/Uses:
1. Produce 6. Impurity 11.
2. Import 7. Reactant 12.
3. Onsite use/processing 8. Formulation Component 13.
4. Sale/Distribution 9. Article Component 14.
5. Byproduct 10. Repackaging
Source: TRI07 2009 (Data are from 2007)
Chemical Processing Aid 
Manufacturing Aid 
Ancillary/Other Uses 
Process Impurity
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Table 5-2. 2008 Acrylamide Production in the United States
C om pany Location
Annual capacity  
(m etric tonsa) Rem arks
Chemtall, Inc. Riceboro, Georgia 65,000 From purchased 
acrylonitrile; captive 
consumption for 
polyacrylamide
Ciba Specialty Chemicals 
Corporation Water & Paper 
Treatment Business 
Segment
Suffolk, Virginia 15,000 From purchased 
acrylonitrile; primarily 
captive consumption for 
polyacrylamide
Kemira Water Solutions, Inc. Waggaman,
Louisiana
41,000 From captive acrylonitrile; 
captive consumption for 
polyacrylamide
Nalco Company Garyville, Louisiana 20,000 From purchased 
acrylonitrile; primarily 
captive consumption for 
polyacrylamide
Total 141,000
aAll production is as solution.
Source: SRI 2008; SRI Consulting estimates as of February 1, 2008.
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Acrylamide is produced as a byproduct when foods are cooked at high temperatures, such as by frying, 
roasting, and baking (Muttucumaru et al. 2008). This occurs by the Maillard reaction, where thermal 
degradation of amino acids occurs in the presence of reducing sugars at temperatures above 120 °C. The 
major precursors for acrylamide formation by the Maillard reaction are free asparagines and reducing 
sugars (Arisseto et al. 2007; Mottram 2002; Muttucumaru et al. 2008; Stadler et al. 2002). Acrylamide 
concentrations in the foods rise with temperature and length of heating, and appear to be affected by water 
content, food composition, and processing conditions (WHO 2002).
5.2 IMPORT/EXPORT
The demand for acrylamide in the United States was reported as 245 and 253 million pounds in 2006 and 
2007, respectively. U.S. imports were 61 and 55 million pounds in 2006 and 2007, respectively, while 
U.S. exports were 57 and 53 million pounds in 2006 and 2007, respectively (CMR 2008).
5.3 USE
Commercially-produced acrylamide is used mainly as an intermediate in the production of 
polyacrylamides (EU 2002; Haberman 2002; O’Neil et al. 2006; WHO 2003). This accounts for 94% of 
manufactured acrylamide (Haberman 2002). Polyacrylamides are then primarily used as flocculants for 
clarifying drinking and treating municipal and industrial effluents (Abdelmagid 1982; EPA 2006c; EU 
2002; Haberman 2002; WHO 2003;). They aid in dewatering sludge from sewage treatment plant 
effluent as well as industrial waste water from pulp and paper plants (Abdelmagid 1982; Haberman
2002). Polyacrylamides are also found in cosmetics and toiletries and are used to prepare polyacrylamide 
gels for use in biotechnology laboratories (EU 2002; Lewis 2007). In the oil industry, acrylamide is used 
as a flow control agent to enhance oil production from wells. Acrylamide and polyacrylamides are also 
used in the production of dyes and organic chemicals such as N-methylacrylamide, in copolymers for 
contact lenses, in permanent-press fabrics, for sizing paper and textiles, as a binder and retention aid for 
pulp and paper production, in the processing of ore, in sugar refining, and as a chemical grouting agent 
and soil stabilizer for the construction of tunnels, sewers, wells, and reservoirs (Abdelmagid 1982; EPA 
2006c; EU 2002; Haberman 2002; Lewis 2007; O’Neil et al. 2006; WHO 2003).
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5.4 DISPOSAL
Acrylamide is typically produced as an intermediate for the production of polyacrylamides (Haberman 
2002; O’Neil et al. 2006), and is therefore consumed in the process. No information was found regarding 
the disposal of acrylamide.
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1 OVERVIEW
Acrylamide has been identified in at least 3 of the 1,699 hazardous waste sites that have been proposed 
for inclusion on the EPA National Priorities List (NPL) (HazDat 2007). However, the number of sites 
evaluated for acrylamide is not known. The frequency of these sites can be seen in Figure 6-1.
Acrylamide is an industrial chemical used mainly in the production of polyacrylamides, which are 
primarily used as flocculants for clarifying drinking and treating municipal and industrial effluents 
(Abdelmagid 1982; EPA 2006c; EU 2002; Haberman 2002; O’Neil et al. 2006; WHO 2003). Acrylamide 
may be released to the environment during production and use of polyacrylamides, which are used as 
clarifiers in water treatment. Residual monomer released from the polyacrylamide coagulants is the main 
source of acrylamide contamination of drinking water (Abdelmagid 1982; Cavalli et al. 2004; EPA 
2006c; WHO 2003), though it can also be released from plastics and dye industries and from acrylamide- 
containing grouting agents used in reservoirs and wells (Cavalli et al. 2004; EPA 2006c). Acrylamide can 
be released to the environment during formulation of cosmetics or other consumer products and in the 
laboratory while gel chromatography is being performed (Boettcher and Angerer 2005; EU 2002). Due to 
its low vapor pressure and high water solubility, acrylamide is rarely identified in atmospheric samples 
(WHO 2003).
Acrylamide is expected to be highly mobile in soil and water (EPA 2006c; HSDB 2009; WHO 2003). It 
is highly susceptible to biodegradation in both soils and surface water (Abdelmagid 1982; EPA 2006c; 
Haberman 2002; WHO 2003). It is not typically present in the atmosphere (HSDB 2009; Pratt 2000). 
Acrylamide is not expected to significantly bioconcentrate (EPA 2006c; Haberman 2002; WHO 2003).
Acrylamide is sometimes present in drinking water due to leaching of monomer during treatment 
processes (Abdelmagid 1982; Cavalli et al. 2004; EPA 2006c; van Dijk-Looijaard and van Genderen 
2000; WHO 2003), as well as release from grouting agents in wells and dams and releases from plastics 
and dye industries (Cavalli et al. 2004). It is rarely found in soil samples (HSDB 2009). Acrylamide is 
not a common air pollutant, due to its low vapor pressure and high water solubility. It is rarely identified 
in atmospheric samples (HSDB 2009; Pratt 2000; WHO 2003).
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Figure 6-1. Frequency of NPL Sites with Acrylamide Contamination
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In 2002, acrylamide was first identified in samples of food cooked at high temperatures (Tareke et al.
2002). Concentrations of acrylamide in food vary with the type of food and method of cooking, and 
typically increase with temperature and length of heating (Sorgel et al. 2002; WHO 2002, 2003). 
Carbohydrate-rich foods typically contain the highest levels of acrylamide (Muttucumaru et al. 2008; 
Tareke et al. 2002; WHO 2003), whereas protein-based foods contain smaller amounts (Tareke et al.
2002). As acrylamide content in food appears to be affected by temperature, water content, food 
thickness, and length of heating, various steps can be taken to minimize the exposure of acrylamide from 
food sources (Sorgel et al. 2002; WHO 2002, 2003).
Acrylamide is a carcinogen with the potential to cause nervous system damage (Arisetto et al. 2007; EPA 
2006c; Lewis 2000). Exposure occurs mainly via ingestion, dermal contact, and inhalation routes (Lewis 
2000; Sorgel et al. 2002). Ingestion of foodstuffs containing acrylamide appears to be one of the most 
common methods of exposure for the general public. Average estimated intake of acrylamide from food 
sources ranged from 0.8 to 6.0 ^g/kg bw/day for short-term exposure and 0.3 to 0.8 ^g/kg bw/day for 
long-term exposure (WHO 2002, 2003). Children may be susceptible to food-borne exposure 2-3 times 
that of adults on a body weight basis (WHO 2002, 2003).
Ingestion of polyacrylamide-treated drinking water containing residual monomer as well as water in 
contact with acrylamide-containing products, such as grouting agents, can result in exposure to 
acrylamide (EPA 2006c; EU 2002; WHO 2003). The presence of acrylamide in tobacco smoke can result 
in inhalation exposure for both adults and children (EU 2002; Moreno Navarro et al. 2007). Dermal 
exposure can result from contact with cosmetics and toiletries containing polyacrylamides (EU 2002). 
Once in the body, acrylamide is widely dispersed by body fluids, and can also cross the placental barrier 
(WHO 2003), resulting in exposure to unborn children. Breast milk of mothers with diets high in 
acrylamide-containing foods can contain high amounts of acrylamide (Sorgel et al. 2002). Occupational 
exposure to acrylamide is primarily due to dermal contact when handling bags and drums of the chemical 
or preparing polyacrylamide gels, followed by inhalation of dust or aerosols (EU 2002; Lewis 2000).
6.2 RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005a). This is not an exhaustive list. Manufacturing and 
processing facilities are required to report information to the TRI only if they employ 10 or more full-time 
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011,
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1081, and 1094), 12 (except 1241), 20-39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes >25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005a).
6.2.1 Air
Estimated releases of 11,791 pounds (~5.3 metric tons) of acrylamide to the atmosphere from 81 domestic 
manufacturing and processing facilities in 2007, accounted for about 0.2% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI07 2009). These releases are 
summarized in Table 6-1.
Acrylamide may be released to the atmosphere during production of polymers, formulation of cosmetics 
or other consumer products, and in the laboratory while gel chromatography is being performed 
(Boettcher and Angerer 2005). Release of tobacco smoke, which was shown to contain acrylamide 
(Schumacher et al. 1977), may also contribute to airborne acrylamide in confined spaces. However, 
acrylamide is not anticipated to be a common air contaminant due to its low vapor pressure and high 
water solubility. Acrylamide is not expected to be removed from soils or water by volatilization (WHO
2003). Limited data indicate that atmospheric acrylamide concentrations are very low, when it is 
identified at all (Pratt 2000; HSDB 2009).
The total national baseline National Toxics Inventory (NTI) emissions for acrylamide during 1900-1998 
were 35.4 tons/year. Total urban emissions were 33.5 tons/year while total rural emissions were 
1.9 tons/year (EPA 2000). The National Emissions Inventory database, maintained by the EPA, reports 
total U.S. acrylamide emissions of 12.12 tons per year in 2005 from various sources, including 
degreasing, waste disposal, pulp and paper, solvents, oil and gas production, industrial surface coatings, 
and oil and gasoline production among others (EPA 2009f).
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Releases to the Environment from Facilities that Produce, Process, or 
Use Acrylamidea
Reported amounts released in pounds per yearb
Total release
i^re Waterf UIg Landh Other1 On-sitej Off-sitek
On- and 
off-site
90 0 0 4 4,555 90 4,559 4,649
55 0 0 1 580 55 581 636
1 No data 0 0 0 1 0 1
0 No data 0 0 0 0 0 0
2 7 0 83 0 9 83 92
0 No data 0 0 0 0 0 0
5,629 0 0 798 0 5,629 798 6,427
99 0 0 0 0 99 0 99
0 No data 0 0 0 0 0 0
1,980 216 873,489 2,936 0 876,491 2,130 878,621
0 No data 0 0 5 0 5 5
2 0 0 0 0 2 0 2
6 0 0 0 0 6 0 6
1,860 0 0 0 0 1,860 0 1,860
2 0 0 0 0 2 0 2
19 0 0 0 0 19 0 19
1,299 0 960,000 10 0 961,299 10 961,309
19 5 0 0 0 24 0 24
500 250 0 0 0 750 0 750
98 No data 0 0 357 98 357 455
26 0 4,303,938 8 0 4,303,971 0 4,303,971
1 0 0 0 0 1 0 1
64 0 0 176 0 64 176 240
21 No data 0 0 0 21 0 21
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or
Use Acrylamidea
Reported amounts released in pounds per yearb
Statec RFd Aire Waterf UIg Landh Other1
Total release
On- and 
On-sitej Off-sitek off-site
WI 3 18 No data 0 0 2,038 18 2,038 2,056
Total 81 11,791 478 6,137,427 4,016 7,535 6,150,510 10,737 6,161,247
aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an
exhaustive list. Data are rounded to nearest whole number.
bData in TRI are maximum amounts released by each facility.
cPost office state abbreviations are used.
dNumber of reporting facilities.
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 
impoundments, other land disposal, other landfills.
Storage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs.
RF = reporting facilities; UI = underground injection
Source: TRI07 2009 (Data are from 2007)
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6.2.2 Water
Estimated releases of 478 pounds (~0.22 metric tons) of acrylamide to surface water from 81 domestic 
manufacturing and processing facilities in 2007, accounted for about 0.01% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI07 2009). These releases are 
summarized in Table 6-1.
Acrylamide in drinking water is typically a result of the release of residual monomer from polyacrylamide 
coagulants that are used as clarifiers in the treatment of raw water (Abdelmagid 1982; Cavalli et al. 2004; 
EPA 2006c; WHO 2003). The clarifiers served to coagulate and trap suspended solids such that they may 
be removed more easily from the water. Acrylamide that does not coagulate is released into the 
environment as a drinking water contaminant (Abdelmagid 1982; EPA 2006c). Use of polyacrylamides 
as grouting agents in reservoirs and wells can result in release to drinking water supplies. They can also 
be released in water from plastics and dye industries (Cavalli et al. 2004; EPA 2006c). When released to 
land, acrylamide does not bind to soil and will thus move rapidly through the soil column (EPA 2006c), 
which can result in increased risk of surface or groundwater contamination.
Total release of acrylamide to water between 1987 and 1993 was 36,287 pounds. Major industries found 
to release acrylamide to water include plastics and resins (19,002 pounds), pulp mills (8,000 pounds), 
industrial organics (3,107 pounds), and industrial inorganics (2,510 pounds) (EPA 2006c). According to 
the EPA’s Toxic Chemical Release Inventory, release of acrylamide to land and water from 1987 to 1993 
was over 40,000 pounds. Acrylamide releases were typically from plastics industries, with the largest 
releases occurring in Michigan (EPA 2006c).
As required by the 1974 Safe Drinking Water Act, EPA developed a maximum contaminant level (MCL) 
for acrylamide, which specifies the concentration at which it is not expected to cause health problems.
The MCL for acrylamide is zero (EPA 2006c). EPA requires water suppliers to control the amount of 
acrylamide added to water during the treatment process. This can be accomplished by limiting the 
amount of acrylamide in the polyacrylamide flocculants or by limiting the dose of flocculants (WHO
2003). Uncoagulated acrylamide in drinking water must be <0.5 ^g/L (ppb) (Cavalli et al. 2004; EPA 
2006c). This concentration corresponds to a maximum authorized dose of polymer of 1 mg/L (for a 
monomer content of 0.05%), as this corresponds to 0.5 ^g/L of monomer in the water (Cavalli et al. 2004;
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WHO 2003). In European Union countries, the maximum allowable concentration in drinking water is 
0.1 ^g/L (Cavalli et al. 2004).
If acrylamide is found to be present in raw water, the concentration can be decreased through ozonation or 
by treating the water with potassium permanganate. Acrylamide is not removed by conventional water 
treatment processes (WHO 2003).
6.2.3 Soil
Estimated releases of 4,016 pounds (~1.8 metric tons) of acrylamide to soils from 81 domestic 
manufacturing and processing facilities in 2007, accounted for about 0.06% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI07 2009). An additional 
6,137,427 pounds (~2,783 metric tons), constituting about 99.6% of the total environmental emissions, 
were released via underground injection (TRI07 2009). These releases are summarized in Table 6-1.
Polyacrylamides releases to land can occur from plastics and dye industries (Cavalli et al. 2004; EPA 
2006c). When released to land, acrylamide does not bind to soil and will thus move rapidly through the 
soil column (EPA 2006c; WHO 2003). Total release of acrylamide to land between 1987 and 1993 was 
5,818 pounds. Major industries found to release acrylamide to land include plastics and resins 
(2,177 pounds), industrial organics (2,200 pounds), and industrial inorganics (500 pounds) (EPA 2006c). 
According to the EPA’s Toxic Chemical Release Inventory, release of acrylamide to land and water from 
1987 to 1993 was over 40,000 pounds. Acrylamide releases were typically from plastics industries, with 
the largest releases occurring in Michigan (EPA 2006c).
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning
Acrylamide is expected to be highly mobile in soil and water. When released to land, acrylamide does 
not bind to soil and will thus move rapidly through the soil column and into groundwater, where it is also 
expected to have high mobility (EPA 2006c; HSDB 2009; WHO 2003). Acrylamide has a higher 
mobility in sandy soils than in clay soils, which can result in increased risk of surface or groundwater 
contamination (Abdelmagid 1982; EPA 2006c; WHO 2003). Acrylamide is not expected to be removed 
from soils or water by volatilization (WHO 2003).
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Acrylamide is not expected to significantly bioconcentrate in aquatic organisms due to its high water 
solubility and its ability to be degraded by microorganisms (EPA 2006c; Haberman 2002; WHO 2003). 
Acrylamide was determined to have a bioconcentration factor (BCF) of around 1 in both the carcass and 
viscera (0.86-1.44 and 1.12-1.65, respectively) of rainbow trout exposed to acrylamide concentrations of 
0.338 and 0.710 mg/L. This indicates that acrylamide did not bioaccumulate significantly in the trout 
(Petersen et al. 1985).
6.3.2 Transformation and Degradation
Acrylamide is susceptible to biodegradation in both soils and surface water (Abdelmagid 1982; EPA 
2006c; Haberman 2002; HSDB 2009; WHO 2003). As it does not bind to soil, acrylamide moves rapidly 
through the soil column where it is quickly degraded (EPA 2006c; WHO 2003).
In sandy soils, acrylamide has a higher mobility and lower rate of degradation than in clay soils 
(Abdelmagid 1982; EPA 2006c; WHO 2003). Acrylamide has been shown to biodegrade in effluent from 
a sludge dewatering process (WHO 2003).
Enzyme-catalyzed hydrolysis is a dominant mechanism for removal of acrylamide from soils (WHO
2003). Abdelmagid (1982) showed that acrylamide is readily hydrolyzed in soils under both aerobic and 
anaerobic conditions, resulting in the release of N H /. The rate of decomposition in soil is influenced by 
temperature and incubation time. Soil type did not appear to be a factor, as acrylamide decomposed in 
both sandy and heavy-textured soils (Abdelmagid 1982).
Acrylamide was shown to degrade by an average of 41.5% by BOD in 14 days at 25 °C and 100 mg/L 
test substance, with 30 mg/L activated sludge (CERI 1999).
6.3.2.1 Air
Limited data indicate that acrylamide concentrations in the atmosphere are very low (HSDB 2009; Pratt 
2000). In the atmosphere, acrylamide is susceptible to degradation via photochemically generated 
hydroxyl radicals and ozone. The rate constant for acrylamide’s reaction with hydroxyl radicals has been 
estimated as 1.1x10-11 cm3/molecule-second, and its reaction with ozone is estimated as 
1.7x10-18 cm3/molecule-second using a structure estimation method (Meylan and Howard 1993). Using 
an average atmospheric hydroxyl radical concentration of 1.5x106 molecules/cm3 and ozone concentration
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of 7x10n molecules/cm3, estimated half-lives of approximately 12 hours (hydroxyl radical reaction) and 
6.5 days (ozone reaction) can be calculated.
6.3.2.2 Water
Acrylamide is expected to be quickly degraded in water by biological processes (Abdelmagid 1982; EPA 
2006c; Haberman 2002; WHO 2003). At an initial concentration of 10 ppm, acrylamide was completely 
degraded in about 12 days using water obtained from the Hackensack River (Cherry et al. 1956). 
Acrylamide, at an initial concentration of 8 ^g/L, was rapidly degraded following a lag period of 
approximately 9 days in well-aerated, sunlit river water obtained from the Thames River, England (Croll 
et al. 1974). Subsequent re-seeding of the water with acrylamide resulted in rapid degradation with little 
or no lag period.
6.3.2.3 Sediment and Soil
When released to land, acrylamide does not bind to soil and will thus move rapidly through the soil 
column, where it is expected to be quickly degraded (EPA 2006c; Haberman 2002; WHO 2003). 
Acrylamide has a higher mobility and lower rate of degradation in sandy soils than in clay soils 
(Abdelmagid 1982; EPA 2006c; WHO 2003).
Enzyme-catalyzed hydrolysis is a dominant mechanism for removal of acrylamide from soils (WHO
2003). Abdelmagid (1982) showed that acrylamide is readily hydrolyzed in soils, producing N H /. The 
rate of decomposition in soil is influenced by temperature and incubation time. Soil type did not appear 
to be a factor, as acrylamide decomposed in both sandy and heavy-textured soils. Acrylamide, therefore, 
does not appear to accumulate in soils (Abdelmagid 1982).
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to acrylamide depends in part on the reliability of 
supporting analytical data from environmental samples and biological specimens. Concentrations of 
acrylamide in unpolluted atmospheres and in pristine surface waters are often so low as to be near the 
limits of current analytical methods. In reviewing data on acrylamide levels monitored or estimated in the 
environment, it should also be noted that the amount of chemical identified analytically is not necessarily 
equivalent to the amount that is bioavailable. The analytical methods available for monitoring acrylamide 
in a variety of environmental media are detailed in Chapter 7.
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6.4.1 Air
Acrylamide is not anticipated to be a common air contaminant due to its low vapor pressure and high 
water solubility. Limited data indicate that acrylamide concentrations in the atmosphere are very low 
(HSDB 2009; Pratt 2000). Air samples were collected at 25 sites throughout Minnesota over various 
periods of time (up to 8 years) from 1991 to 1998. Acrylamide was not identified in any of the samples 
(Pratt 2000). As of 1978, acrylamide concentrations in the air near six U.S. acrylamide/polyacrylamide 
producers or users averaged <0.2 ^g/m3 in vapor or particulate form. Concentrations ranged from <0.1 to
1.1 ^g/m3 (EPA 1978).
The total national baseline NTI emissions for acrylamide during 1900-1998 were 35.4 tons/year. Total 
urban emissions were 33.5 tons/year, while total rural emissions were 1.9 tons per year (EPA 2000).
6.4.2 Water
Acrylamide in drinking water is typically a result of leaching during treatment processes (van Dijk- 
Looijaard and van Genderen 2000). Acrylamide results from the release of residual monomer from 
polyacrylamide coagulants that are used as clarifiers in the treatment of raw water (Abdelmagid 1982; 
Cavalli et al. 2004; EPA 2006c; WHO 2003). Polyacrylamides can enter water supplies due to their use 
as grouting agents in reservoirs and wells in addition to being released in water from plastics and dye 
industries (Cavalli et al. 2004; EPA 2006c).
Acrylamide concentrations of <5 ^g/L were found in river and tap water. In the sampling area, 
polyacrylamides were known to be used in treating potable water (WHO 2003). Public drinking water 
supply wells in West Virginia contained acrylamide concentrations of 0.024-0.041 ^g/L (WHO 2003).
One water sample, taken from downstream of the effluent of a producer of polyacrylamide, contained 
acrylamide at 1,500 ^g/L, while samples from other industrial sites (acrylamide and polyacrylamide 
production and use locations) contained <0.8 ^g/L acrylamide (EPA 1978).
Various effluents in the United Kingdom have been found to contain acrylamide, including effluent from 
a clay pit (16.0 ^g/L), a tailings lagoon (39-42 ^g/L), coal washing lagoon (1.8 ^g/L), colliery/cooking 
plant, (0.74 ^g/L), treated paper mill (0.47-14.4 ^g/L), and paper mill process water (45.4 ^g/L) (Croll et
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al. 1974; IPCS 1985). In Devon, England, 17.4 ppb of acrylamide was detected in sewage effluent 
(Brown and Rhead 1979).
6.4.3 Sediment and Soil
Soil samples obtained near six U.S. acrylamide and/or polyacrylamide producers contained <0.02 ^g/g of 
acrylamide. Concentrations ranged from <0.02 to <0.08 ^g/g (EPA 1978).
6.4.4 Other Environmental Media
Acrylamide was detected in waste materials and containers at 3 of the 1,699 hazardous waste sites that 
have been proposed for inclusion on the EPA NPL (HazDat 2007). Acrylamide was also identified in 
tobacco smoke samples, obtained from nonfiltered cigarettes smoked under typically conditions. The 
presence of acrylamide was identified in the smoke condensate by infrared (IR), mass spectrometry (MS), 
and nuclear magnetic resonance (NMR) (Schumacher et al. 1977).
In 2002, acrylamide was first shown to be produced when foods are cooked at high temperatures (Tareke 
et al. 2002). Concentrations of acrylamide in food vary with the type of food and method of processing 
and cooking. Acrylamide concentrations in food typically increase with temperature and length of 
heating (Sorgel et al. 2002; WHO 2002, 2003). Starchy foods, such as potato-based products, typically 
contain the highest levels of acrylamide (Muttucumaru et al. 2008; Tareke et al. 2002; WHO 2003), 
whereas protein-based foods contain smaller amounts (Tareke et al. 2002).
Tareke et al. (2002) analyzed acrylamide content of various heated foods. Acrylamide concentrations 
were determined by gas chromatography (GC)-MS and liquid chromatography (LC)-MS/MS. In heated 
protein-rich foods, acrylamide concentrations of 5-50 ^g/kg were found. Carbohydrate-rich foods, such 
as potato, beetroot, potato products, and crispbread, contained much higher concentrations, ranging from 
150 to 4,000 ^g/kg. The median acrylamide concentration in fried foods, including beef, chicken, 
soymeal, grated potatoes, boiled mashed potatoes, and grated beetroot were 17, 28, 16, 447, 172, and 
850 ^g/kg, respectively. In microwave-heated grated potatoes, the median acrylamide concentration was 
found to be 551 ^g/kg, while microwave-heated cod was less than the detection limit (<5 ^g/kg). In 
restaurant-prepared or purchased foods, the median acrylamide concentrations for hamburger, French 
fries, potato crisps, and three types of crispbread were 18, 424, 1,739, and 208, respectively. Unheated
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controls and boiled foods contained very little acrylamide, with all results being less than the detection 
limits for the methods (<5 ^g/kg by GC-MS and <10 ^g/kg by LC-MS/MS) (Tareke et al. 2002).
Acrylamide concentrations were analyzed in food samples in Norway, Sweden, Switzerland, the United 
Kingdom, and the United States in various studies (Table 6-2). Almost all items analyzed contained some 
level of acrylamide. Of the food tested, chips and crisps contained the highest average concentrations, 
ranging from not detectable to 3.5 mg/kg (WHO 2002).
Acrylamide concentrations were determined for various foods prepared using home cooking methods, 
including the use of a household oven and microwave oven. The data are presented in Tables 6-3 and 
6-4. The authors concluded that longer cooking times and higher temperatures appear to cause increased 
acrylamide concentrations in food (Sorgel et al. 2002).
The acrylamide content of various carbohydrate-rich Brazilian foods was determined by LC-MS/MS. 
Samples were obtained from grocery stores, restaurants, and fast food restaurants in Campinas, Sao Paulo, 
Brazil between September 2004 and April 2006. The foods sampled included French fries, potato chips, 
bread, crispbread, crackers, breakfast cereals, coffee, beer, and other high carbohydrate foods typically 
processed at high temperatures. Of 111 samples from 19 product categories, acrylamide concentrations 
ranged from <20 to 2,528 mg/kg. Considerable differences in concentration existed between individual 
foods within the same product class. Potato chips, processed at high temperatures, and instant coffee had 
the highest concentrations of acrylamide, while cassava- and maize-based foods, bread, and beer were 
found to have the lowest levels. The detection limit and limit of quantification were 10 and 20 mg/kg, 
respectively (Arisseto et al. 2007).
An ongoing U.S. Food and Drug Administration (FDA) survey collects acrylamide data on U.S. food 
products under the Total Diet Study (TDS). Data on approximately 280 core foods (or TDS foods) were 
collected to determine the nutrient and contaminant levels in the foods from each of the geographic 
regions in the United States (West, North Central, South, and Northeast). Food samples are collected 
from grocery stores and fast food restaurants from three cities in each region, prepared for consumption, 
and then analyzed (FDA 2009). The summary results for the 2003-2006 TDS data on acrylamide are 
presented in Table 6-5. Foods within certain food groups (i.e., grains/starches/baked goods) have been 
found to have very high levels of acrylamide. It should be noted that the high levels within the vegetable 
group were primarily due to potato chips and French fries.
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Table 6-2. Acrylamide Levels in Different Food and Food Product Groups from 
Norway, Sweden, Switzerland, the United Kingdom, and the United States
Acry lam ide  levels (^g /kg )a
Food/product
group M eanb M edian2
M in im um ­
M axim um
N um ber of 
Sam ples
Crisps, potato/sweet 
potatoc
1,312 1,343 170-2,287 38
Chips, potatod 537 330 <50-3,500 39
Batter based 
products
36 36 <30-42 2
Bakery products 112 <50 <50-450 19
Biscuits, crackers, 
toast, bread crisps
423 142 <30-3,200 58
Breakfast cereals 298 150 <30-1346 29
Crisps, corn 218 167 34-416 7
Bread, soft 50 30 <30-162 41
Fish and seafood 
products, crumbled, 
battered
35 35 30-39 4
Poultry or game, 
crumbed, battered
52 52 39-64 2
Instant malt drinks 50 50 <50-70 3
Chocolate powder 75 75 <50-100 2
Coffee powder 200 200 170-230 3
Beer <30 <30 <30 1
aThe limits of detection and quantification varied among laboratories; values reported as less than a value are below 
the limit reported by the laboratory.
bMean and median values were calculated where individual data were available; sample sizes were extremely small, 
particularly for some food categories; where the mean and median are different, it reflects the skewed distribution of
the underlying data that were collected in different countries and may represent different food items within the larger
category.
cProducts that are thinly sliced and fried (such as potato chips). 
dProducts that are more thickly sliced (such as French fries).
Source: WHO 2002
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Table 6-3. Acrylamide in Potato Products
Sam ple S ize (mm)
Cooking
tem pera ture  (°C)
C ooking tim e 
(m inutes)
A cry lam ide
concentra tion
(Mg/kg)
Potato chips 3 180 2 2,557.9
3 140 2 36.3
3 180 4 7,678.3
3 140 4 53.3
1 180 1 121.1
1 140 2 20.0
1 180 3 9,670.2
1 140 4 35.3
French fries 5 180 2 1,716.9
5 160 2 53.8
5 140 2 11
5 180 4 2,687.0
5 160 4 1,049.5
5 140 4 77.0
10 180 2 674.2
10 160 2 <8
10 140 2 <8
10 180 4 1,084.3
10 160 4 87.3
10 140 4 10.0
13 180 4 476.2
13 140 2 <8
13 180 6 880.0
13 140 4 <8
Source: Sorgel et al. 2002
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Table 6-4. Acrylamide Content of Food
S am ple Description C ooking m ethod
C ooking tim e 
(m inutes)
Acry lam ide
concentration
(Mg/kg)
Walnuts Roasted <8
Pine seeds Roasted 16.4
Candied chestnuts Baked 8.3
Crème carmel Boiled <8
Whiskey <8
Liver of beef Baked <8
Breaded fish Baked <8
Goose skin Oven <8
Goose meat Oven <8
Gingerbread Lightly baked 200 °C 12.1
Gingerbread Dark baked 200 °C 113.0
Gingerbread 180.7
Gingerbread balls 639.5
Spiced cookies 143.6
Popcorn Microwave, 800 W 1 29.7
Popcorn Microwave, 600 W 2 50.0
Popcorn Microwave, 800 W 2 132.8
Popcorn Microwave, 600 W 3 250.3
Popcorn Microwave, 600 W 4 307.1
Croquettes 180 °C 2 354.7
Croquettes 180 °C 4 453.4
Hash browns 180 °C 2 446.1
Hash browns 180 °C 4 751.7
Fried potatoes 543.1
Croutons Baked 27.9
Bread crust 370.6
Toast Toasted 54.1
Source: Sorgel et al. 2002
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Table 6-5. Acrylamide Levels in Food Products Sampled for the 2003-2006 Total
Diet Studies (TDS) Summary
TD S food 
category
A cry lam ide  range 
(ppb) fo r 2003
A cry lam ide  range 
(ppb) fo r 2004
Acry lam ide  range 
(ppb) fo r 2005
Acry lam ide  range 
(ppb) fo r 2006
Dairy ND-16 ND ND-16 ND-18
Eggs ND No data ND No data
Baby food ND-267 ND-407 ND-442 ND-381
Meat/poultry/fish ND-26 ND-27 ND-30 ND-19
Legumes ND-93 ND-93 ND-84 ND-54
Grains/starches/ 
baked goods
ND-647 ND-946 ND-616 ND-470
Fruits ND-202 109-355a ND-250 326a
Vegetables ND-536b ND-829b ND-529 ND-393
Mixtures (e.g., 
casseroles, 
sandwiches, soups, 
pizza)
ND-187 ND-210 ND-93 ND-55
Candy/sweets/
Sugars/syrups
ND-29 ND-42 13-50 17-32
Fats/oils ND No data No data No data
Beverages ND-12 ND-21 ND-28 ND
aOnly bottle prune juice was included in this category for 2004 and 2006.
bThe highest levels in the vegetable category are for potato chips and French fries; the majority of the vegetables 
had low or non-detectable levels.
ND = Not detected
Source: U.S. Food and Drug Administration 2006
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Temperature, water content, food thickness, and length of heating appear to be important factors affecting 
the amount of acrylamide that is formed while cooking foods (Sorgel et al. 2002; WHO 2002, 2003). 
Reversing these factors could help minimize acrylamide formation (e.g., heating to <180 °C, making 
products very thick, etc.) (Sorgel et al. 2002). In many countries, food manufacturers have been 
requested to take steps to decrease the formation of acrylamide in their products, which has become an 
important area of research (Amrein et al. 2007).
With potato products, controlling reducing sugars, processing temperature, and moisture content can help 
limit formation of acrylamide (Amrein et al. 2007). It is thought that the amount of asparagine is also an 
important factor in acrylamide formation in potatoes (Muttucumaru et al. 2008). With bakery products, 
the amount of free asparagines as well as the type of baking agent can affect acrylamide concentration. 
Replacing the baking agent NH4HCO3, for example, with NaHCO3 in sweet bakery products can help 
reduce acrylamide content. In almonds, temperature and free asparagine content are thought to affect the 
amount of acrylamide formed during roasting. High concentrations of acrylamide can form during 
heating of olives and dried fruit (Amrein et al. 2007). Additional research is needed to determine the 
acrylamide reduction strategies for each type of food.
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Acrylamide is a probable or confirmed carcinogen with the potential to cause nervous system damage, 
weakness, and incoordination of the legs following short-term exposure to high levels. Long-term effects 
of acrylamide include nervous system damage, paralysis, and cancer (Arisetto et al. 2007; EPA 2006c; 
Lewis 2000). Exposure can occur via ingestion, dermal contact, inhalation, and intraperitoneal routes 
(Lewis 2000; Sorgel et al. 2002). Once in the body, acrylamide is widely dispersed by body fluids. It can 
also cross the placental barrier (WHO 2003).
Exposure to high levels of acrylamide can result from ingestion of various foodstuffs. Acrylamide is 
produced when certain foods are cooked at high temperatures (Tareke et al. 2002). Concentrations of 
acrylamide in food vary with the type of food and method of processing and cooking, and typically 
increase with temperature and length of heating (Sorgel et al. 2002; WHO 2002, 2003). Foodstuffs, 
particularly those rich in carbohydrates, may develop high levels of acrylamide when cooked at high 
temperatures (Moreno Navarro et al. 2007). Potato products, including chips and other potatoes cooked at 
high temperatures, may comprise a large percentage of the total acrylamide intake from food. However,
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foods with lower acrylamide content but eaten at a higher frequency, such as bread, may contribute 
significantly to the total exposure from foods (WHO 2002).
Food was found to contribute significantly to the overall exposure of the general population to 
acrylamide. Short-term dietary intake of acrylamide was estimated using Monte Carlo techniques based 
on data from The Netherlands, United States, and Sweden. The short-term exposure estimates ranged 
from 0.8 to 6.0 ^g/kg-bw/day for the average consumer to the 98th percentile consumer (WHO 2002). 
Average estimated long-term intake of acrylamide from food sources was determined based on data from 
Australia, Norway, The Netherlands, Sweden, and the United States, as well as data from the International 
Agency for Research on Cancer (IARC). Long-term intake estimates ranged from 0.3 to 0.8 ^g/kg- 
bw/day (WHO 2002, 2003). Tareke et al. (2002) concluded that the acrylamide levels found in heated 
foods could result in a daily acrylamide intake of a few tens of micrograms.
Due to the presence of acrylamide in tobacco smoke (EU 2002; Schumacher et al. 1977), the general 
population can be exposed to acrylamide via inhalation (Moreno Navarro et al. 2007). This may include 
second-hand smoke, and is thought to be a significant source of exposure for the general population 
(WHO 2002). Due to its low vapor pressure and high water solubility, acrylamide is not anticipated to be 
a common air contaminant (WHO 2003), and thus, inhalation exposure is likely limited to tobacco smoke 
exposure.
Nonfood exposure to acrylamide is thought to be low for nonsmokers. Exposure can result from 
ingestion of polyacrylamide-treated drinking water containing residual monomer (EPA 2006c; EU 2002; 
WHO 2003), and from water in contact with acrylamide-containing products (e.g., grouting agents in 
dams) (Sorgel et al. 2002, van Dijk-Looijaard and van Genderen 2000). The MCL for acrylamide in 
drinking water, which specifies the concentration at which it is not expected to cause health problems, is 
zero (EPA 2006c). Dermal exposure can result from contact with cosmetics and toiletries containing 
polyacrylamides (EU 2002).
Acrylamide and its metabolite, glycidamide, can react with biomolecules such as hemoglobin. 
Concentrations of adducts in the blood relevant to dietary exposure can be determined, and thus, the 
adducts can be used as biomarkers to determine a time-averaged estimate of acrylamide exposure.
Urinary biomarker use may also be possible (WHO 2002).
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Occupational exposure occurs mainly through dermal contact of acrylamide from solution, followed by 
inhalation of dry monomer or aerosols of solution during manufacture of acrylamide and polyacrylamide 
as well as during acrylamide grouting or preparation of polyacrylamide gels in the laboratory. Ingestion 
is a minimal concern in the workplace (EU 2002; Lewis 2000). A unique danger of acrylamide is its 
ability to be absorbed through unbroken skin (Lewis 2000). In the workplace, handling of dry 
acrylamide, such as emptying bags and drums, results in an inhalation and dermal hazard from dust 
(Haberman 2002).
6.6 EXPOSURES OF CHILDREN
This section focuses on exposures from conception to maturity at 18 years in humans. Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume. A child’s diet often differs from that of adults.
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults. A child’s 
behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Acrylamide exposure to children can occur via ingestion and inhalation. Food was found to contribute 
significantly to the overall exposure of the general population to acrylamide. The short-term exposure 
estimates ranged from 0.8 to 6.0 ^g/kg bw/day, while the estimated long-term intake of acrylamide from 
food sources ranged from 0.3 to 0.8 ^g/kg bw/day for adults. Exposure in children is expected to be 2­
3 times that of adults on a body weight basis (WHO 2002, 2003). Children can also be exposed to 
acrylamide via inhalation of second-hand smoke (Moreno Navarro et al. 2007; WHO 2002).
In the body, acrylamide is widely dispersed by body fluids, and can also cross the placental barrier, 
exposing the fetus to high levels of acrylamide (Sorgel et al. 2002, WHO 2003). Fetuses and newborns 
do not have a fully developed blood-brain barrier, and thus, women who consume large amounts of 
acrylamide-containing foods risk significant acrylamide transfer to the fetus. Postnatally, acrylamide can 
be transferred via breast milk. According to Sorgel et al. (2002), when mothers consume foods with high
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acrylamide concentrations, daily consumption of 500 mL of breast milk can result in up to 10 ^g of 
acrylamide transferred to the baby. Women who eat lesser amounts of acrylamide-containing foods, such 
as potato chips, may still transfer 2 ^g of acrylamide to the baby. For these two scenarios, the doses for a 
3 kg infant would be 3.3 and 0.66 ^g/kg, respectively (Sorgel et al. 2002).
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
In addition to the individuals who are occupationally exposed to acrylamide (see Section 6.5), there are 
several groups within the general population that may receive potentially high exposures (higher than 
background levels) to acrylamide. These populations include individuals living in proximity to sites 
where acrylamide is produced or used in manufacturing or sites where acrylamide is disposed, and 
includes individuals living near the three NPL hazardous waste sites where acrylamide has been detected 
in some environmental media (HazDat 2007). Smokers and those breathing second-hand smoke are 
subject to high acrylamide exposures (Moreno Navarro et al. 2007). Children of mothers whose diets are 
high in acrylamide-containing foods can be exposed to high amounts of acrylamide through breast milk 
(Sorgel et al. 2002).
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of acrylamide is available. Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of acrylamide.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
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Physical and Chemical Properties. The physical and chemical properties of acrylamide are well 
understood and have been discussed in Chapter 4 (Table 4-2). There are no data needs.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency Planning 
and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit 
substance release and off-site transfer information to the EPA. The TRI, which contains this information 
for 2007, became available in February of 2009. This database is updated yearly and should provide a list 
of industrial production facilities and emissions.
Methods of manufacturing, production volumes, and uses of acrylamide are available and have been 
discussed in Chapter 5. Demand and import/export volumes are also available. No data needs are 
identified.
Environmental Fate. The environmental fate of acrylamide is reasonably well understood. If released 
to the environment, acrylamide has a low potential to volatilize to air from water or soil surfaces; 
however, its low soil adsorption coefficient suggests that it has potential to leach into groundwater. 
Acrylamide appears to degrade fairly rapidly by biological processes in both soil (Abdelmagid 1982) and 
water (Cherry et al. 1956; Croll et al. 1974). If released to air, acrylamide is expected to degrade through 
reaction with photochemically generated hydroxyl radicals and ozone molecules. No data needs are 
identified.
Bioavailability from Environmental Media. No data exist regarding acrylamide’s bioavailability 
from environmental media such as soil or drinking water. Acrylamide is produced when certain foods are 
cooked at high temperatures (Tareke et al. 2002). Foodstuffs, particularly those rich in carbohydrates, 
may develop high levels of acrylamide when cooked at high temperatures (Moreno Navarro et al. 2007).
Food Chain Bioaccumulation. Acrylamide is not expected to significantly bioconcentrate due to its 
high water solubility and its ability to be degraded by microorganisms (EPA 2006c; Haberman 2002; 
WHO 2003). Therefore, bioaccumulation through the food chain is expected to be low. No data needs 
are identified.
6.8.1 Identification of Data Needs
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Exposure Levels in Environmental Media. Reliable monitoring data for the levels of acrylamide in 
contaminated media at hazardous waste sites are needed so that the information obtained on levels of 
acrylamide in the environment can be used in combination with the known body burden of acrylamide to 
assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste 
sites.
Exposure Levels in Humans. Acrylamide was found to be present in various foods at high 
concentrations (Tareke et al. 2002). In order to better characterize the degree of exposure from food 
sources, further information is necessary to determine the background levels of acrylamide in both the 
environment and in humans. Additional information concerning methods to decrease acrylamide content 
in foods, and thus decrease exposure, is needed.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Children are exposed to acrylamide by the same routes as adults. Food was 
found to contribute to high levels of exposure in children, possibly 2-3 times that of an adult (WHO 
2002, 2003). Inhalation of second-hand smoke can also result in exposure (Moreno Navarro et al. 2007; 
WHO 2002). Acrylamide has been detected in breast milk, which can result in significant exposure to 
infants (Sorgel et al. 2002). Additional data would be useful to determine the exposures of children to 
acrylamide via these methods.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for acrylamide were located. This substance is not 
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry. The substance will be considered in the future when chemical selection is made for sub­
registries to be established. The information that is amassed in the National Exposure Registry facilitates 
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to 
this substance.
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The Federal Research in Progress (FEDRIP 2009) database provides additional information obtainable 
from a few ongoing studies that may fill data needs identified in Section 6.8.1. Titles for these studies are 
listed in Table 6-6.
6.8.2 Ongoing Studies
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Table 6-6. Ongoing Research Regarding the Environmental Fate and Exposure to
Acrylamide
Investiga to r A ffilia tion Description Sponsor
Lehotay SJ, 
Handel A
Drexel University Development of new methods to detect and control 
acrylamide formation in deep-fat fried foods
USDA
Chen H University of Delaware Improvement of thermal and alternative processes for USDA 
foods
Calder BL, 
Perkins LB, 
Bushway AA, 
et al.
University of Maine Improving the post-harvest quality of fresh-cut and 
processed Maine potatoes
USDA
Daley LS Oregon State University Regulation of photosynthetic processes USDA
USDA = U.S. Department of Agriculture 
Source: FEDRIP 2009
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring acrylamide, its metabolites, and other biomarkers of exposure and effect to 
acrylamide. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is 
to identify well-established methods that are used as the standard methods of analysis. Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision.
7.1 BIOLOGICAL MATERIALS
Methods for the detection of acrylamide in biological materials are summarized in Table 7-1. Acrylamide 
can be detected in biological samples using gas chromatography (GC) with electron-capture detection. 
Acrylamide is converted to its 2,3-dibromopropionamide derivation in aqueous solution, plasma, or tissue 
homogenates by ionic bromination. The limits of detection for this method correspond to 9.5x10-12 g of 
acrylamide on the column or 8.4x10-9 g in the final biological extract of 0.5 mL. Acrylamide recovery by 
this method exceeds 80% at nanogram levels (HSDB 2009).
A liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay was developed to examine 
unchanged acrylamide concentrations in bodily fluids, specifically urine, breast milk, and placental 
perfusion medium. A bioanalytical method was developed to analyze acrylamide in bodily fluids using 
LC-MS/MS following liquid/liquid extraction of acrylamide and evaporation under a stream of N2 at 
35 °C. A reversed-phase column eluted with an isocratic solvent system consisting of water, acetic acid, 
and an organic modifier was used for chromatographic separation. Method detection limits were 1 ng/mL 
for urine, 2 ng/mL for placenta perfusate, and 5 ng/mL for breast milk (Sorgel et al. 2002).
GC-MS methods have been used to determine the adducts of acrylamide and its metabolites (such as 
glycidamide) with hemoglobin in blood samples. These methods are sensitive enough to measure adducts
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Table 7-1. Analytical Methods for Determining Acrylamide in Biological Samples
Sam ple
m atrix Preparation m ethod
Analytica l
m ethod
Sam ple
detection
lim it
Percent
recovery Reference
Urine Liquid/liquid extraction, 
evaporation under N2 
stream at 35 °C
LC-MS/MS 1 ng/mL Sorgel et al. 2002
Breast milk Liquid/liquid extraction, 
evaporation under N2 
stream at 35 °C
LC-MS/MS 5 ng/mL Sorgel et al. 2002
Placental
perfusion
medium
Liquid/liquid extraction, 
evaporation under N2 
stream at 35 °C
LC-MS/MS 2 ng/mL Sorgel et al. 2002
Biological
samples
Ionic bromination of 
acrylamide in sample
GC with 
electron- 
capture 
device
Corresponds 
to 9.5x10-12 g 
acrylamide 
(column), 
8.4x10-9 g 
(extract)
HSDB 2009
GC = gas chromatography; LC = liquid chromatography; MS = mass spectrometry
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at blood levels relevant to potential dietary acrylamide exposure, which allows for use of the adducts as 
biomarkers of exposure (WHO 2002, 2003). A more recent method of detection for hemoglobin adducts 
of acrylamide utilizes LC-MS/MS (Fennell et al. 2003).
Acrylamide and glycidamide were measured in serum and tissues of mice following dosing by 
intravenous, gavage, and dietary routes at 0.1 mg/kg acrylamide and by intravenous and gavage routes at 
equimolar amounts of glycidamide. LC-electrospray (ES)/MS/MS was utilized to measure acrylamide 
and glycidamide in serum and tissues with recoveries of 70% for acrylamide and 63% for glycidamide. 
The limit of detection was below 0.1 pmol/mg tissue for both acrylamide and glycidamide (Doerge et al. 
2005b). Doerge et al. (2005a) detected DNA adducts derived from administration of acrylamide and 
glycidamide to mice and rats. A single intraperitoneal injection containing an aqueous solution of 100 ^L 
of 50 mg/kg acrylamide or 61 mg/kg glycamide was given to the mice. Rats were treated with a single 
intraperitoneal injection of the same concentration using a volume of 100 ^L per 100 g body weight. Six 
hours after dosing, the tissues were removed following gassing by carbon dioxide. Tissues were frozen 
and stored at -80 °C. DNA adducts were analyzed using a Quattro Ultima triple stage guadrupole mass 
spectrometer with an electrospray source, with an ion source temperature of 120 °C, desolvation gas 
temperature of 400 °C, and constant cone voltage of 35 V. DNA was isolated using a Blood and Cell 
Culture Maxi kit and adducts were quantified using LC-/MS/MS. The limit of quantification ranged from 
1 to 1.5 adducts in 108 nucleotides and the limit of detection was 0.5 adducts in 108 nucleotides (Doerge et 
al. 2005a).
7.2 ENVIRONMENTAL SAMPLES
Methods for the detection of acrylamide in environmental samples are summarized in Table 7-2. 
Acrylamide detection in water samples can be achieved using direct injection and a reversed-phase high 
performance liquid chromatography (HPLC)-ultraviolet (UV) absorption procedure, which has a limit of 
detection of 5 ^g/L (Cavalli et al. 2004). An HPLC method can be used to determine the amount of 
acrylamide monomer in natural and polluted aqueous environments. Acrylamide undergoes bromination 
and the resulting dibromopropionamide is assayed. The detection limit for the method was found to be
0.2 ^g/L in river, sea, and estuarine waters as well as potable waters, sewage, and china clay works 
effluents (HSDB 2009).
Solid phase extraction, extraction with activated carbon filter, and GC-MS analyses can also be used 
(Cavalli et al. 2004). A water sample is brominated to form 2,3-dibromopropionamide, which is then
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Table 7-2. Analytical Methods for Determining Acrylamide in Environmental
Samples
Sample matrix
Preparation
method
Analytical
method
Sample 
detection limit
Percent
recovery Reference
Water Direct injection Reversed-phase 5 pg/L
HPLC-UV
absorption
Cavalli et al. 
2004
Natural and 
polluted water
Bromination of 
acrylamide in 
sample
HPLC 0.20 pg/L HSDB 2009
Organic-free 
reagent water
HPLC 10 pg/L HSDB 2009
Aqueous
matrices
GC 0.032 pg/L HSDB 2009
Drinking water Direct injection 
of 500 pL
Ion-exclusion
chromatographic
separation/MS
0.20  ppb Cavalli et al. 
2004
Airborne dust, 
vapors
Differential pulse
polarographic
method
HSDB 2009
Food Water extract 
food, brominates 
sample
GC-MS 5-10 pg/kg WHO 2002
Food Bromination of 
sample
GC-MS 5 pg/kg Tareke et al. 
2002
Food Water extract 
food
LC-MS/MS 20-50 pg/kg WHO 2002
Food LC-MS/MS 10 pg/kg Tareke et al. 
2002
Food LC-MS/MS 10 pg/kg 100-115% Arisseto et al. 
2007
GC = gas chromatography; HPLC = high performance liquid chromatography; LC = liquid chromatography; MS = 
mass spectrometry; SlM = selected ion monitoring; UV = ultraviolet
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE
7. ANALYTICAL METHODS
181
analyzed by GC-MS using methacrylamide as an internal standard (Ahn et al. 2002). Additional methods 
include polarography and electron capture GC (WHO 2003). EPA-OSW 8316 method determines 
acrylamide concentrations by HPLC in organic-free reagent water, with a limit of detection of 10 ^g/L. 
The EPA-OSW 8032A method analyzes acrylamide in aqueous matrices using GC, with a detection limit 
of 0.032 ^g/L (HSDB 2009).
Cavalli et al. (2004) utilized a method for detecting acrylamide in drinking water using a combination of 
ion-exclusion chromatographic separation and MS detection. Drinking water samples are injected 
directly into the microbore ICE-AS1 column and are then detected in the selected-ion monitoring mode 
by a single quadrupole system with electrospray ionization. The detection limit for the method was 
determined to be 0.20 ppb with an injection volume of 500 ^L (Cavalli et al. 2004).
Airborne acrylamide vapors and dust can be determined in air by a differential pulse polarographic 
method (HSDB 2009). Two additional methods of detection in air were found (called Method 21 and 
OSHA PV2004), though only very limited details were provided (HSDB 2009).
Various methods are available to determine the acrylamide content of food. The most common methods 
utilize either GC-MS or LC-MS/MS (Ahn et al. 2002; Arisseto et al. 2007). Water is often used as the 
extraction solvent. Solid-phase extraction (SPE) is typically use to prepare samples. SPE phases that 
have been used for this method include graphitized carbon black, mixed mode anion and cation exchange, 
and polymeric materials (Arisseto et al. 2007)
The GC-MS method of determining acrylamide content in food is well established. A water extract of the 
food is brominated to form 2,3-dibromopropionamide, a derivative of acrylamide with enhanced GC 
properties. The derivative is then analyzed by GC-MS using methacrylamide as an internal standard (Ahn 
et al. 2002; WHO 2002). Detection limits for the GC-MS method are typically in the 5-10 ^g/kg range 
(WHO 2002). Tareke et al. (2002) analyzed food samples for acrylamide using an improved GC-MS 
method involving bromination. A detection limit of 5 ^g/kg was achieved.
The LC-MS/MS method was developed over concerns that artifacts were forming during the bromination 
procedure used with the GC-MS method. LC-MS/MS allows for direct acrylamide analysis without the 
need for a derivative (WHO 2002). In this method, a water extract of food is tested by LC-MS/MS using 
deuterated acrylamide as an internal standard (Ahn et al. 2002). Acrylamide is then identified by its 
retention time and the relative ion intensities. WHO (2002) reports that the detection limits of this
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method are typically 20-50 ^g/kg, although lower detection limits have since been obtained for this 
method.
Tareke et al. (2002) also utilized the LC-MS/MS method to determine underivitized acrylamide 
concentrations. This method had a detection limit of 10 ^g/kg. Sorgel et al. (2002) used a modified LC- 
MS/MS method, similar to that developed for analysis of acrylamide in bodily fluids, to determine 
acrylamide content in food. Brazilian foods were analyzed by LC-MS/MS to determine acrylamide 
content (Arisseto et al. 2007). Detection limits of 10 ^g/kg were achieved, along with a limit of 
quantification of 20 |Jg/kg and mean recoveries ranging from 100 to 115%.
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of acrylamide is available. Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of acrylamide.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs
Methods for Determining Biomarkers of Exposure and Effect.
Exposure. Exposure to acrylamide can be determined directly by LC-MS/MS for biological samples, 
including urine, breast milk, and placental perfusion medium with detection limits of 1, 5, and 2 ng/mL, 
respectively (Sorgel et al. 2002). GC-MS methods are also used to detect the adducts of acrylamide and 
its metabolites in blood and tissue samples (HSDB 2009; WHO 2002, 2003). Methods are described in
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Table 7-1. Additional methods for the detection of acrylamide and its metabolites in biological samples 
would be helpful.
Effect. Information on biomarkers of effect for acrylamide would be useful.
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. There are several variations on methods for identifying acrylamide in water, air, and food. The 
methods are summarized in Table 7-2. The methods for water, primarily involving the use of HPLC and 
GC are fairly sensitive (e.g., ~0.03-10 ^g/L for water (Cavalli et al. 2004; HSDB 2009). In air, a 
differential pulse polarographic method was identified, although limited details were provided (HSDB 
2009). Additional information concerning the detection of acrylamide in air, including detection limits, 
would be useful. Various methods are available to determine acrylamide content of food using primarily 
GC-MS or LC-MS/MS (Ahn et al. 2002; Arisseto et al. 2007). GC-MS involved bromination, while LC- 
MS/MS can determine acrylamide content directly. Detection limits for GC-MS methods typically range 
from 5 to 10 ^g/kg, while limits of detection for the LC-MS/MS method are typically in the range of 10­
50 ^g/kg (Tareke et al. 2002; WHO 2002). More sensitive methods for direct determination of 
acrylamide in food via the LC-MS/MS method would use useful.
7.3.2 Ongoing Studies
The Federal Research in Progress (FEDRIP 2009) database contains a study sponsored by the U.S. 
Department of Agriculture in which new methods are being developed for detecting and controlling 
acrylamide formation in deep-fat fried foods.
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8. REGULATIONS, ADVISORIES, AND GUIDELINES
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be of concern at hazardous waste sites.
ATSDR has derived an acute-duration oral MRL of 0.02 mg/kg/day for acrylamide based on benchmark 
dose (BMD) analysis of results of fertility testing of male F344 rats administered acrylamide by gavage 
for 5 days prior to 1-week mating sessions with untreated female rats (Sublet et al. 1989). The resulting 
BMDL10 of 1.78 mg/kg/day was divided by an uncertainty factor of 100 (10 for extrapolation from 
animals to humans and 10 for human variability). See Appendix A for details regarding BMD analysis.
ATSDR has derived an intermediate-duration oral MRL of 0.002 mg/kg/day for acrylamide based on a 
NOAEL of 0.2 mg/kg/day and a LOAEL of 1 mg/kg/day for ultrastructural changes in peripheral nerve 
fibers in male F344 rats receiving acrylamide from the drinking water for up to 93 days (Burek et al.
1980). The NOAEL of 0.2 was divided by an uncertainty factor of 100 (10 for extrapolation from 
animals to humans and 10 for human variability).
EPA (IRIS 2009) has established an oral reference dose (RfD) for acrylamide of 2x10-4 mg/kg/day based 
on a no-observed-effect-level (NOEL) of 0.2 mg/kg/day for nerve damage in male and female Fischer 344 
rats exposed to acrylamide in the drinking water for 90 days (Burek et al. 1980). The uncertainty factor 
used in this assessment was 1,000 (10 for interspecies extrapolation, 10 for the protection of sensitive 
human subpopulations, and 10 for the uncertainty in the effect of duration when extrapolating from 
subchronic to chronic exposure).
EPA (IRIS 2009) has not derived an inhalation reference concentration (RfC) for acrylamide.
The International Agency for Research on Cancer (IARC) has classified acrylamide as a Group 2A 
carcinogen (probably carcinogenic to humans) (IARC 2009). The National Toxicology Program (NTP) 
has determined that acrylamide is reasonably anticipated to be a human carcinogen (NTP 2005).
EPA has classified acrylamide as a B2 carcinogen (probable human carcinogen) (IRIS 2009). The 
American Conference of Governmental Industrial Hygienists (ACGIH) has classified acrylamide as an 
A3 carcinogen (confirmed animal carcinogen with unknown relevance to humans) (ACGIH 2008).
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OSHA has required employers of workers who are occupationally exposed to acrylamide to institute 
engineering controls and work practices to reduce and maintain employee exposure at or below 
permissible exposure limits (PELs) (OSHA 2009). The employer must use engineering and work practice 
controls to reduce exposures to not exceed 0.3 mg/m3 for acrylamide at any time (OSHA 2009).
EPA has designated acrylamide as a hazardous air pollutant (HAP) under the Clean Air Act (CAA) (EPA 
2009a). Acrylamide is on the list of chemicals appearing in “Toxic Chemicals Subject to Section 313 of 
the Emergency Planning and Community Right-to-Know Act of 1986" and has been assigned a reportable 
quantity (RQ) limit of 5,000 pounds (EPA 2009b). Acrylamide is also considered to be an extremely 
hazardous substance (EPA 2009c). The RQ represents the amount of a designated hazardous substance 
which, when released to the environment, must be reported to the appropriate authority.
The international and national regulations, advisories, and guidelines regarding acrylamide in air, water, 
and other media are summarized in Table 8-1.
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Table 8-1. Regulations and Guidelines Applicable to Acrylamide
A gency Description Inform ation Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification Group 2Aa IARC 2009
WHO Air quality guidelines No WHO 2000
Drinking water quality guidelines 0.0005 mg/Lb WHO 2006
NATIONAL
Regulations and 
Guidelines:
a. Air
ACGIH TLV (8-hour TWA)cd 
TLV-basis (critical effect)
0.03 mg/m3
Central nervous 
system impairment
ACGIH 2008
AIHA ERPG values No AIHA 2008
EPA Hazardous air pollutant Yes EPA 2009a 
42 USC 7412
Second AEGL Chemical Priority List Yese EPA 2008
NIOSH REL (10-hour TWA)f 
IDLH
Potential occupational carcinogen 
Target organs
0.03 mg/m3 
60 mg/m3 
Yes
Eyes, skin, central 
nervous system, 
peripheral nervous 
system, and 
reproductive system
NIOSH 2005
OSHA PEL (8-hour TWA) for general industryf 0.3 mg/m3 OSHA 2009 
29 CFR 1910.1000, 
Table Z-1
b. Water
EPA Drinking water standards and health 
advisories
1 -day health advisory for a 10-kg 
child
10-day health advisory for a 10-kg 
child
DWEL
Lifetime
10-4 Cancer risk
1.5 mg/L
0.3 mg/L
0.007 mg/L 
No data 
0.0008 mg/L
EPA 2006a
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Table 8-1. Regulations and Guidelines Applicable to Acrylamide
A gency Description Inform ation Reference
NATIONAL (cont.) 
EPA
c. Food 
FDA
d. Other 
ACGIH 
EPA
National primary drinking water 
standards
Treatment technique
Potential health effects from 
exposure above the MCL
Common sources of acrylamide in 
drinking water
Public health goal
National recommended water quality 
criteria
EAFUSh
Carcinogenicity classification 
Carcinogenicity classification 
RfC 
RfD
Inhalation unit risk 
Oral slope factor
Superfund, emergency planning, and 
community right-to-know
Designated CERCLA hazardous 
substance
Reportable quantity
Effective date of toxic chemical 
release reporting
Extremely hazardous substances 
and its threshold planning quantity
TSCA health and safety data reporting 
Effective date 
Sunset date
EPA 2003
Yesg
Nervous system or 
blood problems
Added to water during 
sewage/waste water 
treatment; increased 
risk of cancer 
treatment
Zero
No
No
A31
B2j
Value not estimatedk 
2x10-4 mg/kg/day
1.3x10-3 (pg/m3)-1 
4.5 (mg/kg/day)-1
Yes
5,000 pounds 
01/01/1987
1,000/10,000 pounds
10/04/1982
10/04/1992
EPA 2006b
FDA 2008
ACGIH 2008 
IRIS 2009
EPA 2009b 
40 CFR 302.4
EPA 2009d 
40 CFR 372.65
EPA 2009c 
40 CFR 355, 
Appendix A
EPA 2009e 
40 CFR 716.120
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Table 8-1. Regulations and Guidelines Applicable to Acrylamide
A gency Description Inform ation Reference
NATIONAL (cont.)
NTP Carcinogenicity classification Reasonably 
anticipated to be a 
human carcinogen
NTP 2005
aGroup 2A: probably carcinogenic to humans
bFor substances that are considered to be carcinogenic, the guideline value is the concentration in drinking-water 
associated with an upper-bound excess lifetime cancer risk of 10-5 (one additional cancer per 100,000 of the 
population ingesting drinking-water containing the substance at the guideline value for 70 years) (WHO 2006). 
cTWA: inhalable fraction and vapor. Material exerts sufficient vapor pressure such that it may be present in both 
particle and vapor phases.
dSkin: refers to the potential significant contribution to the overall exposure by the cutaneous route. 
eAcryalmide is included on the list of 371 priority chemicals that are acutely toxic and represent the selection of 
chemicals for AEGL development by the NAC/AEGL committee during the next several years. 
fSkin designation
gEach water system must certify, in writing, to the state (using third-party or manufacturers certification) that when it 
uses acrylamide to treat water, the combination (or product) of dose and monomer level does not exceed 0.05% of 
acrylamide dosed at 1 mg/L (or equivalent).
hThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS.
iA3: confirmed animal carcinogen with unknown relevance to humans.
jB2: probable human carcinogen, based on sufficient evidence of carcinogenicity in animals
kThe health effects data for acrylamide were reviewed by the U.S. EPA RfD/RfC W ork Group and determined to be
inadequate for derivation of an inhalation RfC.
Designated CERCLA hazardous substance pursuant to Section 112 of the Clean A ir Act and Section 3001 of the 
Resource Conservation and Recovery Act.
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels; 
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response, 
Compensation, and Liability Act; CFR = Code of Federal Regulations; DWEL = drinking water equivalent level; 
EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency;
ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; GRAS = Generally 
Recognized As Safe; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or 
health; IRIS = Integrated Risk Information System; MCL = maximum contaminant level; NAC = National Advisory 
Committee; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; 
OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; REL = recommended 
exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold limit values; 
TSCA = Toxic Substances Control Act; TWA = time-weighted average; USC = United States Code; WHO = World 
Health Organization
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE
8. REGULATIONS AND ADVISORIES
190
This page is intentionally blank.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 191
9. REFERENCES
*Abdelmagid HM, Tabatabai MA. 1982. Decomposition of acrylamide in soils. J Environ Qual 
11(4):701-704.
*Abernethy DJ, Boreiko CJ. 1987. Acrylonitrile and acrylamide fail to transform C3H/10T1/2 cells. 
Environ Mutagen 9(Suppl 8):2.
Abou-Donia MB, Ibrahim SM, Corcoran JJ, et al. 1993. Neurotoxicity of glycidamide, an acrylamide 
metabolite, following intraperitoneal injections in rats. J Toxicol Environ Health 39(4):447-464.
Abramsson-Zetterberg L, Vikstrom AC, Tornqvist M, et al. 2008. Differences in the frequency of 
micronucleated erythrocytes in humans in relation to consumption of fried carbohydrate-rich food. Mutat 
Res 653(1-2):50-56.
*ACGIH. 2008. Acrylamide. In: Threshold limit values for chemical substances and physical agents 
and biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial 
Hygienists.
*Adinolfi M. 1985. The development of the human blood-CSF-brain barrier. Dev Med Child Neurol 
27(4):532-537.
*Adler ID. 1990. Clastogenic effects of acrylamide in different germ-cell stages of male mice. In: Allen 
B, Bridges B, Lyon M, eds. Biology of mammalian germ cell mutagenesis. Cold Spring Harbor, NY : 
Cold Spring Harbor Laboratory Press, 115-131.
Adler ID, Baumgartner A, Friedman MA. 1999. 1-Aminobenzotriazole reduces acrylamide-induced 
dominant lethal effects in sperm and spermatids of mice. [Abstract]. Environ Mol Mutagen 33:10.
*Adler ID, Baumgartner A, Gonda H, et al. 2000. 1-Aminobenzotriazole inhibits acrylamide-induced 
dominant lethal effects in spermatids of male mice. Mutagenesis 15(2): 133-136.
Adler ID, Gonda H, Hrabe de Angelis M, et al. 2004. Heritable translocations induced by dermal 
exposure of male mice to acrylamide. Cytogenet Genome Res 104(1-4) :271-276.
*Adler ID, Ingwersen I, Kliesch U, et al. 1988. Clastogenic effects of acrylamide in mouse bone marrow 
cells. Mutat Res 206(3):379-385.
*Adler ID, Reitmeir P, Schmoller R, et al. 1994. Dose response for heritable translocations induced by 
acrylamide in spermatids of mice. Mutat Res 309(2):285-291.
*Adler ID, Zouh R, Schmid E. 1993. Perturbation of cell division by acrylamide in vitro and in vivo. 
Mutat Res 301(4):249-254.
* Cited in text
+ Cited in Supplemental Document
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 192
*Adlercreutz H. 1995. Phytoestrogens: Epidemiology and a possible role in cancer protection. Environ 
Health Perspect Suppl 103(7): 103-112.
*Agency for Toxic Substances and Disease Registry. 1989. Decision guide for identifying substance- 
specific data needs related to toxicological profiles; Notice. Agency for Toxic Substances and Disease 
Registry, Division of Toxicology. Fed Regist 54(174):37618-37634.
Agency for Toxic Substances and Disease Registry. 1990. Biomarkers of organ damage or dysfunction 
for the renal, hepatobiliary, and immune systems. Subcommittee on Biomarkers of Organ Damage and 
Dysfunction. Atlanta, GA: Agency for Toxic Substances and Disease Registry.
Agrawal AK, Squibb RE. 1981. Effects of acrylamide given during gestation on dopamine receptor 
binding in rat pups. Toxicol Lett 7:233-238.
Agrawal AK, Seth PK, Squibb RE, et al. 1981. Neurotransmitter receptors in brain regions of 
acrylamide-treated rats: 1. Effects of a single exposure to acrylamide. Pharmacol Biochem Behav 
14(4):527-532.
Aguas PC, Fitzhenry MJ, Giannikopoulos G, et al. 2006. Analysis of acrylamide in coffee and cocoa by 
isotope dilution liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 385(8): 1526­
1531.
Agut J, Font E, Sacristan A, et al. 1983. Effect of oral CDP-choline on acrylamide-induced lesion. 
Arzneimittelforschung 33(7A): 1029-1033.
*Ahn JS, Castle L, Clarke DB, et al. 2002. Verification of the findings of acrylamide in heated foods. 
Food Addit Contam 19(12): 1116-1124.
*AIHA. 2008. Emergency Response Planning Guidelines (ERPG). Fairfax, VA: American Industrial 
Hygiene Association. http://www.aiha.org/1documents/Committees/ERP-erpglevels.pdf. May 19, 2009.
Al Deeb S, Al Moutaery K, Arshaduddin M, et al. 2000. Attenuation of acrylamide-induced 
neurotoxicity in diabetic rats. Neurotoxicol Teratol 22(2):247-253.
Aldous CN, Farr CH, Sharma RP. 1983. Evaluation of acrylamide treatment on levels of major brain 
biogenic amines, their turnover rates, and metabolites. Fundam Appl Toxicol 3(3): 182-186.
Ali SF. 1983. Acrylamide-induced changes in the monoamines and their acid metabolites in different 
regions of the rat brain. Toxicol Lett 17(1-2): 101-105.
Ali SF, Hong JS, Wilson WE, et al. 1983. Effect of acrylamide on neurotransmitter metabolism and 
neuropeptide levels in several brain regions and upon circulating hormones. Arch Toxicol 52(1):35-44.
*Allen B, Zeiger E, Lawrence G, et al. 2005. Dose-response modeling of in vivo genotoxicity data for 
use in risk assessment: Some approaches illustrated by an analysis of acrylamide. Regul Toxicol 
Pharmacol 41(1):6-27.
*Altman PL, Dittmer DS. 1974. In: Biological handbooks: Biology data book. Vol. III. 2nd ed. 
Bethesda, MD: Federation of American Societies of Experimental Biology, 1987-2008, 2041.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 193
9. REFERENCES
+*American Cyanamid Company. 1951. Acute eye, dermal and oral toxicity. Submitted to the U.S. 
Environmental Protection Agency under TSCA Section 8D. EPA878211662. OTS206055.
+*American Cyanamid Company. 1953a. Inhalation toxicity supplement to reports dated May 2, 1951 
and August 13, 1952. Submitted to the U.S. Environmental Protection Agency under TSCA Section 8D. 
EPA879211664. OTS206055.
+*American Cyanamid Company. 1953b. Subacute feeding section I-acrylamide section II-acrylamide 
with metabolic studies supplement to report dated August 13, 1952. Submitted to the U.S. Environmental 
Protection Agency under TSCA Section 8D. EPA878211665. OTS206055.
+*American Cyanamid Company. 1953c. Chronic oral administration-dogs oral administration and 
neurohistology-dogs supplement to reports dated August 13, 1952 and May 8, 1953. Submitted to the 
U.S. Environmental Protection Agency under TSCA Section 8D. EPA878211666. OTS206055.
+*American Cyanamid Company. 1954. Chronic inhalation exposure-acrylamide. Submitted to the U.S. 
Environmental Protection Agency under TSCA Section 8D. EPA878211670. OTS206055.
+*American Cyanamid Company. 1959. Acrylamide toxicity: Effect of polyvinylpyrrolidone (PVP). 
Submitted to the U.S. Environmental Protection Agency under TSCA Section 8D. EPA878211673. 
OTS206055.
+*American Cyanamid Company. 1973. Range finding studies single oral single dermal (FHSA) single 
inhalation. Submitted to the U.S. Environmental Protection Agency under TSCA Section 8D. 
EPA878211677. OTS206055.
+*American Cyanamid Company. 1977. Limited release toxicity tests. Submitted to the U.S. 
Environmental Protection Agency under TSCA Section 8D. EPA878211678. OTS206055.
+*American Cyanamid Company. 1979. A fetal toxicity study of acrylamide in rats. Submitted to the 
U.S. Environmental Protection Agency under TSCA Section 8D. EPA878211679. OTS206055.
+*American Cyanamid Company. 1991. 28-Day subchronic dose toxicity study in rats. Submitted to the 
U.S. Environmental Protection Agency under TSCA Section 8D. OTS0533854.
*Amrein TM, Andres L, Escher F, et al. 2007. Occurrence of acrylamide in selected foods and 
mitigation options. Food Addit Contam 24(Suppl 1): 13-25.
*Andersen ME, Krishnan K. 1994. Relating in vitro to in vivo exposures with physiologically based 
tissue dosimetry and tissue response models. In: Salem H, ed. Animal test alternatives: Refinement, 
reduction, and replacement. New York: Marcel Dekker Inc., 9-25.
*Andersen ME, Clewell HJ, Gargas ML, et al. 1987. Physiologically based pharmacokinetics and the 
risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87(2):185-205.
Andersen ME, Scimeca J, Olin SS. 2005. Kinetic and mechanistic data needs for a human 
physiologically based pharmacokinetic (PBPK) model for acrylamide: Pharmacokinetic model for 
acrylamide. Adv Exp Med Biol 561:117-125.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 194
9. REFERENCES
Anderson RJ. 1981. Selective effect on peripheral nerves after subchronic administration of acrylamide. 
Bull Environ Contam Toxicol 27(6):888-893.
Anderson RJ. 1982. Alterations in nerve and muscle compound action potentials after acute acrylamide 
administration. Environ Health Perspect 44:153-158.
Annola K, Karttunen V, Keski-Rahkonen P, et al. 2008a. Transplacental transfer of acrylamide and 
glycidamide are comparable to that of antipyrine in perfused human placenta. Toxicol Lett 182:50-56.
Annola K, Keski-Rahkonen P, Vahakangas K, et al. 2008b. Simultaneous determination of acrylamide, 
its metabolite glycidamide and antipyrine in human placental perfusion fluid and placental tissue by liquid 
chromatography-electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life 
Sci 876:191-197.
*Ao L, Liu SX, Yang MS, et al. 2008. Acrylamide-induced molecular mutation spectra at HPRT locus in 
human promyelocytic leukemia HL-60 and NB4 cell lines. Mutagenesis 23(4):309-315.
*Arisseto AP, Toledo MC, Govaert Y, et al. 2007. Determination of acrylamide levels in selected foods 
in Brazil. Food Addit Contam 24(3):236-241.
Arocena M. 2006. Effect of acrylamide on the cytoskeleton and apoptosis of bovine lens epithelial cells. 
Cell Biol Int 30(12): 1007-1012.
Aschner M, Cao CC, Wu Q, et al. 2003. The acute effects of acrylamide on astrocyte functions. Ann N 
Y Acad Sci 993:296-304.
Aschner M, Wu Q, Friedman MA. 2005. Effects of acrylamide on primary neonatal rat astrocyte 
functions. Ann N Y Acad Sci 1053:444-454.
Aspengren S, Wielbass L, Wallin M. 2006. Effects of acrylamide, latrunculin, and nocodazole on 
intracellular transport and cytoskeletal organization in melanophores. Cell Motil Cytoskeleton 
63(7):423-436.
+*Augustsson K, Skog K, Jagerstad M, et al. 1999. Dietary heterocyclic amines and cancer of the colon, 
rectum, bladder, and kidney: A population-based study. Lancet 353(9154):703-707.
*Auld RB, Bedwell SF. 1967. Peripheral neuropathy with sympathetic overactivity from industrial 
contact with acrylamide. Can Med Assoc J 96:652-654.
Aureli F, Di Pasquale M, Lucchetti D, et al. 2007. An absorption study of dietary administered 
acrylamide in swine. Food Chem Toxicol 45(7): 1202-1209.
Axelrad DA, Morello-Frosch RA, Woodruff TJ, et al. 1999. Assessment of estimated 1990 air toxics 
concentrations in urban areas in the United States. Environ Sci Policy 2(4-5):397-411.
+*Bachmann M, Myers JE, Bezuidenhout BN. 1992. Acrylamide monomer and peripheral neuropathy 
in chemical workers. Am J Ind Med 21(2):217-222.
*Backer LC, Dearfield KL, Erexson GL, et al. 1989. The effects of acrylamide on mouse germ-line and 
somatic cell chromosomes. Environ Mol Mutagen 13:218-226.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 195
9. REFERENCES
Bailey E, Farmer PB, Bird I, et al. 1986. Monitoring exposure to acrylamide by the determination of S- 
(2-carboxyethyl)cysteine in hydrolyzed hemoglobin by gas chromatography-mass spectrometry. Anal 
Biochem 157(2):241-248.
*Banerjee S, Segal A. 1986. In vitro transformation of C3H/10T1/2 and NIH/3T3 cells by acrylonitrile 
and acrylamide. Cancer Lett 32(3):293-304.
*Barber DS, LoPachin RM. 2004. Proteomic analysis of acrylamide-protein adduct formation in rat 
brain synaptosomes. 201:120-136.
*Barber DS, Hunt JR, Ehrich MF, et al. 2001a. Metabolism, toxicokinetics and hemoglobin adduct 
formation in rats following subacute and subchronic acrylamide dosing. Neurotoxicology 22(3):341-353.
Barber DS, Hunt J, LoPachin RM, et al. 2001b. Determination of acrylamide and glycidamide in rat 
plasma by reversed-phase high performance liquid chromatography. J Chromatogr B Biomed Sci Appl 
758(2):289-293.
Barber DS, Stevens S, LoPachin RM. 2007. Proteomic analysis of rat striatal synaptosomes during 
acrylamide intoxication at a low dose rate. Toxicol Sci 100(1): 156-167.
*BarfknechtTR, Mecca, DJ, Naismith RW. 1988. The genotoxic activity of acrylamide. Environ Mol 
Mutagen 11(Suppl 11):9.
*Barnes DG, Dourson M. 1988. Reference dose (RfD): Description and use in health risk assessments. 
Regul Toxicol Pharmacol 8(4):471-486.
Basile A, Ferranti P, Moccaldi R, et al. 2008. Proteomic approach for the analysis of acrylamide- 
hemoglobin adducts. Perspectives for biological monitoring. J Chromatogr A 1215(1-2):74-81.
*Batiste-Alentorn M, Xamena N, Creus A, et al. 1991. Genotoxicity studies with the unstable Zeste- 
White (UZ) System of Drosophila melanogaster: Results with ten carcinogenic compounds. Environ 
Mol Mutagen 18:120-125.
Baum M, Fauth E, Fritzen S, et al. 2005. Acrylamide and glycidamide: Genotoxic effects in V79-cells 
and human blood. Mutat Res 580(1-2):61-69.
Beiswanger CM, Mandella RD, Graessle TR, et al. 1993. Synergistic neurotoxic effects of styrene oxide 
and acrylamide: Glutathione-independent necrosis of cerebellar granule cells. Toxicol Appl Pharmacol 
118(2):233-244.
Benn TM, Thomas SM. 1997. Acrylamide induces oxidative damage to DNA in in vitro neuronal 
cultures. [Abstract]. Hum Exp Toxicol 16(7):389.
*Berger GS, ed. 1994. Epidemiology of endometriosis. In: Endometriosis: Modern surgical 
management of endometriosis. New York, NY : Springer-Verlag, 3-7.
*Bergmark E. 1997. Hemoglobin adducts of acrylamide and acrylonitrile in laboratory workers, smokers 
and nonsmokers. Chem Res Toxicol 10(1):78-84.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 196
9. REFERENCES
*Bergmark E, Calleman CJ, Costa LG. 1991. Formation of hemoglobin adducts of acrylamide and its 
epoxide metabolite glycidamide in the rat. Toxicol Appl Pharmacol 111(2):352-363.
*Bergmark E, Calleman CJ, He F, et al. 1993. Determination of hemoglobin adducts in humans 
occupationally exposed to acrylamide. Toxicol Appl Pharmacol 120(1):45-54.
Bermudo E, Nunez O, Moyano E, et al. 2007. Field amplified sample injection-capillary electrophoresis- 
tandem mass spectrometry for the analysis of acrylamide in foodstuffs. J Chromatogr A 1159(1-2):225- 
232.
Berti-Mattera LN, Eichberg J, Schrama L, et al. 1990. Acrylamide administration alters protein 
phosphorylation and phospholipid metabolism in rat sciatic nerve. Toxicol Appl Pharmacol 
103(3):502-511.
Besaratinia A, Pfeifer GP. 2003. Weak yet distinct mutagenicity of acrylamide in mammalian cells. J 
Natl Cancer Inst 95(12):889-896.
Besaratinia A, Pfeifer GP. 2004a. Genotoxicity of acrylamide and glycidamide. J Natl Cancer Inst 
96(13): 1023-1029.
*Besaratinia A, Pfeifer GP. 2004b. Genotoxicity of acrylamide in humans and mice: Promutagenic 
glycidamide-DNA adducts in the human p53 gene and the cII transgene. Proc Am Assoc Cancer Res 
45:452. http://www.aacrmeetingabstracts.org/cgi/content/abstract/2004/1/452-b. July 13, 2009.
Besaratinia A, Pfeifer GP. 2005. DNA adduction and mutagenic properties of acrylamide. Mutat Res 
580(1-2):31-40.
*Besaratinia A, Pfeifer GP. 2007. A review of mechanisms of acrylamide carcinogenicity. 
Carcinogenesis 28(3):519-528.
Beyer DJ, Belsito DV. 2000. Allergic contact dermatitis from acrylamide in a chemical mixer. Contact 
Dermatitis 42(3):181-182.
Bikales NM. 1973. Preparation of acrylamide polymers. In: Bikales NM, ed. Water-soluble polymers, 
polymer science and technology series. Vol. 2. New York, NY: Plenum Press, 213-225.
Bishop JB, Chapin RE, Fail P, et al. 1991. Acrylamide induced dominant lethality in mice following low 
dose chronic administration in drinking water. [Abstract]. Environ Mol Mutagen 17(Suppl 19): 11.
Bjellaas T, Olstorn HB, Becher G, et al. 2007c. Urinary metabolites as biomarkers of acrylamide 
exposure in mice following dietary crisp bread administration or subcutaneous injection. Toxicol Sci 
100(2):374-380.
Bjellaas T, Olesen PT, Frandsen H, et al. 2007b. Comparison of estimated dietary intake of acrylamide 
with hemoglobin adducts of acrylamide and glycidamide. Toxicol Sci 98(1): 110-117.
*Bjellaas T, Stolen LH, Haugen M, et al. 2007a. Urinary acrylamide metabolites as biomarkers for 
short-term dietary exposure to acrylamide. Food Chem Toxicol 45(6): 1020-1026.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 197
Blank I. 2005. Current status of acrylamide research in food: measurement, safety assessment, and 
formation. Ann N Y Acad Sci 1043:30-40.
Blasiak J, Gloc E, Wozniak K, et al. 2004. Genotoxicity of acrylamide in human lymphocytes. Chem 
Biol Interact 149(2-3): 137-149.
*Boettcher MI, Angerer J. 2005. Determination of the major mercapturic acids of acrylamide and 
glycidamide in human urine by LC-ESI-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 
824(1-2):283-294.
*Boettcher MI, Bolt HM, Angerer J. 2006b. Acrylamide exposure via the diet: Influence of fasting on 
urinary mercapturic acid metabolite excretion in humans. 80:817-819.
*Boettcher MI, Bolt HM, Drexler H, et al. 2006a. Excretion of mercapturic acids of acrylamide and 
glycidamide in human urine after single oral administration of deuterium-labelled acrylamide. Arch 
Toxicol 80(2):55-61.
*Boettcher MI, Schettgen T, Kutting B, et al. 2005. Mercapturic acids of acrylamide and glycidamide as 
biomarkers of the internal exposure to acrylamide in the general population. Mutat Res 580(1- 
2): 167-176.
Bolger PM. 2005. Overview of dietary acrylamide. [Abstract]. Toxicol Sci 84(1-S):60.
Bondy SC, Tilson HA, Agrawal AK. 1981. Neurotransmitter receptors in brain regions of acrylamide- 
treated rats: 2. Effects of extended exposure to acrylamide. Pharmacol Biochem Behav 14(4):533-538.
Boon PE, de Mul A, van der Voet H, et al. 2005. Calculations of dietary exposure to acrylamide. Mutat 
Res 580(1-2): 143-155.
Borenfreund E, Babich H. 1987. In-vitro cytotoxicity of heavy metals acrylamide and organotin salts to 
neural cells and fibroblasts. Cell Biol Toxicol 3(1):63-73.
Bowyer JF, Latendresse JR, Delongchamp RR, et al. 2008a. The effects of subchronic acrylamide 
exposure on gene expression, neurochemistry, hormones, and histopathology in the hypothalamus- 
pituitary-thyroid axis of male Fischer 344 rats (Erratum in: Toxicol Appl Pharmacol 232:498). Toxicol 
Appl Pharmacol 230(2):208-215.
Bowyer JF, Latendresse JR, Delongchamp RR, et al. 2008b. Corrigendum to "The effects of subchronic 
acrylamide exposure on gene expression, neurochemistry, hormones, and histopathology in the 
hypothalamus-pituitary-thyroid axis of male Fischer 344 rats" (Erratum to: Toxicol Appl Pharmacol 
230:208-215). Toxicol Appl Pharmacol 232:498.
Brady ST, Pfister KK, Bloom GS. 1990. A monoclonal antibody against kinesin inhibits both 
anterograde and retrograde fast axonal transport in squid axoplasm. Neurobiology 87:1061-1065.
Brantsaeter AL, Haugen M, Mul A, et al. 2008. Exploration of different methods to assess dietary 
acrylamide exposure in pregnant women participating in the Norwegian Mother and Child Cohort Study 
(MoBa). Food Chem Toxicol 46(8):2808-2814.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 198
Brat DJ, Brimijoin S. 1993. Acrylamide and glycidamide impair neurite outgrowth in differentiating 
N1E.115 neuroblastoma without disturbing rapid bidirectional transport of organelles observed by video 
microscopy. J Neurochem 60(6):2145-2152.
Brimijoin WS, Hammond PI. 1985. Acrylamide neuropathy in the rat: Effects on energy metabolism in 
sciatic nerve. Mayo Clin Proc 60(1):3-8.
Brismar T, Hildebrand C, Tegner R. 1987. Nodes of Ranvier in acrylamide neuropathy: Voltage clamp 
and electron microscopic analysis of rat sciatic nerve fibres at proximal levels. Brain Res 423(1-
2): 135-143.
*Brown L, Rhead M. 1979. Liquid chromatographic determination of acrylamide monomer in natural 
and polluted aqueous environments. Analyst 104:391-399.
*Brown RP, Delp MD, Lindstedt SL, et al. 1997 Physiological parameter values for physiologically 
based pharmacokinetic models. Toxicol Indl Health 13(4):407-484.
*Bull RJ, Robinson M, Laurie RD, et al. 1984a. Carcinogenic effects of acrylamide in Sencar and A/J 
mice. Cancer Res 44(1): 107-111.
*Bull RJ, Robinson M, Stober JA. 1984b. Carcinogenic activity of acrylamide in the skin and lung of 
Swiss-ICR mice. Cancer Lett 24(2):209-212.
+*Burek JD, Albee RR, Beyer JE, et al. 1980. Subchronic toxicity of acrylamide administered to rats in 
the drinking water followed by up to 144 days of recovery. J Environ Pathol Toxicol 4(5-6): 157-182.
*Butterworth BE, Eldridge SR, Sprankle CS, et al. 1992. Tissue-specific genotoxic effects of acrylamide 
and acrylonitrile. Environ Mol Mutagen 20(3): 148-155.
*Calleman CJ. 1996. The metabolism and pharmacokinetics of acrylamide: Implications for 
mechanisms of toxicity and human risk estimation. Drug Metab Rev 28(4):527-590.
Calleman CJ, Bergmark E, Costa LG. 1990. Acrylamide is metabolized to glycidamide in the rat: 
Evidence from hemoglobin adduct formation. Chem Res Toxicol 3(5):406-412.
Calleman CJ, Bergmark E, He F, et al. 1993a. Determination of hemoglobin adducts and adverse health 
effects in workers occupationally exposed to acrylamide. J Toxicol Environ Health 40(2-3):447-448.
*Calleman CJ, Bergmark E, Stern LG, et al. 1993b. A nonlinear dosimetric model for hemoglobin 
adduct formation by the neurotoxic agent acrylamide and its genotoxic metabolite glycidamide. Environ 
Health Perspect 99:221-223.
*Calleman CJ, Stern LG, Bergmark E, et al. 1992. Linear versus nonlinear models for hemoglobin 
adduct formation by acrylamide and its metabolite glycidamide: Implications for risk estimation. Cancer 
Epidemiol Biomarkers Prev 1(5):361-368.
+*Calleman CJ, Wu Y, He F, et al. 1994. Relationship between biomarkers of exposure and 
neurological effects in a group of workers exposed to acrylamide. Toxicol Appl Pharmacol 
126(2):361-371.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 199
9. REFERENCES
Cao J, Liu Y, Jia L, et al. 2008. Curcumin attenuates acrylamide-induced cytotoxicity and genotoxicity 
in HepG2 cells by ROS scavenging. J Agric Food Chem 56(24): 12059-12063.
Carere A. 2006. Genotoxicity and carcinogenicity of acrylamide: A critical review. Ann Ist Super 
Sanita 42(2):144-155.
Carlson GP, Weaver PM. 1985. Distribution and binding of [14C]acrylamide to macromolecules in 
SENCAR and BALB/c mice following oral and topical administration. Toxicol Appl Pharmacol 
79(2):307-313.
Castle L, Eriksson S. 2005. Analytical methods used to measure acrylamide concentrations in foods. J 
AOAC Int 88(1):274-284.
*Cavalli S, Polesello S, Saccani G. 2004. Determination of acrylamide in drinking water by large- 
volume direct injection and ion-exclusion chromatography-mass spectrometry. J Chromatogr A 
1039(1-2): 155-159.
*Cavanagh JB. 1964. The significance of the "dying back" process in experimental and human 
neurological disease. Int Rev Exp Pathol 3:219-267
Cavanagh JB. 1982. The pathokinetics of acrylamide intoxication: A reassessment of the problem. 
Neuropathol Appl Neurobiol 8(4):315-336.
Cavanagh JB, Gysbers MF. 1980. Dying back above a nerve ligature produced by acrylamide. Acta 
Neuropathol 51(3): 169-178.
Cavanagh JB, Gysbers MF. 1983. Ultrastructural features of the Purkinje cell damage caused by 
acrylamide in the rat: A new phenomenon in cellular neuropathology. J Neurocytol 12(3):413-438.
*CERI. 1999. Biodegradaion database and estimation. Acrylamide. Chemicals Evaluation and 
Research Institute, Japan. http://qsar.cerij.or.jp/cgi-bin/QSAR/index.cgi?e. June 8, 2009.
+*Chapin RE, Fail PA, George JD, et al. 1995. The reproductive and neural toxicities of acrylamide and 
three analogues in Swiss mice, evaluated using the continuous breeding protocol. Fundam Appl Toxicol 
27(1):9-24.
Chauhan NB, Spencer PS, Sabri MI. 1993. Acrylamide-induced depletion of microtubule-associated 
proteins (MAP1 and MAP2) in the rat extrapyramidal system. Brain Res 602(1): 111-118.
*Cherry AB, Gabaccia AJ, Senn HW. 1956. The assimilation behavior of certain toxic organic 
compounds in natural water. Sewage Ind Waste 28(9): 1137-1146.
Chevolleau S, Jacques C, Canlet C, et al. 2007. Analysis of hemoglobin adducts of acrylamide and 
glycidamide by liquid chromatography-electrospray ionization tandem mass spectrometry, as exposure 
biomarkers in French population. J Chromatogr A 1167(2): 125-134.
Chico Galdo V, Massart C, Jin L, et al. 2006. Acrylamide, an in vivo thyroid carcinogenic agent, induces 
DNA damage in rat thyroid cell lines and primary cultures. Mol Cell Endocrinol 257-258:6-14.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 200
Chretien M, Patey G, Souyri F, et al. 1981. Acrylamide-induced neuropathy and impairment of axonal 
transport of proteins: 2. Abnormal accumulations of smooth endoplasmic reticulum as sites of focal 
retention of fast transported proteins: Electron microscope radioautographic study. Brain Res 
205(1): 15-28.
Chu S, Metcalfe CD. 2007. Analysis of acrylamide in water using a coevaporation preparative step and 
isotope dilution liquid chromatography tandem mass spectrometry. Anal Chem 79(13):5093-5096.
*Cihak R, Vontorkova M. 1988. Cytogenetic effects of acrylamide in the bone marrow of mice. Mutat 
Res 209(1-2):91-94.
*Cihak R, Vontorkova M. 1990. Activity of acrylamide in single-, double-, and triple-dose mouse bone 
marrow micronucleus assays. Mutat Res 234:125-127.
Clarke CH, Sickles DW. 1996. Decreased GAP-43 accumulation in neurite tips of cultured hippocampal 
neurons by acrylamide. Neurotoxicology 17(2):397-406.
Clay P. 1991. Procarbazine and acrylamide induce small colony tk-/- mutants in a microwell l5178y 
mouse lymphoma mutation assay. [Abstract]. Mutagenesis 6:432.
Clement FC, Dip R, Naegeli H. 2007. Expression profile of human cells in culture exposed to 
glycidamide, a reactive metabolite of the heat-induced food carcinogen acrylamide. Toxicology 
240(1-2): 111-124.
*Clewell HJ, Andersen ME. 1985. Risk assessment extrapolations and physiological modeling. Toxicol 
Ind Health 1(4):111-131.
*CMR. 2008. Chemical profile: Acrylamide. Chem Market Rep July 21-27
*Collins BW, Howard DR, Allen JW. 1992. Kinetochore-staining of spermatid micronuclei: Studies of 
mice treated with X-radiation or acrylamide. Mutat Res 281(4):287-294.
+*Collins JJ, Swaen GMH, Marsh GM, et al. 1989. Mortality patterns among workers exposed to 
acrylamide. J Occup Med 31(7):614-617.
Comblath DR. 2004. Neuropathy in grout workers. (Letter and author response to Scand J Work 
Environ Health 30(1):21-29). Scand J Work Environ Health 30(3):253-254.
Costa LG, Deng H, Calleman CJ, et al. 1995. Evaluation of the neurotoxicity of glycidamide, an epoxide 
metabolite of acrylamide: Behavioral, neurochemical and morphological studies. Toxicology 98(1-
3): 151-161.
Costa LG, Deng H, Gregotti C, et al. 1992. Comparative studies on the neuro- and reproductive toxicity 
of acrylamide and its epoxide metabolite glycidamide in the rat. Neurotoxicology 13:219-224.
*Crofton KM, Padilla S, Tilson HA, et al. 1996. The impact of dose rate on the neurotoxicity of 
acrylamide: The interaction of administered dose, target tissue concentrations, tissue damage, and 
functional effects. Toxicol Appl Pharmacol 139(1): 163-176.
*Croll BT, Arkell GM, Hodge RP. 1974. Residues of acrylamide in water. Water Res 8(11):989-993.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 201
9. REFERENCES
*Currance PL, Clements B, Bronstein AC. 2007. Tri-ortho-cresyl phosphate (TOCP) and related 
compounds. In: Emergency care for hazardous materials exposure. 3rd ed. St. Louis, MO: MosbyJems, 
482-484.
Damjanov I, Friedman MA. 1998. Mesotheliomas of tunica vaginalis testis of Fischer 344 (F344) rats 
treated with acrylamide: A light and electron microscopy study. In Vivo 12(5):495-502.
Das M, Mukhtar H, Seth PK. 1982. Effect of acrylamide on brain and hepatic mixed-function oxidases 
and glutathione-S-transferase in rats. Toxicol Appl Pharmacol 66(3):420-424.
*Davenport JG, Farrell DF, Sumi SM. 1976. 'Giant axonal neuropathy' caused by industrial chemicals: 
Neurofilamentous axonal masses in man. Neurology 26(10):919-923.
*Dearfield KL, Douglas GR, Ehling UH, et al. 1995. Acrylamide: A review of its genotoxicity and an 
assessment of heritable genetic risk. Mutat Res 330(1-2):71-99.
Degrandchamp RL, Lowndes HE. 1990. Early degeneration and sprouting at the rat neuromuscular 
junction following acrylamide administration. Neuropathol Appl Neurobiol 16(3):239-254.
DeGrandchamp RL, Reuhl KR, Lowndes HE. 1990. Synaptic terminal degeneration and remodeling at 
the rat neuromuscular junction resulting from a single exposure to acrylamide. Toxicol Appl Pharmacol 
105(3):422-433.
Deng H, He F, Zhang S, et al. 1993. Quantitative measurements of vibration threshold in healthy adults 
and acrylamide workers. Int Arch Occup Environ Health 65(1):53-56.
De Rojas TC, Goldstein BD. 1987. Primary afferent terminal function following acrylamide:
Alterations in the dorsal root potential and reflex. Toxicol Appl Pharmacol 88(2): 175-182.
*DFG. 2009. Acrylamide. In: Greim H, ed. The MAK-collection for occupational health and safety. 
Part I: MAK Value Documentations. Vol. 25. Weinheim, Germany: Deutsche 
Forschungsgemeinschaft. Wiley-VCH Verlag, 1-43.
Diembeck W, Dusing HJ, Akhiana M. 1998. Dermal absorption and penetration of acrylamide ([14C] 
acrylamide as tracer) in different cosmetic formulations and polyacrylamide-solution after topical 
application to excised pig skin. Beiersdorf 9.
Dixit R, Das M, Seth PK, et al. 1984. Interaction of acrylamide with glutathione in rat erythrocytes. 
Toxicol Lett 23(3):291-298.
+*Dixit R, Husain R, Mukhtar H, et al. 1981. Effect of acrylamide on biogenic amine levels, 
monoamine oxidase, and cathepsin D activity of rat brain. Environ Res 26(1): 168-173.
Dixit R, Husain R, Seth PK, et al. 1980a. Effect of diethyl maleate on acrylamide-induced neuropathy in 
rats. Toxicol Lett 6(6):417-422.
Dixit R, Mukhtar H, Seth PK, et al. 1980b. Binding of acrylamide with glutathione s transferases. Chem 
Biol Interact 32(3):353-359.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 202
9. REFERENCES
*Dixit R, Seth PK, Mukhtar H. 1982. Metabolism of acrylamide into urinary mercapturic-acid and 
cysteine conjugates in rats. Drug Metab Dispos 10(2): 196-197.
*Dobrzynska MM. 2007. Assessment of DNA damage in multiple organs from mice exposed to X-rays 
or acrylamide or a combination of both using the comet assay. In Vivo 21(4):657-662.
*Doerge DR, da Costa GG, McDaniel LP, et al. 2005a. DNA adducts derived from administration of 
acrylamide and glycidamide to mice and rats. Mutat Res 580(1-2):131-141.
*Doerge DR, Twaddle NC, Boettcher MI, et al. 2007. Urinary excretion of acrylamide and metabolites 
in Fischer 344 rats and B6C3Fj mice administered a single dose of acrylamide. Toxicol Lett 
169(1):34-42.
*Doerge DR, Young JF, McDaniel LP, et al. 2005b. Toxicokinetics of acrylamide and glycidamide in 
B6C3F1 mice. Toxicol Appl Pharmacol 202(3):258-267.
*Doerge DR, Young JF, McDaniel LP, et al. 2005c. Toxicokinetics of acrylamide and glycidamide in 
Fischer 344 rats. Toxicol Appl Pharmacol 208(3): 199-209.
Doerge DR, Young JF, Chen JJ, et al. 2008. Using dietary exposure and physiologically based 
pharmacokinetic/pharmacodynamic modeling in human risk extrapolations for acrylamide toxicity. J 
Agric Food Chem 56(15):6031-6038.
Doerge DR, Young JF, McDaniel L, et al. 2005d. Toxicokinetics of acrylamide and glycidamide in 
B6C3Fj mice and Fischer 344 rats. [Abstract]. Toxicol Sci 84(1-S):60.
*Donovan JW, Pearson T. 1987. Ingestion of acrylamide with severe encephalopathy neurotoxicity and 
hepatotoxicity. [Abstract]. Vet Hum Toxicol 29(6):462.
Doroshyenko O, Fuhr U, Kunz D, et al. 2009. In vivo role of cytochrome P450 2E1 and glutathione-S- 
transferase activity for acrylamide toxicokinetics in humans. Cancer Epidemiol Biomarkers Prev 
18(2):433-443.
*Dourson M, Hertzberg R, Allen B, et al. 2008. Evidence-based dose-response assessment for thyroid 
tumorigenesis from acrylamide. Regul Toxicol Pharmacol 52(3):264-289.
+*Dow Chemical Company. 1957. Results of toxicological tests on acrylamide with cover letter. 
Submitted to the U.S. Environmental Protection Agency under TSCA Section 8D. EPA878210955. 
OTS206135.
+*Dow Chemical Company. 1981. Effects of acrylamide monomer on sensory thresholds in monkeys 
Sept. 15, 1979 to Sept. 18, 1981. Submitted to the U.S. Environmental Protection Agency under TSCA 
Section 8D. EPA878210964. OTS206135.
*D'Souza RW, Francis WR, Andersen ME. 1988. Physiological model for tissue glutathione depletion 
and increased resynthesis after ethylene dichloride exposure. J Pharmacol Expl Ther 245:563-568.
Duale N, Bjellaas T, Alexander J, et al. 2009. Biomarkers of human exposure to acrylamide and relation 
to polymorphisms in metabolizing genes. Toxicol Sci 108(1):90-99.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 203
9. REFERENCES
*Dumitru DL. 1989. Occupational intoxication with acrylamide: Discussion of cases with acute and 
chronic intoxication. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumo 38(4):359- 
364.
Dumont J, Van Sande J, Massart C, et al. 2005. Study in vitro of the tumorigenic action of acrylamide 
on thyroid cells. [Abstract]. Toxicol Sci 84(1-S):142.
Durling LJ, Abramsson-Zetterberg L. 2005. A comparison of genotoxicity between three common 
heterocyclic amines and acrylamide. Mutat Res 580(1-2): 103-110.
Dybing E, Sanner T. 2003. Risk assessment of acrylamide in foods. Toxicol Sci 75(1):7-15.
Dybing E, Farmer PB, Andersen M, et al. 2005. Human exposure and internal dose assessments of 
acrylamide in food. Food Chem Toxicol 43(3):365-410.
*Edwards PM. 1975. The distribution and metabolism of acrylamide and its neurotoxic analogues in 
rats. Biochem Pharmacol 24(20):1277-1282.
Edwards PM. 1976. Insensitivity of the developing rat fetus to the toxic effects of acrylamide. Chem 
Biol Interact 12:13-18.
Edwards PM, Sporel-Ozakat RE, Gispen WH. 1991. Peripheral pain fiber function is relatively 
insensitive to the neurotoxic actions of acrylamide in the rat. Toxicol Appl Pharmacol 111(1):43-48.
*Ehling UH, Neuhaeuser-Klaus A. 1992. Reevaluation of the induction of specific-locus mutations in 
spermatogonia of the mouse by acrylamide. Mutat Res 283(3): 185-191.
El-Din AY, Al-Maskati HA, Mohamed AY, et al. 1993. Acrylamide as an inducer of metabolic 
activation system (S9) in rats. Mutat Res 300(2):91-97.
Eldridge SR, Sprankle CS, Butterworth BE. 1992. Tissue-specific genotoxic effects of acrylamide and 
glycidamide. [Abstract]. Environ Mol Mutagen 19(20): 17.
El-Hadri L, Ghanayem BI. 2004. Comparative metabolism and disposition of 1-14C- and 2, 3-14C- 
acrylamide in cytochrome P450 2E1-null (KO) and wild-type (WT) mice. [Abstract]. Toxicologist 78(1- 
S):297.
*Environ. 2002. Toxicological review of acrylamide (CAS No. 79-06-01). Ruston, Louisiana: Environ 
International Corporation.
EPA. 1976. Investigation of selected potential environmental contaminants: Acrylamides. Final report. 
Washington, DC: U.S. Environmental Protection Agency. EPA560276008.
*EPA. 1978. Environmental monitoring near industrial sites acrylamide. Washington, DC: U.S. 
Environmental Protection Agency. EPA560678001. PB281879.
*EPA. 1990. Interim methods for development of inhalation reference concentrations. Washington, DC: 
U.S. Environmental Protection Agency Office of Health and Environmental Assessment, Office of 
Research and Development, Environmental Criteria and Assessment Office.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 204
*EPA. 1997. Special report on environmental endocrine disruption: An effects assessment and analysis. 
Washington, DC: U.S. Environmental Protection Agency Risk Assessment Forum.
*EPA. 1998. Automated Form R for Windows: User’s guide (RY97). Washington, DC: U.S. 
Environmental Protection Agency Office of Pollution Prevention and Toxics.
*EPA. 2000. National air pollutant emission trends, 1900-1998. Research Triangle Park, NC: U. S. 
Environmental Protection Agency. EPA454R00002. 
http://www.epa.gov/ttn/chief/trends/trends98/trends98.pdf. June 8, 2009.
*EPA. 2003. National primary drinking water regulations. Washington, DC: Office of Ground Water 
and Drinking Water, U.S. Environmental Protection Agency. 
http://www.epa.gov/safewater/contaminants/index.html. May 19, 2009.
*EPA. 2005a. Toxic chemical release inventory reporting forms and instructions: Revised 2004 version. 
Section 313 of the Emergency Planning and Community Right-to-Know Act (Title III of the Superfund 
Amendments and Reauthorization Act of 1986). U.S. Environmental Protection Agency.
*EPA. 2005b. Supplemental guidance for assessing susceptibility from early life exposure to 
carcinogens. Risk assessment forum. Washington, DC: U.S. Environmental Protection Agency. 
EPA630R03003F.
*EPA. 2006a. Drinking water standards and health advisories. Washington, DC: Office of Water, U.S. 
Environmental Protection Agency. http://epa.gov/waterscience/criteria/drinking/. May 19, 2009.
*EPA. 2006b. National recommended water quality criteria. Washington, DC: Office of Water, Office 
of Science and Technology, U.S. Environmental Protection Agency. 
http://www.epa.gov/waterscience/criteria/wqcriteria.html. May 11, 2009.
*EPA. 2008. Acute exposure guideline levels (AEGLs). Second AEGL Chemical Priority List. 
Washington, DC: Office of Pollution Prevention and Toxics, U.S. Environmental Protection Agency. 
http://www.epa.gov/oppt/aegl/pubs/priority_2.htm. May 19, 2009.
*EPA. 2009a. Hazardous air pollutants. Clean Air Act. U.S. Environmental Protection Agency. United 
States Code. 42 USC 7412. http://www.epa.gov/ttn/atw/orig189.html. May 19, 2009.
*EPA. 2009b. Superfund, emergency planning, and community right-to-know programs. Designation, 
reportable quantities, and notifications. U.S. Environmental Protection Agency. Code of Federal 
Regulations. 40 CFR 302.4. http://www.epa.gov/lawsregs/search/40cfr.html. May 20, 2009.
*EPA. 2009c. Superfund, emergency planning, and community right-to-know programs. Extremely 
hazardous substances and their threshold planning quantities. U.S. Environmental Protection Agency. 
Code of Federal Regulations. 40 CFR 355, Appendix A. http://www.epa.gov/lawsregs/search/40cfr.html. 
May 20, 2009.
*EPA. 2009d. Superfund, Emergency Planning, And Community Right-To-Know Programs. Toxic 
Chemical Release Reporting. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 
CFR 372.65. http://www.epa.gov/lawsregs/search/40cfr.html. May 11, 2009.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 205
*EPA. 2009e. Toxic substances control act. Health and safety data reporting. U.S. Environmental 
Protection Agency. Code of Federal Regulations. 40 CFR 716.120. 
http://www.epa.gov/lawsregs/search/40cfr.html. May 20, 2009.
*EPA. 2009f. 2005 National emissions inventory data and documentation. National emissions 
inventory. U.S. Environmental Protection Agency. http://www.epa.gov/ttn/chief/net/2005inventory.html. 
May 26, 2009.
Ericsson AC, Walum E. 1984. Cytotoxicity of cyclophosphamide and acrylamide in glioma and 
neuroblastoma cell lines cocultured with liver cells. Toxicol Lett 20(3):251-256.
+*Eskin TA, Lapham LW, Maurissen JP, et al. 1985. Acrylamide effects on the macaque visual system.
II. Retinogeniculate morphology. Invest Ophthalmol Vis Sci 26(3):317-329.
*EU. 2002. Opinion of the scientific committee on food on new findings regarding the presence of 
acrylamide in food. Brussels: European Union. http://europa.eu.int/comm/food/fs/sc/scf/index.en.html. 
June 3, 2009.
Evans HL, Teal JJ. 1981. Appetitive behaviors as models of the neuro toxicity of acrylamide.
[Abstract]. Fed Proc 40(3 Part 1):677.
Exon JH. 2006. A review of the toxicology of acrylamide. J Toxicol Environ Health B Crit Rev 9:397­
412.
Fail PA, George JD, Grizzle TB, et al. 1993. Dominant lethality of acrylamide and three of its congeners 
after chronic exposure in Swiss mice. [Abstract]. Environ Mol Mutagen 21(Suppl 22): 19.
Fang M, Boobis AR, Edwards RJ. 2007. Searching for novel biomarkers of centrally and peripehrally- 
acting neurotoxicants, using surface-enhanced laser desorption/ionisation-time-of-flight mass 
spectrometry (SELDI-TOF MS). Food Chem Toxicol 45(11):2126-2137.
Favor J, Shelby MD. 2005. Transmitted mutational events induced in mouse germ cells following 
acrylamide or glycidamide exposure. Mutat Res 580(1-2):21 -30.
Favor J, Layton D, Sega G, et al. 1995. Genetic risk extrapolation from animal data to human disease. 
Mutat Res 330:23-34.
*FDA. 2008. Everything added to food in the United States (EAFUS). Washington, DC: U.S. Food and 
Drug Administration. http://vm.cfsan.fda.gov/~dms/eafus.html. May 19, 2009.
*FDA. 2009. Survey data on acrylamide in food: Total diet study results. U.S. Food and Drug 
Administration.
http://www.fda.gov/Food/FoodSafety/FoodContaminantsAdulteration/ChemicalContaminants/Acrylamid 
e/ucm053566.htm. June 8, 2009.
*FEDRIP. 2009. Acrylamide. Federal Research in Progress database. Springfield, VA: National 
Technical Information Service.
Feng Y, Forgac M. 1992. Cysteine 254 of the 73-kDa A subunit is responsible for inhibition of the 
coated vesicle (H+)-ATPase upon modification by sulfhydryl reagents. J Biol Chem 267(9):5817-5822.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 206
9. REFERENCES
Fennell TR, Friedman MA. 2005. Comparison of acrylamide metabolism in humans and rodents. In: 
Friedman M, Mottram D, eds. Chemistry and safety of acrylamide in food. Vol. 561. New York, NY: 
Springer, 109-116.
*Fennell T, Snyder R, Burgess JP, et al. 2004. Metabolism and hemoglobin adducts of [1, 2, 3-13C3] 
acrylamide in humans. [Abstract]. Toxicologist 78(1-S): 173-174.
*Fennell T, Snyder RW, Friedman MA. 2005a. DNA and hemoglobin adducts from oral administration 
of acrylamide to male Fischer 344 rats. [Abstract]. Toxicol Sci 84(1-S): 103.
*Fennell T, Snyder RW, Sumner SC, et al. 2006. Kinetics of elimination of urinary metabolites of 
acrylamide in humans. Toxicol Sci 93(2):256-267.
Fennell TR, Macneela JP, Sumner SCJ. 1990. Metabolism of 1,2,3-13C acrylamide in the rat and mouse 
determined by 13C nuclear magnetic resonance spectroscopy. Proc Annu Meet Am Assoc Cancer Res 
31:114.
*Fennell TR, Snyder RW, Krol WL, et al. 2003. Comparison of the hemoglobin adducts formed by 
administration of N-methylolacrylamide and acrylamide to rats. Toxicol Sci 71(2): 164-175.
*Fennell TR, Sumner SC, Snyder RW, et al. 2005b. Metabolism and hemoglobin adduct formation of 
acrylamide in humans. Toxicol Sci 85(1):447-459.
Ferri GL, Zareh S, Sbraccia M, et al. 1991. Heterogeneous visceral nerve changes in acrylamide 
intoxication. Exp Brain Res 87(2):363-370.
Field EA, Price CJ, Sleet RB, et al. 1989. Teratologic evaluation of acrylamide (ACRL) in CD-1 mice 
and CD rats. [Abstract]. Toxicologist 9(1):273.
+*Field EA, Price CJ, Sleet RB, et al. 1990. Developmental toxicity evaluation of acrylamide in rats and 
mice. Fundam Appl Toxicol 14(3):502-512.
*Fomon SJ. 1966. Body composition of the infant: Part 1: The male reference infant. In: Faulkner F, 
ed. Human development. Philadelphia, PA: WB Saunders, 239-246.
*Fomon SJ, Haschke F, Ziegler EE, et al. 1982. Body composition of reference children from birth to 
age 10 years. Am J Clin Nutr 35(Suppl 5): 1169-1175.
Frantz SW, Dryzga MD. Fresheur NL, et al. 1995. In vitro/in vivo determination of cutaneous 
penetration of residual acrylamide monomer from polyacrylamide water solutions. Dow Chemical 
Toxicology Research Laboratory.
Friedman M. 2003. Chemistry, biochemistry, and safety of acrylamide. A review. J Agric Food Chem 
51(16):4504-4526.
Friedman M, Levin CE. 2008. Review of methods for the reduction of dietary content and toxicity of 
acrylamide. J Agric Food Chem 56(15):6113-6140.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 207
9. REFERENCES
+*Friedman MA, Dulak LH, Stedham MA. 1995. A lifetime oncogenicity study in rats with acrylamide. 
Fundam Appl Toxicol 27(1):95-105.
+*Friedman MA, Tyl RW, Marr MC, et al. 1999. Effects of lactational administration of acrylamide on 
rat dams and offspring. Reprod Toxicol 13(6):511-520.
Friedman MA, Zeiger E, Marroni DE, et al. 2008. Inhibition of rat testicular nuclear kinesins (krp2; 
KIFC5A) by acrylamide as a basis for establishing a genotoxicity threshold. J Agric Food Chem 
56:6024-6030.
*Fuhr U, Boettcher MI, Kinzig-Schippers M, et al. 2006. Toxicokinetics of acrylamide in humans after 
ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicity. 
Cancer Epidemiol Biomarkers Prev 15(2):266-271.
+*Fullerton PM. 1969. Electrophysiological and histological observations on peripheral nerves in 
acrylamide poisoning in man. J Neurol Neurosurg Psychiatry 32:186-192.
*Fullerton PM, Barnes JM. 1966. Peripheral neuropathy in rats produced by acrylamide. Br J Ind Med 
(23):210-221.
Galesa K, Bren U, Kranjc A, et al. 2008. Carcinogenicity of acrylamide: A computational study. J 
Agric Food Chem 56(18):8720-8727.
*Gamboa da Costa G, Churchwell MI, Hamilton LP, et al. 2003. DNA adduct formation from 
acrylamide via conversion to glycidamide in adult and neonatal mice. Chem Res Toxicol 16(10): 1328­
1337.
+*Garey J, Paule MG. 2007. Effects of chronic low-dose acrylamide exposure on progressive ratio 
performance in adolescent rats. Neurotoxicology 28(5):998-1002.
Garey J, Ferguson SA, Paule MG. 2004. Behavioral effects of acrylamide exposure during early 
development in Fischer 344 rats. [Abstract]. Birth Defects Res Part A Clin Mol Teratol 70(5):346.
Garey J, Ferguson SA, Paule MG. 2005. Effect of low-dose acrylamide exposure on preweaning 
behavior of Fisher 344 rats. [Abstract]. Neurotoxicol Teratol 27(3):379-380.
Garey J, Ferguson SA, Paule MG. 2006. Effects of chronic, low-dose acrylamide treatment on spatial 
learning and neurodevelopment in Fischer 344 rats. [Abstract]. Toxicol Sci 90(1-S):298.
Gargas ML, Kirman CR, Sweeney LM, et al. 2009. Acrylamide: Consideration of species differences 
and nonlinear processes in estimating risk and safety for human ingestion. Food Chem Toxicol 
47(4):760-768.
*Garland TO, Patterson MWH. 1967. Six cases of acrylamide poisoning. Br Med J 4:134-138.
Gassner P, Adler ID. 1996. Induction of hypoploidy and cell cycle delay by acrylamide in somatic and 
germinal cells of male mice. Mutat Res 367(4): 195-202.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 208
*Generoso WM, Sega GA, Lockhart AM, et al. 1996. Dominant lethal mutations, heritable 
translocations, and unscheduled DNA synthesis induced in male mouse germ cells by glycidamide, a 
metabolite of acrylamide. Mutat Res 371(3-4): 175-183.
Ghanayem BI, Bai R, Burka LT. 2009. Effect of dose volume on the toxicokinetics of acrylamide and its 
metabolites and 2-deoxy-D-glucose. Drug Metab Dispos 37(2):259-263.
*Ghanayem BI, McDaniel LP, Churchwell MI, et al. 2005c. Role of CYP2E1 in the epoxidation of 
acrylamide to glycidamide and formation of DNA and hemoglobin adducts. Toxicol Sci 88(2):311-318.
*Ghanayem BI, Witt KL, El-Hadri L, et al. 2005a. Comparison of germ cell mutagenicity in male 
CYP2E1- null land wild-type mice treated with acrylamide: Evidence supporting a glycidamide-mediated 
effect. Biol Reprod 72:157-163.
*Ghanayem BJ, Witt KL, Kissling GE, et al. 2005b. Absence of acrylamide-induced genotoxicity in 
CYP2E1-null mice: Evidence consistent with a glycidamide-mediated effect. Mutat Res 578:284-297.
Ghetti B, Wisniewski HM, Cook RD, et al. 1973. Changes in the central nervous system after acute and 
chronic acrylamide intoxication. Am J Pathol 70(2):78a.
Gho M, McDonald K, Ganetzky B, et al. 1992. Effects of kinesin mutations on neuronal functions. 
Science 258:313-316.
+*Gilbert SG, Maurissen JP. 1982. Assessment of the effects of acrylamide, methylmercury and 2,5- 
hexanedione on motor functions in mice. J Toxicol Environ Health 10(1):31-42.
Gipon L, Schotman P, Jennekens FG, et al. 1977. Polyneuropathies and CNS protein metabolism: I. 
Description of the acrylamide syndrome in rats. Neuropathol Appl Neurobiol 3(2): 115-123.
*Giwercman A, Carlsen E, Keiding N, et al. 1993. Evidence for increasing incidence of abnormalities of 
the human testis: A review. Environmental Health Perspectives Supplement 101(2):65-71.
*Gjerl0ff T, Elsborg H, Bonde JP. 2001. [Severe chronic acrylamide intoxication]. Ugeskr Laeger 
163(32):4204-4205.
Gobel A, Kliemant A. 2007. The German minimization concept for acrylamide. Food Addit Contam 
24(Suppl 1):82-90.
Goffeng LO, Heier MS, Kjuus H, et al. 2008a. Nerve conduction, visual evoked responses and 
electroretinography in tunnel workers previously exposed to acrylamide and N-methylolacrylamide 
containing grouting agents. Neurotoxicol Teratol 30(3): 186-194.
Goffeng LO, Kjuus H, Heier MS, et al. 2008b. Colour vision and light sensitivity in tunnel workers 
previously exposed to acrylamide and N-methylolacrylamide containing grouting agents.
Neurotoxicology (Little Rock) 29:31-39.
Gold BG, Griffin JW, Price DL. 1985. Slow axonal transport in acrylamide neuropathy: Different 
abnormalities produced by single-dose and continuous administration. J Neurosci 5(7): 1755-1768.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 209
Gold BG, Griffin JW, Price DL. 1992. Somatofugal axonal atrophy precedes development of axonal 
degeneration in acrylamide neuropathy. Arch Toxicol 66(1): 57-66.
Gold BG, Voda J, Yu X, et al. 2004. The immunosuppressant FK506 elicits a neuronal heat shock 
response and protects against acrylamide neuropathy. Exp Neurol 187(1): 160-170.
*Goldfrank LR, Flomenbaum NE, Lewin NA, et al. 1998. Goldfrank’s toxicologic emergencies. 
Stamford, CT: Appleton & Lange, 322-324, 475.
Goldstein B, Lowndes HE. 1979. Spinal cord defect in the peripheral neuropathy resulting from 
acrylamide. Neurotoxicology 1(1):75-88.
Goldstein BD. 1985a. Acrylamide preferentially affects slowly adapting cutaneous mechanoreceptors. 
Toxicol Appl Pharmacol 80(3):527-533.
Goldstein BD. 1985b. Acrylamide neurotoxicity: Altered spinal monosynaptic responses to quipazine, a 
serotonin agonist, in cats. Toxicol Appl Pharmacol 78(3):436-444.
Goldstein BD, Fincher DR. 1986. Paradoxical changes in spinal cord reflexes following the acute 
administration of acrylamide. Toxicol Lett 31(2):93-99.
Goldstein BD, Lowndes HE. 1977. Mono- and polysynaptic reflexes in cats with experimental 
acrylamide neuropathy. [Abstract]. Pharmacologist 19(2):224.
Goldstein BD, Lowndes HE. 1979. Spinal cord defect in the peripheral neuropathy resulting from 
acrylamide. Neurotoxicology 1(1):75-87.
+*Gorzinski SJ, Morden DC, Albee RR, et al. 1979. Results of papatability (12-day) and tolerance (21- 
day) studies on acrylamide monomer administered in the drinking water to rats. Dow Chemical 
Company. Submitted to the U.S. Environmental Protection Agency under TSCA Section 8D. 
EPA878210959. OTS206135.
Gould RM, Brady ST. 2004. Neuropathology: Many paths lead to hereditary spastic paraplegia. Curr 
Biol 14:R903-R904.
Granath F, Ehrenberg L, Paulsson B, et al. 2001. Cancer risk from exposure to occupational acrylamide. 
Occup Environ Med 58(9):608-609.
Granby K, Fagt S. 2004. Analysis of acrylamide in coffee and dietary exposure to acrylamide from 
coffee. Anal Chim Acta 520(1-2): 177-182.
Graveleau J, Loirat P, Nusinovici V. 1970. Polyneuritis caused by acrylamide. Rev Neurol (Paris) 
123:62-65.
Griffin JW, Price DL, Drachman DB. 1977. Impaired axonal regeneration in acrylamide intoxication. J 
Neurobiol 8(4):355-370.
Guenther H, Anklam E, Wenzl T, et al. 2007. Acrylamide in coffee: Review of progress in analysis, 
formation and level reduction. Food Addit Contam 24 (Suppl 1):60-70.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 210
Gueuning C, Graff GL, Dictus-Vermeulen C. 1978. Neurotoxicity of acrylamide in the rat: I. Subacute 
intoxication, absence of effect on incorporation of plasma phosphate in acid-soluble phosphates of the 
sciatic nerve and the gastrocnemius muscle, in anatomic continuity and after cutting the nerve. Arch Int 
Physiol Biochim 86(2):342-352.
+*Gutierrez-Espeleta GA, Hughes LA, Piegorsch WW, et al. 1992. Acrylamide: Dermal exposure 
produces genetic damage in male mouse germ cells. Fundam Appl Toxicol 18(2): 189-192.
*Guzelian PS, Henry CJ, Olin SS. 1992. In: Similarities and differences between children and adults: 
Implications for risk assessment. Washington DC: International Life Sciences and Press Institute Press.
*Haber LT, Maier A, Kroner OL, et al. 2009. Evaluation of human relevance and mode of action for 
tunica vaginalis mesotheliomas resulting from oral exposure to acrylamide. Regul Toxicol Pharmacol 
53(2): 134-149.
*Habermann CE. 2002. Acrylamide. In: Kirk-Othmer encylcopedia of chemical technology. John 
Wiley & Sons, 1-22.
http://mrw.interscience.wiley.com/emrw/9780471238966/kirk/article/acryhabe.a01/current/pdf. June 08, 
2009.
+*Hagmar L, Tornvist M, Nordander C, et al. 2001. Health effects of occupational exposure to 
acrylamide using hemoglobin adducts as biomarkers of internal dose. Scand J Work Environ Health 
27(4):219-226.
Hagmar L, Wirfalt E, Paulsson B, et al. 2005. Differences in hemoglobin adduct levels of acrylamide in 
the general population with respect to dietary intake, smoking habits and gender. Mutat Res 580(1- 
2): 157-165.
*Hanioka N, Tanaka-Kagawa T, Miyata Y, et al. 2003. Functional characterization of three human 
cytochrome P450 2E1 variants with amino acid substitutions. Xenobiotica 33(6):575-586.
*Harris CH, Gulati AK, Friedman MA, et al. 1994. Toxic neurofilamentous axonopathies and fast 
axonal transport. V. Reduced bidirectional vesical transport in cultured neurons by acrylamide and 
glycidamide. J Toxicol Environ Health 42:343-356.
*Harry GJ. 1992. Acrylamide-induced alterations in axonal transport. Biochemical and 
autoradiographic studies. Mol Neurobiol 6(2-3):203-216.
Hartley CL, Anderson VE, Anderson BH, et al. 1997. Acrylamide and 2,5-hexanedione induce collapse 
of neurofilaments in SH-SY5Y human neuroblastoma cells to form perikaryal inclusion bodies. 
Neuropathol Appl Neurobiol 23(5):364-372.
Hartmann EC, Boettcher MI, Bolt HM, et al. 2008a. N-Acetyl-S-(1-carbamoyl-2-hydroxy-ethyl)-L- 
cysteine (iso-GAMA) a further product of human metabolism of acrylamide: Comparison with the 
simultaneously excreted other mercaptuic acids. Arch Toxicol 83(7):731-734.
Hartmann EC, Boettcher MI, Schettgen T, et al. 2008b. Hemoglobin adducts and mercapturic acid 
excretion of acrylamide and glycidamide in one study population. J Agric Food Chem 56(15):6061-6068.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 211
Hasegawa K, Miwa S, Isomura K, et al. 2008. Acrylamide-responsive genes in the nematode 
Caenorhabditis elegans. Toxicol Sci 101 (2):215-225.
Hasegawa K, Miwa S, Tajima T, et al. 2007. A rapid and inexpensive method to screen for common 
foods that reduce the action of acrylamide, a harmful substance in food. Toxicol Lett 175(1-3):82-88.
Hashimoto K. 1980. Toxicity of acrylamide. Sangyo Igaku 22(4):233-248.
*Hashimoto K, Aldridge WN. 1970. Biochemical studies on acrylamide, a neurotoxic agent. Biochem 
Pharmacol 19:2591-2604.
Hashimoto K, Ando K. 1975. Studies on the percutaneous absorption of acrylamide. [Abstract]. 
Abstracts of the XVIII International Congress on Occupational Health, Brighton, England, September 
1975:453.
*Hashimoto K, Tanii H. 1985. Mutagenicity of acrylamide and its analogs in Salmonella typhimurium. 
Mutat Res 158:129-133.
+*Hashimoto K, Sakamoto J, Tanii H. 1981. Neurotoxicity of acrylamide and related compounds and 
their effects on male gonads in mice. Arch Toxicol 47:179-189.
Hattis D, Shapiro K. 1990. Analysis of dose/time/response relationships for chronic toxic effects: The 
case of acrylamide. Neurotoxicology 11(2):219-236.
*HazDat. 2007. Acrylamdie. HazDat Database: ATSDR’s Hazardous Substance Release and Health 
Effects Database. Atlanta, GA: Agency for Toxic Substances and Disease Registry.
+*He F, Zhang S, Wang H, et al. 1989. Neurological and electroneuromyographic assessment of the 
adverse effects of acrylamide on occupationally exposed workers. Scand J Work Environ Health 
15(2): 125-129.
+*Hersch MI, McLeod JG, Satchell PM, et al. 1989a. Breathing pattern, lung inflation reflex and airway 
tone in acrylamide neuropathy. Respir Physiol 76(2):257-276.
Hersch MI, McLeod JG, Sullivan CE. 1989b. Abnormal cough reflex in canine acrylamide neuropathy. 
Ann Neurol 26(6):738-745.
Hersch MI, Satchell PM, Sullivan CE, et al. 1986. Abnormal pulmonary slowly adapting receptors in 
canine acrylamide neuropathy. J Appl Physiol 60(2):376-384.
*Heudorf U, Hartmann E, Angerer J. 2009. Acrylamide in children-exposure assessment via urinary 
acrylamide metabolites as biomarkers. Int J Hyg Environ Health 212:135-14.
Hilbig A, Freidank N, Kersting M, et al. 2004. Estimation of the dietary intake of acrylamide by German 
infants, children and adolescents as calculated from dietary records and available data on acrylamide 
levels in food groups. Int J Hyg Environ Health 207(5):463-471.
Hill EJ, Woehrling EK, Prince M, et al. 2008. Differentiating human NT2/D1 neurospheres as a versatile 
in vitro 3D model system for developmental neurotoxicity testing. 249:243-250.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 212
9. REFERENCES
Hills BW, Greife AL. 1986. Evaluation of occupational acrylamide exposures. Appl Ind Hyg 1(3): 148­
152.
Hinson JA, Roberts DW. 1992. Role of covalent and noncovalent interactions in cell toxicity: effects on 
proteins. 32:471-510.
*Hoel DG, Davis DL, Miller AB, et al. 1992. Trends in cancer mortality in 15 industrialized countries, 
1969-1986. J Natl Cancer Inst 84(5):313-320.
+*Hogervorst JG, Schouten LJ, Konings EJ, et al. 2007. A prospective study of dietary acrylamide 
intake and the risk of endometrial, ovarian, and breast cancer. Cancer Epidemiol Biomarkers Prev 
16(11):2304-2313.
+*Hogervorst JG, Schouten LJ, Konings EJ, et al. 2008a. Dietary acrylamide intake and the risk of renal 
cell, bladder, and prostate cancer. Am J Clin Nutr 87(5): 1428-1438.
+*Hogervorst JG, Schouten LJ, Konings EJ, et al. 2008b. Dietary acrylamide intake is not associated 
with gastrointestinal cancer risk. J Nutr 138(11):2229-2236.
Holden LJ, Coleman MD. 2007. Assessment of the astrogliotic responses of three human astrocytoma 
cell lines to ethanol, trimethyltin chloride and acrylamide. Toxicology 241(1-2) :75-83.
Holland N, Ahlborn T, Turteltaub K, et al. 1999. Acrylamide causes preimplantation abnormalities in 
embryos and induces chromatin-adducts in male germ cells of mice. Reprod Toxicol 13(3): 167-178.
*Hoorn AJW, Custer LI, Myhr BC. 1993). Detection of chemical mutagens using Muta Mouse: A 
transgenic mouse model. Mutagenesis 8(1):7-10.
+*Hopkins A. 1970. The effect of acrylamide on the peripheral nervous system of the baboon. J Neurol 
Neurosurg Psychiatry 33(6):805-816.
Hopkins AP, Gilliatt RW. 1971. Motor and sensory nerve conduction velocity in the baboon: Normal 
values and changes during acrylamide neuropathy. J Neurol Neurosurg Psychiatry 34(4):415-426.
Howland RD. 1981. The etiology of acrylamide neuropathy: Enolase, phosphofructokinase, and 
glyceraldehyde-3-phosphate dehydrogenase activities in peripheral nerve, spinal cord, brain, and skeletal 
muscle of acrylamide-intoxicated cats. Toxicol Appl Pharmacol 60(2):324-333.
Howland RD. 1985. Biochemical studies of acrylamide neuropathy. Neurotoxicology 6(4):7-15.
Howland RD, Lowndes HE. 1984. Peripheral nerve phospholipids in acrylamide neuropathy. Arch 
Toxicol 55(3): 178-181.
Howland RD, Vyas IL, Lowndes HE, et al. 1980. The etiology of toxic peripheral neuropathies: In vitro 
effects of acrylamide and 2,5-hexanedione on brain enolase and other glycolytic enzymes. Brain Res 
202(1): 131-142.
*HSDB. 2009. Acrylamide. Hazardous Substances Data Bank. National Library of Medicine. 
http://toxnet.nlm.nih.gov. April 27, 2009.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 213
HSE. 1987. Acrylamide in air. Methods for the determination of hazardous substances (MDHS) 57. 
Health and Safety Executive. http://www.hse.gov.uk/pubns/mdhs/pdfs/mdhs57.pdf. May 4, 2009.
Huang CC, Li CM, Wu CF, et al. 2007. Analysis of urinary N-acetyl-S-(propionamide)-cysteine as a 
biomarker for the assessment of acrylamide exposure in smokers. Environ Res 104(3):346-351.
Hurd DD, Saxton WM. 1996. Kinesin mutations cause motor neuron disease phenotypes by disrupting 
fast axonal transport in Drosophila. Genetics 144(3): 1075-1085.
Hurtt ME, Bentley KS, Working PK. 1987. Effects of acrylamide and acrylonitrile on unscheduled DNA 
synthesis (UDS) in rat spermatocytes. Environ Mutagen 9(Suppl 8):49-50.
+*Husain R, Dixit R, Das M, et al. 1987. Neurotoxicity of acrylamide in developing rat brain: Changes 
in the levels of brain biogenic amines and activities of monoamine oxidase and acetylcholine esterase.
Ind Health 25(1): 19-28.
*IARC. 1994. Acrylamide. In: IARC monographs of some industrial chemicals, summary of data 
reported and evaluation. Lyon, France: International Agency for Research on Cancer, 389-433.
*IARC. 2009. Agents reviewed by the IARC Monographs. Volumes 1-99. Lyon, France: International 
Agency for Research on Cancer. http://monographs.iarc.fr/ENG/Classification/index.php. May 19, 2009.
Igisu H, Kinoshita Y. 2007. Magnetic resonance for evaluation of toxic encephalopathies: Implications 
from animal experiments. Neurotoxicology 28(2):252-256.
*Igisu H, Matsuoka M. 2002. Acrylamide encephalopathy. J Occup Health 44:63-68.
*Igisu H, Goto I, Kawamaura Y, et al. 1975. Acrylamide encephaloneuropathy due to well water 
pollution. J Neurol Neurosurg Psychiatry 38:581-584.
*Ikeda GJ, Miller E, Sapienza PP, et al. 1983. Distribution of 14C-labelled acrylamide and betaine in 
fetuses of rats, rabbits, beagle dogs and miniature pigs. Food Chem Toxicol 21:49-58.
*Ikeda GJ, Miller E, Sapienza PP, et al. 1985. Maternal-foetal distribution studies in late pregnancy. II. 
Distribution of [1-14C]acrylamide in tissues of beagle dogs and miniature pigs. Food Chem Toxicol 
23(8):757-761.
Ikeda GJ, Miller E, Sapienza PP, et al. 1987. Comparative tissue distribution and excretion of [1- 
14C]acrylamide in beagle dogs and miniature pigs. Food Chem Toxicol 25(11):871-875.
Imai T, Cho YM, Hasumura M, et al. 2005. Enhancement by acrylamide of N-methyl-N-nitrosourea- 
induced rat mammary tumor development-possible application for a model to detect co-modifiers of 
carcinogenesis. Cancer Lett 230(1):25-32.
Imai T, Takami S, Cho Y, et al. 2006. Inhibitory effects of antioxidants and phase II-enzyme inducers on 
acrylamide induced rat mammary carcinogenesis. [Abstract]. Toxicol Sci 90(1-S):408-409.
*IPCS. 1985. Acrylamide. Environmental Health Criteria 49. International Programme on Chemical 
Safety. http://www.inchem.org/documents/ehc/ehc/ehc49.htm. June 8, 2009.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 214
9. REFERENCES
*IRIS. 2009. Acrylamide. Integrated Risk Information System. Washington, DC: 
http://www.epa.gov/iris/subst/index.html. May 11, 2009.
Jakobsen J, Sidenius P. 1983. Early and dose-dependent decrease of retrograde axonal transport in 
acrylamide-intoxicated rats. J Neurochem 40(2):447-454.
Jennekens FG, Veldman H, Schotman P, et al. 1979. Sequence of motor nerve terminal involvement in 
acrylamide neuropathy. Acta Neuropathol 46(1-2):57-64.
Jiang L, Cao J, An Y, et al. 2007. Genotoxicity of acrylamide in human hepatoma G2 (HepG2) cells. 
Toxicol In Vitro 21(8):1486-1492.
Jin L, Chico-Galdo V, Massart C, et al. 2008. Acrylamide does not induce tumorigenesis or major 
defects in mice in vivo. J Endocrinol 198(2):301-307.
*Johanson CE. 1980. Permeability and vascularity of the developing brain: Cerebellum vs. cerebral 
cortex. Brain Res 190(1):3-16.
Johnson EC, Murphy SD. 1976. Effect of acrylamide intoxication on biochemical components of brain 
and sciatic nerve in rats. [Abstract]. Toxicol Appl Pharmacol 37(1): 131.
Johnson EC, Murphy SD. 1977. Effect of acrylamide intoxication on pyridine nucleotide concentrations 
and functions in rat cerebral cortex. Biochem Pharmacol 26(22):2151-2156.
+*Johnson KA, Beyer JE, Bell TJ, et al. 1984. Acrylamide: A two-year drinking water chronic toxicity- 
oncogenicity study in Fischer 344 rats. American Cyanamid Company. Dow Chemical U.S.A. Nalco 
Chemical Company. The Standard Oil Company. Submitted to the U.S. Environmental Protection 
Agency under TSCA Section 4. OTS0507273.
'J o hnson KA, Beyer JE, Bell TJ, et al. 1985. Acrylamide: A two-year drinking water chronic toxicity- 
oncogenicity study in Fischer 344 rats. Electron microscopy portion. Submitted to the U.S. 
Environmental Protection Agency under TSCA Section 8D. EPA878216184. OTS0506849.
+*Johnson KA, Gorzinski SJ, Bodner KM, et al. 1986. Chronic toxicity and oncogenicity study on 
acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol Appl Pharmacol 85(2): 154­
168.
*Johnsrud EK, Kuokouritaki SB, Divakaran K, et al. 2003. Human hepatic CYP2E1 expression during 
development. J Pharmacol Exp Ther 307(1):402-407. Erratum in: J Pharmacol Exp Ther 309(1):439.
Jones HB, Cavanagh JB. 1986. The axon reaction in spinal ganglion neurons of acrylamide-treated rats. 
Acta Neuropathol 71(1-2):55-63.
Jortner BS, Ehrich M. 1993. Comparison of toxicities of acrylamide and 2,5-hexanedione in hens and 
rats on 3-week dosing regimens. J Toxicol Environ Health 39(4):417-428.
*Jung R, Engelhart G, Herbolt B. 1992. Collaborative study of mutagenicity with Salmonella 
typhimurium TA102. Mutat Res 278:265-270.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 215
9. REFERENCES
*Kadry AM, Friedman MA, Abdel-Rahman MS. 1999. Pharmacokinetics of acrylamide after oral 
administration in male rats. Environ Toxicol Pharmacol 7(2): 127-133.
Kaji R, Liu Y, Duckett S, et al. 1989. Slow recovery of central axons in acrylamide neuropathy. Muscle 
Nerve 12(10):816-826.
Kaplan ML, Murphy SD. 1971. Rotarod performance and sciatic nerve betaglucuronidase activity as 
indices of acrylamide neurotoxicity in rats. Toxicol Appl Pharmacol 19(2):408-409.
Kaplan ML, Murphy SD. 1972. Modification of acrylamide neuropathy in rats by various factors. 
Toxicol Appl Pharmacol 22(2):302-303.
'Kaplan ML, Murphy SD, Gilles FH. 1973. Modification of acrylamide neuropathy in rats by selected 
factors. Toxicol Appl Pharmacol 24:564-579.
Kasamatsu T, Kohda K. 2006. Balancing risks. Regul Toxicol Pharmacol 46(1):100-104.
*Kaster JK, Kamendulls LM, Friedman MA, et al. 1998. Syrian hamsters embryo (SHE) cell 
transformation by acrylamide and hormones. Toxicol Sci 42(1-S):76.
*Kedderis GL, Teo SK, Batra R, et al. 1996. Refinement and verification of the physiologically based 
dosimetry description for acrylonitrile in rats. Toxicol Appl Pharmacol 140:422-435.
*Kesson CM, Baird AW, Lawson DH. 1977. Acrylamide poisoning. Postgrad Med J 53:16-17.
Khanna VK, Husain R, Seth PK. 1992. Protein malnourishment: A predisposing factor in acrylamide 
toxicity in pregnant rats. J Toxicol Environ Health 36(4):293-305.
King DJ, Noss RR. 1989. Toxicity of polyacrylamide and acrylamide monomer. Rev Environ Health 
8(1-4):3-16.
Kinoshita Y, Matsumura H, Igisu H, et al. 2000. Brain of rats intoxicated with acrylamide: Observation 
with 4.7 tesla magnetic resonance. Arch Toxicol 74(8):487-489.
*Kirman CR, Gargas ML, Deskin R, et al. 2003. A physiologically based pharmacokinetic model for 
acrylamide and its metabolite, glycidamide, in the rat. J Toxicol Environ Health A 66(3):253-274.
Kjuus H, Goffeng LO, Heier MS, et al. 2004. Effects on the peripheral nervous system of tunnel workers 
exposed to acrylamide and N-methylolacrylamide. Scand J Work Environ Health 30(1):21-29.
Kjuus H, Hansteen IL, Ryberg D, et al. 2005. Chromosome aberrations in tunnel workers exposed to 
acrylamide and N-methylolacrylamide. Scand J Work Environ Health 31(4):300-306.
*Klaunig JE. 2008. Acrylamide carcinogenicity. J Agric Food Chem 56(15):5984-5988.
Klaunig JE, Kamendulis LM. 2005. Mechanisms of acrylamide induced rodent carcinogenesis. Adv 
Exp Med Biol 561:49-62.
Kliesch U, El-Tarras A, Ingwersen I, et al. 1989. Clastogenicity of acrylamide in somatic and germinal 
cells of mice. Mutagenesis 4:319-320.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 216
9. REFERENCES
*Kligerman AD, Atwater AL, Bryant MF, et al. 1991. Cytogenetic studies of ethyl acrylate using 
C57BL/6 mice. Mutagenesis 6(2): 137-141
*Knaap AC, Kramers PN, Voogd CE, et al. 1988. Mutagenic activity of acrylamide in eukaryotic 
systems but not in bacteria. Mutagenesis 3:263-268.
+Ko MH, Chen WP, Hsieh ST. 2000. Cutaneous nerve degeneration induced by acrylamide in mice. 
Neurosci Lett 293(3): 195-198.
*Ko MH, Chen WP, Hsieh ST. 2002. Neuropathology of skin denervation in acrylamide-induced 
neuropathy. Neurobiol Dis 11(1): 155-165.
+*Ko MH, Chen WP, Lin-Shiau SY, et al. 1999. Age-dependent acrylamide neurotoxicity in mice: 
Morphology, physiology, and function. Exp Neurol 158(1):37-46.
Kohriyama K. 1992. [The suppression of CK activity in the brain by acrylamide]. J UOEH 14(1):47-58.
*Komori M, Nishio K, Kitada M, et al. 1990. Fetus-specific expression of a form of cytochrome P-450 
in human livers. Biochemistry 29(18):4430-4433.
Konings EJ, Ashby P, Hamlet CG, et al. 2007. Acrylamide in cereal and cereal products: A review on 
progress in level reduction. Food Addit Contam 24 (Suppl 1):47-59.
Konings EJ, Baars AJ, van Klaveren JD, et al. 2003. Acrylamide exposure from foods of the Dutch 
population and an assessment of the consequent risks. Food Chem Toxicol 41(11): 1569-1579.
Kopp EK, Dekant W. 2009. Toxicokinetics of acrylamide in rats and humans following single oral 
administration of low doses. Toxicol Appl Pharmacol 235(2): 135-142.
Kopp EK, Sieber M, Kellert M, et al. 2008. Rapid and sensitive HILIC-ESI-MS/MS quantitation of 
polar metabolites of acrylamide in human urine using column switching with an online trap column. J 
Agric Food Chem 56(21):9828-9834.
Koyama N, Sakamoto H, Sakuraba M, et al. 2006. Genotoxicity of acrylamide and glycidamide in 
human lymphoblastoid TK6 cells. Mutat Res 603(2): 151-158.
*Krebs O, Favor J. 1997. Somatic and germ cell mutagenesis in lambda lacZ transgenic mice treated 
with acrylamide or ethylnitrosourea. Mutat Res 388(2-3):239-248.
*Krishna G, Theiss C. 1995. Concurrent analysis of cytogenetic damage in vivo: A multiple endpoint­
multiple tissue approach. Environ Mol Mutagen 25:314-320.
*Krishnan K, Andersen ME. 1994. Physiologically based pharmacokinetic modeling in toxicology. In: 
Hayes AW, ed. Principles and methods of toxicology. 3rd ed. New York, NY: Raven Press, Ltd., 149­
188.
*Krishnan K, Anderson ME, Clewell HJ, et al. 1994. Physiologically based pharmacokinetic modeling 
of chemical mixtures. In: Yang RSH, ed. Toxicology of chemical mixtures. Case studies, mechanisms, 
and novel approaches. San Diego, CA: Academic Press, 399-437.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 217
9. REFERENCES
KS Crump Group, Inc. 1999a. Consideration of the potency classification of acrylamide based on the 
incidence of tunica vaginalis mesothellomas (TVMs) in male F344 rats. June 11, 1999.
KS Crump Group, Inc. 1999b. Mechanism of acrylamide induction of benign mammary fibroadenomas 
in the aging female F344 rat: Relevance to human health risk assessment. December 14, 1999.
Kurebayashi H, Ohno Y. 2006. Metabolism of acrylamide to glycidamide and their cytotoxicity in 
isolated rat hepatocytes: Protective effects of GSH precursors. Arch Toxicol 80(12):820-828.
Kutting B, Uter W, Drexler H. 2008. The association between self-reported acrylamide intake and 
hemoglobin adducts as biomarkers of exposure. Cancer Causes Control 19(3):273-281.
*Lafferty JS, Kamendulis LM, Kaster J, et al. 2004. Subchronic acrylamide treatment induces a tissue- 
specific increase in DNA synthesis in the rat. Toxicol Lett 154(1-2):95-103.
*Làhdetie J, Suutari A, Sjoblom T. 1994. The spermatid micronucleus test with the dissection technique 
detects the germ cell mutagenicity of acrylamide in rat meiotic cells. Mutat Res 309(2):255-262.
Lambert J, Matthieu L, Dockx P. 1988. Contact dermatitis from acrylamide. Contact Dermatitis 
19(1):65.
Lamy E, Volkel Y, Roos PH, et al. 2008. Ethanol enhanced the genotoxicity of acrylamide in human, 
metabolically competent HepG2 cells by CYP2E1 induction and glutathione depletion. Int J Hyg Environ 
Health 211(1-2):74-81.
Lande SS, Bosch SJ, Howard PH. 1979. Degradation and leaching of acrylamide in soil. J Environ Qual 
8(1): 133-137.
*Lapadula DM, Bowe M, Carrington CD, et al. 1989. In vitro binding of [14C]acrylamide to 
neurofilament and microtubule proteins of rats. Brain Res 481(1): 157-161.
Lapin EP, Maker HS, Weissbarth S, et al. 1984. The influence of systemic factors on acrylamide- 
induced changes in brain, nerve, and other tissues. J Neurosci Res 11(4):395-404.
+*Larsson SC, Akesson A, Wolk A. 2009d. Long-term dietary acrylamide intake and breast cancer risk 
in a prospective cohort of Swedish women. Am J Epidemiol 169(3):376-381.
+*Larsson SC, Akesson A, Wolk A. 2009b. Long-term dietary acrylamide intake and risk of epithelial 
ovarian cancer in a prospective cohort of Swedish women. Cancer Epidemiol Biomarkers Prev 
18(3):994-997.
+*Larsson SC, Hakansson N, Akesson A, et al. 2009a. Long-term dietary acrylamide intake and risk of 
endometrial cancer in a prospective cohort of Swedish women. Int J Cancer 124(5): 1196-1199.
+*Larsson SC, Kesson A, Bergkvist L, et al. 2009c. Dietary acrylamide intake and risk of colorectal 
cancer in a prospective cohort of men. Eur J Cancer 45:513-516.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 218
Lee KY, Shibutani M, Kuroiwa K, et al. 2005. Chemoprevention of acrylamide toxicity by antioxidative 
agents in rats-effective suppression of testicular toxicity by phenylethyl isothiocyanate. Arch Toxicol 
79(9):531-541.
*Leeder JS, Kearns GL. 1997. Pharmacogenetics in pediatrics: Implications for practice. Pediatr Clin 
North Am 44(1):55-77.
Lehning EJ, Balaban CD, Ross JF, et al. 2002a. Acrylamide neuropathy. I. Spatiotemporal 
characteristics of nerve cell damage in rat cerebellum. Neurotoxicology 23(3):397-414.
Lehning EJ, Balaban CD, Ross JF, et al. 2002b. Acrylamide neuropathy. II. Spatiotemporal 
characteristics of nerve cell damage in brainstem and spinal cord. Neurotoxicology 23:415-429.
Lehning EJ, Balaban CD, Ross JF, et al. 2003a. Acrylamide neuropathy. II. Spatiotemporal 
characteristics of nerve cell damage in brainstem and spinal cord. Neurotoxicology 24(1): 109-123.
Lehning EJ, Balaban CD, Ross JF, et al. 2003b. Acrylamide neuropathy. III. Spatiotemporal 
characteristics of nerve cell damage in forebrain. Neurotoxicology 24(1): 125-136.
Lehning EJ, Gaughan CL, LoPachin RM, Jr. 1997. Acrylamide intoxication modifies in vitro responses 
of peripheral nerve axons to anoxia. J Peripher Nerv Syst 2(2): 165-174.
Lehning EJ, LoPachin EM, Mathew J, et al. 1994. Changes in Na-K ATPase and protein kinase C 
activities in peripheral nerve of acrylamide-treated rats. J Toxicol Environ Health 42(3):331-342.
Lehning EJ, Persaud A, Dyer KR, et al. 1998. Biochemical and morphologic characterization of 
acrylamide peripheral neuropathy. T oxicol Appl Pharmacol 151(2) :211-221.
*Leikin JB, Paloucek FP. 2002. Leikin & Paloucek’s poisoning and toxicology handbook. 3rd ed. 
Poisoning and toxicology handbook. 3rd ed. Hudson, OH: Lexi-Comp, Inc., 193-194.
+*Leswing RJ, Ribelin WE. 1969. Physiologic and pathologic changes in acrylamide neuropathy. Arch 
Environ Health 18(1):23-29.
*Leung H. 1993. Physiologically-based pharmacokinetic modelling. In: Ballantyne B, Marrs T, Turner 
P, eds. General and applied toxicology. Vol. 1. New York, NY: Stockton Press, 153-164.
*Lewis RJ. 2000. Acrylamide. In: Sax's dangerous properties of industrial materials. 10th ed. New 
York, NY: John Wiley & Sons, Inc., 66-67.
*Lewis RJ. 2007. Acrylamide. In: Hawley's condensed chemical dictionary. 15th ed. Hoboken, NJ: 
John Wiley & Sons, Inc., 19-20.
Lewkowski JP, Yang YY, Orthoefer JG, et al. 1978. Effects of low level exposure to acrylamide in 
water on spontaneous locomotor activity. Toxicol Appl Pharmacol 45(1):251.
Li SX, Cui N, Zhang CL, et al. 2006. Effect of subchronic exposure to acrylamide induced on the 
expression of bcl-2, bax and caspase-3 in the rat nervous system. Toxicology 217(1):46-53.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 219
9. REFERENCES
Lide DR, ed. 2008. [Acrylamide]. In: CRC handbook of chemistry and physics. 88th ed. New York, 
NY: CRC Press, 3-8 to 3-9.
*Lijinsky W, Andrews AW. 1980. Mutagenicity of vinyl compounds in Salmonella typhimurium. 
Teratog Carcinog Mutagen 1:259-267.
Ling B, Authier N, Balayssac D, et al. 2005. Assessment of nociception in acrylamide-induced 
neuropathy in rats. Pain 119(1-3): 104-112.
*Livingston AL. 1978. Forage plant estrogens. J Toxicol Environ Health 4(2-3):301-324.
LoPachin RM. 2004. The changing view of acrylamide neurotoxicity. Neurotoxicology 25(4):617-630.
LoPachin RM. 2005. Acrylamide neurotoxicity: Neurological, morhological and molecular endpoints in 
animal models. Adv Exp Med Biol 561:21-37.
LoPachin RM, Barber DS. 2005. Acrylamide disrupts uptake of dopamine into rat striatal synaptic 
vesicles. [Abstract]. Toxicol Sci 84(1-S):315.
*LoPachin RM, Barber DS. 2006. Synapticcysteine sulfhydryl groups as targets of electrophilic 
neurotoxicants. Toxicol Sci 94:240-255.
*Lopachin RM, Decaprio AP. 2005. Protein adduct formation as a molecular mechanism in 
neurotoxicity. Toxicol Sci 86(2):214-225.
*Lopachin RM, Gavin T. 2008. Acrylamide-induced nerve terminal damage: Relevance to neurotoxic 
and neurodegenerative mechanisms. J Agric Food Chem 56(15):5994-6003.
*LoPachin RM, Lehning EJ. 1994. Acrylamide-induced distal axon degeneration: A proposed 
mechanism of action. Neurotoxicology 15(2):247-259.
*LoPachin RM, Balaban CD, Ross JF. 2003. Acrylamide axonopathy revisited. Toxicol Appl 
Pharmacol 188(3): 135-153.
*LoPachin RM, Barber DS, Gavin T. 2008. Molecular mechanisms of the conjugated alpha, beta- 
unsaturated carbonyl derivatives: Relevance to neurotoxicity and neurodegenerative diseases. Toxicol 
Sci 104(2):235-249.
Lopachin RM, Barber DS, Geohagen BC, et al. 2007a. Structure-toxicity analysis of type-2 alkenes: In 
vitro neurotoxicity. Toxicol Sci 95(1): 136-146.
LoPachin RM, Barber DS, He D, et al. 2006. Acrylamide inhibits dopamine uptake in rat striatial 
synaptic vesicles. 89:224-234.
LoPachin RM, Gavin T, Geohagen BC, et al. 2007b. Neurotoxic mechanisms of electrophilic type-2 
alkenes: Soft-soft interactions described by quantum mechanical parameters. Toxicol Sci 98:561-570.
LoPachin RM, Geohagen BC, Gavin T. 2009. Synaptosomal toxicity and nucleophilic targets of 4- 
hydroxy-2-nonenal. Toxicol Sci 107:171-181.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 220
LoPachin RM, Ross JF, Lehning EJ. 2002a. Nerve terminals as the primary site of acrylamide action: A 
hypothesis. Neurotoxicology 23(1):43-59.
LoPachin RM, Ross JF, Reid ML, et al. 2002b. Neurological evaluation of toxic axonopathies in rats: 
Acrylamide and 2,5-hexanedione. Neurotoxicology 23(1):95-110.
LoPachin RM, Schwarcz AI, Gaughan CL, et al. 2004. In vivo and in vitro effects of acrylamide on 
synaptosomal neurotransmitter uptake and release. Neurotoxicology 25(3):349-363.
Lowndes HE, Baker T. 1976. Studies on drug-induced neuropathies: III. Motor nerve deficit in cats 
with experimental acrylamide neuropathy. Eur J Pharmacol 35(1): 177-184.
Lowndes HE, Baker T, Cho ES, et al. 1978. Position sensitivity of de-efferented muscle spindles in 
experimental acrylamide neuropathy. J Pharmacol Exp Ther 205(1):40-48.
Lu ZR, Zou HC, Park SJ, et al. 2009. The effects of acrylamide on brain creatine kinase: Inhibition 
kinetics and computational docking simulation. Int J Biol Macromol 44(2): 128-132.
Mangan D, Snyder IS. 1978. The effect of acrylamide on human polymorphonuclear neutrophils in vitro. 
Br J Ind Med 35(4):305-311.
Maniere I, Godard T, Doerge DR, et al. 2005. DNA damage and DNA adduct formation in rat tissues 
following oral administration of acrylamide. Mutat Res 580(1-2): 119-129.
*Manjanatha MG, Aidoo A, Shelton SD, et al. 2006. Genotoxicity of acrylamide and its metabolite 
glycidamide administered in drinking water to male and female Big Blue mice. Environ Mol Mutagen 
47(1):6-17.
Mannaa F, Abdel-Wahhab MA, Ahmed HH, et al. 2006. Protective role of Panax ginseng extract 
standardized with ginsenoside Rg3 against acrylamide-induced neurotoxicity in rats. J Appl Toxicol 
26(3): 198-206.
*Mapp C, Mazzotta M, Bartolucci GB, et al. 1977. [La neuropatia da acrilamide: Prime osservazioni in 
Italia]. (Italian) Med Lav 68(1): 1-12.
Marchetti F, Bishop J, Lowe X, et al. 2009. Chromosomal mosaicism in mouse two-cell embryos after 
paternal exposure to acrylamide. Toxicol Sci 107(1): 194-205.
'Marchetti F, Lowe X, Bishop J, et al. 1997. Induction of chromosomal aberrations in mouse zygotes by 
acrylamide treatment of male germ cells and their correlation with dominant lethality and heritable 
translocations. Environ Mol Mutagen 30(4) :410-417.
'Marlowe C, Clark MJ, Mast RW, et al. 1986. The distribution of [14C]acrylamide in male and pregnant 
Swiss-Webster mice studied by whole-body autoradiography. Toxicol Appl Pharmacol 86(3):457-465.
Marsh GM, Lucas LJ, Youk AO, et al. 1999. Mortality patterns among workers exposed to acrylamide: 
1994 follow up. Occup Environ Med 56(3): 181-190.
'M arsh GM, Youk AO, Buchanich JM, et al. 2007. Mortality patterns among workers exposed to 
acrylamide: Updated follow up. J Occup Environ Med 49(1):82-95.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 221
9. REFERENCES
Martenson CH, Sheetz MP, Graham DG. 1995. In vitro acrylamide exposure alters growth cone 
morphology. Toxicol Appl Pharmacol 131(1): 119-129.
'Martins C, Oliveira NG, Pingarilho M, et al. 2007. Cytogenetic damage induced by acrylamide and 
glycidamide in mammalian cells: Correlation with specific glycidamide-DNA adducts. Toxicol Sci 
95(2):383-390.
'M arty JP, Vincent CM. 1998. In vitro percutaneous absorption of acrylamide across human skin. Paris, 
France, Faculty of Pharmacy, Universite de Paris Sud.
Matsuoka M, Igisu H. 1992. Brain energy metabolites in mice intoxicated with acrylamide: Effects of 
ischemia. Toxicol Lett 62(1):39-43.
+'Maurissen JP, Weiss B, Davis HT. 1983. Somatosensory thresholds in monkeys exposed to 
acrylamide. Toxicol Appl Pharmacol 71(2):266-279.
Maurissen JPJ, Weiss B, Cox C. 1990. Vibration sensitivity recovery after a second course of 
acrylamide intoxication. Fundam Appl Toxicol 15(1):93-98.
'M ayr U, Butsch A, Schneider S. 1992. Validation of two in vitro test systems for estrogenic activities 
with zearalenone, phytoestrogens and cereal extracts. Toxicology 74(2-3): 135-149.
+'McCollister DD, Oyen F, Rowe VK. 1964. Toxicology of acrylamide. Toxicol Appl Pharmacol 
6:172-181.
McLean JD, Mann JR, Jacoby JA. 1978. A monitoring method for the determination of acrylamide in an 
industrial environment. Am Ind Hyg Assoc J 39(3):247-250.
Medrano CJ, LoPachin RM. 1989. Effects of acrylamide and 2,5-hexanedione on brain mitochondrial 
respiration. Neurotoxicology 10(2):249-255.
Mei N, Guo L, Tseng J, et al. 2008a. Gene expression changes associated with xenobiotic metabolism 
pathways in mice exposed to acrylamide. Environ Mol Mutagen 49(9):741-745.
'M ei N, Hu J, Churchwell MI, et al. 2008b. Genotoxic effects of acrylamide and glycidamide in mouse 
lymphoma cells. Food Chem Toxicol 46(2):628-636.
Merigan WH, Barkdoll E, Maurissen JP. 1982. Acrylamide-induced visual impairment in primates. 
Toxicol Appl Pharmacol 62(6):342-345.
+'Merigan WH, Barkdoll E, Maurissen JP, et al. 1985. Acrylamide effects on the macaque visual 
system. I. Psychophysics and electrophysiology. Invest Ophthalmol Vis Sci 26(3):309-316.
'Meylan WM, Howard PH. 1993. Computer estimation of the atmospheric gas-phase reaction rate of 
organic compounds with hydroxyl radicals and ozone. Chemosphere 26(12):2293-2299.
+'Michels KB, Rosner BA, Chumlea WC, et al. 2006. Preschool diet and adult risk of breast cancer. Int 
J Cancer 118(3):749-754.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 222
Miller MJ, McQueen CA. 1986. The effect of acrylamide on hepatocellular DNA repair. Environ 
Mutagen 8(1):99-108.
*Miller MJ, Carter DE, Sipes IG. 1982. Pharmacokinetics of acrylamide in Fischer-344 rats. Toxicol 
Appl Pharmacol 63:36-44.
Miller MS, Miller MJ, Burks TF, et al. 1983. Altered retrograde axonal transport of nerve growth factor 
after single and repeated doses of acrylamide in the rat. Toxicol Appl Pharmacol 69(1):96-101.
Miller MJ, Miller MS, Burks TF, et al. 1984. A simple, sensitive method for detecting early peripheral 
nerve dysfunction in the rat following acrylamide treatment. Neurotoxicology 5(2): 15-23.
Mills C, Tlustos C, Evans R, et al. 2008. Dietary acrylamide exposure estimates for the United Kingdom 
and Ireland: Comparison between semiprobabilistic and probabilistic exposure models. J Agric Food 
Chem 56(15):6039-6045.
*Moore MM, Amtower A, Doeer C, et al. 1987. Mutagenicity and clastogenicity of acrylamide in 
l5178y mouse lymphoma cells. Environ Mutagen 9(3):261-267.
*Moreno Navarro IM, Rubio Armendariz C, Gutierrez Fernandez AJ, et al. 2007. La acrilamida, 
contaminante quimico de procesado: Revision. Revista de Toxicologia (Elche, Spain) 24(1): 1-9.
Moretto A, Sabri MI. 1988. Progressive deficits in retrograde axon transport precede degeneration of 
motor axons in acrylamide neuropathy. Brain Res 440(1):18-24.
*Morselli PL, Franco-Morselli R, Bossi L. 1980. Clinical pharmacokinetics in newborns and infants: 
Age-related differences and therapeutic implications. Clin Pharmacokinet 5(6):485-527.
Moser VC, Anthony DC, Sette WF, et al. 1992. Comparison of subchronic neurotoxicity of 2- 
hydroxyethyl acrylate and acrylamide in rats. Fundam Appl Toxicol 18(3):343-352.
Mottram DS, Friedman M. 2008. Symposium on the chemistry and toxicology of acrylamide. J Agric 
Food Chem 56(15):5983.
*Mottram DS, Wedzicha BL, Dodson AT. 2002. Acrylamide is formed in the Maillard reaction. Nature 
419(6906):448-449.
Mucci LA, Wilson KM. 2008. Acrylamide intake through diet and human cancer risk. J Agric Food 
Chem 56(15):6013-6019.
+*Mucci LA, Adami HO, Wolk A. 2006. Prospective study of dietary acrylamide and risk of colorectal 
cancer among women. Int J Cancer 118(1): 169-173.
*Mucci LA, Dickman PW, Steineck G, et al. 2003. Dietary acrylamide and cancer of the large bowel, 
kidney, and bladder: Absence of an association in a population-based study in Sweden. Br J Cancer 
88(1):84-89.
+*Mucci LA, Lindblad P, Steineck G, et al. 2004. Dietary acrylamide and risk of renal cell cancer. Int J 
Cancer 109(5):774-776.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 223
+*Mucci LA, Sandin S, Balter K, et al. 2005. Acrylamide intake and breast cancer risk in Swedish 
women. JAMA 293(11): 1326-1327.
Mukhtar H, Dixit R, Seth PK. 1981. Reduction in cutaneous and hepatic glutathione contents, 
glutathione S-transferase and aryl hydrocarbon hydroxylase activities following topical application of 
acrylamide to mouse. Toxicol Lett 9(2): 153-156.
Muller M, Wacker K, Getts D, et al. 2008. Further evidence for a crucial role of resident endoneurial 
macrophages in peripheral nerve disorders: Lessons from acrylamide-induced neuropathy. Glia 
56(9): 1005-1016.
*Müller W, Engelhart G, Herbold B, et al. 1993. Evaluation of mutagenicity testing with Salmonella 
typhimurium TA102 in three different laboratories. Environ Heath Perspect 101(Suppl 3):33-36.
*Mulloy KB. 1996. Two case reports of neurological disease in coal mine preparation plant workers.
Am J Ind Med 30(1):56-61.
*Muttucumaru N, Elmore JS, Curtis T, et al. 2008. Reducing acrylamide precursors in raw materials 
derived from wheat and potato. J Agric Food Chem 56(15):6167-6172.
Muttucumaru N, Halford NG, Elmore JS, et al. 2006. Formation of high levels of acrylamide during the 
processing of flour derived from sulfate-deprived wheat. J Agric Food Chem 54(23):8951-8955.
+*Myers JE, Macun I. 1991. Acrylamide neuropathy in a South African factory: An epidemiologic 
investigation. Am J Ind Med 19(4):487-493.
Nagao T. 1994. Developmental abnormalities due to exposure of mouse paternal germ cells, 
preimplantation embryos, and organogenic embryos to acrylamide. Congenit Anom (Kyoto) 34(1):35-46.
*Nakagawa-Yagi Y, Choi D, Ogane, N, et al. 2001. Discovery of a novel compound insight into 
mechanisms for acrylamide-induced axonopathy and colchicine-induced apoptotic neuronal cell death. 
Brain Res 909:8-19.
Nalco. 1977. Exhaust AAM sampling data sheets with cover letters. Nalco Chem. Co. Submitted to the 
U.S. Environmental Protection Agency under TSCS Section 8D. 0TS0206160.
*NAS/NRC. 1989. Report of the oversight committee. In: Biologic markers in reproductive toxicology. 
Washington, DC National Academy of Sciences, National Research Council, National Academy Press, 
15-35.
*NCTR. 2009. National Center for Toxicological Research annual report. Research accomplishments 
and plans. Department of Health and Human Services, National Center for Toxicological Research, 52, 
56, 69. http://www.fda.gov/downloads/AboutFDA/CentersOffices/NCTR/ 
ResearchAccomplishmentsPlans/UCM163319.pdf. July 16, 2009.
Nemoto S, Takatsuki S, Sasaki K, et al. 2002. Determination of acrylamide in foods by GC/MS using 
13C-labeled acrylamide as an internal standard. Shokuhin Eiseigaku Zasshi 43(6):371-376.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 224
*Nesterova EV, Dumev AD, Seredenin SB. 1999. Verapamil contributes to the clastogenic effects of 
acrylamide, cyclophosphamide, and dioxidine on somatic cells of BALB/C and C57BL/6 mice. Mutat 
Res 440(2): 171-179.
*Neuhauser-Klaus A, Schmahl W. 1989. Mutagenic and teratogenic effects of acrylamide in the 
mammalian spot test Mutat Res 226(3): 157-162.
Newman B, Oblak L, Kumiski D, et al. 2005. Reductions in neuromuscular junction cholinesterase 
activity by subacute and chronic acrylamide exposure. [Abstract]. Toxicol Sci 84(1-S):317.
Nilsen OG, Toftgard R, Ingelman-Sundberg M, et al. 1978. Qualitative alterations of cytochrome P-450 
in mouse liver microsomes after administration of acrylamide and methylmethacrylate. Acta Pharmacol 
Toxicol 43(4):299-305.
NIOSH. 1985. Health hazard evaluation report No. HETA-84-307-1581, Big Dry Creek Plant, 
Westminister, Colorado. Cincinnati, OH: National Institute for Occupational Safety and Health. 
PB86132792.
*NIOSH. 2005. Acrylamide. In: NIOSH pocket guide to chemical hazards. Atlanta, GA: National 
Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 
http://www.cdc.gov/niosh/npg/. May 19, 2009.
Nordin-Andersson M, Walum E, Kjellstrand P, et al. 2003. Acrylamide-induced effects on general and 
neurospecific cellular functions during exposure and recovery. Cell Biol Toxicol 19(1):43-51.
*NRC. 1993. Pesticides in the diets of infants and children. Washington, DC: National Research 
Council. National Academy Press.
*NTP. 2005. Report on carcinogens, 11th edition. Research Triangle Park, NC: U.S. Department of 
Health and Human Services, Public Health Service, National Toxicology Program. http://ntp- 
server.niehs.nih.gov/ntp/roc/toc11.html. May 11, 2009.
Oishi Y, Yamamoto H, Nagano M, et al. 1996. The effects of 2,5-hexanedione and acrylamide on 
myosin heavy chain isoforms of slow and fast skeletal muscles of the rat. Toxicol Appl Pharmacol 
139(1): 15-21.
Okazaki S, Takashima H, Yamaguchi M, et al. 2003. [Neurobehavioral toxicity of acrylamide and IDPN 
(3,3'-iminodipropionitrile) in rats by 28-day oral administration--problems encountered in collaborative 
study and a commentary on conducting neurobehavioral testing.]. J Toxicol Sci 28 (Suppl 1): 1-14.
+*Olesen PT, Olsen A, Frandsen H, et al. 2008. Acrylamide exposure and incidence of breast cancer 
among postmenopausal women in the Danish Diet, Cancer and Health study. Int J Cancer 122(9):2094- 
2100.
Olstorn HB, Paulsen JE, Alexander J. 2007. Effects of perinatal exposure to acrylamide and glycidamide 
on intestinal tumorigenesis in Min/+ mice and their wild-type litter mates. Anticancer Res 27(6B):3855- 
3864.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 225
9. REFERENCES
*O'Neil MJ, Heckelman PE, Koch CB, et al. 2006. Acrylamide. In: O'Neil MJ, Heckelman PE, Koch 
CB, eds. The Merck index. An encyclopedia of chemicals, drugs, and biologicals. 14th ed. Whitehouse 
Station, NJ: Merck & Co., Inc., 22-23.
*OSHA. 2009. Toxic and Hazardous Substances. Occupational safety and health standards.
Occupational Safety and Health Administration. Code of Federal Regulations. 29 CFR 1910.1000, Table 
Z 1. http://www.osha.gov/comp-links.html. May 19, 2009.
O'Shaughnessy DJ, Losos GJ. 1986. Comparison of central and peripheral nervous system lesions 
caused by high-dose short-term and low-dose subchronic acrylamide treatment in rats. Toxicol Pathol 
14(4):389-394.
Otles S, Otles S. 2004. Acrylamide in food. (Chemical structure of acrylamide). Electron J Environ 
Agric Food Chem 3(5):723-730.
Otles S, Otles S. 2005. Acrylamide in food-formation of acrylamide and its damages to health. Electron 
J Pol Agric Univ 7(2) http://www.ejpau.media.pl/volume7/issue2/food/art-02.html. May 28, 2009.
*Owen GM, Brozek J. 1966. Influence of age, sex and nutrition on body composition during childhood 
and adolescence. In: Falkner F, ed. Human development. Philadelphia, PA: WB Saunders, 222-238.
Pabst K, Mathar W, Palavinskas R, et al. 2005. Acrylamide-occurrence in mixed concentrate feed for 
dairy cows and carry-over into milk. Food Addit Contam 22(3):210-213.
*Pacchierotti F, Tiveron C, D'Archivio M, et al. 1994. Acrylamide-induced chromosomal damage in 
male mouse germ cells detected by cytogenetic analysis of one-cell zygotes. Mutat Res 309(2):273-284.
*Padilla S, Atkinson MB, Breuer AC. 1993. Direct measurement of fast axonal organelle transport in the 
sciatic nerve of rats treated with acrylamide. J Toxicol Environ Health 39(4):429-445.
Palazoglu TK, Gokmen V. 2008. Reduction of acrylamide level in french fries by employing a 
temperature program during frying. J Agric Food Chem 56(15):6162-6166.
*Palmer RB. 2004. Acrylic acid and derivatives. In: Dart RC, ed. Medical toxicology. 3rd ed. 
Philadelphia, PA: Lippincott Williams & Wilkins, 1358-1368.
Pantusa VP, Stock TH, Morandi MT, et al. 2002. Inhalation exposures to acrylamide in biomedical 
laboratories. AIHA J (Fairfax, Va) 63(4):468-473.
*Park J, Kamendulis LM, Friedman MA, et al. 2002. Acrylamide-induced cellular transformation. 
Toxicol Sci 65(2): 177-183.
Parker RD, Sharma RP, Obersteiner EJ. 1978. Acrylamide toxicity in developing chick embryo. 
[Abstract]. Pharmacologist 20(3):249.
Parzefall W. 2008. Mini review on the toxicity of dietary acrylamide. Food Chem Toxicol 46(4):1360- 
1364.
Paule MG, Garey J, Ferguson SA. 2004. Developmental toxicity of acrylamide in Fischer 344 rats. 
[Abstract]. Birth Defects Res Part A Clin Mol Teratol 70(5):312.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 226
9. REFERENCES
*Paulsson B, Grawe J, Tomqvist M. 2002. Hemoglobin adducts and micronucleus frequencies in mouse 
and rat after acrylamide or N-methylolacrylamide treatment. Mutat Res 516(1 -2) :101-111.
Paulsson B, Kotova N, Grawe J, et al. 2003. Induction of micronuclei in mouse and rat by glycidamide, 
genotoxic metabolite of acrylamide. Mutat Res 535(1): 15-24.
Paulsson B, Larsen KO, Tornqvist M. 2006. Hemoglobin adducts in the assessment of potential 
occupational exposure to acylamides-Three case studies. Scand J Work Environ Health 32(2): 154-159.
Paulsson B, Rannug A, Henderson AP, et al. 2005. In vitro studies of the influence of glutathione 
transferases and epoxide hydrolase on the detoxification of acrylamide and glycidamide in blood. Mutat 
Res 580(1-2):53-59.
*Pearson RG, Songstad J. 1967. Application of the principle of hard and soft acids and bases to organic 
chemistry. J Am Chem Soc 89:1827-1836.
+*Pelucchi C, Galeone C, Dal Maso L, et al. 2007. Dietary acrylamide and renal cell cancer. Int J 
Cancer 120(6): 1376-1377.
+*Pelucchi C, Galeone C, Levi F, et al. 2006. Dietary acrylamide and human cancer. Int J Cancer 
118(2):467-471.
*Perrault SD. 2003. Distinguishing between fertilization failure and early pregnancy loss when 
identifying male-mediated adverse pregnancy outcomes. Adv Exp Med Biol 518:189-198.
Peters AK, Steemans M, Hansen E, et al. 2008. Evaluation of the embryotoxic potency of compounds in 
a newly revised high throughput embryonic stem cell test. Toxicol Sci 105(2):342-350.
*Petersen DW, Kleinow KM, Kraska RC, et al. 1985. Uptake disposition and elimination of acrylamide 
in rainbow trout Salmo-gairdneri. Toxicol Appl Pharmacol 80(1):58-65.
Pienta RJ. 1980. Transformation of Syrian hamster embryo cells by diverse chemicals and correlation 
with their reported carcinogenic and mutagenic activities. Chem Mutagens 6:175-202.
*Pleasure DE, Mishler KC, Engel, WK. 1969. Axonal transport of proteins in experimental 
neuropathies. Science 166:524-525.
Poole CF, Sye WF, Zlatkis A, et al. 1981. Determination of acrylamide in nerve tissue homogenates by 
electron-capture gas chromatography. J Chromatogr 217:239-245.
Post EJ. 1978. Unmyelinated nerve fibers in feline acrylamide neuropathy. Acta Neuropathol 42(1): 19­
24.
+*Post EJ, McLeod JG. 1977a. Acrylamide autonomic neuropathy in the cat: 1. Neurophysiological 
and histological studies. J Neurol Sci 33(3):353-374.
*Post EJ, McLeod JG. 1977b. Acrylamide autonomic neuropathy in the cat: 2. Effects on mesenteric 
vascular control. J Neurol Sci 33(3):375-386.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 227
*Poulin P, Krishnan K. 1995. A biologically-based algorithm for predicting human tissue:blood partition 
coefficients of organic chemicals. Hum Exp Toxicol 14:273-280.
*Poulin P, Krishnan K. 1996a. A mechanistic algorithm for predicting blood:air partition coefficients of 
organic chemicals with the consideration of reversible binding in hemoglobin. Toxicol Appl Pharmacol 
136:131-137.
*Poulin P, Krishnan K. 1996. A tissue composition-based algorithm for predicting tissue:air partition 
coefficients of organic chemicals. Toxicol Appl Pharmacol 136:126-130.
*Pratt GC, Palmer K, Wu CY, et al. 2000. An assessment of air toxics in Minnesota. Environ Health 
Perspect 108(9):815-825.
Preston A, Fodey T, Douglas A, et al. 2009. Monoclonal antibody development for acrylamide-adducted 
human haemoglobin; a biomarker of dietary acrylamide exposure. J Immunol Methods 341(1-2): 19-29.
Prineas J. 1969. The pathogenesis of dying back polyneuropathies. Part II. An ultrastructural study of 
experimental acrylamide intoxication in the cat. J Neuropathol Exp Neurol 28:598-621.
Puppel N, Tjaden Z, Fueller F, et al. 2005. DNA strand breaking capacity of acrylamide and 
glycidamide in mammalian cells. Mutat Res 580(1-2):71-80.
Rafales LS, Bornschein RL, Caruso V. 1982. Behavioral and pharmacological responses following 
acrylamide exposure in rats. Neurobehav Toxicol Teratol 4(3):355-364.
Rafales LS, Lasley SM, Greenland RD, et al. 1983. Effects of acrylamide on locomotion and central 
monoamine function in the rat. Pharmacol Biochem Behav 19(4): 635-644.
*Ramsey JC, Young JD, Gorzinsky SJ. 1984. Acrylamide: Toxicodynamics in rats. Submitted to the 
U.S. Environmental Protection Agency under TSCA Section 4. OTS0507270. [Unpublished study for 
peer review]
Rasool CG, Bradley WG. 1978. Studies on axoplasmic transport of individual proteins: 1. 
Acetylcholinesterase (AChE) in acrylamide neuropathy. J Neurochem 31(2):419-426.
Ravindranath V, Pai KS. 1991. The use of rat brain slices as an in vitro model for mechanistic evaluation 
of neurotoxicity-studies with acrylamide. Neurotoxicology 12(2):225-234.
*Raymer JH, Sparacino CM, Velez GR, et al. 1993. Determination of acrylamide in rat serum and 
sciatic nerve by gas chromatography-electron-capture detection. J Chromatogr 619:223-234.
Recio L, Caspary W, Tourous D, et al. 2006. Dose-response comparison of micronucleated reticulocyte 
frequencies in rodent peripheral blood with four genotoxic agents by flow cytometry and slide-based 
enumeration. [Abstract]. Toxicol Sci 90(1-S): 112.
Reid E. 2003. Science in motion: Common molecular pathological themes emerge in the hereditary 
spastic paraplegias. J Med Genet 40(2):81-86.
Reid E, Kloos M, Ashley-Koch A, et al. 2002. A kinesin heavy chain (KIF5A) mutation in hereditary 
spastic paraplegia (SPG10). Am J Hum Genet 71(5): 1189-1194.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 228
9. REFERENCES
+*Rohm and Haas Company. 1975. Acrylamide and methacrylamide. Subchronic percutaneous toxicity 
study in new-born rabbits. Submitted to the U.S. Environmental Protection Agency under TSCA Section 
8D. OTS205982.
*Russell LB, Hunsicker PR, Cacheiro NA, et al. 1991. Induction of specific-locus mutations in male 
germ cells of the mouse by acrylamide monomer. Mutat Res 262:101-107.
*Russo A, Gabbani G, Simoncini B. 1994. Weak genotoxicity of acrylamide on premeiotic and somatic 
cells of the mouse. Mutat Res 309(2):263-272.
Rydberg P, Eriksson S, Tareke E, et al. 2005. Factors that influence the acrylamide content of heated 
foods. Adv Exp Med Biol 561:317-328.
Sabri MI, Spencer PS. 1990. Acrylamide impairs fast and slow axonal transport in rat optic system. 
Neurochem Res 15(6):603-608.
Sabri MI, Dairman W, Fenton M, et al. 1989. Effect of exogenous pyruvate on acrylamide neuropathy in 
rats. Brain Res 483(1): 1-11.
Sahenk Z, Mendell JR. 1981. Acrylamide and 2,5-hexanedione neuropathies: Abnormal bidirectional 
transport rate in distal axons. Brain Res 219(2):397-405.
+*Sakamoto J, Hashimoto K. 1986. Reproductive toxicity of acrylamide and related compounds in 
mice: Effects on fertility and sperm morphology. Arch Toxicol 59:201-205.
+*Sakamoto J, Kurosaka Y, Hashimoto K. 1988. Histological changes of acrylamide-induced testicular 
lesions in mice. Exp Mol Pathol 48(3):324-334.
Sakurai H. 2000. Recommendation of occupational exposure limits. J Occup Health 42(4):213-228.
Saleh SI, El-Okazy AM. 2007. Assessment of the mean daily dietary intake of acrylamide in Alexandria. 
J Egypt Public Health Assoc 82(3-4):331-345.
Sanchez J, Cabrer JM, Rossello CA, et al. 2008. Formation of hemoglobin adducts of acrylamide after 
its ingestion in rats is dependent on age and sex. J Agric Food Chem 56(13):5096-5101.
Satchell PM. 1984. Circulatory control in canine acrylamide neuropathy. J Auton Nerv Syst 10(2):93- 
106.
Satchell PM. 1990. Baroreceptor dysfunction in acrylamide axonal neuropathy. Brain 113 (Pt 1): 167­
176.
+*Satchell PM, McLeod JG. 1981. Megaoesophagus due to acrylamide neuropathy. J Neurol Neurosurg 
Psychiatry 44(10):906-913.
Satchell PM, McLeod JG. 1984. Abnormalities of oesophageal mechanoreceptors in canine acrylamide 
neuropathy. J Neurol Neurosurg Psychiatry 47(7):692-698.
*Rice JM. 2005. The carcinogenicity of acrylamide. Mutat Res 580(1-2):3-20.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 229
9. REFERENCES
Schaumburg HH, Spencer PS, Arezzo JC. 1985. Studies of the primate somatosensory system in 
experimental acrylamide intoxication. Neurotoxicology 6(4):3-6.
Schaumburg HH, Wisniewski HM, Spencer PS. 1974. Ultrastructural studies of the dying-back process:
1. Peripheral nerve terminal and axon degeneration in systemic acrylamide intoxication. J Neuropathol 
Exp Neurol 33(2):260-284.
*Schettgen T, Kutting B, Hornig M, et al. 2004a. Trans-placental exposure of neonates to acrylamide-a 
pilot study. Int Arch Occup Environ Health 77(3):213-216.
Schettgen T, Rossbach B, Kutting B, et al. 2004b. Determination of haemoglobin adducts of acrylamide 
and glycidamide in smoking and non-smoking persons of the general population. Int J Hyg Environ 
Health 207(6):531-539.
Schettgen T, Weiss T, Drexler H, et al. 2003. A first approach to estimate the internal exposure to 
acrylamide in smoking and non-smoking adults from Germany. Int J Hyg Environ Health 206(1):9-14.
Schmid TE, Xu W, Adler ID. 1999. Detection of aneuploidy by multicolor FISH in mouse sperm after in 
vivo treatment with acrylamide, colchicine, diazepam or thiabendazole. Mutagenesis 14(2): 173-179.
Schmidt RE, Plurad SB, Clark HB. 1987. Acrylamide-induced sympathetic autonomic neuropathy 
resulting in pineal denervation. Lab Invest 56(5):505-517.
Schotman P, Gipon L, Jennekens FG, et al. 1977. Polyneuropathies and CNS protein metabolism: II. 
Changes in the incorporation rate of leucine during acrylamide intoxication. Neuropathol Appl Neurobiol 
3(2): 125-136.
Schotman P, Gipon L, Jennekens FG, et al. 1978. Polyneuropathies and CNS protein metabolism: III. 
Changes in protein synthesis rate induced by acrylamide intoxication. J Neuropathol Exp Neurol 
37(6):820-837.
Schulz MR, Hertz-Picciotto I, van Wijngaarden E, et al. 2001. Dose-response relation between 
acrylamide and pancreatic cancer. Occup Environ Med 58(9):609.
+*Schulze GE, Boysen BG. 1991. A neurotoxicity screening battery for use in safety evaluation:
Effects of acrylamide and 3',3'-iminodipropionitrile. Fundam Appl Toxicol 16(3):602-615.
*Schumacher JN, Green CR, Best FW, et al. 1977. Smoke composition. An extensive investigation of 
the water-soluble portion of cigarette smoke. J Agric Food Chem 25(2):310-320.
*Sega GA, Generoso EE. 1990. Measurement of DNA breakage in specific germ-cell stages of male 
mice exposed to acrylamide, using an alkaline-elution procedure. Mutat Res 242:79-87.
*Sega GA, Alcota RP, Tancongco CP, et al. 1989. Acrylamide binding to the DNA and protamine of 
spermiogenic stages in the mouse and its relationship to genetic damage. Mutat Res 216(4):221-230.
*Sega GA, Generoso EE, Brimer PA. 1990. Acrylamide exposure induces a delayed unscheduled DNA 
synthesis in germ cells of male mice that is correlated with the temporal pattern of adduct formation in 
testis DNA. Environ Mol Mutagen 16(3): 137-142.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 230
9. REFERENCES
*Segerback D, Calleman CJ, Schroeder JL, et al. 1995. Formation of N-7-(2-carbamoyl-2- 
hydroxyethyl)guanine in DNA of the mouse and the rat following intraperitoneal administration of 
[14C]acrylamide. Carcinogenesis 16(5):1161-1165.
*Setchell BP, Waites GMH. 1975. The blood testis barrier. In: Creep RO, Astwood EB, Geiger SR, 
eds. Handbook of physiology: Endocrinology V. Washington, DC: American Physiological Society, 
143-172.
Settels E, Bernauer U, Palavinskas R, et al. 2008. Human CYP2E1 mediates the formation of 
glycidamide from acrylamide. Arch Toxicol 82(10):717-727.
Shabana AH, Oboeuf M, Forest N. 1994. Cytoplasmic desmosomes and intermediate filament 
disturbance following acrylamide treatment in cultured rat keratinocytes. Tissue Cell 26(1):43-55.
*Shelby MD, Cain KT, Cornett CV, et al. 1987. Acrylamide: Induction of heritable translocation in 
male mice. Environ Mutagen 9(4):363-368.
Shelby MD, Cain KT, Hughes LA, et al. 1986. Dominant lethal effects of acrylamide in male mice. 
Mutat Res 173(1):35-40.
Shell L, Rozum M, Jortner BS, et al. 1992. Neurotoxicity of acrylamide and 2,5-hexanedione in rats 
evaluated using a functional observational battery and pathological examination. Neurotoxicol Teratol 
14(4):273-283.
*Shipp A, Lawrence G, Gentry R, et al. 2006. Acrylamide: Review of toxicity data and dose-response 
analyses for cancer and noncancer effects. Crit Rev Toxicol 36(6-7):481-608.
*Shiraishi Y. 1978. Chromosome aberrations induced by monomeric acrylamide in bone marrow and 
germ cells of mice. Mutat Res 57:313-324.
Shivakumar BR, Ravindranath V. 1992. Selective modulation of glutathione in mouse brain regions and 
its effect on acrylamide-induced neurotoxicity. Biochem Pharmacol 43(2):263-270.
Shukla PK, Khanna VK, Ali MM, et al. 2002. Protective effect of Acorus calamus against acrylamide 
induced neurotoxicity. Phytother Res 16(3):256-260.
Sickles DW. 1987. Neural specificity of acrylamide action upon enzymes associated with oxidative 
energy-producing pathways: I. Histochemical analysis of NADH-tetrazolium reductase activity. 
Neurotoxicology 8(4):623-630.
Sickles DW. 1989a. Toxic neurofilamentous axonopathies and fast anterograde axonal transport: I. The 
effects of single doses of acrylamide on the rate and capacity of transport. Neurotoxicology 10(1):91- 
102.
Sickles DW. 1989b. Toxic neurofilamentous axonopathies and fast anterograde axonal transport. II.
The effects of single doses of neurotoxic and non-neurotoxic diketones and B,B'-iminodipropionitrile 
(IDPN) on the rate and capacity of transport. Neurotoxicology 10:103-112.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 231
*Sickles DW. 1991. Toxic neurofilamentous axonopathies and fast anterograde axonal transport. III. 
Recovery from single injections and multiple dosing effects of acrylamide and 2,5-hexanedione. Toxicol 
Appl Pharmacol 108(3):390-396.
Sickles DW. 1992. Toxic neurofilamentous axonopathies and fast anterograde axonal transport. IV. In 
vitro analysis of transport following acrylamide and 2,5-hexanedione. Toxicol Lett 61(2-3): 199-204.
Sickles DW, Goldstein BD. 1985. Acrylamide alters oxidative enzyme activity in rat motoneurons. 
Toxicol Lett 26(2-3): 111-118.
Sickles DW, Goldstein BD. 1986. Acrylamide produces a direct, dose-dependent and specific inhibition 
of oxidative metabolism in motoneurons. Neurotoxicology 7(1): 187-196.
Sickles DW, Testino A. 2005. Effects of subacute and chronic acrylamide dosing on fast-transported 
proteins into rat neuromuscular junctions [Abstract]. Toxicol Sci 84(1-S):316-317.
*Sickles DW, Brady ST, Testino A, et al. 1996. Direct effect of the neurotoxicant acrylamide on 
kinesin-based microtubule motility. J Neurosci Res 46(1): 7-17.
Sickles DW, Sperry AO, Testino A, et al. 2007. Acrylamide effects on kinesin-related proteins of the 
mitotic/meiotic spindle. Toxicol Appl Pharmacol 222(1): 111-121.
Sickles DW, Stone JD, Friedman MA. 2002. Fast axonal transport: A site of acrylamide neurotoxicity? 
Neurotoxicology 23(2):223-251.
Sickles DW, Welter DA, Friedman MA. 1995. Acrylamide arrests mitosis and prevents chromosome 
migration in the absence of changes in spindle microtubules. J Toxicol Environ Health 44(1):73-86.
Sidenius P, Jakobsen J. 1983. Anterograde axonal transport in rats during intoxication with acrylamide.
J Neurochem 40(3):697-704.
Simmons JE, Berman E, Jackson M, et al. 1987. In-vitro and in-vivo toxicity a comparison of 
acrylamide cyclophosphamide chlordecone and diethylstilbestrol. J Environ Sci Health A Environ Sci 
Eng Toxic Hazard Sub 22(7):639-664.
Sisti R, Lorenzon G, Cicales R. 2001. Neurotoxic effects of acrylamide in Sprague-Dawley rats by oral 
administration. [Abstract]. Front Fetal Health 3(11-12):288.
Smith EA, Oehme FW. 1991. Acrylamide and polyacrylamide a review of production use environmental 
fate and neurotoxicity. Rev Environ Health 9(4):215-225.
Smith CJ, Perfetti TA, Rumple MA, et al. 2000. "IARC Group 2A Carcinogens" reported in cigarette 
mainstream smoke. Food Chem Toxicol 38(4):371-383.
+*Smith MK, Zenick H, Preston RJ, et al. 1986. Dominant lethal effects of subchronic acrylamide 
administration in the male Long-Evans rat. Mutat Res 173(4):273-277.
SNF S.A.. 2000. Toxicological review of acrylamide (CAS No. 79-06-01). Ruston, Louisiana. Environ 
International Corporation. SNF S. A. Saint-Etienne Cedex, France. November 2002.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 232
+*Sobel W, Bond GG, Parsons TW, et al. 1986. Acrylamide cohort mortality study. Br J Ind Med 
43(11):785-788.
*Solomon JJ, Fedyk J, Mukai F, et al. 1985. Direct alkylation of 2'-deoxynucleosides and DNA 
following in vitro reaction with acrylamide. Cancer Res 45:3465-3470.
*Sörgel F, Weissenbacher R, Kinzig-Schippers M, et al. 2002. Acrylamide: Increased concentrations in 
homemade food and first evidence of its variable absorption from food, variable metabolism and placental 
and breast milk transfer in humans. Chemotherapy 48(6):267-274.
Souyri F, Chretien M, Droz B. 1981. Acrylamide-induced neuropathy and impairment of axonal 
transport of proteins: 1. Multifocal retention of fast transported proteins at the periphery of axons as 
revealed by light microscope radioautography. Brain Res 205(1): 1-13.
Spano M, Cordelli E, Leter G, et al. 1993. Genotoxic and cytotoxic effects of acrylamide on male germ 
cells. [Abstract]. Eur J Histochem 37(Suppl 2):84.
*Spencer PS, Schaumburg HH. 1974. A review of acrylamide neurotoxicity. Part I. Properties, uses 
and human exposure. Can J Neurol Sci 1(2): 143-150.
*Spencer PS, Schaumburg HH. 1977. Ultrastructural studies of the dying back process. IV. Differential 
vulnerability of PNS and CNS fibers in experimental central-peripheral distal axonopathies. J Neuropath 
Exp Neurol 36:300-320.
Spencer PS, Schaumburg HH. 1991. A review of acrylamide neurotoxicity. Part 2. Experimental 
animal neurotoxicity and pathologic mechanisms. Can J Neurol Sci 1(3): 152-169.
Spencer PS, Schaumburg HH. 1988. Analysis of neurotoxic disease: The acrylamide experience. In: 
Galli CL, Manzo L, Spencer PS, eds. Recent advances in nervous system toxicology. New York, NY : 
Plenum Press, 163-176.
*Spencer PS, Sabri MI, Schaumberg HH, et al. 1979. Does a defect of energy metabolism in the nerve 
fiber underlie axonal degeneration in polyneuropathies? Ann Neurol 5:501-507.
*SRI. 2008. Acrylamide. In: 2008 Directory of chemical producers. Menlo Park, CA: SRI Consulting, 
410.
Srivastava SP, Das M, Mukhtar H, et al. 1984. Effect of acrylamide on glutathione-s-transferase activity 
in different regions of rat brain. Bull Environ Contam Toxicol 32(2): 166-170.
Srivastava SP, Das M, Seth PK. 1983. Enhancement of lipid peroxidation in rat liver on acute exposure 
to styrene and acrylamide a consequence of glutathione depletion. Chem Biol Interact 45(3):373-380.
Srivastava SP, Sabri MI, Agrawal AK, et al. 1986. Effect of single and repeated doses of acrylamide and 
bisacrylamide on glutathione-s-transferase and dopamine receptors in rat brain. Brain Res 371(2):319- 
323.
Srivastava SP, Seth PK, Das M, et al. 1985. Effects of mixed-function oxidase modifiers on 
neurotoxicity of acrylamide in rats. Biochem Pharmacol 34(7): 1099-1102.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 233
9. REFERENCES
Stadler RH. 2005. Acrylamide formation in different foods and potential strategies for reduction. Adv 
Exp Med Biol 561:157-169.
Stadler RH, Anklam E. 2007. Update on the progress in acrylamide and furan research. Food Addit 
Contam 24(Suppl 1):1-2.
*Stadler RH, Blank I, Varga N, et al. 2002. Acrylamide from Maillard reaction products. Nature 
419(6906):449-450.
*Stamler JS, Lamas S, Fang C. 2001. Nitrosylation: the prototypic redox-based signaling mechanism. 
Cell 106(6):675-683.
Sterman AB. 1983. Altered sensory ganglia in acrylamide neuropathy: Quantitative evidence of 
neuronal reorganization. J Neuropathol Exp Neurol 42(2): 166-176.
Sterman AB, Panasci DJ, Persons W. 1983a. Does pyruvate prevent acrylamide neurotoxicity? 
Implications for disease pathogenesis. Exp Neurol 82(1): 148-158.
Sterman AB, Panasci DJ, Sheppard RC. 1983b. Autonomic-cardiovascular dysfunction accompanies 
sensory-motor impairment during acrylamide intoxication. Neurotoxicology 4(1):45-52.
Stetkiewicz J, Wronska-Nofer T, Klimczak J, et al. 1988. Metabolic interaction and neurological effect 
of combined exposure to acrylamide and ethanol. Pol J Occup Med 1(2): 127-136.
Stobiecka A, Radecka H, Radecki J. 2007. Novel voltammetric biosensor for determining acrylamide in 
food samples. Biosens Bioelectron 22(9-10):2165-2170.
+*Sublet VH, Zenick H, Smith MK. 1989. Factors associated with reduced fertility and implantation 
rates in females mated to acrylamide-treated rats. Toxicology 55:53-67.
Sumizawa T, Igisu H. 2007. Apoptosis induced by acrylamide in SH-SY5Y cells. Arch Toxicol 
81(4):279-282.
Sumizawa T, Igisu H. 2008. Release of heat shock proteins from human neuroblastoma cells exposed to 
acrylamide. J Toxicol Sci 33(1): 117-122.
Sumner AJ, Asbury AK. 1975. Physiological studies of the dying-back phenomenon. Muscle stretch 
afferents in acrylamide neuropathy. Brain 98:91-100.
Sumner A, Pleasure D, Ciesielka K. 1976. Slowing of fast axoplasmic transport in acrylamide 
neuropathy. J Neuropathol Exp Neurol 35(3):319.
*Sumner SC, Fennell TR, Moore TA, et al. 1999. Role of cytochrome P450 2E1 in the metabolism of 
acrylamide and acrylonitrile in mice. Chem Res Toxicol 12(11): 1110-1116.
*Sumner SC, Macneela JP, Fennell TR. 1992. Characterization and quantitation of urinary metabolites 
of (1,2,3-13carbon)acrylamide in rats and mice using 13carbon nuclear magnetic resonance spectroscopy. 
Chem Res Toxicol 5(1):81-89.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 234
*Sumner SC, Williams CC, Snyder RW, et al. 2003. Acrylamide: A comparison of metabolism and 
hemoglobin adducts in rodents following dermal, intraperitoneal, oral, or inhalation exposure. Toxicol 
Sci 75(2):260-270.
*Suzuki K, Pfaff L. 1973. Acrylamide neuropathy in rats. Acta Neuropathol (Berl) 24(3):197-213.
*Svensson K, Abramsson L, Becker W, et al. 2003. Dietary intake of acrylamide in Sweden. Food 
Chem Toxicol 41(11):1581-1586.
*Swaen GM, Haidar S, Burns CJ, et al. 2007. Mortality study update of acrylamide workers. Occup 
Environ Med 64(6):396-401.
*Takahashi M, Ohara T, Hashimoto K. 1971. Electrophysiological study of nerve injuries in workers 
handling acrylamide. Int Arch Arbeitsmed 28(1): 1-11.
Takahashi M, Shibutani M, Inoue K, et al. 2008. Pathological assessment of the nervous and male 
reproductive systems of rat offspring exposed maternally to acrylamide during the gestation and lactation 
periods-a preliminary study. J Toxicol Sci 33(1): 11-24.
*Takahashi M, Shibutani M, Nakahigashi J, et al. 2009. Limited lactational transfer of acrylamide to rat 
offspring on maternal oral administration during the gestation and lactation periods. Arch Toxicol 
[March 21; Epub ahead of print]
Tandrup T, Braendgaard H. 1994. Number and volume of rat dorsal root ganglion cells in acrylamide 
intoxication. J Neurocytol 23(4):242-248.
Tanii H, Hashimoto K. 1981. In vitro metabolism of acrylamide and related compounds. Arch Toxicol 
48(2-3): 157-166.
+*Tanii H, Hashimoto K. 1983. Neurotoxicity of acrylamide and related compounds in rats: Effects on 
rotarod performance, morphology of nerves and neurotubulin. Arch Toxicol 54(3):203-214.
Tanii H, Hashimoto K. 1985. Effect of acrylamide and related compounds on glycolytic enzymes of rat 
brain. Toxicol Lett 26(1):76-84.
Tanii H, Hashimoto K. 1991. In vitro neurotoxicity study with dorsal root ganglia for acrylamide and its 
derivatives. Toxicol Lett 58(2):209-213.
Tanii H, Hayashi M, Hashimoto K. 1988. Neurofilament degradation in the nervous system of rats 
intoxicated with acrylamide related compounds or 2,5-hexanedione. Arch Toxicol 62(1):70-75.
Tanii H, Miki N, Hayashi M, et al. 1988. Cytotoxicity of acrylamide and related compounds to mouse 
neuroblastoma and rat Schwannoma cells. Arch Toxicol 61(4):298-305.
Tareke E, Lyn-Cook B, Robinson B, et al. 2008. Acrylamide: a dietary carcinogen formed in vivo? J 
Agric Food Chem 56(15):6020-6023.
*Tareke E, Rydberg P, Karlsson P, et al. 2002. Analysis of acrylamide, a carcinogen formed in heated 
foodstuffs. J Agric Food Chem 50(17):4998-5006.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 235
Tareke E, Twaddle NC, McDaniel LP, et al. 2006. Relationships between biomarkers of exposure and 
toxicokinetics in Fischer 344 rats and B6C3F1 mice administered single doses of acrylamide and 
glycidamide and multiple doses of acrylamide. Toxicol Appl Pharmacol 217(1):63-75.
Taubert D, Glockner R, Muller D, et al. 2006. The garlic ingredient diallyl sulfide inhibits cytochrome 
P450 2E1 dependent bioactivation of acrylamide to glycidamide. Toxicol Lett 164(1): 1-5.
Taylor DD, Jortner BS, Walton A, et al. 1995. An immunohistochemical study of the cytoskeleton of 
SH-SY5Y human neuroblastoma cells, and the effects of acrylamide. In Vitro Toxicol 8(3):323-333.
Thomann P, Koella WP, Krinke G, et al. 1974. The assessment of peripheral neurotoxicity in dogs: 
Comparative studies with acrylamide and clioquinol. Inflamm Res 4(1):47-53.
*Thomas K, Colborn T. 1992. Organochlorine endocrine disruptors in human tissue. In: Colborn T, 
Clement C, eds. Chemically induced alterations in sexual and functional development: The 
wildlife/human connection. Princeton, NJ: Princeton Scientific Publishing, 365-394.
+*Tilson HA, Cabe PA. 1979. The effects of acrylamide given acutely or in repeated doses on fore- and 
hindlimb function of rats. Toxicol Appl Pharmacol 47(2):253-260.
Tilson HA, Cabe PA, Spencer PS. 1979. Acrylamide neurotoxicity in rats: A correlated neurobehavioral 
and pathological study. Neurotoxicology 1(1):89-104.
*Tong GC, Cornwell WK, Means GE. 2004. Reactions of acrylamide with glutathione and serum 
albumin. Toxicol Lett 147:127-131.
Tornqvist M, Paulsson B, Vikstrom AC, et al. 2008. Approach for cancer risk estimation of acrylamide 
in food on the basis of animal cancer tests and in vivo dosimetry. J Agric Food Chem 56(15):6004-6012.
Totani N, Yawata M, Ojiri Y, et al. 2007. Effects of trace acrylamide intake in Wistar rats. J Oleo Sci 
56(9):501-506.
*TRI 07 2009. 2009. TRI Explorer. Providing access to EPA's toxics release inventory data. U. S. 
Environmental Protection Agency. http://www.epa.gov/triexplorer. March 18, 2009.
*Tripathy NK, Patnaik KK, Nabi MJ. 1991. Acrylamide is genotoxic to the somatic and germ cells of 
Drosophila melanogaster. Mutat Res 259(1):21-27.
*Tsuda H, Shimizu CS, Taketomi MK, et al. 1993. Acrylamide; induction of DNA damage, 
chromosomal aberrations and cell transformation without gene mutations. Mutagenesis 8(1):23-29.
*Twaddle NC, McDaniel LP, Gamboa da Costa G, et al. 2004. Determination of acrylamide and 
glycidamide serum toxicokinetics in B6C3Fj mice using LC-ES/MS/MS. Cancer Lett 207(1):9-17.
*Tyl RW, Friedman MA. 2003. Effects of acrylamide on rodent reproductive performance. Reprod 
Toxicol 17(1): 1-13.
+*Tyl RW, Friedman MA, Losco PE, et al. 2000a. Rat two-generation reproduction and dominant lethal 
study of acrylamide in drinking water. Reprod Toxicol 14(5):385-401.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 236
9. REFERENCES
+*Tyl RW, Marr MC, Myers CB, et al. 2000b. Relationship between acrylamide reproductive and 
neurotoxicity in male rats. Reprod Toxicol 14(2): 147-157.
+*Union Carbide Corporation. 1947. Range finding tests on acrylamide with cover letter. Submitted to 
the U.S. Environmental Protection Agency under TSCA Section 8D. EPA878212200. OTS206058.
U.S. Army. 2007. A Population-based study of dietary acrylamide and prostate cancer risk. Fort 
Detrick, MD: U.S. Army Medical Research and Material Command. W81XWH-04-1-0288.
Uphouse LL, Nemeroff CB, Mason G, et al. 1982. Interactions between "handling" and acrylamide on 
endocrine responses in rats. Neurotoxicology 3(1): 121-125.
Urban M, Kavvadias D, Riedel K, et al. 2006. Urinary mercapturic acids and a hemoglobin adduct for 
the dosimetry of acrylamide exposure in smokers and nonsmokers. Inhal Toxicol 18(10):831-839.
Valdivia RP, Lafuente NM, Katoh M. 1989. Acrylamide-induced chromosome-type aberrations in 
spermiogenic stages evaluated in the first cleavage metaphases in the mouse. [Abstract]. Environ Mol 
Mutagen 14(Suppl 15):205.
*van Dijk-Looijaard AM, van Genderen J. 2000. Levels of exposure from drinking water. Food Chem 
Toxicol 38(Suppl. 1):S37-S42.
Vanhorick M, Moens W. 1983. Carcinogen-mediated induction of SV40 DNA amplification is enhanced 
by acrylamide in Chinese hamster CO60 cells. Carcinogenesis 4(11): 1459-1463.
Vesper HW, Bernert JT, Ospina M, et al. 2007. Assessment of the relation between biomarkers for 
smoking and biomarkers for acrylamide exposure in humans. Cancer Epidemiol Biomarkers Prev 
16(11):2471-2478.
Vesper HW, Slimani N, Hallmans G, et al. 2008. Cross-sectional study on acrylamide hemoglobin 
adducts in subpopulations from the European Prospective Investigation into Cancer and Nutrition (EPIC) 
Study. J Agric Food Chem 56(15):6046-6053.
*Vieira I, Sonnier M, Cresteil T. 1996. Developmental expression of CYP2E1 in the human liver: 
Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 238(2):476-483.
Vikstrom AC, Eriksson S, Paulsson B, et al. 2008. Internal doses of acrylamide and glycidamide in mice 
fed diets with low acrylamide contents. Mol Nutr Food Res 52(8):974-980.
*Von Tungeln LS, Churchwell MI, Doerge DR, et al. 2009. DNA adduct formation and induction of 
micronuclei and mutations in B6C3F1/Tk mice treated neonatally with acrylamide or glycidamide. Int J 
Cancer 124(9):2006-2015.
Voogd CE, van der Stel JJ, Jacobs JJ. 1981. The mutagenic action of aliphatic epoxides. Mutat Res 
89(4):269-282.
Walden R, Schiller CM. 1981. Quantitative analysis of acrylamide in the milk of lactating rats following 
oral in-vivo exposure. [Abstract]. Fed Proc 40(3 Part 1):678.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 237
9. REFERENCES
+*Walden R, Squibb RE, Schiller CM. 1981. Effects of prenatal and lactational exposure to acrylamide 
on the development of intestinal enzymes in the rat. Toxicol Appl Pharmacol 58:363-369.
*Walker K, Hattis D, Russ A, et al. 2007. Approaches to acrylamide physiologically based toxicokinetic 
modeling for exploring child-adult dosimetry differences. J Toxicol Environ Health A 70(24):2033-2055.
Walker RA, O'Brien ET, Epstein DL, et al. 1997. N-ethylmaleimide and ethacrynic acid inhibit kinesin 
binding to microtubules in a motility assay. Cell Motil Cytoskeleton 37(4):289-299.
Walum E, Flint OP. 1988. Sub-teratogenic neurotoxic effects of acrylamide. [Abstract]. Teratology 
37(5):499.
Walum E, Flint OP. 1993. Selective effects of acrylamide, methylene bisacrylamide, and haloperidol on 
neuronal development in rat embryo midbrain micromass cultures. In Vitro Toxicol 6(2): 125-134.
*Warr TJ, Parry JM, Callander RD, et al. 1990. Methyl vinyl sulphone: A new class of Michael-type 
genotoxin. Mutat Res 245:191-199.
Weir RL, Glaubiger G, Chase TN. 1978. Inhibition of fast axoplasmic transport by acrylamide. Environ 
Res 17(2):251-255.
Wenzl T, Anklam E. 2007. European Union database of acrylamide levels in food: Update and critical 
review of data collection. Food Addit Contam 24 (Suppl 1):5-12.
*West JR, Smith HW, Chasis H. 1948. Glomerular filtration rate, effective renal blood flow, and 
maximal tubular excretory capacity in infancy. J Pediatr 32:10-18.
*WHO. 2000. Air quality guidelines. 2nd edition. Geneva, Switzerland: World Health Organization. 
http://www.euro.who.int/air/activities/20050223_4. May 11, 2009.
*WHO. 2002. Health implications of acrylamide in food. World Health Organization. 
http://www.who.int/foodsafety/publications/chem/en/acrylamide_full.pdf. May 5, 2009.
*WHO. 2003. Acrylamide in drinking-water. World Health Organization. WHO/SDE/WSH/03.04/71. 
http://www.who.int/water_sanitation_health/dwq/chemicals/acrylamide.pdf. May 5, 2009.
*WHO. 2006. Guidelines for drinking-water quality. 3rd edition. Geneva, Switzerland: World Health 
Organization. http://www.who.int/water_sanitation_health/dwq/gdwq3/en/. May 11, 2009.
*Widdowson EM, Dickerson JWT. 1964. Chemical composition of the body. In: Comar CL, Bronner 
F, eds. Mineral metabolism: An advance treatise. Volume II: The elements Part A. New York, NY: 
Academic Press, 1-247.
Wild HM, Kulikowski JJ. 1984. Neurotoxic effects of acrylamide on rat retinogeniculate fibres. Behav 
Brain Res 13(3):201-207.
+*Wilson KM, Balter K, Adami HO, et al. 2009a. Acrylamide exposure measured by food frequency 
questionnaire and hemoglobin adduct levels and prostate cancer risk in the cancer of the prostate in 
Sweden study. Int J Cancer 124(10):2384-2390.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 238
+*Wilson KM, Mucci LA, Cho E, et al. 2009b. Dietary acrylamide intake and risk of premenopausal 
breast cancer. Am J Epidemiol 169(8):954-961.
Wilson KM, Vesper HW, Tocco P, et al. 2009c. Validation of a food frequency questionnaire 
measurement of dietary acrylamide intake using hemoglobin adducts of acrylamide and glycidamide. 
Cancer Causes Control 20(3):269-278.
Wirfalt E, Paulsson B, Tornqvist M, et al. 2008. Associations between estimated acrylamide intakes, and 
hemoglobin AA adducts in a sample from the Malmö diet and cancer cohort. Eur J Clin Nutr 62(3):314- 
323.
+*Wise LD, Gordon LR, Soper KA, et al. 1995. Developmental neurotoxicity evaluation of acrylamide 
in Sprague-Dawley rats. Neurotoxicol Teratol 17(2): 189-198.
Wispriyono B, Matsuoka M, Igisu H. 2004. Acrylamide does not cause apparent changes in genetic 
expression of creatine kinase in rat cerebellum. Journal of UOEH 26(1):51-57.
Woo GH, Shibutani M, Kuroiwa K, et al. 2007. Lack of preventive effects of dietary fibers or 
chlorophyllin against acrylamide toxicity in rats. Food Chem Toxicol 45(8): 1507-1515.
+*Working PK, Bentley KS, Hurtt ME, et al. 1987. Dominant lethal assay of acrylonitrile and 
acrylamide in the male rat. [Abstract]. Environ Mutagen 9(Suppl 8):115.
Wu Q, Sidoryk M, Mutkus L, et al. 2005. Acrylamide stimulates glutamine uptake in Fischer 344 rat 
astrocytes by a mechanism involving upregulation of the amino acid transport system N. Ann N Y Acad 
Sci 1053:435-443.
*Xiao Y, Tates AD. 1994. Increased frequencies of micronuclei in early spermatids of rats following 
exposure of young primary spermatocytes to acrylamide. Mutat Res 309(2):245-253.
Xie Q, Liu Y, Sun H, et al. 2008. Inhibition of acrylamide toxicity in mice by three dietary constituents.
J Agric Food Chem 56(15):6054-6060.
Xie Q, Sun H, Liu Y, et al. 2006. Adduction of biomacromolecules with acrylamide (AA) in mice at 
environmental dose levels studied by accelerator mass spectrometry. Toxicol Lett 163(2): 101-108.
Yang HJ, Lee SH, Jin Y, et al. 2005a. Genotoxicity and toxicological effects of acrylamide on 
reproductive system in male rats. J Vet Sci 6(2): 103-109.
Yang HJ, Lee SH, Jin Y, et al. 2005b. Toxicological effects of acrylamide on rat testicular gene 
expression profile. Reprod Toxicol 19(4):527-534.
Yaylayan VA, Stadler RH. 2005. Acrylamide formation in food: A mechanistic perspective. J AOAC 
Int 88(1):262-267, 253.
Yi C, Xie K, Song F, et al. 2006. The changes of cytoskeletal proteins in plasma of acrylamide-induced 
rats. Neurochem Res 31(6):751-757.
*Young JF, Luecke RH, Doerge DR. 2007. Physiologically based pharmacokinetic/pharmacodynamic 
model for acrylamide and its metabolites in mice, rats, and humans. Chem Res Toxicol 20(3):388-399.
9. REFERENCES
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 239
9. REFERENCES
Yousef MI, El-Demerdash FM. 2006. Acrylamide-induced oxidative stress and biochemical 
perturbations in rats. Toxicology 219(1-3):133-141.
Youssef AF, Santi BW. 1997. Simple neurobehavioral functional observational battery and objective 
gait analysis validation by the use of acrylamide and methanol with a built-in recovery period. Environ 
Res 73(1-2):52-62.
Youssif MI, Ismail AA, Fayed MA, et al. 1995. Effect of acrylamide on the central nervous system of 
rats histochemical and histopathological studies. J Med Res Inst 16(4): 1-17.
Yu S, Son F, Yu J, et al. 2006. Acrylamide alters cytoskeletal protein level in rat sciatic nerves. 
Neurochem Res 31(10):1197-1204.
Yuan Y, Chen F, Zhao GH, et al. 2007. A comparative study of acrylamide formation induced by 
microwave and conventional heating methods. J Food Sci 72(4):C212-C216.
Zaidi SI, Raisuddin S, Singh KP, et al. 1994. Acrylamide induced immunosuppression in rats and its 
modulation by 6-MFA, an interferon inducer. Immunopharmacol Immunotoxicol 16(2): 247-260.
*Zeiger, E. Anderson, B, Haworth, S, et al. 1987. Salmonella mutagenicity tests. III. Results from the 
testing of 255 chemicals. Environ Mutatagen 9(Suppl 9):1-110.
*Zeiger E, Recio L, Fennell TR, et al. 2009. Investigation of the low-dose response in the in vivo 
induction of micronuclei and adducts by acrylamide. Toxicol Sci 107(1):247-257.
+*Zenick H, Hope E, Smith MK. 1986. Reproductive toxicity associated with acrylamide treatment in 
male and female rats. J Toxicol Environ Health 17(4):457-472.
Zhang X, Jiang L, Geng C, et al. 2008. Inhibition of acrylamide genotoxicity in human liver-derived 
HepG2 cells by the antioxidant hydroxytyrosol. Chem Biol Interact 176(2-3): 173-178.
Zhang X, Zhao C, Jie B. 2009. Various dietary polyunsaturated fatty acids modulate acrylamide-induced 
preneoplatic urothelial proliferation and apoptosis in mice. Exp Toxicol Pathol [Jan 29; Epub ahead of 
print]
*Zhu YJ, Zeng T, Zhu YB, et al. 2008. Effects of acrylamide on the nervous tissue antioxidant system 
and sciatic nerve electrophysiology in the rat. Neurochem Res 33(11):2310-2317.
*Ziegler EE, Edwards BB, Jensen RL, et al. 1978. Absorption and retention of lead by infants. Pediatr 
Res 12(1):29-34.
Zodl B, Schmid D, Wassler G, et al. 2007. Intestinal transport and metabolism of acrylamide. 
Toxicology 232(1-2):99-108.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE
9. REFERENCES
240
This page is intentionally blank.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE 241
10. GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response. For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%. The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals). In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure. These may suggest 
some potential topics for scientific research, but are not actual research studies.
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Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome. At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs— Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point 
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero 
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information. A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects.
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Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals.
Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period.
Intermediate Exposure—Exposure to a chemical for a duration of 15-364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration^ )  (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1.
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Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
Mutagen—A substance that causes mutations. A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control. Effects may be produced at this dose, but they are not 
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based 
and physiologically-based. A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose- 
response model that quantitatively describes the relationship between target tissue dose and toxic end
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points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows. These models require a 
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time.
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study. A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure. The qi* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually ^g/L for water, mg/kg/day for food, and 
^g/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. 
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical. The RfDs are not applicable to 
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related 
endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system.
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Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past. Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
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Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest- 
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.
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APPENDIX A. ATSDR MINIMAL RISK LEVELS AND W ORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99­
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance. During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects. MRLs are derived for acute (1-14 days), intermediate (15-364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level 
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that
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are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public. They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-32, Atlanta, Georgia 30333.
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APPENDIX A
MINIMAL RISK LEVEL (MRL) W ORKSHEET
Chemical Name: 
CAS Numbers: 
Date:
Profile Status: 
Route:
Duration:
Graph Key: 
Species:
Acrylamide
79-06-1
August 27, 2009
Draft for Public Comment
[ ] Inhalation [x] Oral
[x] Acute [ ] Intermediate [ ] Chronic
33
Rat
Minimal Risk Level: 0.02 [x] mg/kg/day [ ] ppm
Reference: Sublet VH, Zenick H, Smith MK. 1989. Factors associated with reduced fertility and 
implantation rates in females mated to acrylamide-treated rats. Toxicology 55:53-67.
Experimental design: Groups of male Long-Evans hooded rats (15/group) were administered acrylamide 
(in distilled water) by oral gavage for 5 days at doses of 0, 30, 45, or 60 mg/kg/day (experiment 1) and 0, 
5, or 15 mg/kg/day (experiment 2). Males were then mated on weeks 1, 2, 3, 4, 7, and 10 to proestrus 
females (weeks 1-4 only for experiment 2). Mating was confirmed by vaginal lavage. Females were 
sacrificed on gestation day 15 and numbers of corpora lutea, implantation sites, and fetuses were 
determined and estimates of pre- and postimplantation losses were calculated.
Effect noted in study and corresponding doses: Effects of acrylamide exposure on mating, fertility, and 
pre-and postimplantation losses are summarized in Table A-1. There were no significant treatment- 
related effects on mating index (number of sperm positive/number mated) at any dose level and no 
significant effects on any measures of reproductive success at the 5 mg/kg/day dose level. Assessments 
of reproductive indices at week 1 revealed significantly depressed fertility rates and elevated 
preimplantation losses at doses >15 mg/kg/day. Increased postimplantation loss was seen at weeks 2 and 
3 at doses >15 mg/kg/day. In sperm samples collected from the 45 mg/kg/day group, the percentage of 
motile sperm was modestly (but significantly) decreased (58 vs. 73% in controls) at week 3, but not at 
weeks 2 or 4. This study identified a NOAEL of 5 mg/kg/day and a LOAEL of 15 mg/kg/day for 
significantly decreased fertility and increased preimplantation loss during week 1 posttreatment and 
significantly increased postimplantation loss during weeks 2 and 3 posttreatment.
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Table A-1. Effects of Acrylamide on Selected Reproductive Indices Following 
Gavage Dosing of Male Long-Evans Rats for 5 Days
T reatm ent 
(m g/kg)
Post­
trea tm ent
m ating
w eek
M ating
index
(percent)a
Fertility
index
(percent)b
P re im plantation 
loss index 
(percent)0
Postim planta tion 
loss index 
(percent)d
Controle 1 25/30 83) 22/25 (88) 19.57 4.20
2 26/30 87) 25/26 (96) 11.54 5.70
3 29/30 97) 28/29 (97) 11.46 6.80
4 27/30 90) 26/27 (96) 9.48 5.00
5 1 15/15 100) 12/15 (80) 24.29 8.30
2 14/15 93) 11/14 (79) 25.40 10.80
3 15/15 100) 14/15 (93) 10.77 5.40
4 13/15 (87) 11/13 (85) 17.08 7.10
15 1 13/15 (87) 6/13 (46)f 74.69f 10.30
2 11/15 (73) 11/11 (100) 8.5 15.40f
3 13/15 (87) 12/13 (92) 13.42 15.70f
4 13/15 (87) 12/13 (92) 10.36 5.50
30 1 12/15 (80) 2/12 (17)f 97.83f 0.00
2 15/15 100) 15/15 (100) 15.90 25.40f
3 15/15 100) 14/15 (93) 14.51 35.00f
4 15/15 100) 15/15 (100) 4.90 17.50
45 1 13/15 (87) 2/13 (15)f 85.89f 26.77
2 15/15 100) 12/15 (80) 33.04f 60.77f
3 15/15 100) 10/15 (67)f 59.13f 55.50f
4 15/15 100) 15/15 (100) 11.60 7.67
60 1 15/15 100) 1/15 (7)f 98.33f 33.33
2 15/15 100) 8/15 (53)f 73.39f 77.87f
3 15/15 100) 1/15 (7)f 98.80f 50.00f
4 15/15 100) 9/15 (60)f 70.84* 17.11*
a Mating index = number sperm/positive females/number mated. 
b Fertility index = number pregnant/number sperm-positive females.
c Preimplantation loss = (number of corpora lutea/female -  number of implant sites/female)/(number of corpora 
lutea/female) x 100.
d Postimplantation loss = (number of implant sites/female -  number of fetuses/females)/(number of implant 
sites/female) x 100.
e Control data from “high” and “low” dose dominant lethal studies are combined for tabular presentation. However 
statistical differences associated with acrylamide treatment are based upon comparison with appropriate control 
group. 
p<0.05
Source: Sublet et al. 1989
Dose and end point used for MRL derivation: 1.78 mg/kg/day (BMDL10) for decreased fertility in rats (as 
assessed by number of nonpregnant rats/number of sperm-positive females) following oral administration 
of acrylamide to male Long-Evans hooded rats for 5 days and subsequent mating with untreated female 
rats (see Table A-2).
All dichotomous models in the EPA Benchmark Dose Software (Version 2.1) were fit to the fertility data 
shown in Table A-2. Although the magnitude of the fertility response represents a more serious effect,
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the group sizes in this study (15 male rats/dose) did not support a benchmark response (BMR) lower than 
10%; thus, an extra risk incidence of 10% above controls was selected as the BMR. Model results for the 
data on fertility are shown in Table A-3. All dichotomous models provided adequate fit to the data 
(p>0.1). Comparing across models, a better fit is generally indicated by a lower Akaike’s Information 
Criteria (AIC). The multistage (1-degree polynomial) and quantal linear models converged on the same 
model providing the best fit (as assessed by AIC) to the fertility data; these models both predicted a 
BMD10 of 2.44 mg/kg/day and a BMDLJ0 of 1.78 mg/kg/day. Figure A-1 shows the fit of the multistage 
(1-degree polynomial) model to the fertility data.
Table A-2. Selected Results of Attempted Impregnation by Male Rats 
Administered Acrylamide by Gavage for 5 Days Prior to Mating 
with Untreated Female Rats During Week 1 Posttreatment
APPENDIX A
Dose (m g/kg/day)
0 5 15 30 45 60
Number sperm-positive females 25 15 13 12 13 15
Number nonpregnant females 3 (12%) 3 (20%) 7 (54%) 10 (83%) 11 (85%) 14 (93%)
Source: Sublet et al. 1989
Table A-3. Model Predictions for the Fraction of Unsuccessful Impregnation 
(Number of Nonpregnant Females/Number of Sperm-Positive Females) 
Among Male Rats Administered Acrylamide by Gavage for 5 Days 
and Mated to Untreated Female Rats During Week 1 Posttreatment
Model
BM D 10
(m g/kg/day)
BM D L10
(m g/kg/day) X2 p-value A IC
Gammaa 3.51 1.80 0.84 87.48
Logistic 6.02 4.48 0.53 87.71
Log-logisticb 4.76 1.55 0.95 86.98
Log-probitb 4.79 3.01 0.94 87.01
M ulti-stagec 2.44 1.78 0.91 85.69
Probit 6.02 4.67 0.44 88.31
Weibulla 3.13 1.80 0.83 87.56
Quantal linear 2.44 1.78 0.91 85.69
aPower restricted to >1. 
bSlope restricted to >1.
cBetas restricted to >0; lowest degree polynomial with adequate fit is reported; degree of p o ly n o m ia l!  
AIC = Akaike's Information Criteria; BMD = benchmark dose
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Figure A-1. Predicted and Observed Fractions of Unsuccessful Impregnation 
(Number of Nonpregnant Females/Number of Sperm-Positive Females) by Male 
Rats Administered Acrylamide by Gavage for 5 Days and Mated to Untreated 
Female Rats During Week 1 Posttreatment *
APPENDIX A
Multistage Model with 0.95 Confidence Level
dose
10:57 06/03 2009
*BMD and BMDL associated with a 10% extra risk increase over control are shown; doses given in units of 
mg/kg/day.
[ ] NOAEL [ ] LOAEL [x] Benchmark
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[x] 10 for extrapolation from animals to humans
[x] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? No.
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Other additional studies or pertinent information that lend support to this MRL: As demonstrated in 
Table 3-4 (Levels of Significant Exposure to Acrylamide -  Oral), male-mediated implantation loss and 
decreased mean body weight gain represent the most sensitive effects of acute-duration oral exposure to 
acrylamide. The lowest dose level reported to induce significantly decreased male-mediated implantation 
loss was 15 mg/kg/day in male Long-Evans rats administered acrylamide by gavage for 5 days followed 
by mating sessions with unexposed female rats (Sublet et al. 1989); this study identified a NOAEL of 
5 mg/kg/day. A similarly-designed study (Tyl et al. 2000b) confirmed the findings of acrylamide-induced 
increased implantation loss, although, based on pairwise comparisons with controls, statistical 
significance was achieved only at the highest dose level (60 mg/kg/day). Tyl et al. (2000b) also noted 
significantly decreased body weight gain (>40% lower than controls) during the 5 days of dosing, a 
finding not included in the study report of Sublet et al. (1989). Based on the reproducible results for 
male-mediated implantation loss in the studies of Sublet et al. (1989) and Tyl et al. (2000b) and the lack 
of supporting information regarding the body weight effects, the male-mediated implantation loss was 
selected as the critical effect for deriving an acute-duration oral MRL for acrylamide. The study of Sublet 
et al. (1989) identified the lowest LOAEL for the critical effect and was therefore selected as the principal 
study
Results of several other studies corroborate the findings of male-mediated decreases in fertility and 
increases in implantation losses following oral exposure to acrylamide (Chapin et al. 1995; Sakamoto and 
Hashimoto 1986; Smith et al. 1986; Tyl et al. 2000a; Zenick et al. 1986).
Agency Contacts (Chemical Managers): Patricia Ruiz, Ph.D.; Obaid Faroon, Ph.D.; Moiz Mumtaz, Ph.D.
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APPENDIX A
MINIMAL RISK LEVEL (MRL) W ORKSHEET
Chemical Name: Acrylamide
CAS Numbers: 79-06-1
Date: August 27, 2009
Profile Status: Draft for Public Comment
Route: [ ] Inhalation [x] Oral
Duration: [ ] Acute [x] Intermediate [ ] Chronic
Graph Key: 63
Species: Rat
Minimal Risk Level: 0.002 [x] mg/kg/day [ ] ppm
Reference: Burek JD, Albee RR, Beyer JE, et al. 1980. Subchronic toxicity of acrylamide administered 
to rats in the drinking water followed by up to 144 days of recovery. J Environ Pathol Toxicol 4(5- 
6): 157-182.
Experimental design: Groups of 6-week-old male (23-29/group) and female (10/group) F344 rats were 
administered acrylamide in the drinking water for up to 93 days at concentrations designed to result in 
acrylamide intakes of 0, 0.05, 0.2, 1, 5, or 20 mg/kg/day. Ten rats/sex/group were assigned to the basic 
90-day study and were observed for body weight and water consumption (recorded weekly) throughout 
the treatment period. Following 7 and 33 days of treatment, three control and three high-dose male rats 
were sacrificed for interim electron microscopic examination of the sciatic nerve. Ten male (nine in the 
high-dose group, due to one death prior to treatment termination) and all female rats from each treatment
group were subjected to gross and histopathologic examination of all major organs and tissues at the end
of the treatment period, at which time, three other male rats from each group were processed for electron 
microscopic examination of the sciatic nerve. The remaining rats (all males) in each group were observed 
for signs of recovery from treatment-related effects for up to 144 days following cessation of treatment. 
Three rats/group were subjected to electron microscopic examination of the sciatic nerve on recovery 
days 25, 111, and 144. Body weights were recorded for two rats/dose level prior to sacrifice on recovery 
day 111. At the end of the 144-day recovery period, the remaining four rats of each dose level were 
weighed and sacrificed for gross and histopathologic examination of all major organs and tissues.
All rats were observed daily (during the 5-day work week) for general health and clinical signs. Hindlimb 
foot splay was measured weekly in four control and four high-dose (20 mg/kg/day) male and female rats 
until the onset of neuropathy was detected, after which neuropathy in the high-dose group was monitored 
by clinical signs. After neuropathy was detected in high-dose rats, male and female rats in the 
5 mg/kg/day dose groups were also subjected to weekly testing of foot splay (rats in the lower treatment 
groups were not tested due to the lack of response at 5 mg/kg/day). Blood samples collected from seven 
rats/sex in the control and high-dose groups on treatment day 76 and from all rats alive on day 60 of the 
recovery period were examined for packed cell volume, total erythrocyte count, total and differential 
leukocyte counts, and hemoglobin concentration. The study design included urinary sampling from 
10 control and 10 high-dose rats per sex on treatment day 76 and at the end of the treatment period.
Blood serum was collected from the 10 rats/sex/dose that were sacrificed at the end of treatment and 
from the 4 male rats/group that were maintained throughout the 144-day recovery period. Blood urea 
nitrogen, alkaline phosphatase, serum glutamic pyruvic transaminase, and serum cholinesterase activity 
were determined.
Light microscopic examinations were performed on brain, spinal cord, and peripheral nerves (including 
brachial plexus, sciatic, and femoral nerves) from selected male and female rats of each dose group. 
Nervous tissues were fixed in glutaraldehyde-paraformaldehyde and stained with hematoxylin eosin.
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Additional sections of brain, spinal cord, and peripheral nerves were subjected to the luxol fast blue- 
periodic acid Schiff (LFB/PAS) reaction for myelin staining and to Bodian's stain to elucidate more subtle 
axonal changes. Myelin and axonal degeneration was classified as severe (degeneration in approximately 
50% of the observed fibers), moderate (degeneration in 20-50% of observed fibers), slight (degeneration 
in <20% of observed fibers), very slight (effects restricted to focal or multifocal changes in individual 
nerves), or equivocal (nerves could not be graded as clearly normal). Only sciatic nerve tissues from 
male rats were examined by electron microscopy. Three blocks of sciatic nerve fibers, two longitudinal 
and one transverse, were selected per rat for thin sectioning and ultrastructural analysis. Ultrastructural 
alterations were counted by examining a maximum of 50 fields per block, a field defined as a section 
through any Schwann cell. This resulted in an examined maximum of 150 fields/rat or 
450 fields/treatment group of three rats.
Hematology, urinary and clinical chemistry parameters, body weights, organ-to-body weight ratio data, 
foot spread results, and water consumption were statistically analyzed by one-way analysis of variance 
followed by Dunnett's test. The level of significance chosen was p<0.05. The study report did not, 
however, include individual or averaged incidences or extent of changes in these parameters, so an 
independent analysis of the results of body and organ weights, water consumption, foot splay, 
hematology, urinalysis, or serum chemistry was not possible.
Effect noted in study and corresponding doses: Significantly lower body weights were reported in the 
high-dose male and female rats relative to controls: 8% lower (males and females) on treatment days 13 
and 20, and 21 and 24% lower (males and females, respectively) on treatment day 91. No significant 
body weight effect was seen in rats of lower dose groups. High-dose rats also exhibited treatment-related 
effects on organ weights including significantly decreased absolute liver, kidney, and thymus weights in 
males (also testicular) and females, significantly decreased absolute brain and heart weights in females 
(trend for decreased weights in males), increased relative brain, heart, liver, and kidney weights in males 
and females, and decreased relative thymus (females only) and testicular weight in males. Absolute and 
relative liver weight was increased in 5 mg/kg/day males. Marginally statistically significant increases in 
relative heart weight in 0.05 and 0.2 mg/kg/day females were not considered to be of toxicological 
significance due to the lack of a dose response. High-dose female rats exhibited significantly decreased 
water consumption (15-39% decreased) between treatment days 20 and 90. Although decreased water 
consumption was noted in high-dose males, the decrease reached the level of statistical significance in 
only 4 of the 13 intervals recorded. The few instances of significantly increased water consumption in 
low-dose rats did not follow a consistent pattern or trend, and may be of no toxicological significance. By 
day 144 of the posttreatment recovery period, the high-dose group had recovered with higher (but not 
statistically significant) body weights than controls, significantly higher absolute liver and kidney 
weights, and as significantly higher relative brain and liver weights.
Significantly increased instances of hindlimb foot splay were observed in high-dose male and female rats 
on treatment day 22 (incidences were not reported), which became more pronounced on treatment day 29. 
Foot splay testing was terminated with this treatment group (to prevent injury), but clinical signs of 
neuropathy (including curling of the toes, rear limb splay, incoordination, and posterior weakness) 
progressed in severity throughout the remainder of the treatment period. Beginning on treatment day 29, 
rats of the 5 mg/kg/day dose level were tested, but foot splay was not detected at this treatment level in 
either males or females. No other treatment-related clinical effects were observed in the 5 mg/kg/day 
males or females or any of the lower dose groups. By day 7 of the posttreatment recovery period, the 
high-dose groups showed clear signs of improvements continuing to day 111 with only slight posterior 
weakness and curling of the toes. By day 144, these high-dose rats appeared clinically similar to the 
controls.
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At the end of the treatment period, serum cholinesterase activity was increased and alkaline phosphatase 
activity was statistically significantly increased in high-dose females. Significant decreases in packed cell 
volume, total erythrocyte count, and hemoglobin concentrations in high-dose males and females and 
5 mg/kg/day females were noted. Results of urinalysis did not reveal any acrylamide-induced 
abnormalities. By day 144 posttreatment, the high-dose group (sex not specified) had statistically 
significant decreased serum cholinesterase levels and no significant differences in other clinical chemistry 
parameters.
Upon necropsy, gross observations of rats following the 92- or 93-day treatment period revealed 
treatment-related alterations only in the high-dose group, including perineal soiling, decreased adipose 
tissue, decreased liver size, darkened kidneys, foci or mottled appearance of lungs, decreased size or 
flaccid testicles, decreased size of male accessory genitalia, decreased uterus size, altered appearance of 
peripheral nerves, atrophy of skeletal muscle in the posterior portion of the body, bladder distention, and 
diffuse mural thickening of the stomach. The authors did not include incidence data regarding gross 
examination data, however. Histopathologic examination of high-dose rats revealed effects such as 
atrophy of skeletal muscle (2/10 males, 8/10 females), slightly increased hematogenous pigment in the 
spleen (4/9 males), ulcerative gastritis or hyperkeratosis in the nonglandular stomach (4/10 males), 
atrophy of mesenteric fat (8/10 females), vacuolization of the smooth muscle in the bladder wall 
(1/10 males, 2/9 females), inflammation in the lungs (3/10 males, 5/10 females), and testicular effects that 
included atrophy (10/10), mineralization in seminiferous tubules (5/10), and increased cellular debris 
and/or decreased spermatogenic segments in the tubular lamina of the epididymides (9/10). The 
statistical significance of these findings could not be assessed because incidence data for controls were 
not reported. By day 144 posttreatment, only the high-dose rats had persistent gross pathological effects, 
primarily dark testicles and slightly distended bladders. The testicular histological lesions consisted of 
focal or multifocal atrophy to individual seminiferous tubules, some with mineral and cellular debris, and 
indication of partial reversibility of the testicular atrophy. Light microscopic examination of the sciatic 
nerve sections (stained with hematoxylin and eosin) revealed severe degeneration in the high-dose groups 
that was characterized by demyelinization (LFB/PAS-treated sections) and axonal degeneration 
(Bodian's-treated sections) in 10/10 females and similar but less severe effects in males (degeneration 
moderate in 5/10 and severe in the other 5). These lesions were also seen in other peripheral nerve 
sections (brachial plexus and femoral nerve) but varied in severity from equivocal to severe (incidences 
not reported). The authors noted equivocal to very slight degenerative changes in peripheral nerves of 
5 mg/kg/day males (9/10) and females (6/10) but found no light microscopic evidence of peripheral nerve 
lesions in 0.05, 0.2, or 1 mg/kg/day treatment groups. Very slight to slight degenerative changes 
(demyelinization, swollen astrocytes and axons) were seen in spinal cord sections of high-dose male 
(5/10) and female (9/10) rats. No treatment-related lesions were observed at any dose level within brain 
sections examined by light microscopy. After 144 days of posttreatment recovery, no nerve tissue 
alterations were observed in any of the 5 mg/kg/day or lower dose groups. In the high-dose group, 
alterations ranged from very slight to slight in the sciatic nerve and no alterations were noted in sections 
of the brachial nerve. The authors stated that if the recovery period had been extended beyond 144 days, 
the remaining tissue changes would likely have completely reversed.
Ultrastructural (electron microscope) examinations of sciatic nerve preparations from three male 
rats/group included the examination of fields (defined as a section through any Schwann cell) for signs of 
axolemma invaginations, axonal invaginations with cell organelles and/or dense bodies, and Schwann 
cells without axons and/or with degenerating myelin. After 7 days of treatment, no significant differences 
were seen between control and high-dose rats (other treatment groups were not subjected to 7-day interim 
sacrifice). After 33 days of treatment, high-dose male rats exhibited increased prevalence of fields 
showing axolemma invaginations with cell organelles and/or dense bodies and fields exhibiting Schwann 
cells without axons and/or with degenerating myelin (other groups were not subjected to 33-day interim 
sacrifice). Following 90 days of treatment, severe axonal degeneration and axonal loss were seen in high-
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dose rats. Approximately 55% of the fields examined exhibited alterations in myelinated nerves or 
Schwann cells (compared with 12 and 21% after treatment days 7 and 33, respectively). Similar, but less 
severe, ultrastructural alterations in approximately 34% of the fields examined were seen in the 
5 mg/kg/day dose group. At the 1 mg/kg/day dose level, approximately 24% of the fields examined 
showed axolemma invaginations with cell organelles and/or dense bodies, but not more severe signs of 
ultrastructural alterations. The alterations in the sciatic nerve fields examined in the control, 0.05, and 0.2 
mg/kg-day groups were roughly comparable (15, 9, and 12%, respectively), suggesting that there were no 
adverse effects at the 0.05 and 0.2 mg/kg/day doses. Importantly, the increase in lesions observed via 
electron microscopy in the 1 and 5 mg/kg/day groups appeared to have completely reversed by days 25 
and 111 posttreatment, respectively. The observed lesions in the high-dose group were partially or 
completely reversed by day 144 posttreatment.
In summary, the study of Burek et al. (1980) identified a NOAEL of 0.2 mg/kg/day and a LOAEL of 
1 mg/kg/day, based on ultrastructural degeneration (axolemma invaginations with cell organelles and/or 
dense bodies) in the sciatic nerve of male rats (as detected by electron microscopic examinations, which 
were limited to males). The increased frequency was characterized by the study authors as "slight" for the 
LOAEL at 1 mg/kg/day, and the lesions were reversible (back to control levels) by day 25 posttreatment 
in all 1 mg/kg/day treated rats. At the resolution of the light microscope, the 5 mg/kg/day dose was the 
lowest dose resulting in degenerative effects in the sciatic nerve of male and female rats.
Dose and end point used for MRL derivation: 0.2 mg/kg/day
[x] NOAEL [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[x] 10 for extrapolation from animals to humans
[x] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? No.
Other additional studies or pertinent information that lend support to this MRL: As demonstrated in 
Table 3-4 (Levels of Significant Exposure to Acrylamide -  Oral), degenerative nerve changes and male­
mediated implantation losses represent the most sensitive effects of intermediate-duration oral exposure to 
acrylamide. The lowest dose level reported to induce male-mediated implantation losses was 
2.8 mg/kg/day in male Long-Evans rats receiving acrylamide from the drinking water for 80 days; this 
study identified a NOAEL of 1 mg/kg/day (Smith et al. 1986). Ultrastructural degenerative peripheral 
nerve changes were observed at a dose level as low as 1 mg/kg/day in male F344 rats receiving 
acrylamide from the drinking water for up to 93 days; this study identified a NOAEL of 0.2 mg/kg/day 
(Burek et al. 1980). Available data suggest that neurological effects represent a more sensitive point of 
departure than reproductive effects for deriving intermediate- and chronic-duration oral MRLs for 
acrylamide. Therefore, degenerative nerve change was selected as the critical effect for deriving an 
intermediate-duration oral MRL for acrylamide. The study of Burek et al. (1980) was selected as the 
principal study because it identified the lowest LOAEL for the critical effect. A NOAEL/LOAEL 
approach was selected because results of the ultrastructural evaluations included only 3 of 10 rats/group
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and were reported only as the total numbers of fields (per group) with ultrastructural changes as 
axolemma invaginations or Schwann cells without axons and/or with degenerating myelin. This reporting 
of the electron microscopy data does not support a statistical comparison of the incidence of changes 
between the exposed and control groups because it is unknown within any exposure group how the 
numbers of changes were distributed among the three rats (i.e., whether the apparent increase in incidence 
of fields with changes was due to one, two, or all three rats in the 1, 5, and 20 mg/kg-day groups). 
Therefore, a BMD approach was not feasible.
Interim data from a chronic toxicity and carcinogenicity bioassay of male and female F344 rats receiving 
acrylamide from the drinking water for up to 2 years (Johnson et al. (1984, 1985, 1986) provide support 
to the findings of Burek et al. (1980). In the 2-year study, interim sacrifices were performed at 3, 6, 12, 
and 18 months on some rats from each exposure group. One aspect of interim sacrifices was to evaluate 
the condition of selected peripheral nerve sections using light and electron microscopy. The most 
significant noncancer effects were increased incidences of axolemma invaginations (observed by electron 
microscopy) in the tibial branch of the sciatic nerve of male rats following 3 and 6 months of treatment 
and increased prevalence of "moderate" to "severe" degeneration (observed by light microscopy) in both 
males and females following 2 years of treatment. This study identified a NOAEL of 0.5 mg/kg/day and 
a LOAEL of 2.0 mg/kg/day for light and electron microscope evidence of peripheral nerve fiber 
degeneration in the male rats. Electron microscope evaluations at interims >12 months were not 
considered meaningful due to age-related degenerative effects that could not be distinguished from 
acrylamide-induced effects.
Agency Contacts (Chemical Managers): Patricia Ruiz, Ph.D.; Obaid Faroon, Ph.D.; Moiz Mumtaz, Ph.D.
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APPENDIX B. USER'S GUIDE
Chapter 1 
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release. If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight- 
of-evidence discussions for human health end points by addressing the following questions:
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human 
data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). 
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer 
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
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Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. 
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure.
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance. Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology. MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects. If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans). In 
deriving an MRL, these individual uncertainty factors are multiplied together. The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) tables.
Chapter 3
Health Effects
Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in
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conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures. Representative
examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends
correspond to the numbers in the example table and figure.
LEGEND 
See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document. 
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures.
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15­
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. 
In this example, an inhalation study of intermediate exposure duration is reported. For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3) Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL.
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimens are provided in this column. This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981).
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(7) System. This column further defines the systemic effects. These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems. In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose. A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from 
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 of the profile.
(11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies. CELs are always considered serious effects. The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases.
(12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND 
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 
scale "y" axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
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(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 
corresponds to the entry in the LSE table. The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one of three studies for which CELs were derived. The diamond 
symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the 
LSE table.
(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper- 
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (qi*).
(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
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Table 3-1. Levels of Significant Exposure to [Chemical x] -  Inhalation
Exposure
Key to  frequency/ NO AEL
figu re3 Species duration System  (ppm)
LO AEL (effect)
Less serious 
(ppm)
S erious (ppm)
R eference
INTERMEDIATE EXPOSURE
Systemic
18
5
i
Rat 13 wk
5 d/wk
6 hr/d
CHRONIC EXPOSURE 
Cancer
3B
39
40
Rat
Rat
Mouse
7 8
i i
Resp 3b
1B mo 
S d/wk 
7 hr/d
89-104 wk
5 d/wk
6 hr/d
79-103 wk
5 d/wk
6 hr/d
10 (hyperplasia)
11
i
20
10
10
10
Nitschke et al. 1981
(CEL, multiple 
organs)
(CEL, lung tumors, 
nasal tumors)
Wong et al. 1982
NTP 1982
(CEL, lung tumors, NTP 1982 
hemangiosarcomas)
12 ^  a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
6 9
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APPENDIX C. ACRONYM S, ABBREVIATIONS, AND SYM BOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLx 95% lower confidence limit on the BMDX
BMDS Benchmark Dose Software
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
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DOL
DOT
DOT/UN/
NA/IMDG
DWEL
ECD
ECG/EKG
EEG
EEGL
EPA
F
F i
FAO
FDA
FEMA
FIFRA
FPD
fpm
FR
FSH
g
GC
gd
GLC
GPC
HPLC
HRGC
HSDB
IARC
IDLH
ILO
IRIS
Kd
kg
kkg
Ko c
Ko w
L
LC
LC5 0
LCl o
LD5 0
LDL o
LDH
LH
LOAEL
LSE
LT5 0
m
MA
MAL
Department of Labor
Department of Transportation
Department of Transportation/United Nations/
North America/Intergovernmental Maritime Dangerous Goods Code 
drinking water exposure level 
electron capture detection 
electrocardiogram 
electroencephalogram 
Emergency Exposure Guidance Level 
Environmental Protection Agency 
Fahrenheit 
first-filial generation
Food and Agricultural Organization of the United Nations
Food and Drug Administration
Federal Emergency Management Agency
Federal Insecticide, Fungicide, and Rodenticide Act
flame photometric detection
feet per minute
Federal Register
follicle stimulating hormone
gram
gas chromatography
gestational day
gas liquid chromatography
gel permeation chromatography
high-performance liquid chromatography
high resolution gas chromatography
Hazardous Substance Data Bank
International Agency for Research on Cancer
immediately dangerous to life and health
International Labor Organization
Integrated Risk Information System
adsorption ratio
kilogram
metric ton
organic carbon partition coefficient 
octanol-water partition coefficient 
liter
liquid chromatography
lethal concentration, 50% kill
lethal concentration, low
lethal dose, 50% kill
lethal dose, low
lactic dehydrogenase
luteinizing hormone
lowest-observed-adverse-effect level
Levels o f  Significant Exposure
lethal time, 50% kill
meter
trans,trans'-muconic acid 
maximum allowable level
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE C-3
APPENDIX C
mCi millicurie
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor
MFO mixed function oxidase
mg milligram
mL milliliter
mm millimeter
mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System
NLM National Library of Medicine
nm nanometer
nmol nanomole
NOAEL no-observed-adverse-effect level
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data Sys
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
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OTS Office of Toxic Substances
OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic
PCE polychromatic erythrocytes
PEL permissible exposure limit
Pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
PPb parts per billion
PPm parts per million
PPt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
RfC reference concentration
RfD reference dose
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD5 0 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act
TWA time-weighted average
UF uncertainty factor
U.S. United States
USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization
> greater than
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> greater than or equal to
= equal to
< less than
< less than or equal to
% percent
a alpha
ß beta
Y gamma
5 delta
^m micrometer
Mg, microgram
q i * cancer slope factor
- negative
+ positive
(+) weakly positive result
(-) weakly negative result
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE
APPENDIX C
C-6
This page is intentionally blank.
***DRAFT FOR PUBLIC COMMENT***
ACRYLAMIDE D-1
APPENDIX D. INDEX
absorbed dose............................................................................................................................................ 104, 125
adduct...................................................... 9, 24, 26, 66, 67, 80, 81, 82, 83, 84, 86, 88, 89, 90, 92, 96, 98, 100,
101, 102, 112, 114, 115, 116, 124, 125, 138, 170, 178, 180, 183
adenocarcinoma............................................................................................................................................68, 69
adsorption........................................................................................................................................................... 173
aerobic................................................................................................................................................................ 160
anaerobic............................................................................................................................................................ 160
atrophy................................................................................................................................................................. 23
axolemma.......................................................................................................................................................13, 61
bioaccumulation.................................................................................................................................................173
bioavailability.............................................................................................................................................93, 173
bioconcentration factor.....................................................................................................................................160
biodegradation.......................................................................................................................................7, 152, 160
biomarker..................................................22, 67, 88, 124, 125, 133, 137, 138, 139, 140, 170, 178, 180, 184
body weight........................................................................ 3, 7, 9, 12, 17, 21, 58, 59, 64, 65, 71, 91, 101, 102,
112, 121, 122, 123, 131, 132, 136, 154, 171, 180
body weight effects............................................................................................................... 9, 12, 17, 58, 59, 71
breast milk........................................................................................................... 3, 123, 171, 172, 174, 178, 183
cancer............................3, 8, 16, 28, 29, 65, 66, 67, 68, 70, 75, 118, 121, 122, 126, 134, 137, 169, 189, 190
carcinogen............................................................................................................. 9, 70, 154, 169, 186, 188, 190
carcinogenic................................................................................................9, 10, 15, 16, 70, 118, 122, 186, 190
carcinogenicity..................................................................9, 13, 68, 70, 96, 119, 126, 127, 134, 137, 139, 190
carcinoma................................................................................................................................. 68, 69, 70, 75, 134
cardiovascular........................................................................................................................................17, 56, 71
cardiovascular effects..........................................................................................................................................56
chromosomal aberrations............................................................................................................................. 82, 83
clastogenic............................................................................................................................ 75, 82, 117, 118, 135
death............................................................................................................................................ 15, 16, 30, 59, 71
degenerative effects......................................................................................... 8, 11, 61, 63, 115, 133, 134, 135
deoxyribonucleic acid (see also DNA)............................................................................................... 75, 81, 87
dermal effects..................................................................................................................................17, 58, 71, 133
developmental effects.......................................................................................... 3, 27, 63, 64, 65, 74, 137, 139
DNA (see also deoxyribonucleic acid)....................... 75, 80, 81, 82, 83, 84, 86, 87, 88, 92, 96, 98, 99, 112,
114, 117, 118, 122, 124, 125, 127, 135, 138, 180
DNA adducts.............................................................................  83, 86, 92, 96, 98, 99, 112, 118, 124, 138, 180
dominant lethality............................................................................................................................ 8, 62, 74, 135
dopamine..................................................................................................................................................... 64, 136
endocrine.........................................................................................................................  17, 57, 58, 71, 119, 120
endocrine effects....................................................................................................................................57, 58, 71
erythema............................................................................................................................................................... 22
fertility.................................................................................................................................. 12, 63, 118, 131, 186
fetal tissue.......................................................................................................................................................... 123
fetus.....................................................................................................................................94, 121, 122, 127, 171
foot splay..................................................................................................................................................... 60, 137
g a it........................................................................................................................................ 22, 23, 25, 26, 60, 64
gastrointestinal effects........................................................................................................................................56
general population............................................................................................................... 2, 131, 170, 171, 172
genotoxic.....................................................................................................................  15, 75, 107, 118, 134, 140
genotoxicity.............................................................................................................................9, 75, 118, 134, 139
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groundwater..................................................................................................................................... 158, 159, 173
half-life..........................................................................................................................................96, 99, 103, 124
hematological effects....................................................................................................................................17, 56
hemoglobin....................................................  17, 22, 24, 56, 66, 67, 88, 89, 90, 93, 94, 96, 97, 98, 100, 101,
107, 111, 112, 114, 115, 125, 133, 134, 138, 170, 178, 180
hemoglobin adduct................................................. 17, 22, 66, 67, 88, 89, 90, 93, 94, 98, 100, 101, 107, 112,
114, 115, 125, 133, 134, 138,180
heritable translocations......................................................................................................................75, 118, 135
hindlimb splay................................................................................................................  11, 60, 61, 64, 123, 133
hydrolysis.................................................................................................................7, 96, 99, 110, 138, 160, 161
hydroxyl radical........................................................................................................................................ 160, 173
immunological........................................................................................................................  15, 21, 60, 74, 136
implantation loss..........................................................................................................  12, 13, 62, 126, 131, 132
Kow......................................................................................................................................................................143
LD50................................................................................................................................................ 30, 70, 71, 131
leukemia.........................................................................................................................................................83, 85
lymphatic.............................................................................................................................................................28
lymphopoietic..................................................................................................................................................... 28
lymphoreticular....................................................................................................................................... 21, 60, 74
male-mediated..............................................................................................................  12, 13, 62, 126, 131, 135
mammary gland tum ors............................................................................................................................9, 68, 69
mass spectroscopy............................................................................................................................................. 100
mesotheliomas............................................................................................................................... 9, 68, 126, 134
micronuclei................................................................................................................................................... 82, 83
m ilk........................................................................................................................8, 66, 123, 154, 172, 178, 179
motor function......................................................................................................................................21, 132, 136
musculoskeletal effects.......................................................................................................................................57
neonatal........................................................................................................................................................96, 132
neurobehavioral..................................................................................................................................................120
neurochemical....................................................................................................................................................132
neurodevelopmental................................................................................................................................... 62, 137
neurological effects...........................  8, 11, 13, 21, 22, 27, 58, 60, 61, 62, 74, 115, 116, 126, 131, 133, 137
neurophysiological.............................................................................................................................................. 24
neurotransmitter.................................................................................................................................................117
nuclear........................................................................................................................................................100, 163
ocular effects............................................................................................................................................ 17, 58, 71
odds ratio..............................................................................................................................................................66
partition coefficients......................................................................................................................................... 114
peripheral neuropathy...................................................................8, 11, 24, 26, 57, 60, 61, 116, 123, 129, 131
pharmacodynamic.....................................................................................................................................104, 113
pharmacokinetic............................................................................................  104, 105, 106, 107, 113, 121, 138
placenta..........................................................................................................................................8, 94, 123, 178
placental barrier..............................................................................................................................  154, 169, 171
rate constant......................................................................................................................................... 90, 114, 160
renal effects..........................................................................................................................................................57
reproductive effects...................................................................................... 8, 13, 27, 62, 63, 74, 117, 126, 135
respiratory effects.......................................................................................................................................... 17, 56
retention.....................................................................................................................................................150, 182
rotarod.................................................................................................................................... 11, 60, 61, 122, 137
solubility.................................................................................................................  152, 155, 159, 162, 170, 173
sperm mobility........................................................................................................................................8, 62, 135
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spermatogonia........................
systemic effects......................
T3 (see also triiodothyronine)
T4 (see also thyroxine)...........
testicular atrophy....................
thyroid tumors........................
thyroxine (see also T4)..........
toxicokinetic...........................
tremors....................................
triiodothyronine (see also T3)
tum ors.....................................
tunica vaginalis......................
vapor phase.............................
vapor pressure........................
volatilization..........................
...................................................77, 82
........................................... 17, 30, 71
................................57, 119, 120, 132
................................57, 119, 120, 132
.................................... 8, 63, 126,135
 118
......................................................... 57
.......................... 15, 91, 92, 114, 138
................................................60, 137
......................................................... 57
9, 68, 69, 70, 75, 118, 119, 126, 134
.................................... 9, 68, 119, 134
....................................................... 190
....................  152, 155, 162, 170, 190
155,159
***DRAFT FOR PUBLIC COMMENT***

